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1. Bevezetés  
A biológiai rendszerekben a struktúra és a funkció szerves egységet alkot. A 
szövetek, szervek struktúrájának meghatározásában döntı szerepe van az 
extracelluláris mátrixnak, ezen belül is a bazális membránnak, mely kompartmentekre 
osztja fel a szöveteket, szerveket és a parenchimális sejtek differenciált állapotának 
fenntartásáért is felelıs (1). Ugyan a morfológiai vizsgáló eszközök használata 
önmagában is hozzájárulhat a biológiai folyamatok jobb megértéséhez, a morfológiai 
vizsgálatok lényege, hogy az egyes molekuláris elemeket képes hozzárendelni a 
strukturális elemekhez. A fiziológiás és patológiás folyamatok megismeréséhez 
elengedhetetlen a strukturális elemek és a hozzájuk rendelt molekulák változásának 
nyomon követése. A molekuláris biológiai módszerek elıretörésével azonban a 
morfológiai vizsgálatok érdemtelenül a háttérbe szorultak. Kiterjedt morfológiai 
vizsgálatok hiányában azonban a túlzott általánosítások csapdájába eshetünk, mely a 
nagy ráfordítással kidolgozott molekuláris terápiák hatékonyságát jelentısen 
csökkentheti. Ennek a szemléletnek a példái az angiogenezis kutatás témakörébıl azok 
a nézetek, melyek szerint az érképzıdés domináló formája minden szövetben, szervben 
a bimbózó („sprouting”) angiogenezis, illetve hogy a daganat ereinek struktúrája 
alapvetıen különbözik a normál erek struktúrájától (2,3). Ezek az egyszerősítések 
összefüggésben lehetnek az anti-angiogenezis terápiák nem megfelelı hatékonyságával 
(4-6).  Mint az alábbiakban majd láthatjuk, a kép sokkal árnyaltabb, igazán hatékony 
terápiák kidolgozásához elkerülhetetlen lesz az egyes célszervek és az azokban 
növekvı különbözı daganatokban lezajló folyamatok részletes morfológiai vizsgálata.  
Az alábbiakban két eltérı területen (májregeneráció és daganatos áttétképzés) 
tett megfigyeléseink alapján szeretnénk rámutatni a morfológiai vizsgálatok 
fontosságára.  
A máj kitőnı regenerációs képessége régóta jól ismert (7).  A klasszikus és 
alaposan tanulmányozott, patkányokon kialakított modellben a máj 2/3-ának 
eltávolítása után a májtömeg 7-10 nap alatt teljesen regenerálódik. Ez az egyik 
legtöbbet tanulmányozott in vivo, intenzív sejtproliferációval járó nem daganatos 
növekedési reakció. A regeneráció a megmaradt lebenyek sejtjeinek, döntıen a 
hepatocitáknak a kompenzatórikus hiperpláziája révén valósul meg, tehát az eltávolított 
lebenyek nem nınek vissza.  
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Az elmúlt két évtizedben a májregeneráció alternatív, „tartalék” 
mechanizmusaira derült fény. Ha a májsejtek proliferációja gátolt, akkor új májsejtek 
az ıssejtek aktiválásával és az úgynevezett ovális sejtek közbeiktatásával keletkeznek. 
Az utóbbi években a kutatás homlokterébe került a hemopoetikus ıssejtek segítségével 
lezajló szövetregeneráció. Bár számos közlemény igazolni látszik, hogy a 
hemopoetikus ıssejtek transzdifferenciálódhatnak közvetlenül, vagy ovális sejtek 
közbeiktatásával májsejtekké, a folyamat hatásfoka nagyon alacsonynak bizonyult. 
Magát a transzdifferenciáció folyamatát is több szerzı kétségbe vonja, hiszen 
kimutatták, hogy a legtöbb esetben csak sejtfúzióról van szó (8,9). A hemopoetikus 
ıssejtek segítségével lezajló regeneráció jelentısége azért is megkérdıjelezhetı, mivel 
mint fentebb láthattuk, maga a máj is több regenerációs mechanizmussal rendelkezik, 
melyek a körülményektıl függıen aktiválódnak (8). 
A fentiek alapján látható, hogy a máj ıssejtjeinek lokalizációja és fenotípusa 
nem ismert, tehát ezeknek a meghatározása nagyon fontos lenne ezen sejtpopuláció  
késıbbi terápiás hasznosíthatósága szempontjából.  
A malignus tumorok legjellemzıbb tulajdonsága, hogy növekedésük során 
távoli áttéteket képeznek. (10,11). Legtöbb esetben ez vezet a különbözı malignus 
betegségben szenvedı beteg halálához. A metasztázisképzés folyamatát több, 
egymástól többé-kevésbé elkülöníthetı, de egyenként igen bonyolult lépésre 
oszthatjuk. 
1/ Tumor növekedés, tumorsejt leszakadás, szövetinvázió 
2/ Angiogenezis 
3/ Intravazáció 
4/ Kölcsönhatás a vér alakos elemeivel és oldott alkotórészeivel 
5/ Mechanikus vagy specifikus elakadás/kitapadás a célszerv érrendszerében. 
6/ Extravazáció 
A metasztázisképzés folyamata többször is ismétlıdhet, így másodlagos illetve 
harmadlagos metasztázisok is kialakulhatnak. Ezért, bár a tumorok klinikai 
felismerésekor már legtöbbször mikrometasztásisok vannak jelen, ezen lépések 
nagyobb részének gátlása megakadályozhatja újabb metasztázisok kialakulását. 
A másodlagos és harmadlagos metasztázisok kialakulása nagyrészt úgynevezett 
generalizációs helyeken keresztül történik, melyek fıleg nyirokcsomók, máj és tüdı 
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lehetnek. A generalizációs helyeket általában az anatómiai viszonyok határozzák meg, 
mely legtöbbször a vénás illetve nyirokelfolyásnak felel meg. Tumorsejtek azonban 
átjuthatnak a szervek kapillárishálózatán anélkül, hogy ott elakadnának és áttéteket 
hoznának létre. A két folyamat eredményeképpen jöhet létre a metasztázisok bizonyos 
tumorokra jellemzı szerveloszlása, melynek kialakulását két egymásnak ellentmondó, 
bár egymást nem kizáró elmélet próbálja magyarázni. Az egyik a "mechanikus" elmélet, 
mely szerint a primer tumorból elszabadult tumorsejtek az elsı elért szerv 
kapillárishálózatában hoznak létre áttéteket, míg a "mag-talaj" teória szerint a 
tumorsejtek és a célszerv specifikus tulajdonságai határozzák meg a metasztázisok 
kialakulását és ez független az anatómiai viszonyoktól. Mindkét hipotézist számos 
humán és állati tumor vizsgálatából származó adat támasztja alá (12,13) 
A tumor indukált angiogenezis kettıs szerepet játszik a tumorok 
progressziójában. Az újonnan képzıdött erek egyrészt tápanyaggal látják el a tumort, 
másrészt növelik a hematogén úton képzıdött metasztázisok kialakulásának 
valószínőségét. Az utóbbi évek kutatási eredményei bizonyították a nyirokér 
angiogenezis létét is, valamint az újabban elérhetı specifikus nyirokér markerek 
segítségével összefüggést találtak a nyirokérdenzitás és a tumorok metasztatizáló 
képessége között (14). Az újonnan képzıdött erek nagyon vonzó terápiás célpontot 
kínálnak, hiszen az erek genetikailag stabil sejtekbıl épülnek fel, szemben a 
tumorokkal (bár újabb eredmények a proliferáló endotélsejtek genetikai instabilitására 
utalnak), azonban a számos próbálkozás ellenére az anti-angiogén terápiák nem 
váltották be a hozzájuk főzött reményeket (4-6).   
A metasztázisképzés során, elsısorban az epiteliális tumorok esetében ahhoz, 
hogy a tumorsejtek megtelepedhessenek a célszervben, három bazális membránon kell 
áthatolniuk (epiteliális bazális membrán, vaszkuláris bazális membrán az intravazáció 
és extravazáció során), melyet a tumorterjedés legfıbb gátjának tekintenek. A 
tumorsejtek bazális membránon történı áthatolásának mechanizmusára még mindig a 
Liotta és mtsai. által korábban felállított háromlépéses hipotézis a legelfogadottabb 
(15). Eszerint a tumorsejtek specifikus a bazális membrán komponenseit felismerı, 
fıleg integrin típusú receptorokkal tapadnak a bazális membránhoz. Ezután történik 
meg a bazális membrán emésztése proteolitikus enzimek kaszkádrendszerének 
segítségével, melyet a tumorsejtek migrációja követ.  
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2. Célkitőzések 
Vizsgálataink két nagy kérdéskört ölelnek fel, a májregenerációt illetve a 
metasztázisképzést. A legfontosabb megválaszolandó kérdéseket az alábbiakban 
foglalhatjuk össze.  
1. Májregeneráció 
Milyen a patkány illetve humán máj interlobuláris epeúthálózatának szerkezete 
és immunfenotípusa? 
Hogyan zajlik le a máj szerkezetének helyreállítása májregeneráció során? 
Hol helyezkedhetnek el a májregenerációban résztvevı ıssejtek? 
2. Metasztázisképzés 
2a. Tumor indukált angiogenezis 
Milyen alapvetı angiogenezis formák figyelhetık meg primer tumorok 
környezetében?  
Van-e eltérés az angiogenezis folyamatában különbözı szervekben, 
szövetekben?  Befolyásolja-e az angiogenezis folyamatát a tumorok differenciációs 
foka, a célszerv (bazális membrán) szerkezete? 
Hogyan játszódik le a kísérletes májmetasztázisok arterializálódása?  
2b. Tumorsejt motilitás és szervpreferencia 
Hogyan változnak a tumorsejtek mozgása során a sejtadhéziós helyek és azok 
komponenseinek eloszlása?  
Befolyással van-e a célszerv kapillárisainak szerkezete és extracelluláris mátrix 
összetétele az extravazáció folyamatára illetve a szervpreferenciára? 
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3. Anyag és módszer 
3.1. Állatkísérletek 
A máj epeútrendszerét normál különbözı korú patkány illetve humán májakon 
vizsgáltuk. A normál máj regenerációját a klasszikus parciális hepatektómia (2/3) 
modellben vizsgáltuk. Az ovális sejtek szerepét a májregenerációban egy, a Solt-
Farber- féle karcinogenezis modell (patkány) módosított változatában vizsgáltuk, mely 
2 hetes acetilaminofluorén (AAF) kezelésbıl és a kezelés közepén elvégzett parciális 
hepatektómiából áll. 
Az angiogenezis és metasztázis vizsgálatokhoz különbözı humán in vitro, 
valamint egér in vivo fenntartott tumorvonalakat használtunk.  Primer tumorokban 
lezajló angiogenezist a tumorsejtek (B16 melanóma, C38 kolon karcinóma illetve 
HT25 humán kolon karcinóma) intrakután vagy szubkután oltását követıen vizsgáltuk.  
Agy metasztázisokban lezajló angiogenezist a tumorsejtek karotiszba (3LL-HH 
karcinóma, B16, A2058, WM983 melanómák, 293 veserák), vagy direkt az 
agyszövetbe történı oltását követıen vizsgáltuk (ZR-75-1 emlırák, HT25 kolon 
karcinóma, H1650 tüdı adenokarcinóma, HT1080 fibroszarkóma).  
Májmetasztázisok vaszkularizációját a tumorsejtek lépbe (C38 kolon 
karcinóma,) történı oltását követıen vizsgáltuk. Az arterializáció folyamatát korróziós 
készítmények segítségével vizsgáltuk (A2058 melanóma, Lewis Lung karcinóma, C38 
kolon karcinóma).  
A tumorsejtek extravazációjának a vizsgálatához Lewis lung karcinóma sejteket 
oltottunk farokvénába, szív bal kamrába, és lépbe. 
 
3.2. Morfológiai módszerek 
Megfigyeléseink döntı többsége fagyasztott metszeteken illetve sejtkultúrákon 
elvégzett, immunfluoreszcens vizsgálatokon alapul.  A minták analízisét legtöbbször 
konfokális mikroszkóppal végeztük el, mely lehetıséget adott a detektált jelek 
háromdimenziós rekonstrukciójára is. A kapott eredményeket normál illetve immun-
elektronmikroszkópos vizsgálatokkal egészítettük ki. 3D rekonstrukciót félvékony 
sorozatmetszetek felhasználásával is végeztünk.  A korróziós készítményeket sztereó- 
illetve szkenning elektron mikroszkóp segítségével vizsgáltuk.  
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Vinkulin eloszlását a sejtmigráció során élı sejtekben GFP-vinkulin 
konstrukció transzfekcióját követıen vizsgáltuk.  
Az ovális sejtek sorsának követését retrovírus jelöléssel végeztük el. 
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4. Eredmények és megbeszélés 
4.1. Májregeneráció 
4.1.1. A máj epeútrendszerének szerkezete és immunfenotípusa (I,II). 
Mielıtt rátérnénk a májregeneráció tárgyalására vessünk egy pillantást a patkány 
és humán máj interlobuláris epeútrendszerének szerkezetére és fenotípusára, mert mint 
látni fogjuk ez a rendszer jelentıs szerepet játszik majd a máj ıssejteket is mobilizáló 
regenerációja során.  
A Hering csatornák, az epeútrendszer legtávolabbi szakaszai, melyek 
összeköttetést biztosítanak az epeutak és a hepatociták alkotta epekanalikusok között. 
Elnevezésüket leírójukról kapták, aki elıször figyelt meg olyan rövid, 2-3 sejtsor 
hosszúságú duktulusokat a májban, melyek alkotásában epeúthámsejtek és hepatociták 
egyaránt részt vesznek. Egyértelmő azonosításuk csak elektronmikroszkópos 
vizsgálattal lehetséges.  
Patkánymájban ezek a struktúrák a „limiting plate”-en kívül periportálisan 
helyezkednek el, tehát sosem hatolnak be a parenchimába.  Vizsgálataink kimutatták, 
hogy ezek a struktúrák a CK19+/CK7- immunfenotípust hordozzák. Ugyanakkor a 
nagyobb interlobuláris epeutak CK19+/CK7+ fenotípusúak. CK19+/CK7- 
immunfenotípusú epeutak azonban nem találhatók humán májakban, ebben az esetben 
minden epeút CK19 illetve CK7 pozitív. A CK7 negatív epeutak sajátos entitását 
igazolja, hogy míg a CK7 pozitív epeutak mérete a máj hilusa felé fokozatosan 
növekszik, addig a CK7 negatívaké állandónak adódott, májbeli helyzetüktıl 
függetlenül. A CK7 negatív epeutak több száz mikrométer hosszú kanyarulatos 
struktúrák, melyek több helyen kapcsolódhatnak a májsejtekhez. Bár a Hering kanálisok 
szorosabb definíciójának ezen epeutak nem minden szakasza felel meg, fenotípusuk 
alapján ez a struktúra az epeútrendszernek egy morfológiai és funkcionális egységét 
alkotja (I).  
Ép, humán májakban is jellemeztük az epeútrendszer legdisztálisabb szakaszát 
(II). A CK7 immunreakció alkalmas volt az epeutak és a hepatociták egyértelmő 
elkülönítésére. A CK7-tel jelölt metszetek konfokális mikroszkóppal történı vizsgálata, 
illetve sorozatmetszetekbıl számítógép segítségével végzett 3D rekonstrukciós 
vizsgálatok segítségével megállapítottuk, hogy az ép emberi májakban az epeutak a 
periportális kötıszövetbıl kilépve látszólag beterjednek a májparenchimába. Az 
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infiltráció azonban csak látszólagos, mert az emberi májban is kezdetleges formában 
jelen vannak a néhány más állatfajban fellelhetı jól fejlett interlobuláris vaszkuláris 
(kötıszövetes) szeptumok, amelynek mentén az epeutak terjednek, azaz 
intraparenchimálisak, de mégsem lépnek be a lebenykék állományába. Az epeutak 
közelében NG2 pozitív struktúrák is megfigyelhetık voltak, amely arteriolák jelenlétére 
utal. A tradicionális, eredetileg leírt Hering csatornák csak ezen epeutak terminális 
szegmentumának felelnek meg. Ezeknek a hosszú duktulusoknak az egységes, és 
nagyobb epeutaktól eltérı (EMA-/CD56+/CD133+) immunfenotípusa arra utal, hogy 
sajátos funkcionális egységet alkotnak.  
Különbözı életkorú humán és patkány májakból származó minták vizsgálatával 
megállapítottuk, hogy ez az elrendezıdés és immunfenotípus az újszülöttek májában 
még nem alakul ki, hanem posztnatálisan jön létre.  
Összefoglalva tehát alapvetı különbség van a patkány és a humán máj 
szerkezetében.  Míg patkány májban az epeutak a „limiting plate”-en végzıdnek, humán 
májban az epeutak a lebenyke palástja mentén futnak.  Ez a különbség hatással van az 
arteriás rendszer szerkezetére is. Miután az artériás rendszer a májban fıleg az epeutak 
vérellátásáért felelıs, a humán májban a szerteágazó és a parenchimába is beterjedı 
epútrendszert egy ugyanolyan felépítéső artériás rendszer is követi, mely végül a 
szinuszoidokba ömlik.  Ezzel szemben  patkány májban az epeutak nem hagyják el a 
portális teret, ezért az artériás rendszer elvezetése fıleg a portális rendszerrel alkotott 
anasztomózisokon keresztül valósul meg. Az artériás rendszer hasonló szerkezető egér 
májban is, melynek részletesebb ismertetésére alább kerül sor.  Mind patkány, mind 
humán májban a kis epeutak morfológiai és funkcionális egységet alkotnak 
 
4.1.2 Májregeneráció hepatektómiát követıen (III).  
A májszövet legáltalánosabban elfogadott morfológiai alapegysége a lebenyke 
(lobulus). Az egyes májlebenyek regeneratív növekedése elvileg háromféleképpen 
történhet meg: a/ a májlebenykék méretének növekedése, b/ új májlebenykék 
képzıdése, c/ a két folyamat kombinálódása révén. Meglepı módon napjainkig sem volt 
tisztázva, hogy a fenti három lehetıség közül melyik történik meg a májregeneráció 
során. Ennek magyarázata, hogy a máj lebenykéinek mérete meglehetısen nehezen 
vizsgálható. A májlebenykék egy bonyolult hierarchikus rendszert alkotva építik fel a 
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májszövetet. Ezen a hierarchián belül a lebenykék mérete változik a hilustól való 
távolság alapján, továbbá a különbözı lebenykék tengelye sem párhuzamos. Ebbıl 
adódik, hogy hagyományos szövettani metszeteken a lebenykék méretérıl szinte semmi 
felvilágosítás nem nyerhetı. Munkacsoportunk kidolgozott egy új módszert mely 
lehetıvé teszi a májlebenykék méretének objektív vizsgálatát. Azokat a korábbi 
megfigyeléseket használtuk ki, hogy a/ a májtok alatti lebenykék az említett 
hierarchiában azonos helyet foglalnak el b/ tengelyük, mely lényegében azonos a 
centrális vénák legperifériásabb ágával, merıleges a máj felszínére. Ezért ha a hepatikus 
vénákon keresztül fluoreszcens mőgyantával retrográd módon feltöltjük a centrális 
vénák ágrendszerét és rajtuk keresztül a szinuszoidokat, a máj felszínén megbízhatóan 
kirajzolódnak a lebenykék határai. A máj felszínérıl készített felvételeken a lebenykék 
tetszıleges paraméterei objektíven meghatározhatók. Módszerünk természetesen csak a 
felszíni lebenykék méretérıl nyújt egyértelmő felvilágosítást, de az említett hierarchikus 
elrendezıdés miatt ez legalábbis tendenciájában tükrözi a mélyben zajló folyamatokat 
is. 
A fenti módszert alkalmazva összehasonlítottuk a máj posztnatális, fiziológiás 
növekedését a sebészi parciális hepatektómiát követı regenerációval. Megállapítottuk, 
hogy az egyedfejlıdés születést követı fázisában a máj tömegének gyarapodásához új 
lebenykék képzıdése és a lebenykék fokozatos növekedése is hozzájárul, ez utóbbi 
folyamatban pedig szerepe van a hepatociták megnagyobbodásának is. A regeneratív 
növekedés során viszont kizárólag a már meglévı lebenykék mérete növekszik, új 
lebenykék nem képzıdnek és a hepatociták sem képesek további megnagyobbodásra. A 
regeneráció eredményeként megnagyobbodott lebenykék viszont bonyolultabb 
szerkezetőek. Ez tükrözıdik az egy centrális vénát körülvevı portális vénaágak 
számának megnövekedésében, továbbá abban, hogy különbözı zonális megoszlást 
mutató enzimek (pl. CYP450IIE1, glutamin szintetáz) a szokásos koncentrikus 
elrendezıdés helyett karéjozott mintázatot mutatnak. Feltételezésünk szerint ezen utóbbi 
szerkezeti változások oka, hogy az ideális porto-centrális távolság ne növekedjen 
jelentıs mértékben a lebenykék megnagyobbodása következtében. 
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4.1.3. Májregeneráció a máj ıssejtjeinek részvételével (I, IV-VII). 
Az ıssejtek részvételével lezajló májregenerációt az úgynevezett AAF/Ph 
modellben vizsgáltuk, melynek lényege, hogy AAF kezelés hatására a hepatociták 
osztódása gátolt, aminek következtében a parciális hepatektómiával kiváltott 
proliferációs stimulus hatására ıssejtek aktiválódásával zajlik le a regeneráció.  
Proliferáló ovális/progenitor sejtek - az ıssejtek leszármazottjai - szaporodnak fel a 
májban és késıbb májsejtekké differenciálódnak. Az ıssejtek lokalizációja a májban, 
fenotípus markerük nem lévén, pontosan nem ismert. A legtöbb adat arra utal, hogy az 
ıssejtek az epeutak és a hepatociták között elhelyezkedı speciális képletek a fentebb 
jellemzett Hering csatornák sejtjei között találhatók. Más elképzelések szerint az 
epeútrendszer összes sejtje rendelkezik ıssejt tulajdonsággal. Novikoff és mtsai. (16) 
szerint szintén a terminális epeutakban található, de a bazális membránhoz nem 
kitapadt primitív sejtek lennének a máj ıssejtjei.  Ezekkel szemben olyan elképzelések 
is napvilágot láttak, hogy az ovális sejtek a periportális térben elhelyezkedı nem 
jellemezett sejtek, illetve csontvelıbıl származó ıssejtek leszármazottjai lennének 
(17). 
A következıkben az ıssejtek lokalizációjának meghatározására vonatkozó 
vizsgálatainkat ismertetjük. Azt már korábban tapasztalták, hogy bár az ovális sejtek 
portális térbıl történı kivándorlása csak a hepatektómiát követıen kezdıdik meg, a 
sejtproliferáció a portális térben már két AAF kezelést követıen megindul. A 
proliferáló sejtek pontos lokalizációja azonban nem volt ismert. Vizsgálatainkban 
immun-elektronmikroszkópia segítségével állapítottuk meg a brómdezoxiuridint 
(BrdU) inkorporáló sejtek pontos elhelyezkedését. Összehasonlításképpen 
epeútlekötésen átesett állatok máját is vizsgáltuk, mivel ebben az esetben a lezajló 
epeút proliferáció nem jár ovális sejtek megjelenésével, tehát ıssejt aktivációval sem. 
Megállapítottuk, hogy két AAF kezelést követıen a legnagyobb arányban a Hering 
kanálisok sejtjei proliferáltak szemben az epeút lekötéssel, ahol a nagyobb epeutak 
sejtjei voltak többségben a proliferáló sejtek között (IV). Ez a megfigyelés azt 
támasztotta alá, hogy az ıssejtek a Hering kanálisok sejtjei között helyezkednek el. A 
Hering kanálisok azonban a definíció szerint, mindössze a májsejtekhez kapcsolódó és 
bazális membrán által félkör alakban körülvett néhány sejtbıl álló struktúrák, melyek 
valószínőleg nem tartalmaznak annyi ıssejtet amennyi a máj teljes regenerációjához 
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szükséges. A fentebb ismertetett (CK19+/CK7-) epeút kompartment azonban, mely 
megfelel a legkisebb terminális epeutaknak és magában foglalja a Hering kanálisokat 
is, elegendı ıssejtet tartalmazhat a máj regenerálásához.  Ezen epeutak sejtjei is 
nagyobb proliferációs aktivitást mutattak két AAF dózist követıen, mint a nagyobb 
CK7+ epeutak (I). Véleményünk szerint ezek tartalmazzák a legnagyobb 
valószínőséggel a máj ıssejtjeit. Sajnos ez a fenotípus nem volt stabil, tehát nem 
használható az ıssejtek leszármazottjainak követésére, hiszen a proliferáló ovális sejtek 
expresszálják a CK 7-et. Figyelemreméltó az is, hogy a regeneráció teljes lezajlását 
követıen az ovális sejt-csövek maradványait reprezentáló bazális membránnal 
körülvett kis epeutakat lehet megfigyelni a patkányok májában, melyek újra az eredeti 
fenotípust mutatják. Ez arra utal, hogy a CK7+/CK19+ fenotípus (nagyobb mechanikai 
stabilitás?) megjelenése a növekvı, illetve regenerálódó máj kis epeútjaiban az epeutak 
intenzív növekedésével illetve a sejtproliferációval jár együtt.  
Mint fentebb említettük, ovális sejtek megjelenésére a parenchimában, melyek 
bizonyítottan a periportálisan proliferáló sejtek leszármazottai csak az AAF kezelés 
közepén elvégzett hepatektómiát követıen kerül sor. Bár azt már korábban kimutatták, 
hogy az ovális sejtek a máj epeútrendszerével folytonosságot mutató, 
elektronmikroszkópos vizsgálatok alapján nem folytonos bazális membránnal körülvett 
csırendszert alkotnak, ezen struktúrák pontos viszonya a portális térhez illetve máj 
parenchimájához ismeretlen volt. Olyan elképzelések is napvilágot láttak, hogy az 
ovális sejtek egyesével vagy kisebb csoportokban a Disse térben migrálnak, majd 
beépülnek a hepatociták közé.  Mi konfokális mikroszkóp segítségével vizsgáltuk az 
ovális sejtek és a bazális membrán viszonyát a parciális hepatektómiát követıen azon 
idıponttól kezdve, amikor az ovális sejtek már áttörték a „limiting plate”-et. 
Megfigyeltük, hogy a néhány sejt hosszúságú csövek körül a bazális membrán 
ugyanolyan „U” formában helyezkedik el, mint a Hering kanálisok körül, amely azt 
mutatja, hogy az ovális sejt-csövek a Hering kanálisok meghosszabbításai. A csövek az 
idı elırehaladtával egyre hosszabbak és kanyargósabbak lettek, de végük mindig 
hepatocitákhoz kapcsolódott, így összeköttetésben maradt májsejtek közötti elemi epeút 
rendszerrel (IV). Ez a tény nagy jelentıséggel bír, hiszen azt mutatja, hogy az 
epeelvezetés és így a szerv funkciója a regeneráció során végig biztosított. Ez kiegészül 
azzal a megfigyeléssel is, hogy az ovális sejt-csövek a szinuszoidok között helyezkedtek 
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el arra utalva, hogy növekedésük során a károsodott hepatocita lemez helyét foglalják 
el, ezzel a szerv vérkeringésének zavartalansága is biztosított. Soha nem figyeltünk meg 
bazális membrán nélküli CK19-et expresszáló, a kötıszövetben vagy a Disse térben 
elhelyezkedı sejteket, mely azt jelzi, hogy az ovális sejtek által alkotott csövek 
növekedése szabályozottan, a sejtek polarizált állapotát megtartva történik.  Ezt a tényt 
szem elıtt tartva hasonlóképpen nem tartjuk elképzelhetınek, hogy a máj ıssejtjei az 
epeútrendszeren kívül helyezkedjenek el a portális térben, melyet alátámaszt az a 
megfigyelésünk, hogy nem találtunk citokeratin illetve AFP pozitív sejteket a bazális 
membránon kívül, sem pusztán az AAF kezelést követıen sem az ovális sejt-csövek 
növekedése során. Ezzel összhangban nem figyeltünk meg bazális membránon 
átmigráló sejteket sem. Találtunk ugyan a Novikoff által leírt bazális sejtekhez hasonló 
primitív hemopoetikus sejtekre emlékeztetı sejteket a növekvı ovális sejt csövekben, de 
osztódó alakokat nem találtunk közöttük.  Ilyen sejtek nem voltak jelen a Hering 
kanálisokban illetve a kis epeutakban a két AAF kezelést követıen sem (IV). 
Hemopoetikus sejtekhez hasonló sejtek jelenléte az ovális sejt csövekben felveti annak 
lehetıségét, hogy ezek a sejtek csontvelıi eredetőek és ovális sejtekké 
transzdifferenciálódnak, mint ahogy azt Petersen és munkatársai leírták (17). Ezt a 
nagyon vonzó lehetıséget alátámasztja az is, hogy az ovális sejtek hemopoetikus 
ıssejtek fenotípus jegyeit viselik (c-kit, CD34). Hemopoetikus sejtek ovális sejtekké 
történı transzdifferenciálódását azonban többen kétségbe vonják (6).  Az ovális sejtek 
csontvelıi eredetét saját eredményeink is cáfolják (V), hiszen kimutattuk, hogy a 
csontvelıi ıssejtek markereként ismert Thy-1 molekulát nem az ovális sejtek - mint 
ahogy azt Petersen és munkatársai leírták-, hanem a bazális membránon kívül 
elhelyezkedı SMA pozitív miofibroblaszt populáció expresszálja, míg a dezmin pozitív 
aktivált „stellate” sejtek elenyészı mértékben mutattak Thy-1 pozitivitást. Kollagenáz 
perfúziót követıen izolált ovális sejtekbıl illetve szövettani metszetekbıl 
mikrodisszekált ovális sejtekbıl izolált RNS-ben valós idejő RT-PCR módszerrel nem 
volt kimutatható a Thy-1 mRNS, ami viszont jelen volt a miofibroblasztokat is 
tartalmazó frakcióból izolált RNS-ben, igazolva, hogy a Thy-1 molekula RNS szinten 
sem termelıdik az ovális sejtekben. A Thy-1-et expresszáló sejtek szorosan követik a 
növekvı ovális sejt csöveket, és a feltételezések szerint növekedési faktorok 
termelésével segítik az ovális sejtek proliferációját. Szerepük lehet azonban az ovális 
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sejt- csövek növekedéséhez szükséges extracelluláris mátrix illetve bazális membrán 
termelésében is, hiszen kimutatták például, hogy a tüdıfibrózis kialakulása során a 
fibroblasztok által expresszált Thy-1 „shedding”-je következik be (18). 
Összefoglalva tehát vizsgálataink eredményeit azt mondhatjuk, hogy a máj 
ıssejtek a Hering kanálisokat is magukba foglaló terminális epeutakban helyezkednek 
el és hasonlóan más szervek ıssejtjeihez (bél, bır, agy), a bazális membránon 
nyugszanak (19). Utódsejtjeik (ovális sejtek) polarizált sejtek melyek duktusokat 
alkotnak és migrációjuk illetve szaporodásuk során folytonos bazális membránt 
építenek fel.   
Az ıssejtek részvételével megvalósuló májregeneráció utolsó lépése az ovális 
sejtek májsejtekké történı differenciációja, mely folyamatra vonatkozó vizsgálatainkat 
ismertetjük az alábbiakban. 
Korábbi vizsgálatokból kiderült, hogy az általunk használt modellben az ovális 
sejtek differenciációja májsejtekké függ az AAF alkalmazott dózisától. Eszerint a 
nagydózisú AAF gátolta az ovális sejtek differenciációját, míg az AAF alacsonyabb 
koncentrációja gyors májsejt irányú differenciációt eredményezett. Alaposabban 
megvizsgálva ezt a jelenséget két különbözı típusú differenciációt figyeltünk meg az 
AAF dózisától függıen (VI). Kis dózisú AAF kezelés az ovális sejtek szinte egyidejő 
differenciációját eredményezte 5-6 nappal a hepatektómiát követıen. Ezzel szemben 
differenciálódó sejtek csak késıbb (11-13. nap a hepatektómiát követıen) jelentek meg 
a májban fókuszokat alkotva és az ovális sejtek nagy többsége nem alakult át 
májsejtekké nagy dózisú kezelést követıen.  Itt fontos megjegyezni, hogy a portális 
térbıl kiinduló ovális sejtes reakció nagysága is függött az AAF dózisától, jelezve, 
hogy a hepatocita károsodás méretének megfelelıen változik az ovális sejtek által 
létrehozott csövek hossza, vagyis a regenerációhoz szükséges sejtek száma. Nem 
tudunk magyarázatot adni arra, hogy a nagy dózisú AAF kezelés esetében miért nem 
differenciálódott az összes ovális sejt májsejtté. Egy lehetséges magyarázat, hogy nagy 
dózisú AAF valóban gátolja a differenciációt, és az AAF koncentráció csökkenésével 
bizonyos ovális sejtek gyorsan differenciálódnak és tovább szaporodnak, mely a többi 
ovális sejt átalakulását már feleslegessé teszi. Felmerülhet az AAF mutagén hatása is, 
mely a feltehetıen klonális proliferációhoz vezet, de ennek ellentmond, hogy az AAF 
ezen dózisa nem bizonyult karcinogénnek, valamint, hogy ez a folyamat is funkcionális 
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regenerált májat eredményezett. Ezek után nem meglepı, hogy az ovális sejtek 
májsejtekké történı differenciációja teljesen hasonló módon zajlott le, az eredmény 
mindkét esetben kis hepatociták megjelenése volt. A kis dózis esetében a kis 
hepatociták elrendezıdése megegyezett az ovális sejtek elrendezıdésével, vagyis 
duktusokat alkottak, melyek a portális terek körül sugár irányban helyezkedtek el.  
Nagy dózis esetében a kis hepatociták fókuszokba rendezıdtek, de ezen belül ebben az 
esetben is duktusokat formáltak. Mindkét esetben a kis hepatociták által formált 
duktusok összeköttetésben maradtak a máj epeútrendszerével. A differenciálódás 
legmarkánsabb jele a bazális membrán eltőnése volt az ovális sejt-csövek körül, 
amellyel teljesen párhuzamosan történt a HNF-4α-nak, a májsejtek terminális 
differenciációját meghatározó transzkripciós faktornak a megjelenése (VI). Közvetlen 
összefüggés azonban valószínőleg nincs a bazális membrán lebomlása és a HNF-4α 
megjelenése között, hiszen a bazális membrán lebomlásának elmaradása és a HNF-4α 
megjelenése a nagydózisú kezelés során gyakran megfigyelt intesztinális 
metapláziához vezet. HNF-4α kondicionális mutáns egerek vizsgálata azt mutatta, hogy 
a HNF-4α rendkívül sok fehérje expressziójának regulációja mellett közvetlenül felelıs 
a hepatocita funkció ellátását alapvetıen meghatározó sejtkapcsoló struktúrák, köztük a 
connexinek kifejezıdéséért (20). Saját vizsgálataink is azt mutatták, hogy a kis 
májsejtek megjelenése együtt jár az epeút specifikus connexin 43 eltőnésével, illetve a 
májsejtspecifikus connexin 32 megjelenésével. A kis dózisú differenciálódás esetében 
lehetett a legjobban megfigyelni a duktusok disztális részén ultrastukturálisan a bazális 
membrán fragmentálódását, illetve teljes lebomlását, valamint a májsejtekre jellemzı 
sejtorganellumok megjelenését. A bazális membrán eltőnésével párhuzamosan az α6 
integrin alegység expressziója is csökkent, amely fehérje a kizárólagosan laminint kötı 
integrinek alegysége és jelen van a máj epeútrendszerének minden szegmensében. 
Ezzel szemben a duktuláris struktúrákat alkotó kis hepatociták bazális és laterális 
részén megjelenik a α1 integrin amely elsısorban kollagént köt és a normál hepatociták 
jellemzı adhéziós molekulája (VI). Megfigyeléseinket alátámasztják Sell 
munkacsoportjának eredményei (21) is miszerint izolált progenitor sejteket  bazális 
membrán mátrixon tenyésztve azok epeút irányú differenciációt mutattak. A bazális 
membrán lebomlása nem jár együtt a duktuláris szerkezet azonnali felbomlásával és 
egyelıre nem tudjuk, hogy a normál májsejt gerendák hogyan alakulnak ki. Annyi 
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azonban bizonyos, hogy a bazális membrán lebomlását követıen rögtön megkezdıdik 
az elemi epeutak kialakulása a kis májsejtek között, amit az igen sajátos csillagszerő 
elrendezıdést mutató CD26 expresszió jelez. A differenciálódás során képzıdı elemi 
epeutak közvetlen kapcsolatban maradnak az elvezetı nagyobb epeutak lumenével, 
melyet az epeútrendszer fluoreszcens lektinnel való retrográd feltöltésével sikerült 
igazolnunk.  
Összefoglalva a normál és az ıssejtek segítségével történı májregenerációra 
vonatkozó vizsgálatainkat azt mondhatjuk, hogy a regeneráció a máj eredeti 
szerkezetének felhasználásával zajlik le, új szöveti struktúrák nem keletkeznek.  
Az úgynevezett primer hepatocita mitogének elızetes májkárosodás nélkül is 
jelentıs hepatocita hiperpláziát képesek elıidézni. Ha a nagydózisú AAF/Ph protokollal 
kezelt állatokat primer mitogénekkel kezelünk, (trijódtironin (T3) vagy ólomnitrát) a 
májsejtek proliferációja elmarad. Ehelyett az ovális sejtek mitotikus aktivitásának 
fokozódását lehetett megfigyelni, melyet nagyon gyorsan, a kezelést követı 48 órán 
belül az ovális sejtek jelentıs részének hepatocita irányú differenciálódása követett 
(VII). A differenciálódás folyamata teljesen megegyezett a fentebb leírt alacsony dózisú 
differenciálódás folyamatával. A hormonkezelt állatok szérumában a bilirubin szint 
szignifikáns csökkenését, illetve a máj szintetikus funkcióját tükrözı protrombin szint 
emelkedését is meg lehetett figyelni, jelezve, hogy a differenciálódásnak szervezet 
szintjén is észlelhetı májfunkció javulás volt a következménye. Annak igazolására, 
hogy a májban hirtelen megjelenı „kis” hepatociták valóban az ovális sejtekbıl 
származnak, az ovális sejteket a hormonkezelés elıtt retrovírussal „jelöltük meg”, mely 
jelzés késıbb a kis hepatocitákban volt fellelhetı. 
Eredményeink azt bizonyítják, hogy a máj ıssejtek részvételével zajló 
regenerációja felgyorsítható. Ez a megfigyelés elvi háttérül szolgálhat a klinikai 
gyakorlatban például fulmináns májelégtelenségben a regeneráció felgyorsítására 
irányuló próbálkozásokhoz. 
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4.2. Tumor indukált angiogenezis (VIII, IX) 
Mint a bevezetıben említettük az anti-angiogenezis terápiák csak részben 
váltották be a hozzájuk fızött reményeket. Ennek egyik oka lehet, hogy a terápiák 
tervezésekor figyelmen kívül hagyták azt a lehetıséget, hogy a tumorok 
vaszkularizációja eltérı mechanizmussal játszódhat le különbözı szervekben, 
szövetekben. (VIII, IX). 
Az elsı angiogenezis modellt Folkman és mtsai. dolgozták ki a 70-es évek 
végén. Megállapították, hogy a tumorok angiogenezis függıek, azaz nem képesek 
növekedni egy bizonyos (1-2 mm) méreten túl, a tápanyagellátást biztosító új erek 
képzıdése nélkül (22). Vizsgálataikban fıleg az újonnan, bimbózással („sprouting”) 
képzıdött erekre koncentráltak, melyekrıl feltételezték, hogy azok a tumorsejtek 
inváziójához hasonlóan növekednek, majd a tumorokba belenıve hozzák létre a 
növekedéshez szükséges tápanyagellátást biztosító érhálózatot. A tumorsejt invázió és 
az angiogenezis közötti hasonlóság abban áll, hogy az angiogenezis elsı lépésében is a 
bazális membrán degradációja következik be, melyet a polarizációjukat vesztett 
endotélsejteknek a kötıszövetbe történı migrációja követ. Az új erek lumenének 
kialakulására ez a modell semmilyen magyarázatot nem tudott adni. Ezzel szemben mi 
korábban egy ettıl eltérı angiogenezis modellt írtunk le, mely szerint az endotélsejtek 
megtartják polarizált állapotukat (a sejtkapcsoló struktúrák nem bomlanak fel az 
endotélsejtek proliferációjának migrációjának megindulásakor) és a bazális membrán 
lokális degradációja után az endotélsejtek egymással párhuzamosan migrálnak, így az 
endotélsejtek között azonnal egy résszerő lumen keletkezik, amely folytonos az eredeti 
ér lumenével.  Az éretlen kapilláris növekedése során folyamatosan történik a bazális 
membrán szintézise és depozíciója. (VIII, IX). 
Itt érdemes egy kis kitérıt tennünk, hogy összehasonlítsuk az általunk leírt 
sprouting típusú angiogenezis valamint májregeneráció során megfigyelt eseményeket. 
A legfontosabb hasonlóság a két folyamat között hogy a kapillárisok és az ovális sejtek 
által felépített csatornák növekedésekor résztvevı sejtek dedifferenciációja nem 
következik be (véleményünk szerint ez a jelenség szövetregeneráció során lezajló 
biológiai folyamatok egy alapvetı törvénye lehet), amiben kulcsszerepet játszik a 
bazális membránnak a migráló sejtek által történı folyamatos felépítése. A bazális 
membrán azonban, mint arra több adat is utal nem a polarizáltság kialakulásában, 
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hanem fıleg a differenciált állapot fenntartásában játszik szerepet (1). Ezt alátámasztja, 
hogy az angiogenezis során a növekvı kapilláris csúcsán migráló endotélsejtek is 
polarizáltak maradnak, feltehetıen az intakt sejtkapcsoló struktúráknak köszönhetıen, 
miközben közvetlen kapcsolatban vannak a kötıszöveti kollagénekkel. Eltérés van 
azonban a két folyamat között abban, hogy a májregeneráció során a növekvı ovális 
sejt-csövek csúcsán elhelyezkedı sejtek sejtkapcsolókkal kötıdnek májsejtekhez (ami 
ebben az esetben is meghatározza a polaritást), tehát a duktusok növekedési iránya a 
májgerendák által többé-kevésbé meghatározott. (Ebben az esetben nem is volt 
megfigyelhetı bazális membrán mentes rész a duktusok májsejtekhez kapcsolódó 
részén, bár meg kell jegyezni, hogy ez a terület kapillárisok esetében is csak 
maximálisan egy sejt hosszúságú volt).  Ezzel szemben a kapillárisnövekedés során, a 
csúcson elhelyezkedı sejtek a kemotaktikus szignálok érzékelésében játszhatnak 
kulcsszerepet. Fontos eltérés a két folyamat között az is, hogy míg a májregeneráció 
esetében a duktusok lumene növekedés során is funkcionális marad, addig az 
angiogenezis folyamata során a lumen kitágulása és a vérkeringés megindulása csak 
egy késıbbi stádiumban, a periciták megjelenése után következik be. Ennek fı oka 
lehet, hogy ezen angiogenezis típusban az erek növekedése intersticiális kollagéneket 
tartalmazó kötıszövetben folyik, így a réslumen kialakulása a szövet mechanikai 
ellenállásának minimálisra csökkentését szolgálja. 
A malignus tumorok vérellátásáért több, egymástól eltérı mechanizmus is 
felelıs lehet. Ezek közül a talán legjelentısebbnek tartható érbimbózás (sprouting) 
fentebb ismertetett két angiogenezis modellje azonban csak azon, fıként primer 
tumorok (melanóma, emlı, vastagbélrák) kiindulási helyeként szereplı szövetek 
esetében érvényes, melyek nagy arányú kötıszöveti kollagént tartalmaznak, ami teret 
biztosít új kapillárisok növekedéséhez.  Az érdenzitás növekedését a fenti tumorok 
estében egy másik mechanizmus, az úgynevezett „intusszuszceptív” angiogenezis is 
biztosíthatja, mely valójában a venulák osztódását jelenti, lefolyásának mechanizmusa 
azonban vitatott.  
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4.2.1.Angiogenezis primer tumorokban 
4.2.1.1. Melanómák vaszkularizációja (X). 
Mint fentebb említettük a melanómák vaszkularizációja esetében a bimbózó 
angiogenezis játszhatja a fı szerepet. Humán melanómák esetében a vaszkularizáltság 
és a prognózis között összefüggést keresı tanulmányokban már korábban leírták, hogy 
a tumor szélén az érdenzitás mindig sokkal magasabb, mint a tumorok belsejében. Saját 
vizsgálataink hasonló eredményt hoztak kiegészítve azzal a fontos megfigyeléssel, 
hogy a vastagabb tumorok belsejében az erek kerülete szignifikáns emelkedést mutatott 
a peritumorális szövethez képest. Érdekes módon a metasztázisok kialakulása és a 
túlélés az intratumorális érdenzitással mutatott szoros összefüggést. Ez a megfigyelés 
megkérdıjelezi az úgynevezett „hot spot”-ok (23) (különbözı tumorok érdenzitásának 
meghatározására alkalmazott módszer, melyek során kiválasztják a 
legvaszkularizáltabb régiót a tumorban és azon belül határozzák meg a látótérre esı 
erek számát) használhatóságát, legalábbis melanómák esetében, a prognózis és az 
érdenzitás közötti összefüggés vizsgálatára. A humán melanómákban megfigyelt 
éreloszlás létrejöttének részletesebb vizsgálatára, egy a humán viszonyokat hően 
visszaadó egér modellt alakítottunk ki, mely során a tumorsejteket intrakután 
(ortotopikusan) oltottuk. Az egér melanóma növekedése során is kialakult a tumor 
alapján a humán tumorokban megfigyelt denz érhálózat, melynek sőrősége a tumor 
belseje felé csökkent. Az egyes régiók érdenzitásának idıbeni változását vizsgálva azt 
tapasztaltuk, hogy a tumor perifériáján az érdenzitás sokkal gyorsabban növekszik, 
mint a peritumorális régióban, azt jelezve, hogy a növekvı tumor a bır eredetileg is 
meglévı ereit az újonnan képzıdött kapillárisokkal együtt inkorporálja. Ezt a 
következtetést alátámasztotta a tumor-stróma határon levı érhálózat szerkezetének 
háromdimenziós analízise is, ami kimutatta, hogy mind a humán mind az egér 
melanómák esetében a kapillárishálózat a daganat felszínével párhuzamos lefutású, 
sőrőn egymás mellett elhelyezkedı kapillárisok kötegeibıl épül fel. A tény, hogy a 
daganatok érstruktúrájának vizsgálatakor radiális lefutású, a tumor centruma felé 
mutató kapillárisokat nem észleltünk, már önmagában bizonyítja, hogy a melanómák 
elsısorban a peritumorális kapillárisfonat bekebelezésével tesznek szert a 
vérellátásukat biztosító érhálózatra. 
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Az érdenzitásnak a tumor belseje felé megfigyelt csökkenése elsısorban annak 
a következménye, hogy a tumor a növekedése során „felhígítja” az inkorporált 
érhálózatot. Az endotélsejtek proliferációjára vonatkozó vizsgálataink kimutatták, hogy 
a tumor belsejében az endotél proliferáció kisebb, mint peritumorálisan, ami szintén 
alátámasztja az érdenzitás ebben a régióban megfigyelt csökkenését. Az érdenzitás 
csökkenésének egy másik nagyon fontos oka lehet, hogy a tumorban megszőnik az erek 
bimbózása, ennek következtében az alacsony szintő endotél proliferáció az erek 
méretének növekedését eredményezi. Az érbimbózás megszőnésének egyik oka, hogy a 
tumorban (melanómák) nem áll rendelkezésre megfelelı extracelluláris mátrix 
(kollagén I) a kapillárisok növekedéséhez, illetve a tumorba került erek bazális 
membrán szerkezetének megváltozása sem teszi lehetıvé a bimbózást. Ez utóbbi 
lehetıségre utalnak azok a megfigyeléseink, melyek szerint a tumor belsejében levı 
erek tumorsejtek általi folyamatos inváziója zajlik, ami az erek körüli koncentrikusan 
elhelyezkedı bazális membrán rétegek kialakulásához vezet, feltehetıen meggátolva 
ezzel a bimbózást. A bazális membrán inváziója azonban szerepet játszhat az erek 
kerületének megfigyelt növekedésében. 
Általánosan elfogadott nézet, hogy az újonnan képzıdött kapillárisok érési 
folyamatának fontos eleme a periciták megjelenése az erek körül (24). Pericita borítás 
nélkül az újonnan képzıdött kapillárisok regressziója figyelhetı meg VEGF illetve 
PDGF megvonását követıen (25). Megfigyeléseink szerint intrakután növekvı 
melanómák esetében mind a peritumorális mind az intratumorális erek pericita borítása 
komplett volt. Ez azt jelenti, hogy a bırben lezajló angiogenezis során, szemben a 
szubkután tumorok esetében megfigyelt angiogenezissel, a periciták rögtön 
megjelennek a bimbózó kapilláriskezdemények körül, így érett kapillárisok kerülnek 
inkorporációra. Bár az általánosan elfogadott, hogy a tumorokban található erek 
szerkezete nagymértékben eltér a normál erekétıl, amit a tumorinváziót elısegítı 
tényezınek tartanak (26), eredményeink alapján azonban melanómák esetében ez a 
jelenség nem lehet az intratumorális érdenzitás és metasztázisképzés közötti 
összefüggés oka. 
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4.2.1.2  Az intusszuszceptív angiogenezis egy új mechanizmusa (XI) 
Megfigyeléseink szerint egerekben növı szubkután oltott kolonrákok esetében 
az angiogenezis fı formája az intusszuszceptív angiogenezis (érosztódás), míg a 
sprouting (bimbózó) típus alig fordul elı.  Ezen daganatok vaszkularizációjának 
vizsgálata során érdekes jelenséget figyeltünk meg. Venulák lumenében úgynevezett 
oszlopok („pillar”) voltak jelen, amelyek erre az angiogenezis típusra jellemzı 
struktúrák (27). Eltérıen azonban az elfogadott pillar szerkezettıl, kezdeti stádiumban 
ezek az oszlopok nem tartalmaztak kötıszöveti sejteket illetve pericitákat, hanem 
kizárólag egy kollagén kötegbıl álltak, melyet endotélsejtek borítottak. Az 
intusszuszceptív angiogenezis elfogadott mechanizmusa szerint a pillar képzıdés elsı 
lépése az érlumen szemközti falainak benyomódása, mely az endotélsejtek 
érintkezéséhez, illetve késıbb a sejtkapcsoló struktúrák reorganizációjához vezet. Arra 
azonban nincs kielégítı magyarázat, hogy mi szolgáltatja az erıt ehhez a folyamathoz.  
Az elfogadott magyarázat erre a jelenségre, hogy perivaszkuláris sejtek nyomják be az 
erek falát, ami erısen megkérdıjelezhetı, hiszen sejtek csak elenyészı mértékben 
képesek nyomóerı kifejtésére. Ezzel szemben több százszor akkora húzóerıt képesek 
kifejteni. Megfigyeléseink szerint azokon a területeken ahol intenzív intusszuszceptív 
angiogenezis zajlott, mindig megfigyelhetı volt az úgynevezett „bridging” is, vagyis 
endotél hidak voltak jelen az érlumenben. Elképzelésünk szerint ezek az endotél hidak 
képesek a kötıszöveti kollagén kötegeket az érlumenen áthúzni. Ezt alátámasztja, hogy 
az oszlopokban található kollagén kötegek mérete szinte teljesen megegyezik a 
kötıszövetben található kötegek méretével. Ezenkívül számos vinkulint tartalmazó 
adhéziós pont található a kollagén kötegek mentén, valamint az oszlopot felépítı 
endotélsejtek nagy mennyiségben tartalmaznak  mikrofilamentumokat, mely struktúrák 
összehúzó erı kifejtésére utalnak. Megfigyelhetık voltak olyan kollagén kötegek is, 
melyek nem teljesen értek végig az oszlopon, egy részük viszont a kötıszövetben 
helyezkedett el, ami szintén arra utal, hogy a kötegek a kötıszövetbıl kerülnek az 
oszlop belsejébe, nem ott szintetizálódnak. Ultrastrukturális vizsgálatok nem mutattak 
ki bazális membránt az endotélsejtek és a kollagén köteg között, az endotélsejtek 
közvetlenül tapadtak a kollagén rostokhoz. Az adhéziós helyek szerkezete különlegesen 
érdekes volt, mivel az egyes kollagén rostok mentén szabályosan számos elektrondenz 
adhéziós pont (~50nm) helyezkedett el, melyeket mikrofilamentumok kötöttek össze. 
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Az oszlopok érése során kötıszöveti sejtek és periciták migrálnak be az oszlopokba, 
amit új kollagén tartalmú mátrix depozíciója, ezáltal az oszlop méretének növekedése 
követ, mely folyamat végül az ér osztódásához vezet. 
 
4.2.2. Angiogenezis metasztázisokban 
4.2.2.1. Glomeruloid testek kialakulása kísérletes agymetasztázisokban  (XII) 
A glomeruloid testek kapillárisokból felépülı, jellegzetes érstruktúrák, amelyek 
nevüket a vese glomerulusaihoz való látszólagos hasonlóságuk alapján kapták. 
Leggyakrabban a központi idegrendszer primer daganataiban és metasztázisaiban 
figyelhetık meg. Elıfordulnak azonban más szövetek tumoraiban is (tüdı-, prosztata-, 
emlırák, melanóma), jelenlétüket pedig összefüggésbe hozták a rossz prognózissal 
(28). Kialakulásuk pontos mechanizmusa nem ismert, de az erek dilatációja, majd az 
ezt követı endotél proliferáció, valamint hídképzıdés, az intusszuszceptív 
angiogenezishez hasonló folyamatra enged következtetni. Legrészletesebben Dvorak és 
mtsai. foglalkoztak a VEGF-A hatására kialakuló glomeruloid testek vizsgálatával 
szubkután- és agyszövetben tumormentes környezetben (29). İk az értágulatot és 
hídképzıdést követıen az endotélsejtek erıteljes proliferációját figyelték meg az 
érfalban mely késıbb a sejtszaporulat érlumenbe való expanziójához vezetett. Ebben a 
fejlıdési stádiumban ugyan megfigyeltek néhány kapilláris lument az eredeti ér 
lumenén belül, de modelljük végül is arra alapozódik, hogy az endotélsejtek elvesztik 
eredeti polaritásukat és a felszaporodott bazális membrán mátrixban tovább osztódva, a 
késıbbiekben nagyszámú új lument képeznek, melyeket periciták vesznek körül.  
Mi a glomeruloid testek kialakulásának egy további, nagyon egyszerő formáját 
írtuk le agymetasztázisokban (XII). Érdekes, hogy a számos felhasznált különbözı 
eredető humán és rágcsáló tumor (tüdırák, melanóma, veserák) megegyezı struktúrájú 
glomeruloid testeket hozott létre. Vizsgálataink kimutatták, hogy a tumorsejtek az 
extravazációt követıen az agykapillárisok bazális membránjához tapadtak és azon 
kiterültek. Már egyes sejtek estében is megfigyelhetı volt az a jelenség, hogy a 
tumorsejtek által befedett kapilláris szegmenseken elıször egy, majd több egyszerő 
csavarulat keletkezett. A tumorsejtek szaporodásuk közben nem távolodtak el a 
kapillárisoktól, hanem annak mentén terjedtek, illetve több rétegben helyezkedtek el a 
kapillárisok körül. A mikrometasztázisok növekedése során, a kapillárisokon képzıdött 
               dc_301_11
 24 
hurkok egyre bonyolultabbak lettek és végül kaotikus, a tumorsejt fészkek belsejében 
elhelyezkedı érgombolyagok alakultak ki. A folyamat magyarázata lehet, hogy a 
kapillárisok bazális membránjához α6 integrin segítségével tapadó és azon kiterült 
tumorsejtek aktin citoszkeletonja a kapillárishurkok kialakulásához vezetı húzóerıt fejt 
ki. Ezt alátámasztja az a megfigyelésünk, hogy a szomszédos tumorsejt fészkek között 
levı kapilláris szakaszok sokszor elvékonyodtak, sıt néhány esetben el is szakadtak. A 
folyamatban nagy szerepet játszhat, hogy az agyszövetben nincs kötıszöveti típusú 
extracelluláris mátrix, így az agyszövet mechanikai stabilitása kicsi, lehetıvé téve a 
kapillárisok elmozdulását. További érdekessége a folyamatnak, hogy az endotélsejtek 
proliferációs indexe nem emelkedik, jelezve, hogy sem bimbózó sem egyéb más 
endotél proliferációt igénylı angiogén folyamat nem zajlik (erre az erek morfológiája 
sem utalt), az érdenzitás növekedése a tumorban kizárólag az agyszövet meglévı 
érhálózatának átrendezıdésével jött létre. 
 
4.2.2.2.  Angiogenezis vizsgálata kísérletes agymetasztázisokban (XIII) 
A fentiekben ismertettük a glomeruloid testek egy lehetséges keletkezési 
mechanizmusát, amihez a tumorsejteket az állatok karotiszába oltottuk. A módszer 
hátránya, hogy nagyszámú mikrometasztázist eredményez, ami gyorsan az állatok 
pusztulásához vezet. Ezért egy másik kísérletsorozatban a tumorsejteket közvetlenül az 
agyszövetbe oltottuk, hogy a tumorok elérjék az angiogenezis megindulásához 
szükséges méretet („angiogenic switch”, 1-2 mm átmérı) (22). Morfometriai 
vizsgálatok azt mutatták, hogy angiogenezis nem zajlik a peritumorális területeken. 
Ezzel összhangban angiogenezis egyszerő sebzést követıen sem volt megfigyelhetı az 
agyszövetben. A tumorok csupán a meglévı erek bekebelezése által tettek szert saját 
érrendszerre. Ezek a megfigyelések szöges ellentétben állnak az elfogadott nézettel, 
miszerint agytumorokban és metasztázisokban valamint érelzáródást követıen intenzív 
angiogenezis tapasztalható a sérülés határterületén. Mindegyik tumor esetében az 
érdenzitás alacsonyabb, emellett az érátmérı, illetve az ereket alkotó sejtek 
proliferációja magasabb volt intratumorálisan, mint peritumorálisan. Ez a már fentebb 
említett jelenségre utal miszerint a tumorok növekedésük következtében az inkorporált 
érhálózatot folyamatosan „kihígítják”. Negatív összefüggést találtunk a bekebelezett 
erek száma, valamint az ereket alkotó sejtek proliferációja között, aminek hátterében az 
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állhat, hogy az alacsony érdenzitású tumorokban az egyes erek felületének nagyfokú 
növelésével jön létre a tumor növekedéséhez szükséges érfelület.   A differenciáltabb 
tumorokban, melyek ún. „pushing” típusú növekedési mintázatot mutattak, alacsonyabb 
volt az érdenzitás, magasabb az erek sejtjeinek proliferációja, szemben az invazív 
növekedési mintázatú tumorokkal. A tumor differenciációs foka tehát hatással van a 
vaszkularizáció mintázatára, azaz nyilvánvaló hogy a kompakt szerkezető (differenciált) 
tumorok inkorporációs képessége alacsonyabb, mint a lazább szerkezető 
differenciálatlanabb tumoroké. A bekebelezett erek amellett, hogy a tumorsejtek 
eltávolították róluk az asztrocitákat, megtartották normál struktúrájukat. Az ér bazális 
membránjával létrejött kapcsolat az emlıkarcinóma sejtek differenciációjához vezetett. 
A tumor szélén a parenchimában mintegy „úszó” izolált sejtek az erek bazális 
membránjával való kölcsönhatást követıen mirigyszerő struktúrákba szervezıdtek 
apikális felszínükön klaudin 3-t és EMA-t expresszáltak, míg bazális felszínükön 
laminin5-öt tartalmazó extracelluláris mátrixot szekretáltak, ami az agykapillárisok 
bazális membránjának felszínéhez kötıdött. 
Az intusszuszceptív angiogenezishez rendkívül hasonló folyamat volt 
megfigyelhetı a fibroszarkóma sejtvonal agymetasztázisaiban. A tumorsejtek érfalhoz 
tapadása ismeretlen módon az érlumen kettéosztását eredményezte, és az így kialakult 
őröket tumorsejtek töltötték meg. Az érhálózat ilyen formában történı átrendezıdése 
azonban nem tekinthetı igazi angiogenezisnek, mivel a folyamat a tumorsejtek 
aktivitásától függ. Érdekes módon sem a sejtvonalak fehérje szintő VEGF expressziója, 
sem az intratumorális VEGF mRNS szintje nem mutatott korrelációt az intratumorális 
erek sejtjeinek proliferációjával. Mindemellett az emelkedett növekedési faktor receptor 
szintek (VEGFR1, PDGFRβ, Tie-2) kapcsolatban állhatnak az erek sejtjeinek 
megnövekedett proliferációjával, illetve a bekebelezett erek struktúrájának 
stabilizációjával.   
Ezek az adatok arra utalnak, hogy kísérletes körülmények között az 
agymetasztázisok növekedéséhez nem szükséges bimbózó (sprouting) angiogenezis. 
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4.2.2.3.  Májmetasztázisok vaszkularizációja (XIV) 
A máj a metasztázisképzés egyik leggyakoribb célszerve. Vermeulen és mtsai. 
három különbözı kolorektális karcinóma metasztázis típust írtak le: „replacement”, 
„pushing” és „desmoplastic” (30). Az elsı metasztázis típusnál a tumor növekedése 
során a máj szinuszoidális szerkezete többé-kevésbé megtartott, de a májsejtek helyét 
tumorsejtek foglalják el.  A második és harmadik típusú metasztázis növekedése során 
a máj szerkezete torzul, a tumorsejtek komprimálják a májszövetet, illetve nagy 
mennyiségő kötıszövet halmozódik fel a metasztázisok perifériáján. 
A „pushing”  típusú metasztázisok vaszkularizációjára egy új mechanizmust 
írtunk le a C38 egér kolonrák tumorvonal esetében (XIV). A májszinuszoidokba 
bejuttatott tumorsejtek szolid fészkeket képeztek, mely struktúrák  avaszkulárisak 
maradtak,  amíg méretük el nem érte az 500-600 µm-t. A tumorok felszínén azonban 
már ekkor megjelentek simaizom aktint kifejezı sejtek, és megkezdıdött a 
szinuszoidok kapillarizációja (fenesztrációk számának csökkenése, α6 integrin 
megjelenése, emelkedett laminin depozíció). A simaizom aktint kifejezı sejtek 
megjelenésével párhuzamosan a májsejtek eltőntek a tumor felszínével szomszédos 
szinuszoidok közül („hátraléptek”), amelynek következtében szinuszoidok fúzióját 
lehetett megfigyelni. Ez a folyamat egy fordított intusszuszceptív angiogenezisnek is 
tekinthetı. Késıbb a simaizom aktint expresszáló sejtek teljesen körbevették a 
fúzionált szinuszoidokat. Ezek a sejtek azonban nem tekinthetık pericitáknak mivel 
nem voltak közvetlen kapcsolatban az endotélsejtekkel és bazális membrán sem volt 
megfigyelhetı körülöttük. 
Felmerül annak a lehetısége is, hogy a kontraktilis sejtek megjelenésének oka a 
növekvı metasztázisok által okozott nyomásnövekedés lenne. Ezt alátámasztja azon 
megfigyelésünk is, hogy epeútlekötést követıen két nappal is hasonló sejtek jelennek 
meg a proliferáló epeutak körül.  A simaizom aktin pozitív sejtek egyrészt elhatárolják 
a metasztázist a környezı májszövettıl, másrészt biztosítják, hogy a keletkezett 
„sérülés” mérete a lehetı legkisebb maradjon. Érdekes, hogy a tumor felszínének 
közelében sem apoptotizált sem nekrotizált májsejteket nem tudtunk megfigyelni, ami 
arra utal, hogy a májsejtek feltehetıen a tumor nyomása valamint a simaizom aktint 
kifejezı és intersticiális kollagént szintetizáló sejtek felszaporodása következtében 
szorultak ki errıl a területrıl.  
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A tumor szferoidoknak csak a felszíni 100 µm-es rétegében voltak élı 
tumorsejtek.   Az egyre növekvı mérető centrális nekrózis feltehetıen megakadályozta, 
hogy a tumor továbbra is gömb formában növekedjék, amely végül azt eredményezte, 
hogy a tumorban jellegzetes szerkezető invaginációk keletkeztek. Az invaginációkat 
kívülrıl a tumor bazális membránja határolta, ennek közvetlen közelében a simaizom 
aktint expresszáló sejtekbe ágyazott fuzionált szinuszoidok helyezkedtek el, legbelül 
pedig májsejtek voltak találhatók. Érdekes, hogy ezen májsejtek között szinuszoidok 
nem voltak megfigyelhetık, ami tovább erısíti annak lehetıségét, hogy a májsejtek 
kimigráltak a szinuszoidok közül és az invaginációk közepén torlódtak fel. Kezdetben 
annak a lehetıségét is felvetettük, hogy a májsejtek epiteliális-mezenchimális 
átalakulása következik be, és ez vezet a májsejtek eltőnéséhez, valamint a simaizom 
aktint expresszáló sejtek megjelenéséhez a tumor perifériáján. Számos közlemény 
bizonyítja ugyanis, hogy például vese- illetve tüdıfibrózis esetében ez az átalakulási 
folyamat lezajlik. Tüdı esetében in vitro és in vivo is kimutatták, hogy II. típusú 
pneumocitákban egyszerre lehet jelen az epiteliális eredetre utaló TTF-1 magi 
transzkripciós faktor és a mezenchimális átalakulásra utaló simaizom aktin (31). Mi 
nem tudtunk azonosítani olyan sejteket, amelyek egyszerre expresszálták volna egy 
májsejtspecifikus transzkripciós faktort (HNF-4) illetve a mezenchimális eredetre utaló 
simaizom aktint, ezért inkább azon egyszerőbb magyarázatot fogadtuk el, hogy a 
simaizom aktint expresszáló sejtek vagy a máj miofibroblasztjainak vagy aktivált Ito 
sejteknek felelnek meg, míg a májsejtek eltőnését más okok („hátralépés”) 
magyarázhatják. 
Az invaginációknak a tumor centruma felé esı részén azonban már csak ritkán 
voltak májsejtek megfigyelhetık, itt a kapillárisok centrális pozíciót foglaltak el. Az 
invaginációk mélyülésével párhuzamosan feltehetıen a tumor által kifejtett nyomás is 
nıtt, fıleg az invaginációk alapjára, ami végül ahhoz vezetett, hogy az invaginációk 
belsı része részlegesen elvált a környezı májszövettıl. A folyamat végül kötıszövetes 
oszlopok kialakulásához vezetett a tumorszövetben. Ezen oszlopokban, melyeket a 
tumor bazális membránja határol, simaizom aktint kifejezı sejtek, nagy mennyiségő 
újonnan szintetizált kötıszöveti kollagén, valamint egy centrálisan elhelyezkedı 
kapilláris található. Kialakulásukhoz azonban szükség volt a tumor bazális 
membránjának úgynevezett „back-to-back” fúziójára, melyet humán kolorektális 
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karcinómák esetében írtak le elıször (32). A képzıdött oszlopok azonban 
tengelyirányban összeköttetésben maradtak a máj szinuszoidális rendszerével, ami a 
vérkeringés fennmaradására utal. Ez a jelenség azt is sejteti, hogy a metasztázisok 
vérellátása szinuszoidális, tehát fıleg vénás eredető. 
Hasonlóan a korábban Lewis lung karcinóma esetében leírtakhoz (IX), a C38 
kolonrák esetében sem figyeltünk meg a tumorok közvetlen közelében elhelyezkedı 
szinuszoidokban emelkedett endotél proliferációt, ami kizárja, hogy érbimbózás folyna 
ebben a régióban. Tekintve azonban a máj szinte maximális vaszkularizáltságát, 
megfelelı tér sem áll rendelkezésre az ilyen típusú angiogenezishez. Érdekes azonban, 
hogy mindkét tumor esetében megindult az endotélsejtek proliferációja az 
inkorporációt követıen, bár a kialakult érszerkezet teljesen eltérı volt. A kolon 
karcinómában található oszlopokban felhalmozódott kötıszövet már elég teret 
biztosított a „sprouting” típusú angiogenezis beindulásához is. 
Vizsgálataink arra utalnak, hogy a tumor differenciációs foka hatással lehet a 
májmetasztázisok vaszkularizációjára.  Alacsonyan differenciált tumorok 
„replacement” típusú növekedést mutatnak. Erre jó példa a Lewis lung karcinóma 
általunk korábban leírt szinuszoidális típusú metasztázisainak vaszkularizációja, 
melynek során a tumorsejtek a szinuszoidális bazális membránok mentén, a Disse 
térben migrálnak és leválasztják az endotélsejteket saját bazális membránjukról, 
aminek következtében kanyarulatos érrendszer alakul ki a metasztázisokban (IX). 
Differenciáltabb tumorok „pushing” típusú növekedést mutatnak. Az érhálózat 
kialakulásában mindkét típusú növekedés során nagy szerepet játszik a módosult 
(fúzionált) májszinuszoidok inkorporációja, mely a primer melanómák és az 
agymetasztázisok esetében megfigyelt jelenségekkel együtt arra utal, hogy a 
gazdaszövet meglévı ereinek inkorporációja, függetlenül a gazdaszövettıl, alapvetı 
szerepet játszik a tumorok vaszkularizációjában.  
Véleményünk szerint a kolon karcinóma esetében lezajló vaszkularizáció egy 
általános érvényő, minden a májban növekvı differenciált tumorra alkalmazható 
modell lehet, az oszlopokat felépítı és a kötıszöveti kollagént szintetizáló simaizom 
aktint és  fibronektin receptort expresszáló sejtek jelenthetnek egy új terápiás célpontot.  
A kolon karcinómában található oszlopokat felépítı simaizom aktint expresszáló sejtek 
nem tekinthetık pericitáknak, valamint a Lewis lung karcinóma metasztázisainak 
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érhálózata is pericita sıt bazális membrán mentes volt, aminek terápiás vonzata is 
lehet, hiszen kimutatták, hogy a pericita borítás nélküli éretlen erek érzékenyebbek a 
különbözı angiogenezis ellenes terápiákra (25). 
 
4.2.2.4. Májmetasztázisok vérellátásának vizsgálata (XV, XVI) 
A májmetasztázisok kezelésének napjainkban is elfogadott módszerei (intra-
arteriális kemoterápia, embolizáció) azon az elven alapulnak, hogy vérellátásuk artériás 
eredető (33). Olyan közlemények is napvilágot láttak azonban, melyek a portális véna 
szerepét hangsúlyozzák a májmetasztázisok vérellátásában (34). Korábban leírtuk a 
vaszkularizáció egy lehetséges folyamatát Lewis lung karcinóma esetében (IX) ami a 
fentebb ismertetett „pushing” típusú metasztázisok vaszkularizációja során tett 
megfigyeléseinkkel együtt azt mutatta, hogy a metasztázisokban található erek 
közvetlen kapcsolatban vannak a szinuszoidokkal.  Ez a jelenség azt sugallja, hogy a 
metasztázisok vérellátása szinuszoidális eredető tehát a tumorok döntı többségükben 
kevert vért kapnak. Ezen megfigyelések lehetséges hatását a májmetasztázisok 
kezelésére egy levélben összegeztük, hangsúlyozva a portális rendszer szerepét a 
kemoterápiás szerek májmetasztázisokba történı eljuttatásában, mely közlésére sor is 
került, de a leírtak nagyobb visszhangot nem kaptak (XV).  
Három tumorvonal esetében végeztük el a májmetasztázisok vérellátásának 
vizsgálatát (XVI). (Lewis lung karcinóma, C38 kolon karcinóma, A2058 humán 
melanóma). Miután a három tumor különbözı növekedési mintázatot mutatott 
kísérleteink során arra is választ kaptunk, hogy a tumor invazivitása milyen módon 
befolyásolja a metasztázisok vérellátását.  
Normál egér mikrovaszkulatúrájának vizsgálata megmutatta, hogy nagyszámú 
anasztomózis található az artériás és a vénás rendszer között, valamint hogy az artériás 
rendszernek minden lebenykéhez általában egy csatlakozópontja van, mely a lebenyke 
alján helyezkedik el. Ezek a csatlakozópontok megtalálhatók mind a nagy portális ágak 
mentén, mind a periférián elhelyezkedı lebenykék esetében. A korróziós 
készítményeken az artériákból a szinuszoidokba ömlı vér piramis formájú struktúrák 
alakjában jelenik meg, melyeknek csúcsa a centrális véna felé mutat. Hasonló 
struktúrákat írtak le korábban a portális rendszer feltöltése során, amelyeket 
mikrocirkulációs alegységeknek neveztek el (HMS, Hepatic Microcirculatory Subunit) 
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(35). Ennek alapján, a megfigyelt struktúrákat arteriális mikrocirkulációs alegységnek 
neveztük el (aHMS). Az arteriális HMS azonban egy virtuális alegység, nem szabad 
tehát figyelmen kívül hagyni azt, hogy bár ezek a struktúrák az arteriális rendszernek 
szinuszoidokkal való közvetlen kapcsolata révén jönnek létre, ezek is kevert vért 
tartalmaznak. Elhelyezkedésük azt mutatja, hogy lebenykének csak egy "szelete" kap 
emelkedett oxigén  koncentrációjú artériás vért, ami egyrészt megkérdıjelezi az artériás 
vér szerepének jelentıségét májsejtek ellátásában, másrészt arra is utal, hogy ezek a 
struktúrák csak az epeutak által elhasznált vér vénás rendszerbe történı eljuttatására 
szolgálnak.  
A májmetasztázisokat vizsgálva azt tapasztaltuk, hogy a metasztázisok 
növekedésük során új erek képzıdése helyett a szinuszoidok fúzióját váltják ki (mely 
folyamatot az elızı fejezetben ismertettünk), és ezek inkorporációja során alakul ki a 
tumorok érhálózata, függetlenül attól, hogy a tumor milyen növekedési mintázatot 
mutat.  A folyamat során az arteriális HMS-ek szinuszoidjainak fúziója is bekövetkezik, 
ami végül az artériás rendszert határoló struktúrák destrukciójához és a metasztázisok 
arterializálódásához vezet. A metasztázisok elméletileg tehát egy lebenykének 
megfelelı méret elérése után már arterializálódnak. Adataink szerint azonban a 
metasztázisok 95%-a csak a 2mm-es méret elérése után arterializálódik, de ebben 
eltérések mutatkoznak a tumorok növekedési mintázatának és a növekedési 
sebességének megfelelıen.  Differenciált és/vagy lassan növekvı tumorok késıbb 
arterializálódnak, de 2,5mm-es méret felett minden metasztázis elsıdlegesen artériás 
ellátású. Az artériás ellátás kialakulása együtt jár a tumorba vezetı artériák 
kitágulásával. Érdekes, hogy az 1,8 mm átmérınél kisebb metasztázisok 85-95%-át 
egyetlen artéria látja el és ezek az artériák nagyrészt a metasztázis centrumában 
helyezkednek el.  Ennek a jelenségnek a hátterében feltehetıen az áll, hogy a növekvı 
tumorok nem képesek, szemben a portális és centrális rendszer ágaival, a nagynyomású 
artériális ágakat komprimálni illetve a tumor perifériájára szorítani. A metasztázis tágult 
véredényrendszere, amelyben feltehetıen az arteriális nyomáshoz közeli nyomás 
uralkodik (prekapilláris záróizom szinuszoid fúzió során történı destrukciója) 
tulajdonképpen egy söntöt képez az artériás és vénás (centrális) rendszer között.  
A fenti eredmények azt mutatják, hogy korábbi nézetünket felülvizsgálni szükséges, 
mert annak ellenére, hogy a máj szinuszoidális rendszere és a tumor vaszkulatúrája 
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között közvetlen kapcsolat van, a metasztázisok nem portális (szinuszoidális) ellátásúak.  
A szinuszoidok fúziójuk következtében csak a metasztázis véredényrendszerének 
kialakításában játszanak szerepet az arteriális HMS-ek inváziója elengedhetetlenül már 
nagyon korán a metasztázisok arterializációjához vezet. A metasztázis centrumában 
elhelyezkedı artéria következtében a vér feltehetıen a metasztázisból kifelé a centrális 
vénák felé áramlik.  Az intra-arteriális kemoterápiák létjogosultsága tehát 
megkérdıjelezhetetlen.  
Összefoglalva, tumor indukált angiogenezis tanulmányozása során tett 
megfigyeléseinket, azt mondhatjuk, hogy hatásos anti-angiogenezis vagy anti-
vaszkuláris terápiák csak akkor lesznek kialakíthatók, ha minden fontos célszerv 
esetében sikerül feltérképezni az alapvetı erezıdési típusokat. 
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4.3. Metasztázisképzés 
4.3.1. Sejtmigráció (XVII) 
A tumorsejtek motilitási képessége alapvetı szerepet játszik a metasztázisok 
kialakulásában (36).  A tumorsejteknek jelentıs távolságot kell leküzdeniük, míg a 
primer tumorból eljutnak az elsı vér- vagy nyirokérig, ahol aztán át kell hatolniuk az 
érfalon (intravazáció). A célszervbe eljutva a kitapadás után újabb migráció, a 
kapilláris falon való áthatolás történik meg (extravazáció), végül a tumorsejt 
megtelepszik a célszerv kötıszövetében. Mint a bevezetıben említettük a bazális 
membránok nagyon fontos szerepet játszanak ezekben a folyamatokban. Számos in 
vitro kísérleti rendszert dolgoztak ki a bazális membránok inváziójának vizsgálatára. 
Ezekben a modellekben azonban legtöbbször nagyon vastag bazális membrán 
komponensekbıl felépített mátrixot használnak, mely jelentısen eltér a bazális 
membrán fiziológiás, gyakorlatilag kétdimenziós szerkezetétıl. Tekintve a bazális 
membrán vastagsága és a tumorsejtek mérete közötti jelentıs eltérést, in vivo a bazális 
membrán inváziójának már kezdeti stádiumában más kötıszöveti mátrix elemek is 
befolyásolni fogják a tumorsejtek viselkedését. A bazális membránok felszíne mentén 
történı migráció kevesebb figyelmet kapott, pedig a jelenség fontos szerepet játszik a 
szövetinvázióban és vaszkularizációban.  
A sejtek kitapadása az extracelluláris mátrixhoz fıképpen integrinek 
segítségével történik. In vitro ezeket a kitapadási helyeket fokális adhézióknak nevezik, 
melyek az integrinek erıteljes aggregációja következtében jönnek létre. A membrán 
citoplazma felöli oldalán találhatók a fokális adhéziók azon komponensei (valamint 
számos más szignáltranszdukciós elem), melyek az integrinek és az aktin citoszkeleton 
közötti összeköttetést biztosítják (37). A ma elfogadott és a tumorsejtek kétdimenziós 
migrációjára is érvényes modell szerint a sejtekben keletkezı erı párhuzamos a mozgás 
irányával. Ez a modell azonban számos jelenséget nem tud magyarázni. 1. Tekintve a 
mozgó sejtek in vitro általánosan megfigyelt legyezı formáját, nem világos, hogy mi 
lesz a sorsa azon nagyszámú adhéziónak, melyek a vezetı lamella élén keletkeznek, és 
mint ismeretes stacionáriusak maradnak a szubsztráthoz képest, miközben a sejt elhalad 
felettük, hiszen a mozgó sejtek hátsó részén általában csak néhány adhézió található. 2. 
A sejtek kontraktilitását aktin kötegek biztosítják, melyek polarizáltan a fokális 
adhéziókban végzıdnek. A migráció során tehát a sejtnek teljesesen át kellene rendezni 
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a citoszkeletonját ahhoz, hogy a sejt elején keletkezett adhéziókhoz tapadó aktin 
kötegek ellentétes irányultsággal tapadjanak ugyanezekhez az adhéziókhoz, amikor a 
sejt már elhaladt felettük. 3. A mozgó sejtekben gyakran figyelhetık meg aktin 
kötegek, melyek a sejt teljes hosszát áthidalják. Az adhézióknak a sejt hátulján történı 
megszőnésekor a vezetı élen található adhézió is szükségszerően megszőnik, hiszen az 
adhéziók létének feltétele, hogy a hozzájuk tapadó aktin kötegek feszültség alatt 
legyenek. Ez a jelenség jelentısen csökkentené a vezetı lamella stabilitását. 
Létezik azonban egy másik sejtmigrációs modell, melyet hal keratociták 
migrációjára dolgoztak ki. Ebben az esetben érdekes módon a legnagyobb erık a 
migráció irányára merılegesek, de a mérések szerint a sejt mozgásáért kisebb közel 
sugárirányú erık felelısek. Ezek a sejtek a mozgásuk során félkör alakot vesznek fel 
melyet hosszabb idejő migráció során is fenn tudnak tartani. A mozgásukra kidolgozott 
kinematikai modell szerint (Graded Radial Extension, GRE modell) ahhoz, hogy a 
sejtek a mozgás során félkör alakjukat megtarthassák, minden, a félkörön található 
pontnak az érintıre merıleges irányban kell elmozdulnia (38). Mivel ez az elmozdulás 
a sejt csúcsától az átmérı felé haladva a szubsztráthoz képest egyre kisebb, a vezetı él 
minden pontja egy görbe vonalat ír le, míg a sejthez viszonyítva a pontok a sejt 
csúcsától a sejt egyenlítıje felé mozognak.  
Humán fibroszarkóma sejtek mozgását vizsgálva bazális membrán mátrix 
(Matrigél) felszínén egy érdekes jelenségre figyeltünk fel (XVII). Meglepı módon a 
kiterülést követıen a tumorsejtek a hal epidermisz sejtekhez hasonlóan mozogtak. 
Mozgó sejtek fokális adhézióit tanulmányozva azt figyeltük meg, hogy adhéziók csak a 
vezetı élen, egy-két sorban, félkör alakban, az sejt peremére merılegesen helyezkedtek 
el. Ezek az adhéziók tartalmaztak minden, a fokális adhéziókra jellemzı komponenst, 
(vinkulin, talin, FAK, α6 integrin), ami nem támasztja alá az adhéziók korábban 
feltételezett érési folyamatát a sejtmigráció során.  
GFP-vinkulint kifejezı humán fibroszarkóma sejtek fluoreszcens video 
mikroszkópiával történı vizsgálata azt mutatta, hogy az adhéziók a sejtmigráció során 
a GRE modellnek megfelelıen elıre és oldalra haladnak, majd elérve a sejt egyenlítıi 
régióját a sejt belseje felé kezdenek csúszni a szubsztrát felszínén, végül eltőnnek a 
sejtben. Ezzel szemben az adhéziók a vezetı élen diszkrét pontok formájában 
keletkeztek néhány mikrométerre a már meglévı adhéziósor elıtt. A mozgó sejtek 
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aktin citoszkeletonját vizsgálva azt figyeltük meg, hogy a nagyobb aktin kötegek a 
mozgásirányra merılegesek, de enyhén ívelt formájúak voltak. (homorú oldaluk 
mutatott a mozgás irányába). Miután az aktin kötegek a sejt szélén elhelyezkedı fokális 
adhéziókhoz tapadnak, és azokon keresztül fejtenek ki erıt a szubsztrátra, a megfigyelt 
ívek összehúzódása nagyon hatékonyan képes elıre mozgatni a sejttestet, amihez 
hozzájárul az is, hogy adhéziók nem voltak megfigyelhetık a sejttest alatt. A mozgás 
során az aktin kötegek ívelt formája a sejtmag tehetetlenségébıl eredı ellenerı 
következtében alakulhat ki. A modellünk szerint a sejt csúcsán mindig újabb adhéziók 
és aktin kötegek képzıdnek, mely utóbbiak folyamatosan nınek, ahogy a sejt elıre 
halad. Az aktin kötegek elrendezıdése arra utal, hogy a szubsztrátra kifejtett erı 
közelítıleg sugár irányú a vezetı élen és ezen erık eredıje felelıs a sejt mozgásáért. 
Modellünk egyszerően képes magyarázni a fibroblasztok mozgására kidolgozott 
modell által felvetett problémákat. 1. Az adhéziók a vezetı élen állandóan 
újraképzıdve, GRE modell által megadott utat követve jutnak el a sejt két széléig. 2. 
Az aktin kötegek irányultságának hirtelen nagymértékő megváltozására nincs szükség, 
hiszen az adhéziók folyamatosan újraképzıdnek a vezetı élen miközben orientációjuk 
feltehetıen az aktin ívek által kifejtett egyre növekvı erı hatására folyamatosan 
változik (0-90 fok). 3. Az adhéziók egyszerre bomlanak le egy-egy aktin köteg végén 
(melyek már elérték a sejt egyenlítıi vonalát), melynek következtében az egész aktin 
köteg is lebomlik. Ez a folyamat nincs hatással a lamella többi adhéziójának és aktin 
kötegének stabilitására. 
A GRE modell, valamint az általunk kidolgozott sejtmozgás modell 
segítségével összefüggést találhatunk a sejtmozgás és a sejtek kiterülésének 
(„spreading”) folyamata között. A kiterülés során a sejtek kör alakúak (adhéziók csak a 
sejt szélén figyelhetık meg), az általuk elfoglalt terület nı, tehát a sejt kerületének 
minden pontja az érintıre merılegesen mozdul el, ugyanakkor ez az elmozdulás a 
sejtmozgással szemben minden irányban egyforma. A kiterült sejtekben is hasonló ívelt 
aktin kötegeket figyelhetünk meg mint a mozgó sejtekben,  azonban ebben az esetben 
az ívek több irányba mutatnak. Az aktin kötegek ívelt formája a többi aktin köteg 
erejének hatására alakul ki, hasonlóan egy kifeszített tőzoltóponyvához. Az összes ív 
által kifejtett erı egyensúlyban van, ami rögzíti a sejtmagot és a többi sejtalkotót. A 
migráció megindulásakor a sejtadhéziók megszőnnek a mozgás irányával ellentétes 
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oldalon, ami az erıegyensúly megbomlásához és a migráció azonnali megindulásához 
vezet.  
Természetesen ez a modell csak a sejtek kétdimenziós mozgását írja le, ami 
ebben a formában nem alkalmazható közvetlenül a sejtek háromdimenziós szövetben 
történı mozgására, egyrészt a sejtek geometriájának másrészt a szubsztrát fizikai 
tulajdonságának megváltozása miatt.  Ezzel összefüggésben Yamada munkacsoportja 
kimutatta, hogy az adhéziók összetétele különbözik a szubsztrát képlékenységétıl 
függıen (39). Merev szubsztrátokon stacionárius sejtekben a sejtek perifériáján 
elhelyezkedı fokális adhéziókban nincs jelen α5 integrin, mely ezen a szubsztráton a 
sejttest alatt található fibrilláris adhéziók komponense, ahol a sejt a fibronektin 
filamentumokhoz kapcsolódik. Ezzel szemben háromdimenziós gélekben megfigyelt 
adhéziókban az elıbb leírt adhéziók összes komponense jelen van. Miután mindkét 
adhézióhoz tapadnak a sejtek mozgásáért felelıs aktin filamentumok modellünk 
érvényességét csak az adhéziók, illetve az aktin filamentumok eloszlásának illetve 
szerkezetének háromdimenziós gélekben történı meghatározása tudná eldönteni. A 
fibroszarkóma sejtek háromdimenziós, merev szubsztráton történı mozgására 
vonatkozó elızetes vizsgálataink során azt tapasztaltuk, hogy ebben az esetben is csak 
egy adhéziósor található a sejtek elején, ami azt sejteti, hogy a modell érvényes lehet 
háromdimenziós mozgásra is.   
 
4.3.2. Extravazáció és szervpreferencia (XVIII, XIX) 
A szervpreferencia problémájának vizsgálatára már a 80-as évek elejétıl kezdve 
próbáltak olyan sejt- és tumorvonalakat kialakítani melyek szervpreferenciát, illetve 
magas metasztatizáló képességet mutattak. Ezek segítségével számos tényezıt 
(sejtadhéziót, migrációt illetve proliferációt befolyásoló faktorok) sikerült ugyan 
azonosítani, de csak néhány olyan fehérjét illetve gént sikerült izolálni, melyek szerepet 
játszanak a szervpreferencia kialakulásában. A területen végzett kutatásoknak újabb 
lendületet adhat Ruoslahti és munkacsoportjának kutatási stratégiája, melyben fág 
könyvtárakban expresszált peptidek különbözı szervek endotélsejtjeihez való 
kitapadását vizsgálják in vivo. Ennek a módszernek a segítségével sikerült izolálni egy 
emlıráksejtek felszínén található proteint, a metadherint, mely felelıs a 
tüdımetasztázisok kialakulásáért (40). Sajnos az endotélsejtek felszínén található 
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ligandját még nem sikerült izolálni.  Egyéb, a tüdı- és csontmetasztázisok kialakulását 
meghatározó receptor-ligand párokat is azonosítottak már, melyek közül a tüdı 
endotélsejtjeinek felszínén található CD26-nak (a molekula enzimatikus aktivitásától 
függetlenül köti a tumorsejtek felszínén található fibronektint), CLCA-1-nek (klór 
csatorna fehérje, mely a tumor sejtek felszínén található α4 integrint köti) illetve a 
CXCR4 kemokin receptor ligandjának a SDF-1-nek a szerepét sikerült bizonyítani a 
metasztázisképzés folyamatában (41-43). Utóbbi ugyan egy a fehérvérsejtek 
kemotaxisát befolyásoló faktor, de már korábban kimutatták, hogy a kemokinek által 
kiváltott endotélsejtekhez történı specifikus kitapadást nem a kemokin grádiense, 
hanem az endotélsejtek által prezentált szolid fázisú kemokin határozza meg (45).  
A tumorsejtek extravazációját tekintve az általánosan elfogadott nézet, hogy 
azok a limfocitákhoz hasonlóan, tekintet nélkül a célszerv endotélsejtjeinek szerkezetére 
egy lépésben hatolnak át az endotélsejteken és a bazális membránon. A helyzet azonban 
ennél sokkal összetettebb, hiszen már a neutrofil leukociták is, mint késıbb látni fogjuk, 
ettıl eltérı módon extravazálnak. A tumorsejtek esetében a helyzet pedig még 
árnyaltabb, hiszen az irodalomban található adatok szerint különbözı tumorvonalak 
tüdıben történı extravazációját vizsgálva a fentebb említetten kívül a tumorsejtek a 
kötıszövetbe való kijutásának még legalább háromféle módja ismeretes. Ezek a 
következık: 1/ a tumorsejtek intravaszkuláris szaporodása, amely folyamat végül az ér 
destrukciójához vezet, 2/ az endotélsejtek retrakcióját követıen a tumorsejttel érintkezı 
bazális membrán számos tumorsejt nyúlvány által történı fragmentációja, amely szintén 
a kapilláris destrukciójához vezet, 3/ a tumorsejtek endotelizációja (endotélsejtekkel 
történı befedése) és az azt követı áthatolás a bazális membránon.  
Mi a Lewis lung tumorvonal extravazációját vizsgáltuk ultrastrukturálisan, 
amelynek során kimutattuk, hogy különbözı szervekben (máj, tüdı, mellékvese, vese, 
agy) a tumorsejtek extravazációja eltérı módon (szervspecifikusan) zajlik le (XVIII). A 
tumorsejtek endotelizációja történik meg tüdıben, májban és részben vesében, míg a 
tumorsejtek egyszerre hatolnak át az endotéliumon és a bazális membránon a 
mellékvesében és az agyban. Az endotelizáció folyamatának kezdeti lépésében az 
endotélsejtek az apikális felszínükrıl nyúlványokat bocsátanak ki, melyek a tumorsejtek 
felszínéhez tapadnak. Ezt követıen a nyúlványok növekedése valamint az endotélsejtek 
retrakciója következik be, mely folyamat a tumorsejtek endotélsejtekkel történı teljes 
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befedéséhez vezet. Ekkor azonban már az endotélsejtek bazális felszíne érintkezik a 
tumorsejtekkel, jelezve, hogy a nyúlvány növekedése során a tumorsejtekkel 
kapcsolatban levı plazmamembrán polaritás váltása történik meg (apikális-bazális).  Az 
endotelizáció fentebb ismertetett folyamata arra utal, hogy az endotélsejtek sokkal 
aktívabb szerepet játszanak az extravazáció folyamatában, mint korábban gondoltuk.  
A nyolcvanas évek elején Liotta és munkatársai foglalkoztak a tumorsejtek 
felszínén található extracelluláris mátrix molekulák metasztázisképzésben játszott 
szerepével (46). Azt tapasztalták, hogy intravénás oltás elıtt a tumorsejteket lamininnal 
inkubálva a tüdımetasztázisok száma megemelkedett. Ultrastrukturális vizsgálatokat 
nem végeztek, így nem ismert, hogy az exogén laminin milyen mechanizmus szerint 
hatott a tumorsejtek extravazációjára. Ezt annál inkább is fontos lenne tudni, mivel 
késıbb kimutattuk, hogy a vizsgálatokhoz használt B16 melanóma egy másik 
variánsának sejtjei endotelizálódnak az extravazáció során (47). Érdekes, hogy az 
idézett munkacsoport vizsgálatait ez irányban nem folytatta, így eredményeik késıbb 
feledésbe merültek. Azonban mint fentebb láthattuk a tumorsejtek által termelt 
extracelluláris mátrix molekulák újabb vizsgálatok szerint is fontos szerepet játszhatnak 
a metasztázisképzésben hiszen fibronektin és kollagén-I mediálhatja a 
tüdımetasztázisok kialakulását az endotélsejtek felszínén található CD26-hoz 
kapcsolódva. Hogy e folyamat során a tumorsejtek endotelizációja lezajlik-e nem 
ismert, de újabban kimutatták, hogy neutrofil leukociták is képesek laminin termelésre 
(48), amely jelentıs szerepet játszhat a leukociták extravazációjában, hiszen ismert, 
hogy ezen sejtek is endotelizálódhatnak a bazális membrán áttörése elıtt (49). Saját, 
még nem publikált adataink szerint az LLT-HH valamint a B16 tumorsejtek jelentıs 
mennyiségő laminint expresszálnak a sejtfelszínen, amely mind az LLT-HH mind a B16 
tumorsejtek tüdıben korábban megfigyelt endotelizációjáért felelıs lehet.  Lamininnel 
bevont mikrogömbök intravénás beoltását követıen azt tapasztaltuk, hogy a 
mikrogömbök endotélsejtekkel történı befedése a tumorsejtekhez hasonló idıbeni 
lefutást mutat tüdıben, bár a mikrogömbök nem kerülnek kapcsolatba a bazális 
membránnal. Ez a jelenség arra utalhat. hogy bizonyos szervekben a tumorsejtek 
extraluminális helyzetbe történı kerüléséhez elegendı az extracelluláris mátrix 
molekulák jelenléte a sejtfelszínen. E feltétel teljesülése annál is valószínőbb, hiszen jól 
ismert, hogy epiteliális eredető tumorok esetében a bazális membrán folytonosságának 
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hiánya nemcsak az emelkedett degradáció illetve csökkent szintézis eredménye, hanem 
a helytelen depozició is, amely magában foglalja annak lehetıségét, hogy a tumorsejtek 
felszínükön bazális membrán komponenseket hordozzanak inváziójuk során és az 
intravazációt követıen.  Ezzel szemben laminin szerepét a tumorsejtek kitapadásában 
Mushel és munkacsoportja abban látja, hogy a tumorsejtek a tüdı endotéliumában 
normális körülmények között is elıforduló résekhez tapadnak a laminin 5 kötı α3β1 
integrin segítségével (50).  Mi nagyszámú tumorsejtet vizsgáltunk ultrastrukturálisan 
több sejtvonal esetében, de a tumorsejtek kezdeti kitapadása mindig intakt endotél 
réteghez történt. 
Az LLT-HH tumorsejtek endotelizációját követıen a tüdıben a bazális membrán 
lokális degradációja következett be. A tumorsejtek a keletkezett 1-2 µm mérető résen 
keresztül a kötıszövetbe migráltak. A máj szinuszoidjaiban nem található jól strukturált 
bazális membrán, egyes komponensek amorf formában vannak jelen a májsejtek 
mikrovillusai között (Disse tér). Itt nem is figyeltük meg a tüdı, a mellékvese és az agy 
esetében elıforduló jellemzı morfológiájú a bazális membrán kis résén átmigráló 
tumorsejteket. Ehelyett itt a tumorsejtek az endotelizáció után alakváltoztatás nélkül 
mintegy belesüllyedtek a májsejtekbe (XVIII).  
Az extravazáció intravitális és ultrastrukturális vizsgálatából származó 
megfigyelések legnagyobb része arra utal, hogy a tumorsejtek többsége a célszervbe 
való bejutást követıen a kapillárisokban mechanikusan, a kapilláris és a tumorsejt 
méretébıl adódó különbség miatt akad el. Ez a mechanikai stressz a tumorsejtek 
nagymértékő pusztulásához vezet, ami egyik fı oka a metasztázisképzés megfigyelt 
alacsony hatékonyságának. Érdekes, hogy ezt a széles körben elfogadott elméletet 
korábban megkérdıjelezte Chambers és munkacsoportja, akik szerint minden a 
célszervbe bejutott sejt extravazál, és életképes marad (alvó tumorsejtek) (51). Mi nem 
osztjuk ezt a nézetet, és bár részletes kvantitatív analízist nem végeztünk, több 
tumorvonal extravazációjának ultrastrukturális vizsgálata azt mutatta, hogy a tüdıben 
fellelhetı tumorsejtek száma az idı elırehaladtával egyértelmően csökken. A 
tumorsejtek a célszerv kapillárisaiban történı mechanikus elakadását több 
munkacsoport is megkérdıjelezte, sıt eredményeik szerint a tumorsejtek a tüdıben a 
már nagyobb arteriolákban kitapadnak az érfalhoz és nem extravazálnak, ehelyett a 
metasztázisok a tumorsejtek intravaszkuláris növekedése útján alakulnak ki (52). Ez az 
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elképzelés ellentétben áll a mi megfigyeléseinkkel, hiszen az LLT-HH és négy további 
tumorvonal sorsának a tüdıben történt ultrastrukturális vizsgálata azt mutatta, hogy a 
tüdıkapillárisokban túlélı tumorsejtek az oltást követı egy napon belül extravazálnak. 
Az LLT-HH tumorvonal esetében azt tapasztaltuk, hogy a tumorsejtek szinte kizárólag 
kapillárisokban akadtak el jelezve, hogy ezen tumorvonal esetében, a leukociták 
végleges adhézióját megelızı és a tumorsejtek esetében is vizsgált úgynevezett 
„rolling”, nem játszik jelentıs szerepet az endotélsejtekhez történı kitapadásban.  
Korábbi B16 melanóma sejtekkel végzett vizsgálataink azt mutatták, hogy ezek a sejtek 
képesek voltak kitapadni arteriolákban, de ennek során a tumorsejtek kezdetben nem 
kerültek kapcsolatba az endotélsejtekkel, mivel a tumorsejtek trombusok belsejében 
helyezkedtek el, tehát a kitapadást nem a tumorsejtek, hanem a trombus alkotóelemei 
mediálták (47).  A nagyobb erekben való kitapadási hajlam mögött feltehetıen, a B16 
tumorvonal erısebb véralvadást indukáló képessége rejlik. Meg kell azonban jegyezni, 
hogy több tumorvonal esetében is megfigyeltük, hogy az oltást követıen nagy számban 
keletkeznek olyan trombusok melyek nem tartalmaznak tumorsejteket. Ezek és a 
tumorsejteket is tartalmazó trombusok endotelizációja (mely folyamat a trombus 
szervülésének elsı lépése) hasonlóképpen zajlott le, a trombusok sokszor több 
endotélsejt részvételével feltehetıen a trombus alkotóelemeinek (fibrin, fibronektin) 
hatására, mintegy fagocitálódtak. Feltehetı, hogy az endotelizáció jelensége a tüdı és a 
máj esetében egy olyan védekezési mechanizmus része, amely minden szilárd fázisú 
anyagnak a keringésbıl történı eltávolítására szolgál, és amelyet a tumorsejtek 
felhasználnak a keringésbıl történı minél gyorsabb kikerülésre.  
Korábban kimutattuk az intézetünkben izolált magas metasztatizáló képességő 
Lewis lung tumorvonal úgynevezett „látens” májpreferenciáját (53). A kifejezés arra 
utal, hogy a szervpreferencia csak az arteriális rendszerbe történı oltást követıen 
nyilvánult meg. A metasztázisok látszólag ebben az esetben is a mechanikus elméletnek 
megfelelıen az elsı elért szerv(ek)ben képzıdnek, azonban különösen a májban, de a 
mellékvesékben is, a lökettérfogati arányokat  messze meghaladó gyakorisággal 
alakultak ki metasztázisok. Ezzel szemben, a tumorvonal agy, de izom, bél, bır 
esetében is negatív preferenciát mutatott. Mint fentebb említettük a metasztázisképzés 
hatékonysága nagyon alacsony, amelynek fı oka a tumorsejtek mechanikus és 
immunológiai hatásokra bekövetkezı pusztulása lehet, így döntı jelentıséggel bírhat, 
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hogy a tumorsejtek mennyi idıt töltenek el ellenséges környezetben az extravazációt 
megelızıen. Vizsgálataink azt mutatták, hogy az extravazáció a leghamarabb a májban 
és a mellékvesékben zajlik le (6 óra) mely szervekre pozitív preferencia mutatkozik, 
míg a leghosszabb idıt a kapillárisokban a tumorsejtek az agyban töltik, mely szervre a 
tumorvonal negatív preferenciát mutat. Miután az extravazáció módja (endotelizáció vs. 
direkt áthatolás az endotélsejteken és a bazális membránon) és a szervpreferencia között 
nem volt összefüggés azt mondhatjuk, hogy a szervpreferencia kialakulásában az 
extravazáció sebessége lehet az egyik meghatározó tényezı (XVIII).  
A szervpreferencia lehetséges okait vizsgálva, ellentétben számos más korábbi 
vizsgálattal, nem találtunk összefüggést a tumorvonal szervkolonizációs képessége és a 
különbözı szervekbıl származó kemotaktikus faktorok által kiváltott migráció között.  
Hasonlóképpen nem volt összefüggés a tumorvonal fagyasztott metszetekhez való 
adhéziós képessége és a májpreferencia között. Megfigyeltük azonban, hogy a 
tumorsejtek a különösen májból származó fagyasztott metszetek esetében elıszeretettel 
tapadtak az erekhez. A metszetek részletes elektronmikroszkópos vizsgálata kimutatta, 
hogy a tumorsejtek a portális venulák és szinuszoidok bazális membránjához tapadtak 
(XIX). Ez a jelenség felvetette annak lehetıségét, hogy az erek bazális membránja 
szerepet játszhat a szervpreferencia kialakulásában. Ennek részletesebb vizsgálatára 
különbözı bazális membrán komponensek elleni antitestekkel (perlekán, laminin, 
fibronektin) kezeltünk egereket intravénásan, majd a szív bal kamrájába oltottuk a 
májpreferenciát mutató LLT-HH tumorsejt vonalat. Azt tapasztaltuk, hogy bár 
mindhárom antitest csökkentette a vese, illetve a laminin és fibronektin elleni antitestek 
a tüdı kolonizációját is, a májmetasztázisok kialakulását csak a perlekán elleni antitest 
volt képes jelentısen gátolni. Tovább vizsgálva a kérdést megállapítottuk, hogy az 
egerek májából izolált nagy molekulasúlyú proteoglikán frakció nem fejt ki 
kemotaktikus hatást a tumorsejtekre. Ezzel szemben perlekán elleni antitest gátolta a 
tumorsejtek adhézióját a májból izolált proteoglikánhoz. Ultrastrukturális vizsgálataink 
azt mutatták, hogy a szinuszoidokban elakadt tumorsejtek az endotélsejtek 
fenesztrációján keresztül nyúlványokat bocsátanak a Disse térbe, ahol nagy mennyiségő 
perlekán található (XVIII). Ezt nem követi ugyan a tumorsejtek migrációja, de a 
jelenség szerepet játszhat a tumorsejtek specifikus kitapadásában vagy specifikus 
növekedési szignálok közvetítésében. Utóbbi megvalósulhat különbözı növekedési 
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faktorok prezentálásában a tumorsejtek számára, illetve a máj bazális membránjában 
jelenlévı perlekán laminin kötı képességén keresztül. Meg kell azonban jegyezni, hogy 
a perlekán mellett más molekulák is szerepet játszhatnak a májpreferencia 
kialakulásában, hiszen csak a máj esetében figyeltünk meg specifikus elektrondenz 
sejtkapcsoló struktúrákat a tumor és endotélsejtek között (XVIII), melyek molekuláris 
összetétele egyelıre ismeretlen.  
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5. Új eredmények. 
 
1. A patkánymáj epeút rendszerének egy új, CK7-/CK19+ kompartmentjét írtuk 
le, mely magába foglalja a Hering kanálisokat is, és a legnagyobb valószínőséggel 
tartalmazza a máj ıssejtjeit. Humán májban ezek a struktúrák CK7 pozitívak, benyúlnak 
a vaszkuláris szeptumba, ahol arteriolák kísérik ıket. Fenotípusuk: EMA-, CD56+, 
CD133+.  
 
2. Az ovális sejtek által képzett struktúrák a Hering kanálisok 
meghosszabbításának tekinthetık. Az ovális sejtek proliferációjuk és migrációjuk során 
folyamatosan bazális membránt szintetizálnak és megtartják polarizált állapotukat.  Az 
általuk alkotott csırendszert funkcionális kapcsolatot biztosít a hepatociták és az epeút 
rendszer portális térben elhelyezkedı elemei között.  
 
3. Az ovális sejtek nem fejezik ki a Thy-1 (CD90) hemopoetikus ıssejt markert, 
tehát megjelenésükben transzdifferenciáció nem játszik szerepet. Thy-1-t a máj 
miofibroblasztjai expresszálják.   
 
4. Az ovális sejtek májsejtekké történı differenciálódása két, hisztológiailag 
jelentısen eltérı módon mehet végbe, a sejtszintő események - melyek legfontosabb 
jellemzıje a bazális membrán eltőnése illetve a HNF4, májsejtspecifikus transzkripciós 
faktor megjelenése- azonban megegyeznek a két folyamat során. Az ovális sejtek 
differenciálódása primer hepatocita mitogén kezeléssel elısegíthetı.  
 
5. Kimutattuk, hogy a humán és kísérletes melanómák beerezıdése a tumor 
felszínén képzıdött kapillárishálózat bekebelezésével megy végbe, ami a 
kapillárisdenzitás csökkenéséhez és az erek méretének növekedéséhez vezet a tumor 
centrum irányában. Humán melanómák esetében az intratumorális érdenzitás bír 
prognosztikus jelentıséggel.  
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6. Az intusszuszceptív angiogenezis egy új formáját írtuk le, melynek során a 
„pillar” képzıdés elsı lépése endotélsejt hidak kialakulása az ér lumenében majd 
kötıszöveti kollagén kötegek transzportja az érlumenen keresztül az endotélsejtek 
segítségével.  
 
7. A glomeruloid test képzıdés egy új formáját írtuk le agyi mikrometasztázisok 
esetében. A folyamat során érdenzitás növekedés a tumorban jelentısebb endotélsejt 
proliferáció nélkül, az agy meglévı kapillárisrendszerének a tumorsejtek által elıidézett 
átrendezıdésével megy végbe.  
  
8. Kimutattuk, hogy kísérletes agymetasztázisok környezetében nem zajlik 
angiogenezis, a tumorok érhálózatukat kizárólag a már meglévı erek inkorporációjával 
hozzák létre.  
 
9. A vaszkularizáció egy új formáját írtuk le jól differenciált kísérletes kolonrák 
májmetasztázisainak esetében. A folyamat lényege a tumor felszínén keletkezı fuzionált 
szinuszoidok inkorporációja.  
 
10. Kimutattuk, hogy a kísérletes májmetasztázisok artériás vérellátásra tesznek 
szert 2mm-es tumor méret felett. Az arterializálódás folyamata a májlebenykék arteriális 
mikrocirkulációs alegységét felépítı szinuszoidok fúziójának és az ezt követı 
inkorporációjának következtében alakul ki.    
 
11. A sejtmozgás egy új mechanizmusát írtuk le in vitro. A sejt folyamatos 
mozgását a vezetı élen folytonosan megújuló, de a mozgás során ív formában haladó 
adhéziós pontokhoz kapcsolódó konkáv aktin kötegek biztosítják.   
 
12. Kimutattuk, hogy az extravazáció folyamata szervfüggı lehet. Az 
extravazáció sebessége, nem módja függ össze a szervpreferenciával.  
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13. Kimutattuk, hogy a Lewis lung karcinóma májpreferenciája mögött 
legnagyobb valószínőséggel a tumorsejtek szinuszoidok heparánszulfát 
proteoglikánjához történı specifikus adhéziója áll.   
 
 
               dc_301_11
 45 
 
6. Az értekezéshez felhasznált saját közlemények 
 
6.1. Májregeneráció 
 
I. Paku S, Dezsı K, Kopper L,  Nagy P. Immunohistochemical analysis of cytokeratin 7 
expression in resting and proliferating biliary structures of rat liver. 
Hepatology 42: 863-870. 2005. 
IF: 9, 792 
 
II. Dezsı K, Paku S, Papp V, Turányi E, Nagy P. 
Architectural and immunohistochemical characterization of biliary ductules in normal 
human liver. 
Stem Cells Dev. 18: 1417-22. 2009 
IF: 4,146 
 
III. Papp V, Dezsı K, László V, Nagy P, Paku S. 
Architectural changes during regenerative and ontogenic liver growth in the rat. 
Liver Transplantation 15: 177-183. 2009. 
IF: 3,751 
 
IV. Paku S, Schnur J, Nagy P, Thorgeirsson SS.  Origin and structural evolution of the 
early proliferating oval cells in rat liver. 
Am J Pathol. 158:1313-1323. 2001. 
IF: 7,103 
 
V. Dezsı K, Jelnes P, László V, Baghy K, Bödör C, Paku S, Tygstrup N, Bisgaard H.C, 
Nagy P. Thy-1 is expressed in hepatic myofibroblasts and not oval cells in stem cell-
mediated liver regeneration. 
Am J Pathol 171:1529-1537. 2007.  
IF: 5,796 
 
               dc_301_11
 46 
VI. Paku S, Nagy P, Kopper L, Thorgeirsson SS. AAF-dose dependent differentiation 
of oval cells into hepatocytes: confocal and electron microscopic studies.  
Hepatology  35: 1353-1361. 2004. 
IF: 10,416 
 
VII. László V, Dezsı K, Baghy K, Papp V, Kovalszky I, Sáfrány G, Thorgeirsson SS, 
Nagy P, Paku S. 
Triiodothyronine accelerates differentiation of rat liver progenitor cells into hepatocytes. 
Histochem Cell Biol. 130:1005-14. 2008. 
IF: 2,320 
 
6.2. Angiogenezis 
VIII.  Döme B, Hendrix MJC, Paku S, Tóvári J, Tímár J.  
Aleternative vascularization mechanisms in cancer. 
Am J Pathol 170: 1-15. 2007. 
IF: 5,796 
 
IX. Paku, S.: Current concepts of tumor-induced angiogenesis. 
Pathol Oncol Res 4: 62-75. 1998. 
 
X. Döme B, Paku S, Somlai B, Tímár J. Vascularization of cutaneous melanoma 
involves vessel co-option and has clinical significance. 
J Pathol. 197: 355-62.  2002. 
IF: 4,563  
 
XI. Paku S, Dezsı K, Bugyik E, Tóvári J, Tímár J, Nagy P, László V, Klepetko W, 
Döme B. A new nechanism for pillar formation during tumor-induced intussusceptive 
angiogenesis.  
Am J Pathol 179: 1573-1585. 2011. 
IF: 5,224 
 
               dc_301_11
 47 
XII. Döme B,  Tímár J, Paku S. A novel concept of glomeruloid body formation in 
experimental cerebral metastases.  
J Neuropathol Exp Neurol 62: 655-661. 2003. 
IF: 5,005 
 
XIII. Bugyik E,  Dezsı K, Reiniger L, László V, Tóvári J, Tímár J, Nagy P, Klepetko 
W, Döme B, Paku S. Lack of angiogenesis in experimental brain metastases.  
J Neuropathol Exp Neurol 70: 979-991. 2011. 
IF: 4,190 
 
XIV. Paku S, Kopper L, Nagy P. Development of the vasculature in “pushing-type” 
liver metastases of an experimental colorectal cancer.  
Int J Cancer 115: 893-902. 2005. 
IF: 4,700 
 
XV. Paku, S., Bodoky, G., Kupcsulik, P., Tímár, J.: Blood supply of tumor metastatic 
hepatic tumors: suggestions for improved delivery of chemotherapeutic agents. 
J Natl Cancer Inst 90: 936-937. 1998. (letter) 
 
XVI. Dezsı K, Bugyik E, Papp V, László V, Döme B, Tóvári J, Tímár J, Nagy P, Paku 
S. Development of Arterial Blood Supply in Experimental Liver Metastases. 
Am J Pathol. 175: 835-843. 2009. 
IF: 5,673 
 
6.3. Sejtmozgás, szervpreferencia 
 
XVII.  Paku S, Tóvári J,  Lırincz Zs,  Tímár F,  Döme B,  Kopper L, Raz A,  Tímár J. 
Adhesion dynamics and cytoskeletal structure of gliding human fibrosarcoma cells: a 
hypothetical model of cell migration. 
Exp Cell Res   290: 246-253. 2003.  
IF: 3,949 
 
               dc_301_11
 48 
XVIII. Paku S, Döme B, Tóth R, Tímár J. Organ-specificity of the extravasation 
process: an ultrastructural study. 
Clin Exp Metastasis.18:481-92. 2001. 
IF: 1,966 
 
XIX. Tóvári, J., Paku, S., Rásó, E., Pogány, G., Kovalszky, I., Ladányi, A., Lapis, K., 
Tímár, J. Role of sinusoidal heparan sulphate proteoglycan in liver metastasis 
formation. 
Int. J. Cancer 71: 825-831. 1997. 
IF: 3.362  
 
 
               dc_301_11
 49 
 
7. Irodalom 
 
1. Bissel M, Hines WC. Why we don’t get more cancer? A proposed role of the 
microenvironment in restraining cancer progression.NATURE MEDICINE 17: 320-
329. 2011. 
2. Senger DE, Davis DE. Angiogenesis. Cold Spring Harb Perspect Biol 3:a005090. 
2011. 
3. Carmeilet P, Jain RK. Molecular mechanisms and clinical applications of 
angiogenesis. NATURE 473: 298-307. 2011. 
4. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M. 
Tumor-associated endothelial cells with cytogenetic abnormalities.CANCER 
RESEARCH 64: 8249-8255. 2004. 
5. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on 
anti-VEGF therapy for cancer. NATURE CLINICAL PRACTICE ONCOLOGY 3: 24-
40. 2006.  
6. Azam F, Mehta S, Harris AL. Mechanisms of resistance to angiogenesis therapy. 
EUR J CANCER 46: 1323-1332. 2010. 
7. Riehle KJ, Dan YY, Campbell JS, Fausto N. New concepts in liver regeneration J 
GASTROENTEROL HEPATOL 26: 203-212. 2011.  
8. Fausto N. Liver regeneration and repair: Hepatocytes, progenitor cells, and stem 
cells.HEPATOLOGY 39: 1477-1487. 2004. 
9. Thorgeirsson SS, Grisham JW. Hematopoietic cells as hepatocyte stem cells: A 
critical review of the evidence.HEPATOLOGY 43: 2-8. 2006. 
10. Gupta GP, Massague J.Cancer metastasis: Building a framework.CELL 127 (4): 
679-695. 2006. 
11. Tarin D. Cell and tissue interactions in carcinogenesis and metastasis and their 
clinical significance. SEMINARS IN CANCER BIOLOGY 21: 72-82. 2011. 
12. Weiss L. Patterns of metastasis. CANCER METASTASIS REVIEWS 19: 281-301. 
2000. 
13. Fidler IJ. Timeline - The pathogenesis of cancer metastasis: the 'seed and soil' 
hypothesis revisited. NATURE REVIEWS CANCER 3: 453-458. 2003.  
               dc_301_11
 50 
14. Das S, Skobe M. Lymphatic vessel activation in cancer. ANN NY ACAD SCI 1131: 
235-241. 2008. 
15. Liotta LA.  Tumor invasion and metastases- role of the basement membrane. 
AMERICAN JOURNAL OF PATHOLOGY 117: 339-348. 1984.  
16. Novikoff PM, Yam A, Oikawa I. Blast-like cell compartment in carcinogen 
induced proliferating bile ductules. AM J PATHOL 148: 409-422. 1996. 
17. Petersen BE, Goff JP, Greenberger JS, Michalopoulos GK. Hepatic oval cells 
express the hematopoietic stem cell marker Thy-1 in the rat. HEPATOLOGY 27:  433–
445. 1998. 
18. Hagood JS, Prabhakaran P, Kumbla P, Salazar L, MacEwen MW, Barker TH, Ortiz 
LA, Schoeb T, Siegal GP, Alexander CB, Pardo A, Selman M.Loss of fibroblast Thy-1 
expression correlates with lung fibrogenesis.AMERICAN JOURNAL OF 
PATHOLOGY 167: 365-379. 2005.  
19. Fuchs E, Tumbar T, Guasch G.Socializing with the neighbors: Stem cells and their 
niche.CELL 116: 769-778. 2004. 
20. Battle MA, Konopka G, Parviz F, Gaggl AL, Yang CH, Sladek FM, Duncan SA. 
Hepatocyte nuclear factor 4 alpha orchestrates expression of cell adhesion proteins 
during the epithelial transformation of the developing liver.PROCEEDINGS OF THE 
NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 
103: 8419-8424. 2006.  
21. Yin L, Sun M, Ilic Z, Leffert HL, Sell S. Derivation, characterization and 
phenotypic variation of hepativ progenitor cell lines isolated from rats.  
HEPATOLOGY 35: 315-324. 2002. 
22. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? 
CANCER RES 46:467-473. 1986. 
23. Hlatky L, Hahnfeldt P, Folkman J.Clinical application of antiangiogenic therapy: 
Microvessel density, what it does and doesn't tell us.  JOURNAL OF THE NATIONAL 
CANCER INSTITUTE 94: 883-893.  2002.  
24. Hellberg C, Ostman A, Heldin CH. PDGF and vessel maturation. 
RECENT RESULTS CANCER RES 180: 103-114. 2010.  
25. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, 
Ullrich A, Vajkoczy P.  Combined inhibition of VEGF- and PDGF-signaling enforces 
               dc_301_11
 51 
tumor vessel regression by interfering with pericyte-mediated endothelial cell survival 
mechanisms.FASEB JOURNAL 17: 338-340.  2003. 
26. Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF.  Heterogeneity of the 
tumor vasculature. Semin Thromb Hemost 36: 321–331. 2010.  
27. Styp-Rekowska B, Hlushcuk R, Pries AR, Djonov V. Intussusceptive angiogenesis: 
pillars against the blood flow. Acta Physiol 202: 213-223. 2011. 
28. Straume O, Chappuis PO, Salvesen HB, Halvorsen OJ, Haukaas SA, Goffin JR, 
Begin LR, Foulkes WD, Akslen LA. Prognostic importance of glomeruloid 
microvascular proliferation indicates an aggressive angiogenic phenotype in human 
cancers.CANCER RESEARCH 62: 6808-6811. 2002.  
29. Stiver SI, Tan X, Brown LF, Hedley-Whyte ET, Dvorak HF. 
VEGF-A angiogenesis induces a stable neovasculature in adult murine brain. 
JOURNAL OF NEUROPATHOL AND EXP NEUROLOGY 63: 841-855 2004.  
30. Vermeulen PB, Colpaert C, Salgado R, Royers R, Hellemans H, Van den Heuvel E, 
Goovaerts G, Dirix LY, Van Marck E. Liver metastases from colorectal 
adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia.J 
PATHOL 195: 336-342. 2001. 
31. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du Bois RM, 
Borok Z.  Induction of epithelial-mesenchymal transition in alveolar epithelial cells by 
transforming growth factor-ss 1 - Potential role in idiopathic pulmonary fibrosis. 
AMERICAN JOURNAL OF PATHOLOGY 166: 1321-1332. 2005.  
32. Hewitt RE, Powe DG, Holland CM, Gray T, Turner DR. Apparent fusion of 
basement membranes in colorectal carcinoma. INT J CANCER 50: 20-25. 1992. 
33. Ong ES, Poirier M, Espat NJ.  Hepatic intra-arterial chemotherapy. ANNALS OF 
SURGICAL ONCOLOGY 13: 142-149. 2006. . 
34. Terayama N, Terada T, Nakanuma Y.A morphometric and immunohistochemical 
study on angiogenesis of human metastatic carcinomas of the liver. 
HEPATOLOGY 24:816-9. 1996. 
35. McCuskey RS: Morphological mechanisms for regulating blood flow through 
hepatic sinusoids. Liver 2000, 20:3-7. 
36. Yamaguchi H, Wyckoff J, Condeelis J. Cell migration in tumors.CURRENT 
OPINION IN CELL BIOLOGY 17: 559-564. 2005.  
               dc_301_11
 52 
37. Mitra SK, Hanson DA, Schlaepfer DD.Focal adhesion kinase: In command and 
control of cell motility.NATURE REVIEWS MOLECULAR CELL BIOLOGY 6: 56-
68. 2005. 
38. Lee J, Ishihara A, Theriot JA, Jacobson K. Principles of locomotion for simple-
shaped cells. Nature 362, 167-171. 1993. 
39. Harunaga JS, Yamada KM. Cell matrix interactions in 3D.  
MATRIX BIOL 30: 363-368. 2011. 
40. Brown DM, Ruoslahti E.Metadherin, a cell surface protein in breast tumors that 
mediates lung metastasis.CANCER CELL 5: 365-374. 2004.   
41. Cheng HC, Abdel-Ghany M, Pauli BU.A novel consensus motif in fibronectin 
mediates dipeptidyl peptidase IV adhesion and metastasis. JOURNAL OF 
BIOLOGICAL CHEMISTRY 278: 24600-24607. 2003.  
42. Abdel-Ghany M, Cheng HC, Elble RC, Pauli BU.Focal adhesion kinase activated by 
beta(4) integrin ligation to mCLCA1 mediates early metastatic growth. JOURNAL OF 
BIOLOGICAL CHEMISTRY 277 (37): 34391-34400.  2002.   
43. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald 
DD, Jin DK, Shido K, Kerns SA, Zhu ZP, Hicklin D, Wu Y, Port JL, Altorki N, Port 
ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D.  VEGFR1-positive 
haematopoietic bone marrow progenitors initiate the pre-metastatic niche NATURE 
438: 820-827. 2005.   
44. Cabioglu N, Sahin A, Doucet M, Yavuz E, Igci A, Yildirim EO, Aktas E, Bilgic S, 
Kiran B, Deniz G, Price JE.  Chemokine receptor CXCR4 expression in breast cancer as 
a potential predictive marker of isolated tumor cells in bone marrow. CLINICAL & 
EXPERIMENTAL METASTASIS 22: 39-46.  2005.   
45. Rot A, von Andrian UH.Chemokines in innate and adaptive host defense: Basic 
chemokinese grammar for immune cells. ANNUAL REVIEW OF IMMUNOLOGY 22: 
891-928. 2004.  
46. Barsky SH, Rao CN, Williams JE, Liotta LA 
Laminin molecular domains which alter metastasis in a murine model. 
J CLIN INVEST 74: 843-848. 1984. 
47. Lapis K, Paku S,  Liotta L.A.Endothelialization of embolised tumor cells during 
metastasis formation.CLIN EXP METAST  6: 73-89. 1988. 
               dc_301_11
 53 
48. Wondimu Z, Geberhiwot T, Ingerpuu S, Juronen E, Xie X, Lindbom L, Doi M, 
Kortesmaa J, Thyboll J, Tryggvason K, Fadeel B, Patarroyo M .An endothelial laminin 
isoform, laminin 8 (alpha 4 beta 1 gamma 1), is secreted by blood neutrophils, promotes 
neutrophil migration and extravasation, and protects neutrophils from apoptosis.  
BLOOD 104: 1859-1866. 2004. 
49. Feng D, Nagy JA, Pyne K, Dvorak HF, Dvorak AM. Neutrophils emigrate from 
venules by a transendothelial cell pathway in response to FMLP. 
J EXP MED 16;187: 903-915. 1998. 
50. Wang H, Fu WL, Im JH, Zhou ZY, Santoro SA, Iyer V, DiPersio CM, Yu QC, 
Quaranta V, Al-Medhi A, Muschel RJ. Tumor cell alpha(3)beta(1) integrin and vascular 
laminin-5 mediate pulmonary arrest and metastasis. JOURNAL OF CELL BIOLOGY 
164: 35-941. 2004.  
51. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, 
Groom AC. Multistep nature of metastatic inefficiency - Dormancy of solitary cells 
after successful extravasation and limited survival of early micrometastases.  
AMERICAN JOURNAL OF PATHOLOGY 153: 865-873.1998  
52. Wong CW, Song C, Grimes MM, Fu WL, Dewhirst MW, Muschel RJ, Al-Mehdi 
AB.Intravascular location of breast cancer cells after spontaneous metastasis to the 
lung.AMERICAN JOURNAL OF PATHOLOGY 161: 749-753. 2002.  
53. Paku S, Rot A, Ladányi A, Lapis K. 
Demonstration of the organ preference of liver selected high metastatic Lewis lung 
tumor cell line. Clin. Expl. Metastasis 7: 599-607. 1989. 
               dc_301_11
 54 
 
8. Köszönetnyilvánítás 
 
Köszönettel tartozom az Isz. Patológiai és Kísérleti Rákkutató Intézet 
igazgatóinak, Lapis Károlynak, Szende Bélának, Kopper Lászlónak, valamint Matolcsy 
Andrásnak, hogy biztosították számomra a szabad és önálló tudományos munkavégzés 
feltételeit. Közülük is kiemelném Lapis Károlyt, aki közel 30 éve a morfológiai 
vizsgálatok és metasztázis kutatás felé terelte figyelmemet és Kopper Lászlót, aki az 
akadémiai munkacsoport megszőnte után lehetıvé tette, hogy továbbra is az intézetben 
folytathassam tudományos munkámat.  Köszönettel tartozom Schaff Zsuzsának, akinek 
a laborjában az elektronmikroszkópos technikákat elsajátítottam.  
Közvetlen munkatársaim közül kiemelném Nagy Pétert és Dezsı Katalint, 
akikkel a májregeneráció, illetve Döme Balázst, Tímár Józsefet és Tóvári Józsefet, 
akikkel az metasztázisképzés és az angiogenezis témakörben dolgoztam együtt és még 
remélhetıleg a jövıben is együtt fogok dolgozni.  
Köszönettel tartozom Neidhard Paweletz-nek, Avraham Raz-nak és Alex Eberle-
nek akiknek a laborjában sok hasznos tudományos tapasztalattal gazdagodtam.  
 
               dc_301_11
LIVER BIOLOGY AND PATHOBIOLOGY
BIOLOGY
Immunohistochemical Analysis of Cytokeratin 7
Expression in Resting and Proliferating Biliary
Structures of Rat Liver
Sa´ndor Paku,1 Katalin Dezso˝,2 La´szlo´ Kopper,2 and Peter Nagy2
Cytokeratins are the largest subfamily of intermediate ﬁlament proteins and include more
than 20 different gene products, which are expressed in an epithelial tissue-speciﬁc manner.
We studied by immunohistochemistry and confocal microscopy the distribution of cytoker-
atin subtypes in the biliary system of adult rat liver. A cytokeratin (CK)19/7 cholangio-
cyte population was observed in the smaller branches of the biliary tree including the canals
ofHering. They proliferated after 2-acetaminoﬂuorene (AAF) administration, although later
the typical oval cells expressed CK7. This observation suggests that cholangiocytes with this
cytokeratin phenotype may harbor adult hepatic stem cells. The CK19/7 cholangiocytes
were not present in the rat liver at birth, but developed postnatally. Similar cell populations
were not observed in human livers. In conclusion, we propose that the CK19/7 pheno-
type may be characteristic for adult hepatic stem cells in rat liver and that these cells are
generated de novo after birth. Supplementary material for this article can be found on the
HEPATOLOGY website (http://www.interscience.wiley.com/jpages/0270-9139/suppmat/index.
html). (HEPATOLOGY 2005;42:863-870.)
The canals of Hering or terminal ductules are tran-sitional structures between the hepatocytes andbile ducts. The cells of these structures are the
primary candidates for the liver-residing adult hepatic
stem cell. This explains the tremendously increased inter-
est for these ductules. Unfortunately, identifying them
unequivocally is not always easy. Several markers exist for
the cholangiocytes, such as OV-1, OV-6 antibodies, and
the histochemical reaction for gamma glutamyltrans-
ferase,1-3 but these reactions decorate all segments of the
biliary tree equally. Therefore, the canals of Hering can be
reliably recognized from their position only by electron-
or confocal microscopy.4 Because the compositions of cy-
tokeratin subtypes are characteristic for cell types, we de-
cided to analyze the distribution of different cytokeratin
ﬁlaments in the liver. Hepatocytes have long been known
to contain CK8 and 18, whereas CK7 and 19 occurs in
the biliary epithelium in addition to 8/18.5,6 A detailed
examination showed a slightly different situation. All the
biliary structures in the adult rat liver contained CK19.
However, CK7 was present only in the larger biliary
ducts, whereas the smaller branches, including the canals
of Hering, were consistently negative. Thus, the stem cell
population of the adult rat liver may be recognized from
the CK19/7 cytokeratin expression. This suggestion
is supported by the preferential proliferation of
CK19/7 cholangiocytes after 2-acetaminoﬂuorene
(AAF) administration.
Materials and Methods
Animal Experiments. Male F-344 rats (160-180 g)
were used for all experiments and were kept under stan-
dard conditions. At least 4 animals were used for each
experimental time point (unless otherwise marked). The
animal study protocols were conducted according to Na-
tional Institutes of Health guidelines for animal care.
AAF/Partial Hepatectomy Experiment. AAF (2
mg/mL suspended in 1% dimethylcellulose) 5 mg/kg was
administered to rats daily for 4 consecutive days by ga-
Abbreviations: AAF, 2-acetaminoﬂuorene; PH, partial hepatectomy; CK, cyto-
keratin.
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vage. Traditional two-thirds partial hepatectomy (PH)
was performed7 on the 5th day, which was followed by 5
additional AAF treatments. Animals were killed at various
times as indicated in the text.
Bile Duct Ligation. The common bile duct was li-
gated, and the animals were killed 2 days after the opera-
tion.
Young Rats. The rats were killed at birth and at 14
and 28 days of age.
Human Samples. Three morphologically normal hu-
man liver specimens were taken from the non-tumorous
part of the liver removed for colorectal tumor metastases.
The experimental procedure was approved by the ethical
committee of our University under the code TUKEB
156/2003.
Morphological Analysis. Frozen sections (10-20m)
were ﬁxed in methanol and were incubated overnight
with a mixture of the primary antibodies (Table 1) and
with appropriate secondary antibodies afterward (Jackson
Immunoresearch, West Grove, PA). All samples were an-
alyzed by confocal laser-scanning microscopy using Bio-
Rad MRC-1024 system (Bio-Rad, Richmond, CA).
BrdU Incorporation. BrdU incorporation was ana-
lyzed on serial sections. Portal tracts were selected on the
CK7 and pancytokeratin stained sections. The same por-
tal tracts were identiﬁed on pancytokeratin-, BrdU-, and
4,6-diamidine-2-phenylindole (DAPI)-stained sections.
BrdU pulse (100 mg/kg) was given 24 hours after the last
AAF dose and 1 hour before killing. The labeling index of
the CK7 negative and positive biliary cells were deter-
mined after 2 days of AAF treatment, using 4 animals and
counting 217 to 555 cells in the CK7-negative and 170 to
396 cells in the CK7-positive compartment. BrdU reac-
tion was performed as described.4
Morphometry. Frozen sections from 3 control rats
(15 m) were stained for CK7, laminin, and pancytok-
eratin. The combination of pancytokeratin and CK7
staining was chosen for these experiments because the
pancytokeratin antibody decorated all the biliary
duct(ule)s and hepatocytes to let us study the connection
between these 2 cell compartments. The portal tracts were
divided into 3 categories according to their CK7 staining:
1. Portal tracts containing no CK7-positive bile
ducts
2. Portal tracts containing ducts stained partially by
CK7 (majority of cells stained positively for CK7 but
negative cells were also present in the duct) beside the
CK7-negative ductules
3. Portal tracts containing large bile ducts stained
completely by CK7 in addition to the structures of the
previous categories. Cells of the large ducts of category 3
stained more brightly for CK7 than the cells of the CK7-
positive ducts in category 2
The smallest diameter of all bile duct(ule)s and portal
veins, present on a given cryosection, was determined,
using the Bio-Rad Lasersharp software.
The total area of the cryosections were determined us-
ing the Olympus Vanox Cue 2 software.
To determine the length of the CK7-negative bile
ductules, series of 15-m thick (15-40 sections) were
cut. A canal of Hering was selected based on its char-
acteristic U-shaped laminin staining. This structure
was followed through the serial sections until it reached
its end, then in the opposite Z direction the bile
ductule was tracked down until it opened into a CK7-
positive bile duct. The length of the ductule was calcu-
lated by multiplying the number of sections in Z
direction by the thickness of the sections and by adding
the extension of the duct in the XY dimensions. Only
those ductules were counted in which both ends could
be identiﬁed with certainty.
Results
Cytokeratin Expression in the Adult Rat Liver.
Because all commercially available cytokeratin subtype
speciﬁc antibodies are monoclonal, their colocalization
can be analyzed only on serial sections. The cytokeratin
antibodies were usually co-stained with a polyclonal lami-
nin antibody, which outlined the blood vessels, bile ducts,
and made orientation on the section easier. The canals of
Hering can be identiﬁed as biliary structures circum-
scribed only partially by laminin-positive basement mem-
brane.
A pancytokeratin antibody reacted with all the cholan-
giocytes as well as hepatocytes, but the staining pattern
was completely different between the 2 cell types (Fig.
1A). The hepatocytes showed faint reticular staining,
whereas there was a strong cytoplasmic reaction in the
Table 1. Primary Antibodies Used for the
Immunohistochemical Studies
Antibody Species Manufacturer Catalog Number Dilution
Pan cytokeratin
FITC labeled
Dako F0859 1:20
Laminin Rabbit
polyclonal
Dako Z0097 1:300
BrdU Mouse
monoclonal
Becton
Dickinson
347580 1:50
CK7 Mouse
monoclonal
Biogenex MU 255-UC 1:50
CK7 Mouse
monoclonal
Dako N7018 1:50
CK19 Mouse
monoclonal
Novocastra NCL-CK19 1:50
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cholangiocytes and they were surrounded by continuous
basement membrane. All the biliary structures labeled by
the pancytokeratin antibody were CK19 positive on a
parallel section (Fig. 1B). However, small biliary struc-
tures remained unstained with 2 different CK7 antibod-
ies, whereas the large bile ducts showed a bright positive
reaction with these antibodies (Fig. 1A). The canals of
Hering, recognized from the U-shaped laminin staining,4
were consistently negative for CK7 albeit they were
stained by CK19 (Fig. 1 A,B). We were curious whether
there are CK7-negative biliary structures in addition to
the canals of Hering and followed 45 CK7-negative
ductules through serial sections derived from 3 different
animals (Table 2). Three main types of these ductules
could be observed (Fig. 2A-F and online Supplementary
Materials for Fig. 2A,C-D):
1. Simple ductules, showing no ramiﬁcations with a
single attachment to hepatocytes (Fig. 2A-B),
2. Ductules divided into generally 2 to 4 branches
(each branch had contact with hepatocyte(s) (Fig. 2C-D),
3. Ductules with attachments to 2 to 4 hepatocytes of
the limiting plate (Fig. 2C-E). Occasionally there were
branching ductules with attachments to more than 1
hepatocyte.(Fig. 2C-D).
The 3 types were represented roughly equally. These
structures never entered into the liver lobule through the
limiting plate. Where there was no contact with the liver
plate, the ductules were covered completely with contin-
uous basement membrane. When these small ductules
joined to larger bile ducts, a clearly recognizable border
was usually present between the CK7-negative ductular
and CK7-positive ductal cells. (Figs. 2B, 3).
Fig. 1. Portal area of a normal adult rat liver; panels A and B are serial sections (10-m distance). Section A was triple labeled for pancytokeratin
(green), CK7 (red), and laminin (blue). For clarity, the localization of pancytokeratin, laminin and CK7, laminin are shown in panels A and A,
respectively. Section B was double labeled for CK19 (green) and laminin (red). Pancytokeratin (A) and CK19 (B) stains equally the small, including
canals of Hering (arrows), and large bile duct(ule)s, whereas CK7 (A) stains only the larger ones. Note that the lower large duct is stained only
partially by CK7 and the upper large bile duct is stained more brightly than the lower one. (Type 3 portal area). Scale bar: 50 m.
Table 2. Morphometric Characteristics of CK7-Negative Bile Ductules
Type of Portal Area
CK7 Negative Bile
Ductules Only
CK7 Negative and Partially
CK7 Positive Bile Duct(ule)s
CK7 Negative. Completely
(and Partially) CK7
Positive Bile Duct(ule)s
Total area 293.4 mm2
Number of portal areas 111 306 53
Diameter of CK7-ductules, mean  SE 7.9 0.8 m 7.4 0.7 m 8.2 0.4 m
Range (n: SD) 4–18 m (193:6.7) 4–17 m (537:6.4) 4–17 m (171:7.9)
Diameter of CK7 ducts NA 13.2 2.2 m 23.5 3.4 m
Range (n: SD) NA 5–33 m (368:11.9) 7–70 m (90: 34.8)
Number of duct(ule)s/portal area 1.74 2.96 4.92
Diameter of portal vein 17.9 1.4 m 25.9 2.9 m 62.6 9.3 m
Length of CK7-ductules, mean  SD 104 66 m
Range (n) 18–315 m (45)
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We also analyzed the size (diameter, length) of the bile
duct(ule)s. The examined portal areas were divided into 3
groups based on the CK7 staining pattern of biliary struc-
tures (Table 2). The portal areas containing only CK7-
negative ductules had the narrowest portal veins. The
diameter of the portal veins was larger alongside the par-
tially CK7-positive ductules and increased further in the
portal tracts with completely CK7-positive bile ducts.
The diameter of the partially and completely positive
ducts correlated with that of the actual portal veins. In-
terestingly, the size of the small CK19/7 biliary
ductules was almost independent of the above parameters
of the portal tract. The standard diameter throughout the
liver and the unique cytokeratin composition may indi-
cate that these structures constitute a well-deﬁned entity
in the biliary system.
Cytokeratin Staining in the Postnatal Developing
Liver. Many bile duct(ule)s were arranged at the periph-
ery of the portal spaces in the newborn rat liver at birth.
All these ducts were surrounded by laminin-positive base-
ment membrane, and the cells were stained by CK19 as
well as by CK7 antibodies (Fig. 4A-B). We could not
identify any CK7-negative biliary structure. The number
of the bile ducts decreased by 14 days of age, but their
cytokeratin composition did not change (Fig. 4C-D).
However, CK19/7 biliary ductules were observed in
the liver of 28-day-old rats (Fig. 4E-F).
Cytokeratin Staining of Proliferating Biliary Cells.
The AAF/PH experiment is an established protocol to
induce oval cell proliferation.8 AAF treatment itself is able
to induce the proliferation of the biliary cells, although
they remain in the periportal space.9 Later, after PH, these
ductularly arranged cells invade the liver lobule and form
the typical oval cell ducts.
Two AAF treatments did not change the cytokeratin
expression compared with the normal liver (Fig. 5A-B),
but the CK7-negative biliary ductules showed more than
3-fold higher proliferative activity than the positive ones
(Table 3). When the oval cells invaded the liver lobule,
after PH, they gained weak CK7 positivity (Fig. 5C-F),
Fig. 2. (A-B) Short bile ductule (type A) having single contact site with the limiting plate (small arrow). The section was triple labeled for
pancytokeratin (green), CK7 (red), and laminin (blue). (A) Single horizontal view of the pancytokeratin staining (37 optical sections taken at 0.4-m
distance). (B) Single optical sections of the CK7 and laminin staining, demonstrating that the ductule is covered by basement membrane as it leaves
the limiting plate, and enters into a CK7 positive duct (large arrow). (C-D) Single horizontal view of pancytokeratin-stained sections. Both views contain
40 optical sections taken 0.4 m apart. (C) Branching (type B) bile ductule. Large arrowheads indicate the branching points. Note the bile canaliculi
(small arrowheads) running toward and entering into the canals of Hering (arrows). (D) Bile ductule (type C) running along the limiting plate ( small
arrowheads). The ductule is connected to hepatocytes at 3 different points (large arrowheads). Before it enters the large duct, it meets another short
ductule, which has only 1 attachment site (arrow). (E) Type C bile ductule connected to the limiting plate at 3 different locations (arrows). The section
is stained for pancytokeratin (green) and laminin (blue). Note that laminin is present only at the connective tissue side of the ductule, where it is
connected to the hepatocytes. It is delineated on both sides by basement membrane (arrowheads) between the attachments. (F) Schematic
representation of the 3 main types of the CK7-negative ductules. On the left, type A ductule with a single attachment to the limiting plate. At the
center, type B ductule with 2 branches each connected to a hepatocyte. On the right, type C ductule has segmental contact with hepatocytes. Types
B and C ductules are interrelated, depending on the length of the branches. Scale bar: 20 m.
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but the staining intensity was obviously weaker than in
the large bile ducts.
Three months after PH, the oval cells disappeared, but
numerous bile duct–like tubules crossing the lobules re-
mained in the liver. These ducts inside the liver lobule
were CK7 negative but reacted with CK19 antibody and
were surrounded by laminin (Fig.5G-H).
Biliary cell proliferation also can be induced by the
ligation of the common bile duct, which results in the
development of tortuous interlobular bile ducts. This re-
action is frequently referred to as “bile duct proliferation.”
All of these well-differentiated bile ducts were CK19/
CK7 positive (Fig. 6). Essentially all of the CK7-negative
ductules disappeared from the livers 48 hours after the
ligation of the common bile duct.
Cytokeratin Staining in the Normal Human Liver.
Three histologically normal adult human liver specimens
were stained for the cytokeratin subtypes. All the biliary
structures were positive for pancytokeratin as well as for
CK7 (Fig. 7) and CK19 (not shown). As opposed to the
rat liver, no CK7-negative biliary cells were observed.
Discussion
Here we report the existence of a CK19/7 biliary
cell population in the adult rat liver. The small biliary
branches including the canals of Hering are composed of
CK7-negative cholangiocytes. These CK7-negative cells
are the precursors of the oval cells, but they are able to
differentiate into CK19/7 biliary cells as well. They
are not present in the liver at birth but are generated de
novo in the postnatal period.
The cholangiocytes are morphologically and function-
ally heterogeneous along the intrahepatic biliary tree.10,11
The canals of Hering are the most distal part of this sys-
tem. Unfortunately, they have no speciﬁc immunophe-
Fig. 3. Serial sections follow a CK7-negative ductule (arrows) as it enters into a CK7-positive interlobular bile duct. The sections were cut at 15-m
distances and triple-labeled for pancytokeratin (green), CK7 (red), and laminin (blue). For clarity, the localization of pancytokeratin and laminin is
shown on pictures 1-8, and CK7 and laminin is shown on pictures 1-8. The ductule is conﬁned throughout its pass to the periportal space. At its
origin, it is partially surrounded by laminin (traditional canals of Hering) (pictures 1-2). It enters into another CK7-negative ductule (picture 2), which
separates into 2 branches as it passes around a vessel leaving the portal vein (pictures 4-6). Under the vessel (picture 7), the branches are joined
and the ductule takes a sharp turn (picture 8), thereby running in the plane of the section, and enters the CK7-positive duct. During its path, the
ductule remains CK7 negative until it reaches an interlobular bile duct (picture 8). Scale bar: 100 m.
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notypic or other morphological marker. They can be
identiﬁed only from their position as an interface between
the hepatocytes and bile ducts.4,12 In all cases, in our
hands these positively identiﬁed structures are negative
for CK7. When the CK7-negative ductules are followed
through serial sections, they do not have continuous con-
tact with the hepatocytes. That is, if we apply strictly the
deﬁnition of the canal of Hering, not all segments fulﬁll
the criteria. These CK7-negative ductules form a func-
tional and anatomical unit, however. Contrary to the tra-
ditional view of the canals of Hering, the CK7-negative
ductules can be long, winding, dividing but uniform-
sized tubules, which have contact segmentally with hepa-
tocytes of the limiting plate collecting the bile from the
canalicular system. Based on this arrangement, we pro-
pose that the CK7-negative biliary ductules, including the
traditional canals of Hering, constitute a special morpho-
logical and functional segment of the biliary system in the
rat liver.
Cytokeratin molecules are extremely labile unless they
can ﬁnd a partner for the assembly of the ﬁlaments. Usu-
ally CK7 and 19 are partners in the cholangiocytes. CK7
protein disappears spontaneously in CK18 null mice,14
and CK19 in this case can be a partner of CK8. That is,
the lack of CK7 does not result in the instability of CK19
in the ductules.
We have previously shown that AAF treatment induces
biliary proliferation in rat and these proliferating cells are
the precursors of later oval cells.9 Because oval cells are
considered the progenies and amplifying compartment of
the hepatic stem cells, the AAF administration can be
regarded as a functional assay for hepatic stem cell activa-
tion. In our experiment, AAF induces the preferential
proliferation of CK7-negative biliary cells. Therefore, we
suggest that the CK19/7 cholangiocytes may harbor
the adult hepatic stem cells in rat. Several “oval” or hepatic
“stem cell” markers exist, such as OV1, OV6, A-6,13 c-
kit,15 but they react with all the cholangiocytes. The
CK19/7 phenotype distinguishes a special segment of
the biliary tree. As far as we know, this cytokeratin com-
position is the most stringent immunophenotypic con-
ﬁnement of the liver-residing adult stem cell
compartment. Stem cells in other organs also have unique
cytokeratin composition.16,17 Marceau18 postulated that
the hepatic stem cells should be CK7 negative and CK14
positive, but we could not reveal any CK14 positivity in
our experimental models (data not shown).
The ligation of the common bile duct induces the pro-
liferation of biliary cells.19 All these bile ducts stain posi-
tively with the CK7 antibody, as well as CK19.
Interestingly, the CK7-negative biliary ductules almost
completely disappear from these livers. Thus, we can con-
clude that BDL induces CK7 upregulation associated
with biliary differentiation of the stem cell population.
The early proliferative ductules were completely nega-
tive in the AAF/PH experimental system. However, the
classical oval cells, after PH, stained weakly. Why the
CK7 protein becomes visible at this step, before it disap-
pears again, is not clear. The CK7 positivity appears when
the bile ducts are rapidly elongating (ontogenic liver de-
velopment, expansion of oval cells, bile duct ligation) and
disappears when their growth is arrested (adult liver, rem-
nants of oval cells). The CK7 negativity is not stable on
Fig. 4. Portal ﬁeld of a newborn (A-B), 14- (C-D), and 28-day (E-F)-old rat liver. Serial sections were double labeled for CK7 (red), laminin (blue)
(A,C,E), and for CK19 (green) and laminin (red) (B,D,F). All the bile ducts and ductules are CK7 and CK19 positive in newborn (A-B) and 14-day-old
(C-D) rat livers regardless of their size. The bile ductules (arrows) of the 28-day-old rat liver (E-F) express CK19 but not CK7. Scale bar: 50 m.
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manipulation; thus, it is not suitable for tracing progenies
of stem cells.
The generation of the adult stem cells is a relatively
neglected ﬁeld of stem cell biology. Two options exist:
either the stem cells are leftover undifferentiated cells
from embriogenesis or they develop de novo. Initial data
favor the second hypothesis.20,21 CK7 is the last cytoker-
atin subtype upregulated during the development of the
biliary system.22,23 Therefore, the CK7-negative cholan-
giocytes might have been left-over, not terminally differ-
entiated cholangiocytes. However, our data, that the
CK19/7 cells are not present at birth but appear in
the liver 4 weeks later, indicate that the adult hepatic stem
cell compartment is generated postnatally. We do not
know whether the presence of CK7 molecules has any
inﬂuence on the “stemness” of this cell population, but
experimental data demonstrate the different behavior of
the cholangiocytes at 3 weeks of age.24 By all means the
disappearance of CK7 might be an indicator for the de-
velopment of stem cell population.
In conclusion, Thiese et al.15 described elongated
CK19 canals of Hering in the human liver (CK7 ex-
pression was not studied). We could not ﬁnd CK19/
CK7 biliary structures in human liver. There is an
additional basic difference between the rat and human
liver. In the normal rat liver, we could never observe the
spreading of the canals of Hering into the hepatic lobule
through the limiting plate. Nonetheless, this was com-
mon in the human specimens studied by Thiese et al.15
We saw similar structures in the rat liver 3 months after
Fig. 5. Distribution of cytokeratins (CK7, CK19) in the AAF/PH exper-
iment. (A-B) Sections of a rat liver treated by 2 doses of AAF (no partial
hepatectomy). (C-H) Sections of rat livers that underwent the AAF
treatment and partial hepatectomy. (C-D) 2 days, (E-F) 6 days, and
(G-H) 3 months after partial hepatectomy. Serial sections were double-
labeled for CK7 (red), laminin (blue) (A,C,E,G), and for CK19 (green) and
laminin (red) (B,D,F,H). Most of the CK19-positive ductules remain CK7
negative after 2 AAF treatments (A-B). Two and 6 days after PH, the oval
cells penetrate the limiting plate and become CK7 positive, although the
expression is weaker than in the interlobular bile duct (arrows) (C-F).
CK19-positive ducts surrounded by laminin staining are inside the lobule
3 months after the beginning of the experiment, but the CK7 staining
disappears (G-H). Scale bar: 50 m.
Table 3. Proliferation of CK7 Negative and Positive
Compartments of the Biliary Tree After 2 Days of AAF
Administration
CK7 Negative Cells CK7 Positive Cells
Total number of cell nuclei
examined
1,384 1,050
Labeling index (%) 6.9 1.8 2.1 0.7*
*P  .05.
Fig. 6. Rat liver 2 days after the ligation of the common bile duct (A).
Serial sections were double labeled for CK7 (red), laminin (blue) (A), and
for CK19 (green) and laminin (red) (B). All “proliferating” bile ducts are
positive for CK7 and CK19. Scale bar: 50 m.
Fig. 7. Human liver (A,A). The section was triple labeled for pancy-
tokeratin (green), CK7 (red), and laminin (blue). For clarity, the local-
ization of pancytokeratin, laminin and CK7, laminin are shown on A and
A, respectively. No CK7 negative ductules are present in the normal,
human liver tissue. Scale bar: 50 m
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the AAF/PH experiment in otherwise normal liver tissue
and thought them the remnants of oval cells, which lost
CK7 expression again. Because Thiese et al. used livers
containing metastatic cancer, the entrance of the small
ductules into the liver lobule may not represent the nor-
mal situation.
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A. Conner for correcting the English language.
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Architectural and Immunohistochemical Characterization of 
Biliary Ductules in Normal Human Liver
Katalin Dezso˝, Sándor Paku, Veronika Papp, Eszter Turányi, and Peter Nagy
The canals of Hering or biliary ductules have been described to connect the bile canaliculi with the interlobular 
bile ducts, and thus forming the distal part of the biliary tree. Studies in the last two decades suggested that the 
cells constructing these ductules could behave as hepatic progenitor cells. The canals of Hering are con! ned 
to the periportal space in the rat, while they have been reported to spread beyond the limiting plate in human 
liver. The distribution of the distal biliary ductules in normal human hepatic tissue has been investigated in our 
recent experiments. We could demonstrate the presence of interlobular connective tissue septa in a rudimentary 
form in healthy livers. The canals of Hering run in these septa in line with the terminal branches of the portal 
vein and hepatic arteries. This arrangement develops in the postnatal period but regresses after early childhood. 
The canals of Hering can be identi! ed by the unique epithelial membrane antigen (EMA)−/CD56+/CD133+ 
immunophenotype. The canals of Hering leave the periportal space and spread into the liver parenchyma along 
rudimentary interlobular septa outlining the hepatic lobules. Our observations re! ne the original architectural 
description of the intraparenchymal portion of the canals of Hering in the human liver. The distinct immuno-
phenotype supports their unique biological function.
Introduction
The existence of a progenitor cell population in the liver has become generally accepted [1,2], and the clinical 
application of these cells have been of tremendous interest 
[3,4]. Today, liver transplantation is the only available cura-
tive treatment for liver failure, either in cirrhosis or in fulmi-
nant liver necrosis. However, the number of available donor 
livers sets the limit for the application of this procedure and 
alternative treatments are being sought. Transdifferentiation 
of bone marrow cells into hepatocytes does not seem to be 
ef! cient enough for clinical application [5–7]. Conversely, 
ef! cient hepatic regeneration has been recorded from the 
endogenous liver progenitor cells in human [8,9].
Most data refer to the canals of Hering as the site of the 
hepatic progenitor cell compartment [1,2,10]. This structure 
was described by Hering as “hepatic capillaries” [11], which 
maintained the link between bile ducts and the hepato-
cyte canalicular system. Later, it had been proposed to be 
the niche for hepatic progenitor cells [12,13]. The niche is a 
special microenvironment, which has a major impact on 
the maintenance and activation of the stem/progenitor cell 
compartment [14]. Therefore, the exact identi! cation and 
characterization of this structure is necessary to understand 
its behavior under normal and pathological conditions.
The canals of Hering are usually shown as short, straight 
ductules at the border of the periportal connective tissue and 
liver parenchyma, but probably this conformation is oversim-
pli! ed. We have recently characterized the hepatic progenitor 
cell niche in rat liver by laser scanning confocal microscopy 
[15]. Long, branching ductules have been observed, strictly 
inside the periportal connective tissue. They had contact with 
the bile canalicular system at the limiting plate. Their unique 
CK19+/CK7− immunophenotype has made their identi! -
cation within the biliary tree easier. However, no CK7− bil-
iary structures could be observed in human liver specimens. 
Furthermore, the canals of Hering have been described to 
spread into the hepatic lobule in the normal human liver [16]. 
These observations suggest that the organization of the canals 
of Hering in human liver is different from the traditional sim-
ple view as well as from the architecture we saw in rat liver.
In our present study, we set out to collect normal human 
liver tissue from individuals of various ages and analyzed 
the architecture and immunophenotype of the biliary 
ductules by confocal microscopy.
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on hepatocytes, they were surrounded by typical U-shaped 
basement membrane (Fig. 2B inset), and the hepatocytes did 
not participate in the composition of the ductules beyond 
these connections. The “empty” space around the ductules 
was ! lled by collagenous matrix (Fig. 2A) and contained 
CD31+ small blood vessels (Fig. 2B), some of which were 
also labeled by the arterial marker NG-2 [17] (Fig. 2C). Taken 
together, confocal analysis of normal human liver revealed 
the deposition of small amounts of extracellular matrix 
between hepatic lobules, with expanding biliary ductules 
and blood vessels. This kind of arrangement of the blood 
vessels was described earlier as the vascular septum [18,19]. 
The small amount of matrix could not be visualized on tra-
ditional histological sections by special stainings on any of 
our liver samples.
Alterations of the hepatic ductules with age
The maturation of the biliary system continues in post-
natal life in humans [20,21], and major changes are also 
observed in rats [15,22]. Therefore, we decided to examine 
the distribution of the canals of Hering in healthy livers of 
individuals of various ages.
Materials and Methods
Normal human liver specimens were collected from 
cadavers of spontaneous premature birth neonates with-
out developmental abnormalities and individuals who died 
suddenly in accidents without morphological signs and 
anamnestic data of any liver disease. (Age and gender of the 
patients: 3 males, 23rd week of pregnancy; 4 females, 23rd 
week of pregnancy; 1 male, 39th week of pregnancy; 2 males, 
3 years; 1 female, 3 years; 1 female, 13 years; 1 male, 20 years; 
1 male, 26 years old.) All autopsies were performed within 
24 h following death. The liver samples were thoroughly 
examined on formalin-! xed, paraf! n-embedded liver sec-
tions with H&E, diastase PAS, Prussian blue, orcein and 
Masson’s trichrome stainings; no ! brosis, ductular reaction, 
or other pathological alterations were observed. Snap frozen 
liver samples were stored at −80°C.
Frozen sections (10–20 µm) were ! xed in methanol and 
were incubated at room temperature (1 h) with a mixture of 
primary antibodies (Supplementary Table 1; Supplementary 
materials are available online at http://www.liebertpub.com/) 
followed by the appropriate V uorescent secondary antibodies 
(Jackson Immunoresearch, West Grove, PA). All samples were 
analyzed by confocal laser scanning microscopy using Bio-
Rad MRC-1024 system (Bio-Rad, Richmond CA).
The procedure has been approved by the ethical commit-
tee of Semmelweis University.
Quantitative analysis of immunohistochemical staining
The livers of two 3-year-old children and the 20-, 26-year-
old adults were used for quantitation. Consecutive frozen 
sections were co-stained for CK7/EMA, CK7/CD56, and CK7/
CD133. The number of CK7-stained structures was deter-
mined. The double-stained structures were counted and the 
results were given as percent of the CK7+ structures.
Results
Distribution of hepatic ductules in the liver 
parenchyma
When sections from the livers of 3-year-old healthy chil-
dren were stained for panCK, CK7, and laminin, hepatic 
ductules surrounded by basement membrane could be 
observed in the parenchyma far from the portal spaces 
(Fig. 1A and 1B). Low power examination revealed that these 
ductules were not randomly arranged. They outlined dimly 
polygonal structures with terminal veins in the centers 
and portal triads at the corners, that is, the classical hepatic 
lobules. When micrographs of 40 serial sections stained 
for cytokeratin-7 were digitally aligned and merged (Fig. 
1C), this kind of perilobular arrangement of the ductules 
was even more obvious. Two other characteristics could 
be observed on this composite image: (i) no CK7+ biliary 
ductules were present inside the hepatic lobules; (ii) the 
ductules at the interlobular border spread until the half of 
the porto-portal distances, which resulted in watershed-like 
empty gaps in the middle of these stretches.
High power examination of individual biliary ductules 
showed that these narrow tubules did really extend beyond 
the limiting plate. The ductules spread in virtual “empty” 
spaces among hepatocytes on cytokeratin antibody stained 
sections (Fig. 1D), where only the epithelial elements of the 
hepatic tissue were decorated. When the ductules terminated 
A B
C D
FIG. 1. Confocal images of normal human liver from a 
3-year-old child. (A and B) Triple labeling for CK7 (red), 
laminin (blue), and pan CK (green). (A) CK7 (red) and lami-
nin (blue) staining. (B) Merged image. Comparing the two 
images, the perilobular arrangement of the laminin-framed 
ductules is clearly discernible. (C) CK7 (green)-stained bil-
iary ductules sharply outline the hepatic lobule when 40 
thick serial sections are merged. Note the “gaps” (arrows) 
halfway of the porto-portal distances. (D) Horizontal view 
of 42 optical sections stained for panCK. Note the numerous 
connections of the bile ductules with the liver parenchyma 
(arrowheads). The collecting bile ductule is running in an 
“empty” space toward the portal area. Scale bars for A and 
B = 500 μm; C = 100 μm; and D = 50 μm.
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39th week of pregnancy. It was mostly outlined by Thy-1-
positive myo! broblasts, but a few CK7+ ductules were also 
present in these septum fundaments outside the portal ! elds 
(Fig. 2E).
The vascular septa and all of its components were mostly 
developed in the livers of young children of the age of 3 
years (Fig. 1A and 1B). The only available liver specimen 
from a 13-year-old girl contained relatively regressed vas-
cular septa, and although all the elements described earlier 
were present in the livers of young adults (20 and 26 years), 
they were more scarce (Fig. 2F).
The portal areas in the liver of immature neonates born 
on the 23rd week of pregnancy were “closed.” There were 
numerous bile ducts in the periportal connective tissue, 
especially at the periphery, as the remnants of the ductal 
plate. However, no signs of vascular septa were seen; no 
matrix deposition, blood vessels, or biliary ductules could 
be observed outside the limiting plate in any of the exam-
ined specimens (Fig. 2D).
Early signs of vascular septum formation could already 
be recognized in a liver sample derived from a fetus of the 
A B C
D E F
FIG. 2. Confocal images of normal human livers from a 
(A and B) 3- and a (C) 13-year-old child. (D–F) hepatic lobules 
in (D) 23- and (E) 39-week-old fetuses and (F) in a 26-year-old 
adult liver. (A) Double staining for CK7 and collagen I. CK7 
(green)-stained perilobular ductules are embedded in rudi-
mentary collagenous matrix (red) in the portal spaces and 
in the interlobular septa. The inset shows the vascular sep-
tum at a higher magni! cation on a different section. (B and 
C) High power view of the “vascular septum.” (B) Laminin 
(blue) surrounded CK7+ (green) ductules are accompanied 
by CD31 (red)-decorated blood vessels (arterioles). The larger 
vessel (arrow) probably represents a terminal branch of the 
portal vein. The inset shows the connection of a ductule on 
the hepatic plate (cannot be seen with this staining); note the 
sharp ending of the U-shaped basement membrane at the 
ducto-parenchymal border (arrowheads). (C) Note the prox-
imity of NG-2+ (red) arterioles to the CK7 (green)-stained 
ductules. The empty laminin (blue) circles (arrows) proba-
bly represent portal vein branches. (D) The portal tracts are 
“closed”; laminin (red) surrounded CK7+ (green) ductules 
are con! ned to the border of the portal space. Note the 
high number of ductules marking the ductogenesis from 
the ductal plate. (E) Thy-1 (red)-stained myo! broblasts ini-
tiate the formation of the interlobular septa with a few CK7+ 
(green) ductules (arrows). The CYP450 (blue) staining shows 
the zonality of the hepatic lobule with a Thy-1-positive ter-
minal vein in the center. (F) Laminin (red) and CK7 (green) 
marked ductules outline the hepatic lobule in the adult liver, 
but they are rarer in the septa than in children (compare with 
Fig. 1C, 1D). Scale bar for A, D, E, and F = 100 μm; and B and 
C = 50 μm.
A B
C D
E F
FIG. 3. Immunophenotypical characterization of the hep-
atic ductules in (A–C) adult and (D–F) 3-year-old livers. (A 
and B) There is a sharp apical epithelial membrane antigen 
(EMA) (red) staining in CK7 (green) and laminin (blue) 
marked bile ducts (arrows) inside the portal space, while 
EMA staining is absent in the small ductules (arrowheads) 
at the periphery. For better visibility of the EMA staining, B 
shows only the red and blue channels. (C) There is an api-
cal CD133 (red) staining in a CK7 (green) marked ductule 
(arrowhead), while this marker is not present in an interlobu-
lar bile duct (arrow). The inset shows the apical CD133 posi-
tivity of ductules. (D) CD56 (red) stains only the small nerves 
(arrowheads) in the portal space, the CK7 (green) and laminin 
(blue) labeled bile duct is negative (arrow). (E) High magni-
! cation of a CK7 (green) and laminin (blue) stained ductule 
within the septum reveals membranous CD56 (red) positiv-
ity (arrowheads). (F) CD56+ (green) bile ductules (arrowheads) 
are attached to hepatocytes (not highlighted by this stain-
ing), are surrounded by laminin-positive (red) U-shaped 
basement membrane (small arrows). The laminin (red)-posi-
tive “empty” structure surrounded by basement membrane 
(large arrow) represents a blood vessel. Scale bar = 50 μm.
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cells. Insofar, most evidence shows that the canals of Hering 
have the highest potential to behave as hepatic progenitor 
cells [1,2,6,13]. Therefore, the accurate architecture of these 
structures is a key issue to understand their behavior under 
normal and pathological conditions.
The canals of Hering were originally described [11] as 
short straight ducts at the limiting plate, which connect 
the bile canaliculi to the interlobular bile ducts. However, 
Theise et al. [16] demonstrated the extension of hepatic 
ductules through the limiting plate into the hepatic lobule. 
Our results con! rm the presence of these structures deep 
in the hepatic parenchyma; moreover, a clear orientation of 
the ductules could be observed on our confocal images. The 
ductules spread into the parenchyma along the porto-portal 
axis. The hexagonal structures outlined by hepatic ductules 
correspond to the classical hepatic lobules. High power 
examination of individual ductules revealed their close cor-
relation with bile canaliculi enabling their drainage.
In addition to former observations [19,24] that venular 
branches are present in vascular septa, we noticed NG-2-
stained arterioles running in line with the ductules. There 
have been speculations about bile ductule escorting hepatic 
arterioles [18,19,25,26,27] but no convincing evidence has 
been published so far. Gouw et al. [19] and van der Heuvel 
et al. [28] emphasize the importance of the microvascu-
lar compartment for the ef! cient regeneration of ductules. 
Since—contrary to several other species—no arterio-portal 
anastomoses exist in the human liver, the presence of arterial 
Immunophenotypic characterization of bile ductules
There are several proposed markers for hepatic progen-
itor cells in human liver (1,2), but most of them did not dis-
tinguish hepatic ductules of the vascular septa from larger 
interlobular bile ducts in our hands. Some of the markers 
(AFP, chromogranin, synaptophysin, DMBT, DLK, CEA, 
CK20, CK14) did not label any biliary structures, while others 
(EpCAM, E-cadherin, CK7, CK19) stained the complete bili-
ary tree (data not shown). Only three markers reacted differ-
entially with bile ducts and ductules. Epithelial membrane 
antigen (EMA) resulted in a very sharp characteristic linear 
apical staining in the interlobular bile ducts. Conversely, it 
was absent in the ductules even on cross sections (Fig. 3A 
and 3B). The staining pattern of CD133 (Fig. 3C) and CD56 
(Fig. 3D, 3E, and 3F) was opposite. In specimens up to the age 
of 3 years, there was a consistent apical CD133 staining in all 
segments of the biliary tree. However, in samples from older 
individuals the staining was strictly con! ned to the small 
ductules of the vascular septa. The distribution of CD56 in 
all specimens was similar to this latter case: it labeled exclu-
sively the small ductules.
Quantitative evaluation of the immunohistochemical 
reactions (Table 1) showed that only a small portion of the 
biliary structures were stained for EMA, and this staining 
was restricted to the periportal area. No such preferen-
tial distribution was noticed with the two other markers. 
Almost all ducts/ductules were decorated by CD133 in the 
livers of the children, while in adulthood the ratio of CD56+ 
and CD133+ ductules were similar. The CK7 antibody 
reacted sometimes with very small bile ductules occasion-
ally appearing as single cells especially along the vascular 
septa. Since the CD56 and CD133 reaction was not as strong 
and diffuse as the CK7, the number of the CD56 and CD133 
ductules was probably underestimated.
Discussion
We have analyzed the architecture of biliary ductules in 
normal human livers and observed them to circumscribe 
the classical hepatic lobules by participating in the forma-
tion of the so-called vascular septa (Fig. 4). This arrangement 
develops in postnatal life and can be most obviously seen in 
early childhood. The hepatic ductules are characterized by a 
unique EMA−/CD56+/CD133+ immunophenotype.
There are several candidates for the liver stem/progeni-
tor cell niche. Kuwahara et al. [10] proposed four structures 
to harbor such cells: the canals of Hering, intralobular bile 
ducts, periductal “null” mononuclear cells, and peribiliary 
hepatocytes. After all, stemness has been proposed to be not 
an entity but function [23] and—depending on the situation—
different cell populations can behave as hepatic progenitor 
Table 1. Immunophenotype of Biliary Structures 
in Normal Liver
Sample CK7+ EMA+ CD56+ CD133+
3 years 100% (1,112) 4.8% 62.9% 96.3%
Adult 100% (1,125) 6.7% 54.4% 59%
Abbreviation: EMA, epithelial membrane antigen.
( ) Total number of counted bile ducts.
CD133, CD56
EMA
CK7
FIG. 4. Schematic representation of hepatic lobule (brown), 
with bile ducts/ductules (green) and accompanying arteri-
oles (red). Note that these structures extend only halfway 
into the porto-portal distances; however, they cover the 
whole “lateral” surface of the lobule. For simplicity, the por-
tal vein branches are not shown.
               dc_301_11
STEM CELL NICHE IN HUMAN LIVER 1421
from HCC proved to be highly tumorigenic and have been 
reported as tumor stem cells [41]. Increased expression of 
CD133 has also been reported in a subset of cholangiocel-
lular carcinomas, which were claimed to have a progenitor 
cell origin [42].
The combined application of these three antibodies pro-
vides an ef! cient tool for the identi! cation of the canals of 
Hering in the normal human liver. Furthermore, the distinct 
immunophenotype of the hepatic ductules supports their 
different biological potential.
In conclusion, we present a re! nement for the widely 
cited architectural description [16,27,43] of the intraparen-
chymal biliary ductules in normal human liver. The canals 
of Hering with escorting vessels are situated in the vascular 
septum and are components of a rudimentary interlobular 
septum. They can be distinguished from larger bile ducts 
by a unique immunophenotype. Better comprehension of 
canals of Hering’s architecture in normal human liver may 
promote our understanding of their behavior in various 
pathological/biological reactions.
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Architectural Changes During Regenerative and
Ontogenic Liver Growth in the Rat
Veronika Papp, Katalin Dezso¨, Vikto´ria La´szlo´, Peter Nagy, and Sa´ndor Paku
First Department of Pathology and Experimental Cancer Research, Semmelweis University,
Budapest, Hungary
Although liver architecture has a major impact on function, morphological aspects of liver growth are relatively neglected. In our
recent experiments, the architectural changes of the rat liver were compared during 2 basic processes: ontogeny and
regenerative liver growth. The hepatic tissue is constructed as structural/functional units, and probably the most established
and well-deﬁned such unit is the classic lobule. The extent and orientation of the lobules are variable in the liver, and this
renders their accurate size determination more difﬁcult. The ﬁlling of the liver vasculature by a colored resin nicely outlined the
surface lobules, enabling an analysis of the alterations of these structures during liver growth. There are 3 structural
components of postnatal physiological liver development: enlargement of the hepatocytes and expansion and multiplication of
the liver lobules. However, the enlargement of the lobules is exclusively responsible for the regenerative liver growth following
partial hepatectomy. The number of hepatic lobules does not change during this latter reaction, but they gain a more complex,
irregular structure. Liver Transpl 15:177-183, 2009. © 2009 AASLD.
Received April 15, 2008; accepted August 18, 2008.
Partial hepatectomy (Phx) along with the subsequent
regenerative response is one of the most studied non-
tumorous growth processes in mammalians. There are
several excellent reviews summarizing the available in-
formation about the regulation of this well-synchro-
nized hyperplastic process.1-3 The dynamics of cell
proliferation/apoptosis are also well documented;
therefore, that was not the object of this study. Unfor-
tunately, our knowledge is much more limited regard-
ing the structural changes,4 so this aspect of the growth
was analyzed in this work. Although this process is
mostly called liver regeneration, in a biological sense it
should be referred to as compensatory hyperplasia be-
cause the resected lobes do not grow back. Instead, the
remaining lobes enlarge as a result of hepatocyte pro-
liferation. The liver size also increases several-fold dur-
ing postnatal life. This growth process has been studied
in several species,5-8 but it has not been compared with
compensatory hyperplasia. The liver has a modular ar-
chitecture.9,10 Although the liver lobules may not be the
true functional units, they are well-deﬁned compart-
ments that build up the liver. Therefore, hepatic growth
can be achieved by an increase in the size and/or num-
ber of lobules. This question was addressed in our re-
cent experiment in rats. The ﬁlling of the hepatic and
portal venous system outlined the lobules on the liver
surface very nicely. Morphometric analysis of the right
lateral liver lobe revealed that the number of liver lob-
ules did not change, but their size increased during
compensatory growth. Conversely, during the studied
postnatal period, the liver grew by enlargement and
multiplication of the lobules. In summary, the adult
liver lobes seem to be constructed with a standard
number of lobules, and the fully developed liver is not
able to form new lobules upon a further proliferative
trigger.
MATERIALS AND METHODS
Experimental Design
Several parameters of the hepatic lobules were mea-
sured in 4-week-old (50 g), 8-week-old (160 g), and
12-week-old (250 g) male F344 rats; in rats 4 weeks
Abbreviations: CTR, control; nd, not determined; Phx, partial hepatectomy; RLL, right lateral lobe.
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(250 g) after Phx at 8 weeks of age (160 g); and at certain
interim experimental points. The schema of the mea-
surements and the number of the investigated rats are
shown on Fig. 1. The animal study protocols were con-
ducted according to the National Institutes of Health
guidelines for animal care.
Liver Regeneration
Traditional, two-thirds Phx11 was performed on rats
weighing 160 g under ether anesthesia. The size of the
liver lobules was measured 1, 2, and 4 days and 1, 2, 3,
and 4 weeks after the operation. The surface lobules of
the right lateral lobe were counted on control rats
(160-g bodyweight) and 2 and 4 weeks after Phx. The
size of the hepatocytes was determined 4 weeks after
the operation.
Physiological Liver Growth
The size of the surface lobules was measured in normal
rats with the following bodyweights: 20, 50, 100, 160,
200, and 250 g. The number of surface lobules was
counted on the right lateral lobe of rats with a body-
weight of 50 or 160 g. The average size of the hepato-
cytes was also measured for rats with a total body-
weight of 50, 160, 200, or 250 g.
Determination of the Size of the Lobules
For outlining the surface liver lobules, a cannula,
washed with heparin, was inserted into the inferior
vena cava. The blood was washed out from the liver with
phosphate-buffered saline through the left ventricle of
the heart. When the ﬂush ﬂuid became colorless, the
vena cava was ligated above the level of the hepatic
veins, and the portal vein was opened. The hepatic
veins and the sinusoids were ﬁlled up through the vena
cava cannula by a ﬂuorescent dye containing polystirol
resin and were monitored by eye with a stereomicro-
scope. The ﬁlling was stopped when the resin ﬁlled up
the central veins and partially ﬁlled the hepatic sinu-
soids on the surface of the liver. At this stage, the
negatives of the interlobular borders were outlined by
the resin. The right lateral liver lobe was removed from
the rats, its weight was recorded, and all further mea-
surements were performed on this lobe.
The lobe was placed onto a wet slide and examined
with a Nikon TE200 inverted microscope. The surface
image of the lobe was captured with a Bio-Rad (Rich-
mond, CA) MRC1024 confocal system (Ex488/
Em520  16 nm). The periportal zone appeared on the
pictures as black areas. Interlobular borders were high-
lighted by a line drawn halfway between the central
veins (along the vascular septa). The approximate cen-
ter of the black areas determined the corners of the
polygon representing the lobules. In cases of neighbor-
ing overﬁlled central veins, the border was determined
by an analysis of the direction of the sinusoids. At the
border zone, the sinusoids changed their direction from
running toward one another other to running along the
border. The circumference and surface area of the lob-
ules were determined with the Image J program.
Counting of the Surface Liver Lobules
In another set of rats, the portal venous system was
ﬁlled with a blue-stained resin in addition to the red
resin–outlined hepatic veins. The blood was removed
from the liver as described previously. The portal vein
was ﬁlled with blue resin until it just entered the sinu-
soids, and this was followed by ﬁlling of the central
veins. This method could not be applied to the determi-
nation of the size of lobules because of the slight en-
largement of the liver. These animals were used to
count the absolute number of liver lobules on the con-
vex surface of the right lateral lobe. Counting of the
lobules was performed by the placement of a mark on
each lobule with an Indian ink pen with a 0.2-mm line
width. The number of portal vein branches around a
central vein was also counted on these specimens.
Hepatocyte Size Determination
Frozen sections from the liver were stained with ﬂuo-
rescein isothiocyanate–labeled pancytokeratin anti-
body (catalog number F0859, Dako, Glostrup, Den-
Figure 1. Schematic represen-
tation of the experimental de-
sign. The upper line illustrates
the time points of experiments
after partial hepatectomy; the
lower illustrates those during
ontogeny. Numbers in parenthe-
ses represent the number of in-
vestigated rats. Abbreviations:
C, CYP450 II E1 expression; H,
hepatocyte size determination;
N, total number of hepatic lob-
ules on the convex surface of the
right lateral lobe; P, portal vein
number around the central vein;
S, size determination (surface
area and circumference) of he-
patic lobules.
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mark; dilution, 1:10), which outlined the cell
membranes of the hepatocytes. The nuclei were stained
with propidium iodide. The circumference and surface
of 50 pericentral hepatocytes were measured in each
liver lobule on 3 randomly selected ﬁelds. The size of
hepatocytes is dependent on their zonal position,12 so
data from different animals are more comparable if they
are referring to a conﬁned compartment, such as the
pericentral zone. Furthermore, the radial orientation of
the pericentral sinusoids makes possible a more exact
determination of the outline of the hepatocyte borders
versus the more irregular arrangement of the periportal
hepatocytes.
Zonality of the Liver Lobules
The right lateral liver lobe was frozen under slight pres-
sure to produce a ﬂat surface for cutting. Frozen sec-
tions were made from the livers of control rats and the
livers of rats 4, 8, and 12 weeks after Phx in a plane
parallel with the surface. The section was ﬁxed in meth-
anol (20°C) and stained for CYP450 II E1 (catalog
number BV-3084-3, MBL, Woburn, MA; dilution,
1:100) for an hour at room temperature, and the reac-
tion was visualized by a ﬂuorescein isothiocyanate–
labeled secondary antibody (30 minutes at room tem-
perature). The sections were counterstained with pro-
pidium iodide.
Statistical Analysis
Statistical analysis was performed with the Student t
test.
RESULTS
Morphometric Analysis of the Surface Liver
Lobules During Liver Regeneration
The partial ﬁlling of the central veins and liver sinusoids
through the hepatic veins outlined the lobules on the
liver surface. This image was captured with a micro-
scope, and the lobule borders were drawn on the digi-
talized image (Fig. 2A-C). Phx was performed on young,
adult rats (8 weeks old, 160-g bodyweight), which are
optimal for this procedure. All the investigated param-
eters of the livers were compared to the values mea-
sured on the right lateral lobe of unoperated rats (con-
trols, 160 g). Both the circumference and surface area
of the lobules grew gradually during the regenerative
growth of the right lateral liver lobe. Both parameters
increased rapidly in the ﬁrst 7 days, and this was fol-
lowed by a slight but not signiﬁcant increase in the
upcoming 3 weeks. Finally, the average lobular circum-
ference increased 1.51-fold and the surface area in-
creased 2.3-fold during our observation period. The
weight of the studied lobe was also recorded, and it
grew 3.29-fold (Fig. 3A). The number of liver lobules on
the convex surface of the right lateral lobe was also
counted in 160-g unoperated control rats and at 2 se-
lected time points during regeneration. It did not show
any signiﬁcant alterations (Table 1). In brief, the liver
grew by the enlargement of the liver lobules, whereas
their number did not change.
However, the architecture of the enlarged lobules
showed some characteristic changes. The images of the
central veins on the liver surface became elongated and
more branched. The shape of the lobules became more
variable and polygonal. This observation was supported
by the increased number of portal vein branches
around the central veins (Fig. 4A-D and Table 1). The
CYP II E1 enzyme showed a typical zonal distribution in
the liver lobule.13 It was preferentially expressed by the
pericentral and midzonal hepatocytes. The positive
cells were surrounded by an evenly broad band of the
negative cells in the control liver. The immunostaining
of this enzyme showed a peculiar, arborescent distribu-
tion in the regenerated liver throughout our 3-month
observation period, demonstrating the permanent
functional modiﬁcation of the lobular structure (Fig.
4E,F).
Structural Characterization of Postnatal Liver
Growth
In order to compare the regenerative/hyperplastic
growth response of the liver lobules with the physiolog-
ical, ontogenic liver growth, similar measurements were
performed on the livers of rats of various ages. All these
studies were also conﬁned to the right lateral liver lobe.
Figure 2. Retrograde ﬁlling of the hepatic sinusoids through
the terminal (central) veins with green ﬂuorescent resin: (A-C)
2, 4, and 28 days after partial hepatectomy and (D-F) livers of
rats with bodyweights of 50, 160, and 250 g. The lobular
borders (red lines) are shown in parts B and E. Note the en-
largement of the lobules with increasing time (after partial
hepatectomy) and age. Scale bar: 1 mm.
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Similarly to the regenerative growth, the enlargement of
the hepatic lobules was recorded with age (Fig. 2D-F).
Although the bodyweight of the rats increased from 20
to 250 g (12.5-fold), the weight of the studied lobe in-
creased 11.27-fold. The average surface area of the lob-
ules increased 5.16-fold, and the circumference in-
creased 2.68-fold. Additionally, the number of surface
lobules also increased by approximately 30% (Table 1)
while the bodyweight changed from 50 to 160 g (Fig.
3B). It is important to emphasize that the absolute
values of these parameters are not comparable to those
of the hepatectomized rats because the studied lobe
represents a much smaller portion of the whole liver
than that in the other experimental model.
Alteration of Hepatocyte Size During Liver
Growth
Expansion of the lobules can be a result of hepatocyte
enlargement. Therefore, the size of these cells was also
measured. Indeed, obvious hepatocyte enlargement
could be observed in the rats while the bodyweight
increased from 50 to 160 g (Fig. 5). The average hepa-
tocyte surface area grew 1.66-fold, and the circumfer-
ence grew 1.29-fold. The weight of the investigated lobe
increased 2.9-fold during this period. The size of the
hepatocytes slightly but statistically not signiﬁcantly
increased further during ontogeny. Although the inves-
tigated lobe grew more than 3-fold during the regener-
ation, the size increase of the hepatocytes did not reach
a signiﬁcant level (Figs. 5 and 6) in that model either.
DISCUSSION
We have investigated the size of the surface liver lobules
in 2 different liver growth models: during the regener-
ative response following Phx and during physiological
postnatal liver growth. The liver grew exclusively by
enlargement of the hepatic lobules during regeneration.
Conversely, an increase in the number and size of the
lobules contributed to the postnatal liver growth of on-
togeny.
The liver tissue has a modular architecture.9,10 There
is relatively little information available about the behav-
ior of these modules during hepatic growth. There are
still ongoing debates about the real functional unit of
the liver.14 This issue was not addressed by these ex-
periments. We chose to study the classic liver lob-
ule15,16 because it is widely used and can be deﬁned
even in species (eg, in rat) in which it is not surrounded
by interlobular connective tissue septa. However, the
examination of these lobules is not an easy task, and
this may be the explanation for the fact that the model
of liver regeneration was described almost a century
ago, but what happens with the lobules during this
process is still not known.1 There are observations in-
dicating the enlargement of the hepatic lobules during
regeneration,17,18 but this process has not been ana-
lyzed in detail. The 3-dimensional construction of the
rat liver was carefully analyzed by Teutsch et al.9 Ac-
cording to this study, the size and shape of Teutsch et
al.’s primary hepatic units (which correspond to the
classic liver lobule) are variable. They are arranged in
cone-shaped secondary units. The size of the primary
units decreases toward the top of the secondary unit
(the liver surface). Such morphogenetic plasticity ex-
plains why a traditional histological section does not
provide reliable and comparable information regarding
the size of the lobules: it will cut lobules at different
positions in the hierarchy at different angles. In our
present work, we took advantage of the fact that super-
ﬁcial lobules (in contact with the Glisson capsule) have
a uniform apicobasal arrangement (perpendicular to
the liver surface) and occupy an identical position in the
liver hierarchy,5 contrary to the variable orientation,
size, and situation of the lobules that are located deep
in the parenchyma and are visible on a traditional his-
tological section. The terminal branch of the hepatic
vein is in the center of these lobules, generally oriented
perpendicularly to and opening at the surface. Because
the terminal portal venules terminate about 0.2 mm
below the liver surface,9 only ﬁlling the liver retro-
gradely through the hepatic vein allowed us to deter-
Figure 3. The numerical dimensions of the growing liver dur-
ing regeneration following (A) Phx and (B) ontogeny: () the
circumference and (‚) the surface of the hepatic lobules. The
bars represent the standard error. Abbreviations: CTR, con-
trol; Phx, partial hepatectomy; RLL, right lateral lobe.
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mine the size of the surface lobules precisely. Thus,
when sinuses of the surface lobules were ﬁlled up ret-
rogradely through the hepatic veins, the outlines of the
lobules provided reliable information about the 2-di-
mensional extension of these structural units. Enlarge-
ment of the liver lobules during the regenerative growth
could be clearly demonstrated in this way. Because the
number of subcapsular liver lobules did not change, the
enlargement of the lobules was alone responsible for
restoration of the liver mass. The measurements were
conﬁned to the 2-dimensional extension of the subcap-
sular hepatic lobules, and so they do not provide direct
information about the changes deep in the liver tissue.
However, considering the strictly deﬁned cone shape of
the primary and secondary units in Teutsch et al.’s
model, we must assume an increase in the axial dimen-
sion of the subcapsular lobules as well as similar alter-
ations of the deep hepatic lobules. Furthermore, Wa-
genaar et al.18 measured increased portocentral
distances on traditional histological sections in regen-
erating livers and concluded that the lobules were en-
larged; this experiment provided rough data about the
deep lobules.
Teutsch et al.’s model9,10 also maintains that rat and
human livers are constructed of several layers of lob-
ules. The weight/volume of the right lateral liver lobe
expanded more than 3-fold during regeneration. This
could have been accomplished, according to Teutsch et
al.’s model, either by enlargement of the lobules or by
the formation of an additional layer of lobules on the
liver surface. Our results clearly support the ﬁrst op-
tion. Highly developed mammalian organisms have a
quite limited capacity for regeneration of complex
structures.19 Therefore, it is reasonable that the lost
liver parenchyma is regenerated exclusively by the en-
largement of the preexisting lobules.
The enlarged liver lobules had a more complex struc-
ture throughout our observation period. The projection
of the central vein on the liver surface was elongated
and frequently divided. The number of portal vein
branches at the periphery of the lobules also increased.
This more complex structure of the lobules was re-
ﬂected very well in the arborescent shape of the zonally
distributed CYP II E1 expression, which was the result
of the adaptive changes of hepatocytes.20 The distribu-
tion of 2 other zonally expressed enzymes (glutamine
synthase and carbamoyl phosphate synthase) showed
similar alterations (data not shown). This modiﬁed ex-
pression pattern was present throughout our observa-
tion period (3 months), indicating a permanent or at
least long-lasting architectural change. The cause of
the altered lobular structure is not clear, but it probably
helps to maintain or approach the normal portocentral
distance.
Although the size of the lobules grew during the in-
vestigated postnatal period of ontogeny, their number
also increased. This is in agreement with previous ob-
servations. It is well known that the maturation of the
TABLE 1. Number and Complexity of Surface Lobules in the Right Lateral Lobe of Growing Livers
Control (Body Weight) Days After Phx
50 g 160 g 14 28
Number 586  10.29 794.5  37.1* 730.75  54.15 719.33  31.18
Number of portal vein branches
around the central vein
nd 6.04  0.2 nd 8.13  0.38#
Abbreviations: nd, not determined; Phx, partial hepatectomy.
*P  0.05 between the 160-g control and the 50-g control.
#P  0.05 between 28 days after Phx and the 160-g control.
Figure 4. Architectural changes of the liver lobules during
regeneration. (A-D) Double ﬁlling of the liver vasculature by
blue (portal veins) and red (central veins) resins: (A,B) control
liver and (C,D) 28 days after partial hepatectomy. Note the
enlargement of the hepatic lobules and the more complex
branching pattern of the central veins in the regenerated liv-
ers. (E,F) Immunohistochemical staining for CYP450 II E1
(green) on (E) a control liver and (F) a regenerated liver 28 days
after partial hepatectomy. Note the arborescent distribution
of CYP450 II E1 on the regenerated liver. Nuclei were stained
with propidium iodide. Scale bar: 1 mm.
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biliary system and thus that of the lobular arrangement
are completed only postnatally.21 The hilar-peripheral
orientation of this process has been clearly demon-
strated by the characterization of the liver of Alagille’s
patients.22 That is, a new layer of lobules might be
formed postnatally. Ekataksin also reported the elon-
gation of the portocentral distance13,15 and multiplica-
tion of the liver lobules in the developing human liver.
The size of lobular units increasing with age has been
described in the rat liver.7 Studies of pigs have also
shown that the average diameter, as well as the num-
bers of lobules, increases during normal growth of the
liver.8 This growth involves an increase in the number
and size of the hepatocytes. In fact, we have also ob-
served the enlargement of the hepatocytes during the
earlier period of the postnatal liver growth, as reported
before.23 The periphery of the hepatocytes increased
1.29-fold during this period, and this predicted growth
in the liver volume of 1.293 (2.15-fold). However, the
liver weight (which is related to the liver volume) in-
creased 2.9-fold, and this indicated that an increase in
the cell number also contributed to liver growth. Later,
during ontogeny and liver regeneration, the size of the
hepatocytes did not grow signiﬁcantly, probably be-
cause they approached the limit beyond which they
could not function properly.
In conclusion, we observed 3 different structural
mechanisms—enlargement of hepatocytes and multi-
plication and expansion of the hepatic lobules—con-
tributing to postnatal liver growth during ontogeny. It
seems that 2 of these parameters, the size of the hepa-
tocytes and the number of lobules in a given liver lobe,
are ﬁxed by adulthood, and the liver is able to adapt by
changing the size of the lobules. Under extreme condi-
tions, the hepatocytes are able to further enlarge,24 but
this state of the liver is not stable. The potential func-
tional consequences and limitations of lobular enlarge-
ment remain to be studied.
ACKNOWLEDGMENT
The authors thank Noemi Baffy for correcting their use
of the English language in this article.
REFERENCES
1. Michalopoulos GK, DeFrances M. Liver regeneration. Sci-
ence 1997;276:60-66.
2. Taub R. Liver regeneration: from myth to mechanism. Nat
Rev Mol Cell Biol 2004;5:836-847.
3. Fausto N, Campbell JS, Riehle KJ. Liver regeneration.
Hepatology 2006;43:S45–S53.
4. Fausto N, Webber EM. Liver regeneration. In: Arias IM,
Boyer JL, Fausto N, Jakoby WB, Schachter DA, Schafritz
DA, eds. Liver Biology and Pathobiology. New York, NY:
Raven Press; 1994:1059-1084.
5. Ekataksin W, Wake K. Liver units in three dimensions. I.
Organization of argyrophylic connective tissue skeleton in
porcine liver with particular reference to the compound
hepatic lobule. Am J Anat 1991;191:113-153.
6. Ekataksin W, Nishida J, McDonnel D, Krasovich M, Mc-
Cuskey RS. Postnatal development of the hepatic micro-
vasculature and microcirculation in rats [abstract]. Hepa-
tology 1993;18:157A.
7. Vollmar B, Pradarutti S, Richter S, Menger MD. In vivo
quantiﬁcation of ageing changes in the rat liver from early
juvenile to senescent life. Liver 2002;22:330-341.
8. Ekataksin W, Kaneda K. Liver microvascular architecture:
an insight into the pathophysiology of portal hypertension.
Semin Liver Dis 1999;19:359-382.
9. Teutsch HF, Scheuerfeld D, Groezinger E. Three-dimen-
Figure 5. (A) Surface and (B)
circumference of the pericentral
hepatocytes in rats with differ-
ent liver weights and 28 days af-
ter partial hepatectomy. The
bars represent the standard er-
ror.
Figure 6. Immunohistochemical staining for cytokeratin
(green) outlines the cell membranes of the hepatocytes; the
nuclei are decorated by propidium iodide (red). Representa-
tive images of pericentral hepatocytes in the livers of rats with
different bodyweights are shown: (A) 50 g, (B) 160 g, (C) 250 g,
and (D) 28 days after Phx. Note the increasing cell size from
part A to part C. (D) The examined liver lobe grew further
during regeneration without a change in the size of the hepa-
tocytes. Scale bar: 50 m.
182 PAPP ET AL.
LIVER TRANSPLANTATION.DOI 10.1002/lt. Published on behalf of the American Association for the Study of Liver Diseases
               dc_301_11
sional reconstruction of parenchymal units on the liver of
the rat. Hepatology 1999;29:494-505.
10. Teutsch HF. The modular microarchitecture of human
liver. Hepatology 2005;42:317-325.
11. Higgins GM, Anderson RM. Experimental pathology of the
liver. Arch Pathol 1931;12:186-202.
12. Schmucker DL, Mooney JS, Jones AL. Stereological anal-
ysis of hepatic ﬁne structure in the Fischer 344 rat. J Cell
Biol 1978;78:319-337.
13. Ingelman-Sundberg M, Johansson I, Penttila KE, Glau-
mann H, Lindros KO. Centrilobular expression of ethanol
inducible cytochrome P-450 (II E1) in rat liver. Biochem
Biophys Res Commun 1988;157:55-60.
14. MacSween NM, Desmet VJ, Roskams T, Scothorne RJ.
Developmental anatomy and normal structure. In: Mac-
Sween NM, Burt AC, Portmann BC, Ishak KG, Scheuer PJ,
Anthony PP, eds. Pathology of the Liver. London, England:
Churchill Livingstone; 2002:2-66.
15. Kiernan F. The anatomy and physiology of the liver. Philos
Trans R Soc London (Biol) 1833;123:711-770.
16. Ekataksin W, Wake K. New concepts in biliary and vascu-
lar anatomy of the liver. Prog Liver Dis 1997;15:1-30.
17. Huang RQ, Schiano TD, Amolat MJ, Miller CM, Thung SN,
Saxena R. Hepatocellular proliferation and changes in mi-
croarchitecture of right lobe allografts in adult transplant
recipients. Liver Transpl 2004;10:1461-1467.
18. Wagenaar GTM, Chamuleau AFM, Pool CW, deHan JG,
Maas MAW, Korfage HAM, Lamers WH. Distribution and
activity of glutamine synthase and carbamoylphosphate
synthase upon enlargement of the liver lobule by repeated
partial hepatectomies. J Hepatol 1993;17:397-407.
19. Elder D. Why is regenerative capacity restricted in higher
organisms? J Theor Biol 1979;81:563-568.
20. Christoffels VM, Sassi H, Ruijter JM, Moorman AFM,
Grange T, Lamers WH. A mechanistic model for the devel-
opment and maintenance of portocentral gradients in
gene expression in the liver. Hepatology 1999;29:1180-
1192.
21. Lemaigre FP. Development of the biliary tract. Mech Dev
2003;120:81-87.
22. Libbrecht L, Spinner NB, Moore EC, Cassiman D, Van
Damme-Lombaerts R, Roskams T. Peripheral bile duct
paucity and cholestasis in the liver of a patient with
Alagille syndrome. Am J Surg Pathol 2005;29:820-826.
23. Gupta S. Hepatic polyploidy and liver growth control. Se-
min Cancer Biol 2000;10:161-171.
24. Nagy P, Teramoto T, Factor VM, Sanchez A, Schnur J,
Paku S, et al. Reconstitution of liver mass via cellular
hypertrophy in the rat. Hepatology 2001;33:339-345.
REGENERATIVE AND ONTOGENIC LIVER GROWTH 183
LIVER TRANSPLANTATION.DOI 10.1002/lt. Published on behalf of the American Association for the Study of Liver Diseases
               dc_301_11
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Sandor Paku,* Janos Schnur,† Peter Nagy,†‡ and
Snorri S. Thorgeirsson‡
From the Joint Research Organization of the Hungarian
Academy of Sciences and Semmelweis University of Medicine,*
Budapest, Hungary; the First Institute of Pathology and
Experimental Cancer Research,† Semmelweis University of
Medicine, Budapest, Hungary; and the Laboratory of
Experimental Carcinogenesis,‡ National Cancer Institute,
National Institutes of Health, Bethesda, Maryland
We have analyzed the histological changes in rat liver
after 2-acetylaminofluorene (AAF) administration.
The data demonstrate that AAF-induced oval cells
were preferentially generated by proliferation of the
terminal biliary ductules that we suggest constitute
the primary hepatic stem cell niche. The oval cells
formed ductular structures, representing an exten-
sion of the canals of Hering. This histological organi-
zation provides continuous bile drainage of the hepa-
tocytes and uninterrupted blood flow in the
sinusoids. The oval cell ductules are surrounded by a
continuous basement membrane that is intermit-
tently disrupted by processes of stellate cells that
form direct cell-cell contact with the oval cells. Al-
though both AAF treatment and bile duct ligation re-
sults in proliferation of biliary epithelial cells, the
mechanism(s) responsible for the proliferation of the
biliary epithelium seems to differ in the two models.
In contrast to the biliary proliferation stimulated by
bile ligation, AAF-induced oval cell proliferation as
well as the capacity of these cells to differentiate into
hepatocytes, bile epithelial cells and possibly other
cell lineages can be blocked by administration of
dexamethasone. (Am J Pathol 2001, 158:1313–1323)
Although a substantial amount of knowledge has been
accumulated throughout the last 2 decades about liver
stem cells,1,2 numerous aspects of this intriguing cell
compartment remain undefined. Indeed, there are con-
flicting data on the exact location of liver stem cells and
even the growth pattern of these cells is not completely
understood. The proliferating oval cells—the progeny of
the stem cells—always expand into liver parenchyme
from the portal area. Furthermore, selective damage of
the periportal zone reduces oval cell proliferation.3 These
observations support the notion that the stem cells must
reside somewhere in the periportal region. The pheno-
typic resemblance between the oval cells and biliary
epithelium suggests that they derive from the biliary tree,
and terminal hepatic ductules (canals of Hering) that
connect the most distal hepatocyte of the hepatic plate to
the interlobular bile ducts are thought to harbor the he-
patic stem cells.4–7 However, there is no general agree-
ment on this issue. In fact, potential candidates for the
stem cells outside the biliary system have been pro-
posed.8
In the absence of a specific marker for the hepatic
stem cells, several investigators using different models
have attempted to identify the stem cells by labeling the
dividing cells in the early phase of oval cell expan-
sion.4,8–10 However, most of the experimental protocols
for the activation of the hepatic stem cell compartment
require a relatively long time and this may explain the
divergent results. The 2-acetylaminofluorene (AAF)/par-
tial hepatectomy (PH) model of oval cell proliferation/
differentiation has been extensively used to analyze the
hepatic stem cell compartment during the last few
years.11–13 We have recently modified the classical
AAF/PH model14 and demonstrated that after a single
dose of AAF administration a notable cell proliferation
takes place in the periportal zone and at least some of
these proliferating cells are the precursors of oval cells.
Therefore AAF administration provides a uniquely fast
and synchronized activation of the oval cell precursors
without any major disruption of the hepatic structure. We
could identify dividing cells in the interlobular bile ducts
after AAF treatment, whereas the exact nature of the rest
of the thymidine-labeled cells could not be unambigu-
ously defined by traditional light microscopy.14
Biliary cell proliferation can also be induced in rats by
the ligation of the common bile duct (BDL).15,16 This
reaction is, however, morphologically and phenotypically
very different from the oval cell proliferation. After BDL,
proliferating biliary cells do not show any signs of differ-
entiation into other cell types. Another difference between
BDL- and AAF-induced biliary cell proliferation is illus-
trated by selective inhibition of oval cell proliferation by
dexamethasone.17
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In the present work we have characterized the early
cellular events in the liver during the proliferative re-
sponse induced by AAF or BDL. To obtain a more de-
tailed morphological assessment, the samples were an-
alyzed by, in addition to traditional light microscopy, both
confocal and electron microscopy. Both AAF and BDL
induced an intense biliary cell proliferation. The fre-
quency of dividing cells after AAF treatment was signifi-
cantly higher in the terminal hepatic ductules. Morpho-
logical analysis revealed that the early oval cells are
strictly confined to ductular structures surrounded by
basement membrane, representing an extension of the
canals of Hering.
Materials and Methods
Animal Experiments
Male F-344 rats (180 to 200 g) were used for all experi-
ments and kept under standard conditions. The animal
study protocols were conducted according to NIH guide-
lines for animal care.
AAF/PH Experiment
AAF (1.5 mg) suspended in dimethyl-cellulose was
given to the rats on 4 consecutive days by gavage.
Traditional 70% PH18 was performed on the fifth day,
which was followed by five additional AAF treatments.
Animals were sacrificed at the described time points (at
least three at each time point).
BDL
BDL was done according to Cameron and Oakley.19
The rats were sacrificed 48 hours after the operation.
Electron Microscopy
Preparation of liver tissue for electron microscopy was
done by perfusing the livers under anesthesia (35 mg/kg,
Nembutal; Serva, Heidelberg, Germany) via the portal
vein with phosphate-buffered saline (PBS) for 10 minutes
and with 2.5% glutaraldehyde in 0.05 mol/L Na-cacody-
late (pH 7.2) for 15 minutes at room temperature. Livers
were cut into 1 3 3 mm pieces and immersed in 2.5%
glutaraldehyde for 2 hours. The pieces were postfixed
in 1% OsO4, 0.05% K-ferrocyanide in 0.05 mol/L Na-
cacodylate for 1 hour, dehydrated in a graded series of
alcohol, contrasted en bloc with 2% uranylacetate, and
embedded in Spurr’s mixture. Ultrathin sections were
stained with lead citrate and examined on a Philips
CM10 electron microscope.
Ultrastructural Analysis of 5-Bromo-29-Deoxy-
Uridine (BrdU)-Labeled Periportal Cell
BrdU (100 mg/kg) was injected intraperitoneally after two
doses of AAF, 24 hours after the second treatment or 2
days after BDL. One hour after the injection, the animals
were anesthetized and perfused via the portal vein with
PBS for 10 minutes, followed by 4% paraformaldehyde
for 20 minutes. Livers were removed, cut into 5-mm thick
slices and postfixed for 24 hours. The fixed tissues were
washed in PBS and immersed in 15% sucrose for 24
hours followed by 30% sucrose for another 24 hours.
Specimens were frozen in isopentane cooled by liquid
nitrogen.
Cryosections (15 mm thick) were mounted on micro-
scope slides coated with parlodion. The cryosections
were rinsed in PBS and incubated for 20 minutes in 3 N
HCl at room temperature. After washing in PBS, the sec-
tions were incubated with monoclonal anti-BrdU antibody
(diluted 1:100; Becton-Dickinson, Mountain View, CA) for
3 hours and later with biotinylated anti-mouse antibody
(Vector Laboratories, Burlingame, CA) for 2 hours. The
reaction was developed by an ABC reaction (Elite ABC
Kit, Vector Laboratories) using diaminobenzidine as
chromogen. The sections were osmificated (1% OsO4 in
PBS), dehydrated in graded series of ethanol, and em-
bedded in Epon 812. Blocks were removed by immersing
the slides in liquid nitrogen. Semithin sections were
slightly stained by 0.5% toluidine blue (pH 8.5), portal
areas containing BrdU-labeled cells were trimmed out
and unstained ultrathin sections were analyzed on a Phil-
ips CM 10 electron microscope. Labeled cells were
divided into three categories based on their localiza-
tion: 1) cells residing outside the basement mem-
branes in the periportal connective tissue; 2) cells
confined within the basement membrane, as part of
bile ducts; and 3) cells of the canals of Hering. The
cells comprising the canals of Hering were in direct
contact with a hepatocyte or were separated from a
hepatocyte by only one biliary cell.
Immunofluorescent Analysis
Double Labeling for Laminin-Cytokeratin and
Laminin-Desmin
Cryostat sections (6 mm) were fixed in acetone (220°C
for 20 minutes) and incubated overnight with a mixture of
rabbit polyclonal anti-laminin antibody (diluted 1:50,
Z0097; DAKO, Glostrup, Denmark) and fluorescein iso-
thiocyanate-conjugated mouse monoclonal antibody di-
rected against human cytokeratin 5, -6, -8, -17, and -19
(diluted 1:10, M0859; DAKO) or anti-laminin and mouse
monoclonal anti-desmin (diluted 1:50, M0724; DAKO),
respectively. After washing with PBS the sections were
incubated for 60 minutes with tetramethylrhodamine B
isothiocyanate-conjugated anti-rabbit IgG (diluted 1:20,
R0156; DAKO) for the laminin-cytokeratin double labeling
or with the combination of the same tetramethylrhodam-
ine B isothiocyanate-conjugated anti-rabbit IgG and flu-
orescein isothiocyanate-conjugated anti-mouse IgG (di-
luted 1:50, F5262; Sigma) for the simultaneous detection
of laminin and desmin.
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Double Labeling for Laminin and a-Fetoprotein (AFP)
Liver samples were fixed in 10% formaldehyde, em-
bedded, and cut. After deparaffinization and hydration,
the sections were microwaved for 15 minutes in ethyl-
enediaminetetraacetic acid buffer (pH 8.0), followed by
incubation in 0.1% Triton X-100 in PBS for 20 minutes,
and digested with Proteinase K (2 mg/ml, 15 minutes,
37°C). The sections were washed with PBS and incu-
bated overnight with a mixture of rabbit polyclonal anti-
laminin (diluted 1:20, Z0097; DAKO) and goat anti-rat
AFP no. 89 antibody (diluted 1:100; generous gift from Dr.
Stewart Sell, Department of Pathology and Laboratory
Medicine, Albany Medical College, Albany, NY). Tetram-
ethylrhodamine B isothiocyanate-conjugated anti-rabbit
IgG (as described above), and in a second step, fluores-
cein isothiocyanate-conjugated anti-goat IgG (diluted
1:400, F7367; Sigma), were used as secondary antibod-
ies. All samples were analyzed by confocal laser-scan-
ning microscopy using the Bio-Rad MRC-1024 system
(Bio-Rad, Richmond, CA).
Results
BrdU Labeling of Dividing Cells after BDL and
AAF Administration
The ligation of the common bile duct resulted in a very
intensive biliary cell proliferation. The cells were labeled
with BrdU 48 hours after the ligation. In agreement with
previous results,20 most of the labeled cells were in the
interlobular bile ducts. Immunoelectron-microscopic analy-
sis of the localization of labeled cells revealed ,6% of the
BrdU-positive biliary epithelial cells in the canals of Hering
(Figure 1A). Additionally, dividing inflammatory and fibro-
blastic cells could be found in the periportal connective
tissue and a few labeled hepatocytes were also present.
Figure 1. A: Distribution of BrdU-labeled cells, between bile ducts and canals of Hering, analyzed by immunoelectronmicroscopy. The first two columns represent
the distribution after two treatments with AAF, and the second two 48 hours after BDL. Total number of labeled cells analyzed was 141 in the AAF-treated group
and 143 in the BDL group. B: Immunoelectron micrograph 2 days after AAF treatment showing a canal of Hering consisting of four cells. Three of them are labeled
by BrdU. Two cells of the canals are attached to the hepatocytes (H) (arrowheads). The fourth labeled cell (asterisk) is located in the periportal connective
tissue outside the basement membrane of the terminal hepatic ductule. Scale bar, 2 mm. C: Activated cell in the canal of Hering (He) 2 days after AAF treatment.
The nucleus is enlarged and contains euchromatin and a prominent nucleolus (small arrow). Continuous basement membrane is visible on the connective tissue
side of the cell (arrowheads). The bile ductule lumen is sealed by intercellular junctions (large arrows) (H, hepatocyte). Scale bar, 1 mm.
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Similarly to our earlier observations,14 a single dose of
AAF resulted in cell proliferation in the periportal region.
However, because the number of the BrdU-labeled cells
was higher after two doses of AAF, without any apparent
adverse effects, we selected the 48-hour time point for
the quantitative electron-microscopic analysis. Approxi-
mately 80% of the labeled biliary cells were inside the
well-defined interlobular bile ducts. However, 22% of the
BrdU-positive epithelial cells were located in the canals
of Hering (Figure 1A). Only those biliary cells having
direct connection with a hepatocyte or separated by only
one interposed biliary cell from the hepatocyte were
counted as lining cells of the canals of Hering (Figure
1B). It is possible that by using these strict criteria we
underestimated the number of labeled cells in the canals
of Hering. However, the observation that 22% of the
labeled biliary cells were in these structures can be taken
as preferential labeling, considering that the overwhelm-
ing majority of the biliary epithelial cells belong to the
interlobular and larger bile ducts.
After AAF treatment the terminal hepatic ductules were
surrounded, by an almost continuous basement mem-
brane that terminated on a hepatocyte of the limiting plate
(Figure 1C). In addition, administration of AAF also in-
duced proliferation outside the biliary system. Mostly sin-
gle cells residing in the periportal extracellular matrix
were labeled. Although the exact nature of these cells
could not be established by electron microscopy they
most likely represent mesenchymal cells.
Immunohistochemical Analysis of the Liver 2
Days after AAF Administration
The cell density increased in the periportal space after
one or two doses of AAF, but the proliferating ductules
did not infiltrate the liver lobules. To determine the char-
acteristics of the proliferating cells in the periportal
space, double labeling for laminin/cytokeratin, laminin/
desmin, and laminin/AFP was performed. Immunofluores-
cent-stained liver sections were analyzed by confocal
microscopy. The cytokeratin antibody gave a weak mem-
brane and reticular cytoplasmic staining in the hepato-
cytes, whereas producing a strong cytoplasmic reaction
in the biliary epithelial cells. Therefore, the two cell pop-
ulations could be easily distinguished. The laminin anti-
body, a well-established marker of the basement mem-
brane, sharply circumscribed the bile ducts and the
blood vessels, whereas the liver acini were completely
negative. The terminal hepatic ductules were intensely
decorated by the laminin/cytokeratin double labeling. In
the appropriate plane of the section, the basement mem-
brane stained with laminin surrounded the bile ductules
and terminated on hepatocytes at the limiting plate (Fig-
ure 2A). The basement membrane extended without in-
terruption along the biliary ducts and ductules. If the
nuclei were stained by propidium iodide in combination
with the double-immunofluorescent reaction, increased
cell density was revealed periportally after AAF treatment
(Figure 2, A and B). However, we did not observe cyto-
keratin-labeled cells outside the basement membrane in
the periportal space. Combined laminin/AFP immunohis-
tochemistry showed that basement membrane sur-
rounded a few AFP-positive biliary cells after two doses of
AAF (Figure 2C). Similar to the cytokeratin reaction, no
AFP-stained cells were observed outside the basement
membrane. Immunostaining with a desmin antibody re-
vealed an increased number of activated stellate cells
outside the basement membrane. These cells and their
processes showed a very intimate connection with the
proliferating ductules (Figure 2D).
Morphological Alterations after PH in
AAF-treated Rats
To study later events during stem cell activation, we used
the AAF/PH model and the structural alterations were
analyzed 3 days after the partial hepatectomy. By this
time the oval cells had extensively infiltrated the liver
lobules. Electron microscopic examination revealed that
the oval cells always formed ductules (Figure 3A). These
growing ductules reached the sinusoids and passed
along or between them. During this process the sinusoids
were left intact, preserving their normal function. The
basic structure of these oval cell ductules was not differ-
ent from the normal canals of Hering except for the elon-
gation. The ductules grew by the continuous proliferation
of the ductular epithelial cells (Figure 3B), whereas the
sides of these tubules were continuously sealed by des-
mosomes. Also, the ductules always terminated at a he-
patocyte (Figure 3C). This hepatocyte was probably the
one connected with the original canal of Hering. In this
way the original connection between the bile canaliculi
and the bile duct system was preserved throughout the
regenerative process. The growing tubules were sur-
rounded mostly by basement membrane that terminated
on the hepatocyte. However, there were segments along
these growing ductules where no structured basement
membrane could be seen by electron microscope. Again
no cells penetrating through the basement membrane
could be observed. There were, however, plenty of pro-
liferating cells outside the basement membrane without
characteristic ultrastructural features. These cells did not
show epithelial phenotype or form desmosomes, yet
had a very close contact with the expanding ductular
epithelial cells. Higher magnification showed that small
processes of these nonepithelial cells appeared to
have direct cell-cell contact with the epithelial cells
(Figure 3D).
Immunohistochemical observations confirmed the
electron-microscopic data. The cytokeratin-stained oval
cells formed ductules that were elongations of the portally
located canals of Hering. The tubular structure of these
ductules with a central lumen was much more obvious in
the pictures generated by confocal microscopy. The ma-
jor difference between the two methods was that, al-
though the basement membrane could not be continu-
ously followed along these ductules ultrastructurally, the
immunohistochemistry showed consistent laminin positiv-
ity around them (Figure 4A). The cylinder formed by the
basement membrane had an open end plugged by a
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hepatocyte, and desmin-positive stellate cells accompa-
nied the ductular structures outside the basement mem-
brane (Figure 4B).
Ten days after the partial hepatectomy the cytokeratin-
laminin immunohistochemistry did not reveal any basic
change in the structure of advancing ductules, demon-
strating that the oval cells still formed ductular structures
extensively infiltrating into the liver parenchyma and
maintained contact with hepatocytes at their origin
(Figure 5, A and B). The oval cells still could be easily
distinguished from the hepatocytes by the strong
cytoplasmic cytokeratin staining. The proliferating oval
cells were heterogeneously decorated by the AFP antibody.
Similar to earlier time points, these cells were always sur-
rounded by basement membrane and no AFP-positive cells
were seen outside the laminin staining (Figure 5C). At this
stage, oval cells were neither identified outside the ductular
structures nor interposed between hepatocytes. The
desmin reaction verified that activated stellate cells sur-
rounded the advancing ductules and formed processes
that penetrated and caused focal discontinuity of the base-
ment membrane (Figure 5D).
Figure 2. A: Portal area of a control liver stained for cytokeratin (green) and laminin (red). The section was additionally stained with propidium iodide to localize
nuclei. Basement membrane of portal vein (V), capillaries (small arrowheads), bile duct (small arrow), and a canal of Hering (large arrow) are stained by
the anti-laminin antibody. Nuclei of two connective tissue cells can be detected (large arrowheads) in the periportal area. The bile duct and canal of Hering
lining cells show a stronger cytoplasmic staining for cytokeratin than the hepatocytes. Scale bar, 10 mm. B: Portal area stained for cytokeratin and laminin 2 days
after AAF treatment. Localization of basement membranes are similar to that of control liver. Note the presence of numerous cytokeratin-negative cells in the
periportal connective tissue (arrowheads), but there are no cytokeratin-positive cells in the periportal space outside the basement membrane. The canal of
Hering (arrow) shows normal structure. Scale bar, 10 mm. C: Two days after AAF treatment AFP-positive (green) bile ductule cells are present strictly within
basement membrane (red). Scale bar, 10 mm. D: Portal area 2 days after AAF treatment, stained for laminin (red) and desmin (green). The section was additionally
stained with propidium iodide to localize nuclei, as shown in A and B. Numerous cells in the connective tissue, which proved to be negative for cytokeratin (B),
stain positively for desmin. Some of the desmin-positive cells positioned closely to the basement membrane of the bile ducts (B) (arrows). A, arteriole; V, venule.
Scale bar, 10 mm.
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Figure 3. Ultrastructure of a portal area 3 days after PH in an AAF-treated rat. A: Oval cells forming a ductule (arrowheads; L, ductule lumen), squeeze between
sinusoids (S). The ductule terminates on hepatocytes (H, arrows). One cell of the ductule is in mitosis (asterisk). Several stellate-like cells (I) are located closely
to the advancing ductule. Scale bar, 5 mm. B: Higher magnification of the mitotic oval cell shown in A in a different sectioning plane. The cell is connected to
the other cells forming the ductule by desmosomes (arrowheads). A small amount of basement membrane-like material (arrows) is visible under the process
of a ductule cell. Scale bar, 1 mm. C: Detail of the ductule shown in A. Terminal cell of the growing ductule D1 is connected to the hepatocyte (H) by desmosomes
(arrowhead) and tight junctions (small arrowheads). Desmosome (large arrow) is also discernible between the two ductule cells (D1, D2). Well-defined
basement membrane (small arrows) with small gaps can be observed under the ductule cells. Scale bar, 1 mm. D: Ito-like cell (I) is in direct contact with the
ductule cell (D), through the small gaps (arrowheads) of the basement membrane (arrows). Scale bar, 1 mm.
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Discussion
We have compared the BDL- and AAF-induced ductular
cell proliferation in the rat liver by electron microscopy
and immunohistochemistry. Both treatments resulted in
the proliferation of the biliary epithelial cells. However, the
distribution of the dividing biliary cells was different. The
percentage of BrdU-labeled cells in the canals of Hering
was significantly higher after AAF administration. Analy-
sis of morphological changes in the AAF/PH model re-
vealed that proliferating oval cells always formed
ductules that were elongated and tortuous extensions of
the pre-existing canals of Hering. These oval cell
ductules were always surrounded by laminin and termi-
nated at hepatocytes located at the limiting plate. These
ductular structures were always accompanied by acti-
vated and proliferating stellate cells.
Studies similar to our own have been done by several
investigators8,13,21–24 using the AAF-induced oval cell
reaction. The difference between these studies and ours
is that we examined earlier time points of the model to
observe the first proliferating cells under conditions in
which the original histological structure of the liver is
minimally affected. Our results support the notion of oval
cells being derived from the biliary epithelium, strongly
indicating that liver stem cells are located in the biliary
system.
Among other candidates for liver stem cells are the
so-called “nondescript” periductular cells. Sell and Sal-
man8 observed that the first proliferating cells after AAF
feeding in rats maintained on a choline-deficient diet are
periductal and the ductular cells follow them 1 or 2 days
later. These periductal cells are located outside the base-
ment membrane and contained no ultrastructural fea-
tures that identified them. Interestingly, the increase in
the number of thymidine-labeled periductular cells was
equal to or greater than the labeled ductal cells. Studying
a similar model to that of Sell and colleagues21 (but
without the choline-deficient diet), we have also observed
periductal proliferating cells. Cytokeratin, however, dec-
orated strictly laminin-surrounded cells in the periportal
area, ie, no epithelial cells were seen outside the base-
ment membrane. AFP is an extensively used marker of
the oval cells in the rat liver25,26 and the presence of AFP
also indicates a hepatocytic directed commitment of the
cells. AFP staining in some of the biliary epithelial cells
after two doses of AAF supports the hypothesis that these
cells are the precursors of the oval cells. In addition, the
persistent lack of AFP staining outside the basement
membrane throughout the experimental period strongly
argues against the potential periductal origin of the oval
cells. According to studies in other stem cell systems,27
in which a high cell production rate is required, the stem
cells fulfill this task via a dividing transit or amplification
cell population. The cells of this compartment constitute
an intermediary or transition population between the stem
cells and the mature functional compartment, and they
usually acquire one or more differentiation markers. Tra-
ditionally the oval cells are thought to represent this am-
plification compartment in this experimental model.1 If the
nondescript periductal cells studied by Sell and col-
leagues21 were the stem cells, we would not expect them
to proliferate at the same rate as the dividing transit
compartment represented by the oval cells. Another pos-
sibility might be that the periductal cells are (alone or
together with the ductular cells) the amplification com-
partment. These cells are, however, cytokeratin- and
AFP-negative, and do not show any phenotypic or mor-
phological (even at the ultrastructural level) sign of differ-
entiation. Furthermore, the nondescript periductal cells
would be expected to penetrate the basement mem-
Figure 4. A: Portal area stained for cytokeratin (green) and laminin (red) 3 days after PH in an AAF-treated rat. The bifurcating ductule (D) strongly positive for
cytokeratin, is surrounded by continuous basement membrane. Minute discontinuities (arrows) can be observed only at the vicinity of hepatocytes (H). Scale
bar, 10 mm. B: Portal area containing a bifurcating ductule (D) stained for laminin (red) and desmin (green). The basement membrane is continuous, except
minute gaps where it is penetrated by desmin-positive Ito cell processes (arrowhead). Numerous other desmin-positive cells are spread along the basement
membrane (arrows). Scale bar, 50 mm.
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brane in great numbers during the process of differenti-
ation, but neither Sell and Salman8 nor we observed any
sign of this. Therefore, our data do not support the stem
cell nature of the periductal cells. There are, however,
plenty of desmin-positive stellate cells actively proliferat-
ing around the ductules in the AAF/PH model. Although
we have not precisely quantitated the number of stellate
cells, it seems to be approximately equal to that of oval
Figure 5. Immunohistochemistry of the liver 10 days after partial hepatectomy in the AAF/PH-treated rat. A: Low-power micrograph of a liver lobule stained for
cytokeratin (green) and laminin (red). Numerous ductules surrounded by laminin are infiltrating the liver parenchyme toward the central vein (V). Several
U-shaped laminin-stained structures, with open endpoints toward the central vein (arrows), can be seen at the border of the oval cell infiltration. (PV, portal vein).
Scale bar, 100 mm. B: High magnification of a ductule (D) at the infiltration border. Oval cells are attached to a hepatocyte (H). Laminin staining encloses only
the ductule, and it does not extend over the hepatocyte (H). Scale bar, 10 mm. C: Tortuous oval cell built ductules in the liver lobule stained for laminin (red)
and AFP (green). The ductules are surrounded by laminin and AFP staining is observable only inside the basement membrane. Scale bar, 10 mm. D: Similar ductules
as in C stained for laminin (red) and desmin (green). Numerous desmin-positive cells are spreading along the basement membrane (arrowheads). At several places
processes of these cells puncture the basement membrane (arrows), but these processes never extend over the basement membrane. Scale bar, 10 mm.
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cells. It is therefore possible that at least some of the
periductal proliferating cells described by Sell and Sal-
man8 might be stellate cells.
Several studies have supported possibilities of the
stem cells being located in the biliary system. These
include terminal hepatic ductules;4,5,22,28 all biliary epi-
thelial cells,29–32 and a very primitive looking cell, re-
ferred to as a “basal cell” inside the bile duct.23,24 The
basal cells proliferated 2 to 3 days after the partial hep-
atectomy in the livers of rats treated according to Solt and
colleagues33 carcinogenesis schedule. We also saw
these small, intraepithelial cells in our sections, but they
never incorporated BrdU or showed morphological signs
of proliferation. The reason for this difference is not alto-
gether clear. Novikoff and colleagues23 and Novikoff and
Yam24 used the DEN-initiated Solt-Farber model,
whereas we avoided DEN administration. Although the
oval cell reaction is similar, the histological changes are
more complex in the Solt-Farber model according to our
experience. Anilkumar and colleagues34 also described
divergent histological reactions in the two models. It is
however evident that oval cell proliferation can be in-
duced without the participation of the basal cells in our
experimental model. Therefore, the biliary epithelial cells
can function as facultative liver stem cells in the AAF/PH
experimental model. We can, of course, not exclude the
possibility that the basal cells represent an even more
ancient stem cell population that is activated by a more
drastic, carcinogenic protocol and may be responsible,
eg, for the frequently observed metaplastic hemopoiesis
in hepatocarcinogenesis experiments.35,36 Recently Pe-
tersen and colleagues37 and Theise and colleagues38
have provided evidence that hemopoietic stem cells can
give rise to oval cells and hepatocytes. The basal cells
may perhaps represent a common precursor for the two
systems. Although these observations have a dramatic
impact on our view of stem cell biology, there is a general
agreement that under most circumstances the liver re-
generates from cell populations confined to the liver.
These cells are the focus of this study and the participa-
tion of hemopoietic cells in liver regeneration is not ad-
dressed here.
The notion of which segment(s) of the biliary tree har-
bors the stem cells is still controversial. Although a sub-
stantial amount of data indicate that the liver stem cells
are confined to the terminal hepatic ductules, arguments
have been made suggesting that any component of the
biliary tree can give rise to oval cells.29–32 We have
previously shown that chronic dexamethasone treatment
is able to prevent the oval cell proliferation triggered by
the AAF/PH protocol while not at all inhibiting the BDL-
induced proliferation of the larger, mostly interlobular bile
ducts.17 The preferential BrdU labeling of cells in the
canals of Hering after AAF administration, suggested that
selective inhibition of cell proliferation in these cells might
be achieved by dexamethasone. Contrary to expecta-
tions dexamethasone completely inhibited the AAF-in-
duced biliary cell proliferation regardless of their loca-
tion.17 These results fail to provide a functional
confirmation that the terminal ductules are the exclusive
sources of the oval cells. Furthermore, the proliferations
of morphologically and topologically identical biliary cells
were differently regulated by dexamethasone. These
data suggest that there are at least two different mecha-
nisms regulating proliferation of the biliary epithelium,
each providing functionally different progeny. Although
the dexamethasone-sensitive pathway provides cells
with stem cell potential, the dexamethasone-resistant
pathway produces only biliary epithelial cells. These re-
sults may, at least in part, be analogous to the regulation
of hepatocyte cell cycle induced by the partial hepatec-
tomy and primary mitogens.39 It is well established that
these proliferative models have different biological poten-
tials; eg, hepatocyte proliferation induced by partial hep-
atectomy has carcinogenic promoting capacity whereas
the other one induced by direct mitogens has none.40
There are already observations indicating the differential
regulation of these two biliary reactions. Mice harboring
congenitally defective SCF/c-kit system retain an intact
proliferative response after BDL,41 whereas the oval cell
proliferation is remarkably suppressed in rats with defi-
cient c-kit kinase activity.42
The fact that hepatocytic differentiation occurs in the
pancreas43,44 and extrahepatic bile ducts45 also argues
against the restricted occurrence of multipotential stem
cells in the canals of Hering. Our observation that AAF
targets preferentially the cholangioles while BDL targets
the larger bile ducts can be explained by topological
factors. The primary stimulus for biliary proliferation after
BDL is the increased intraductal pressure.15 The pres-
sure is probably higher in the interlobular bile ducts, than
in the ductules. Differential expression of drug metabo-
lizing enzymes by different segments of the biliary tree46
may provide an alternative or additional explanation for
the differential response to AAF. Potten47 described a
hierarchy of the stem cells in the small intestine glands.
Depending on the severity of injury, more and more re-
sistant cells participate in the repair. Additionally, this
hierarchy is related to the topography of the cells. A
similar arrangement cannot be excluded in the biliary
system. This notion is supported by the well-known het-
erogeneity of cholangiocytes.48,49
Experiments using injection of pigmented gelatin me-
dium and related substances into the biliary tree have
demonstrated that the majority of oval cells are part of a
ductular reaction.10,13,50 However, together with these
observations, occurrence of isolated oval cells, some-
times located between pre-existent fully mature hepato-
cytes, have been described.13 There is also conflicting
assessments on the continuity of the basement mem-
brane around the ductules.24,50 To address this problem
we studied earlier time points and complemented the
electron microscopy with confocal laser microscopy. The
confocal microscopy provided a much better overview of
the histological reaction in addition to allowing simulta-
neous use of more than one marker. The laminin/cytoker-
atin double staining decorated very clearly the biliary
ductules that would otherwise be difficult to recognize.
There was a distinct continuous laminin staining around
the canals of Hering that terminated at hepatocytes lo-
cated at the limiting plate.
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The traditional light microscopic view of the oval cell
reaction is very complicated. The confocal microscopy,
however, clearly revealed that the oval cells always form
ductules surrounded by basement membrane that origi-
nate from the canals of Hering and terminate on a hepa-
tocyte. As these oval cell ductules grow, they become
tortuous, but they appear not to lose contact with their
terminating hepatocyte, as was described by Betto and
colleagues51 in Long-Evans rats. To accomplish this task,
it seems that the canal of Hering is ideally situated and
therefore may provide the stem cell niche in the liver.
Furthermore, this arrangement allows for continuous bile
drainage throughout this complex reaction. The preser-
vation of the original contact between the liver plate and
the extending biliary ductule, which is composed of oval
cells, may be extremely important for the maintenance of
the liver architecture. We hypothesize that the disruption
of the contact between the ductules and hepatocytes
may occur in chronic interface hepatitis resulting in aim-
less ductular proliferation, followed by fibrosis, and finally
reorganization of the liver structure resulting in cirrhosis.
The basement membranes frequently play an impor-
tant role in the regenerative process. In certain tissues
(eg, kidney tubules) the integrity of the basement mem-
brane is required for the regeneration because it pro-
vides a track for the dividing epithelial cells.52 The situa-
tion is probably different in the liver. There is no
structured basement membrane along the liver plates.
The fact that the regular basement membrane is some-
times missing ultrastructurally around the ductules, while
they are always surrounded by laminin according to our
immunohistochemical data, may indicate that it is in sta-
tum nascendi, providing a substrate for proliferation and
migration. This process is similar to that observed during
angiogenesis.53 Activated stellate cells are always inti-
mately associated with these ductules. Sometimes the
processes of the stellate cells brake through the base-
ment membrane and form direct cell-cell contact with the
ductular epithelial cells. This connection that has not
been described before may form the structural basis for
the intensive cross talk between these two cell types.
In conclusion, although it has been known that most of
the oval cells are organized into ductular structures
sprouting from pre-existing bile ductules, this was not
generalized to every oval cell and the development of
these ductules was obscure. We suggest that the oval
cell-formed ducts are simply extensions of the biliary
ductules. The connection between the last ductular bili-
ary cell and the corresponding hepatocyte is maintained
for an extended period of time. The oval cells are prefer-
entially generated by proliferation of the terminal biliary
ductules that we suggest constitute the primary hepatic
stem cell niche. However, the stem cell potential of the
larger biliary ducts cannot be excluded. In fact, there
seems to be two independently activated and regulated
mechanisms for the proliferation of the biliary epithelium.
One of these that can be blocked by dexamethasone
results in progenies with the capacity for both differenti-
ating into hepatocytes and possibly other cell lineages.
The ductules are composed of oval cells and surrounded
by continuous basement membrane that is intermittently
disrupted by processes of stellate cells that form direct
cell-cell contact with the oval cells.
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Thy-1 Is Expressed in Hepatic Myofibroblasts
and Not Oval Cells in Stem Cell-Mediated Liver
Regeneration
Katalin Dezso˝,* Peter Jelnes,† Vikto´ria La´szlo´,*
Korne´lia Baghy,* Csaba Bo¨do¨r,* Sa´ndor Paku,*
Niels Tygstrup,‡ Hanne Cathrine Bisgaard,†
and Peter Nagy*
From the First Department of Pathology and Experimental
Cancer Research,* Semmelweis University, Budapest, Hungary;
the Department of Cellular and Molecular Medicine,† The Danish
Stem Cell Research Centre, The Panum Institute, University of
Copenhagen, Copenhagen, Denmark; and the Department of
Hepatology,‡ Rigshospitalet, Copenhagen University Hospital,
Copenhagen, Denmark
Thy-1, a marker of hematopoietic stem cells, has been
reported to be expressed by oval cells proliferating
during stem cell-mediated regeneration in rat liver,
suggesting a relationship between the two cell popu-
lations. Consequently, Thy-1 has become an accepted
cell surface marker to sort hepatic oval cells. In the
present study we used the well-characterized
2-acetylaminfluorene/partial hepatectomy model to
induce transit-amplification of hepatic oval cells in
the regenerating liver and characterized Thy-1 ex-
pression using Northern hybridization, quantitative
reverse transcriptase-polymerase chain reaction anal-
ysis, immunofluorescence confocal microscopy, and
immunoelectronmicroscopy. We found that Thy-1 ex-
pression was induced during transit-amplification of
the oval cell population, but Thy-1 mRNA was not
present in the -fetoprotein-expressing oval cells.
Thy-1 protein was consistently present outside the
basement membrane surrounding the oval cells. It
overlapped frequently with smooth muscle actin
staining. A similar cellular localization of the Thy-1
protein was found on human liver specimens with
ductular reactions obtained from patients with fulmi-
nant liver failure. Furthermore, Thy-1 was expressed by
myofibroblasts in experimental liver fibrosismodelswith-
out oval cell proliferation.We conclude that Thy-1 is not
a marker of oval cells but is present on a subpopula-
tion ofmyofibroblasts/stellate cells. (Am J Pathol 2007,
171:1529–1537; DOI: 10.2353/ajpath.2007.070273)
Thy-1 (CD-90) is a rather promiscuous molecule. It is
expressed by several different cell types, and, among
others, it is present on the surface of the bone marrow
stem cells. It was also reported to be present in the rat
liver on the oval/progenitor cells in stem cell-mediated
liver regeneration.1–4 Later, a precursor-product relation-
ship was described between bone marrow cells and oval
cells/hepatocytes in several experimental models1,3,5,6
as well as in humans,7 raising the very exiting possibility
of liver cells being derived from hematopoietic cells. Sev-
eral groups confirmed the Thy-1 expression in oval
cells,1–4 resulting in the extensive use of Thy-1 as a cell
surface marker to sort out liver progenitor cells. How-
ever, the issue of stem cell transdifferentiation has
subsequently been one of the most debated issues in
hepatic pathobiology, and most of these observations
can now be explained by cell fusion and not transdif-
ferentiation. The most comprehensive review of this
topic recently concluded that although “data are suffi-
cient to indicate that mesodermal hematopoietic cells
can generate hepatocytes at a very low frequency, this
is not an effective pathway under most conditions.”8 At
the same time, others described cells coexpressing
Thy-1 and smooth muscle actin (SMA) in similar exper-
imental settings,9 questioning the identity of the Thy-1-
expressing cells in the liver. To resolve this contradic-
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tion we performed detailed morphological expression
analysis to identify the location of Thy-1 in the normal
liver and in damaged liver with and without oval cell
proliferation.
Materials and Methods
Animal Experiments
Male F-344 rats (160 to 180 g) were used for all experi-
ments and were kept under standard conditions. Animal
protocols were approved by the Danish Council for Su-
pervision with Experimental Animals.
AAF/PHx Experiment
The animals received 2-acetylaminofluorene (AAF) (sus-
pended in 1% dimethylcellulose) at 4.5, 9, 12, or 18
mg/kg/day administered daily for 4 consecutive days by
gavage. Traditional two-thirds partial hepatectomy
(PHx)10 was performed on the 5th day, followed by four
additional AAF treatments. Groups of three animals were
sacrificed 1, 5, 9, 14, and 21 days after PHx. Controls
included untreated animals and rats subjected to a PHx
or a sham laparotomy only. After resection of the liver,
samples were taken for histological examinations and the
rest snap-frozen in liquid nitrogen for RNA extraction.
Bile Duct Ligation
Ligation of the common bile duct was done according to
Cameron and Oakley.11 The rats were sacrificed 2 weeks
after the operation.
CCl4 Fibrosis
Twenty percent CCl4 (0.5 ml/kg, dissolved in vegetable
oil) was administered by gavage to rats twice a week
while the animals were kept on 0.05% phenobarbital in
the drinking water. The experiment was terminated after
8 weeks.12
Human Tissue
Snap-frozen human liver specimens for immunohisto-
chemical examination were obtained from two patients
who underwent orthotopic liver transplantation because
of fulminant liver failure of unknown etiology. The proce-
dure was approved by the ethical committee of the Sem-
melweis University.
Isolation of Oval Cells for Northern Blot Analysis
Isolation of oval cells was performed using control liver,
and animals were treated according to the AAF/PHx pro-
tocol (18 mg/kg/day) and sacrificed at day 9 after PHx.
The isolation and enrichment procedure has been de-
scribed in detail.13 In brief, liver cells were released by a
three-step perfusion procedure in situ. Viable nonparen-
chymal cell populations were purified by centrifugation
through a two-step Percoll gradient. Kupffer cells were
removed by selective adherence to plastic tissue culture
dishes. Removal of macrophages, endothelial cells, and
red blood cells was achieved by selective panning using
the mouse monoclonal antibody OX43 (catalog no.
MCA276; Serotec, Oxford, UK). Cell preparations were
snap-frozen in liquid nitrogen and stored at 70°C until
processed for total RNA isolation and Northern blot
analysis.
Northern Blot Analysis
Northern blotting with cDNA probes was performed as
previously described.14 The cDNA for rat Thy-1 encom-
passed nucleotides 46 to 531 (GenBank accession no.
NM_012673), and for -fetoprotein (AFP), nucleotides
101 to 329 (GenBank accession no. X02361). The filters
were hybridized with rat S18 to assess the integrity and
ensure equal loading of the RNA.
Quantitative Real-Time Reverse
Transcriptase-Polymerase Chain Reaction Analysis
Frozen sections (8 m) were fixed in acetone, dried at
room temperature, and stained with RNase-free hema-
toxylin. Laser microdissection of oval cells was per-
formed by using the PALM MicroBeam system, and 500
to 1000 cells were collected in RNA-Later. For whole liver
quantitative real-time reverse transcriptase-polymerase
chain reaction (qRT-PCR) analysis, frozen sections from
normal and AAF/PHx-treated liver were collected in lysis
buffer.
Total RNA was isolated by RNAqueous micro kit (catalog
no. AM 1931; Ambion, Austin, TX). A high capacity cDNA
reverse transcription kit (catalog no. 4368814; ABI) was
used for cDNA synthesis as recommended by the supplier.
PCR was performed by the ABI Prism 7300 sequence de-
tection system (Applied Biosystems, Weiterstadt, Ger-
many), using ABI TaqMan gene expression assays for AFP
(assay ID: Rn00560661_m1), SMA (assay ID: Rn01759928_
g1), and Thy-1 (assay ID: Rn00562048_m1) according to
the manufacturer’s instructions. Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was used as endogenous
control. All samples were run in triplicate, in a 20-l reaction
volume. Results were obtained as threshold cycle (CT) val-
ues. Expression levels were calculated using the CT
method. The values were calculated as the mean values of
three independent measurements, and the expression lev-
els of mRNA in all samples were defined as a ratio to
GAPDH expression.
Morphological Analysis
Frozen sections (10 to 20 m) were fixed in methanol and
were incubated at room temperature (1 hour) with a mix-
ture of the primary antibodies (Table 1) and with appropriate
secondary antibodies afterward (Jackson ImmunoResearch,
West Grove, PA). All samples were analyzed by confocal
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laser-scanning microscopy using the Bio-Rad MRC-1024
system (Bio-Rad, Richmond, CA). Negative controls were
performed by replacing the primary antibodies with preim-
mune sera (data not shown).
Co-localization analysis was performed using the Im-
age J program (National Institutes of Health, Bethesda,
MD). The red (channel 1) and green (channel 2) images
were acquired separately and sequentially to avoid
bleed-through. The area fraction (%) occupied by red
and green fields was determined by manual threshold-
ing. Analysis of co-localized points (%) was determined
using the co-localization plug-in.
Preparation of liver tissue for immunoelectronmicros-
copy was described by Paku and colleagues.15 Cryosec-
tions were rinsed in phosphate-buffered saline and incu-
bated with the primary antibody Thy-1 (dilution 1:100, 3
hours), followed by peroxidase-conjugated anti-mouse
antibody (dilution 1:500, catalog no. 715-035-1500; Jack-
son ImmunoResearch). Semithin sections were slightly
stained by 0.5% toluidine blue (pH 8.5), and unstained
ultrathin sections were analyzed on a Philips CM 10 elec-
tron microscope (Philips, Eindhoven, The Netherlands).
Results
Thy-1 Expression in the Normal Liver
Transcripts for Thy-1 were not detected by Northern blot
analysis in mRNA preparations from whole normal liver
(Figure 1A) and were undetectable in preparations of
nonparenchymal cells isolated from normal liver and en-
riched with a protocol for oval cells (Figure 1B). Likewise,
qRT-PCR analysis detected low AFP, Thy-1, and SMA
expression in normal liver (Figure 2).
Thy-1 expression by immunohistochemistry was detect-
able and confined to the periportal region (Figure 3, A, B, C,
and E; and Supplemental Figure 1A available at http://ajp.
amjpathol.org). There was some faint cloudy staining around
the major interlobular bile ducts (Figure 3A, and Supple-
mental Figure 1A available at http://ajp.amjpathol.org).
Figure 1. Northern blot analysis for the expression of Thy-1, AFP, and S18.
A: RNA was isolated from whole liver of normal, sham-operated (sham),
partially hepatectomized (PHx), and AAF/PHx-treated animals. The numbers
refer to the daily dose of AAF. Animals were sacrificed at 1, 5, and 9 days after
PHx. B: RNA was isolated from the oval cell fraction from control and
AAF/PHx (AAF dose, 18 mg/kg/day)-treated rats. The strong AFP band in the
second lane confirms the presence of oval cells in the enriched cell popu-
lation. Notice the lack of Thy-1 expression in this cell population.
Table 1. Primary Antibodies Used for the Immunohistochemical Studies
Antibody Species Manufacturer* Catalog number Dilution
Laminin Rabbit polyclonal DAKO Z0097 1:200
Anti-rat Thy-1 Mouse monoclonal BD Pharmingen 554895 1:100
FITC-labeled anti-rat Thy-1 Mouse monoclonal BD Pharmingen 554897 1:50
Anti-human Thy-1 Mouse monoclonal BD Pharmingen 550402 1:100
FITC-labeled anti-human Thy-1 Mouse monoclonal BD Pharmingen 555595 1:50
GFAP Mouse monoclonal BD Pharmingen 556330 1:100
Anti-human cytokeratin-19 Mouse monoclonal BioGenex MU246-UC 1:50
Anti-rat cytokeratin-19 Mouse monoclonal Novocastra NCL-CK19 1:50
OV-6 Mouse monoclonal R&D Systems MAB2020 1:100
FITC-labeled cytokeratin Mouse monoclonal DAKO F0859 1:10
Desmin Rabbit polyclonal Neomarkers RB-9014-P1 1:100
Smooth muscle actin Mouse monoclonal DAKO M0851 1:100
OX-62 Mouse monoclonal Serotec MCA1029G 1:100
Mononuclear phagocyte (rMPh/ED-1) Mouse monoclonal BD Pharmingen 554954 1:100
Lyve-1 Rabbit polyclonal Reliatech 102-PA505 1:100
CD45 Mouse monoclonal BD Pharmingen 550566 1:100
DAKO, Glostrup, Denmark; BD Pharmingen, San Jose, CA; Biogenex, San Ramon, CA; Novocastra, Newcastle upon Tyne, UK; R & D System,
Minneapolis, MN; Neomarkers, Fremont, CA; Serotec, Oxford, UK; Reliatech, Bvaunschweig, Germany.
Figure 2. qRT-PCR analysis of AFP, Thy-1, and SMA mRNA in whole liver of
normal and AAF/PHx (9 days after PHx)-treated animals and in microdis-
sected oval cell populations. The relative expression levels of AFP, Thy-1,
and SMA were determined by comparing with that of GAPDH expression
level (100%).
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Thy-1 antibody decorated more intensely and sharply the
cross sections of peripheral nerves (Figure 3A, and Sup-
plemental Figure 1A available at http://ajp.amjpathol.
org). These nerves were also positive for synaptophysin
(data not shown). Scattered undefined cells inside the
portal areas also expressed Thy-1 (Figure 3, C and E).
Desmin antibody reacted with nonparenchymal cells in
the liver lobule in addition to the muscular wall of the
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blood vessels and scattered single cells in the periportal
connective tissue (Figure 3, C and D). Conversely, no
SMA-positive cells were seen inside the liver lobule; only
the vessel walls were stained (Figure 3, D and E). Glial
fibrillary acidic protein (GFAP), an established marker of
hepatic stellate cells, decorated scattered single cells in
the liver lobules. There was no overlap between the GFAP
and Thy-1 reaction (Figure 3B).
Thy-1 Expression in the Stem Cell-Mediated
Liver Regeneration
In rat liver treated according to the AAF/PHx protocol,
oval cells formed ductules invading the liver lobules dur-
ing the first 7 to 10 days. These ductules are surrounded
by continuous basement membrane, and there are nu-
merous stellate cells/myofibroblasts around them.15 The
number of transit-amplifying oval cells depends on the
dose of AAF as demonstrated by the levels of AFP tran-
scripts—the most widely used marker for rat oval cells
(Figure 1A). A similar expression pattern was found in
whole liver for Thy-1, confirming that Thy-1 expression is
induced during oval cell-mediated liver regeneration
(Figure 1A). However, when isolated oval cells from AAF/
PHx-treated animals were examined, no expression of
Thy-1 was detectable despite increased levels of AFP
transcripts (Figure 1B). qRT-PCR also failed to detect
Thy-1 (and SMA) expression in RNA isolated from micro-
dissected oval cells, while AFP RNA was present. How-
ever, Thy-1 and SMA expression could be demonstrated
by qRT-PCR from whole liver sections. Therefore, we
performed a thorough immunohistochemical analysis of
the Thy-1 expression.
The staining pattern with the different antibodies was
identical in all studied time points. The laminin-containing
basement membrane surrounded the CK-19-positive
oval cell ductules. The Thy-1 reaction was observed con-
sistently outside the basement membrane (Figure 3, F
and G; and Supplemental Figure 1, B and C, available at
http://ajp.amjpathol.org). The antibody sometimes labeled
round, cellular body-like elements, but frequently only
stripes or cell processes were positive. Thy-1 immunore-
actions were easily abolished by detergent pretreatment.
If sections were pretreated for 5 minutes in 0.05% Triton
X-100, the staining was faint whereas pretreatment for 10
minutes resulted in complete disappearance of the reac-
tion (data not shown). Thy-1 antibody also decorated
cellular elements and long processes outside the base-
ment membrane in human livers with extensive ductular
reactions because of fulminant liver failure (Figure 3H).
The pattern of Thy-1 reaction was reminiscent of stellate
cell/myofibroblast architecture, which also could be found
outside the basement membrane. Therefore, in the rat liver
we performed co-staining of Thy-1 and SMA or desmin, the
two most widely used stellate cell/myofibroblast markers.
SMA-positive cells appeared very early in the experiment at
the limiting plate and spread along the ductules formed by
oval cells into the parenchyma. The desmin antibody re-
acted with scattered nonparenchymal cells throughout the
liver lobule from the beginning of the experiment, but they
became more frequent in the zone of the oval cells. In the
co-staining experiments, Thy-1 showed frequent co-local-
ization with SMA (Figure 4, A–C). Of the Thy-1-positive
areas 80.3 9.6% stained with SMA, but only 58 9.3% of
the SMA-positive field was decorated by Thy-1.
Thy-1 positivity hardly overlapped with desmin; the value
of co-localization index was 6.8  2.3% (Figure 4D and
Supplemental Movie 1 available at http://ajp.amjpathol.org).
This was surprising because SMA and desmin have been
used to identify stellate cells/myofibroblasts. The co-local-
ization index of these two markers was also negligible
(7.16  1.2%) (Figure 4E).
To investigate Thy-1 co-localization with other marker
antigens, we performed further double-staining experi-
ments. Lyve-1, a new marker for the endothelial cells of
lymphatic vessels and hepatic sinusoids,16,17 did not show
any co-staining with Thy-1 in the neighborhood of the oval
cells (Figure 4F), a result that was similar to OX 62 and rMPh
markers of hepatic dendritic18 and Kupffer cells (data not
shown). In addition, CD45, a general leukocyte marker, did
not stain the Thy-1-positive structures (Figure 4G).
Immunoelectron microscopic examination of Thy-1 ex-
pression also revealed long cell processes running
clearly outside the basement membrane. Because of
immunoelectronmicroscopic processing of the samples,
the ultrastructure of labeled cells could not be examined
in detail. However, our morphological evaluation sug-
gested that the marked cells displayed features of stel-
late cells/myofibroblasts (Figure 5, A and B).
Figure 3. Thy-1 expression examined by confocal microscopy. A–E: Normal rat liver. F and G: Rat liver from an AAF/PHx experiment, 14 and 21 days after PHx.
H: A human liver with ductular reaction. C–E: Serial sections of an interlobular bile duct and its neighborhood. A: The section is triple labeled for Thy-1 (green),
cytokeratin-19 (red), and laminin (blue). The portal vein, the hepatic artery branch, and the major interlobular bile duct are surrounded by laminin-positive (blue)
basement membrane. Thy-1-positive nerve fibers (arrowheads) are present around the vessels. There is a fine Thy-1 staining around the larger interlobular bile
ducts (large arrow), but it cannot be observed around the small bile duct branches (small arrows). B: The section is triple labeled for Thy1 (green), GFAP (red),
and laminin (blue). GFAP-positive stellate cells are present only in the liver parenchyma. Thy-1 and GFAP staining show separate structures in normal liver. C:
The sections are stained for Thy-1 (green) and desmin (red). Desmin positivity can be observed in the wall of hepatic artery branches and in the capillaries of
peribiliary plexus. Note the co-localization of desmin and Thy-1 in the wall of peribiliary vascular plexus (arrowheads). Desmin-positive cells can also be
discerned within the portal area and in the liver parenchyma. There are scattered Thy-1-positive cells in the portal area (arrow). The nuclei are stained with toto-3
(blue). D: The section is stained for SMA (green) and desmin (red). SMA and desmin co-localize in hepatic artery branches and in the wall of capillaries of the
peribiliary plexus (arrowheads). SMA-positive cells cannot be found in the liver parenchyma. The nuclei are stained with toto-3 (blue). E: The section is stained
for Thy1 (green) and SMA (red). Note the co-localization of SMA and Thy-1 in the wall of peribiliary vascular plexus (arrowheads). Scattered Thy-1-positive cells
are present in the portal area (arrows). F: AAF/PHx experiment, 14 days after PHx. Triple staining for Thy-1 (green), CK-19 (red), and laminin (blue). The
CK-19-positive (red) oval cell-formed ductules (arrows) are surrounded by laminin-positive (blue) basement membrane. The oval cells are not labeled by the
Thy-1 antibody. Thy-1-positive cells were situated exclusively among the ductules, strictly outside the basement membrane. G: AAF/PHx experiment, 22 days after
PHx. Thy-1-positive (green) cells are clearly localized outside the basement membrane (laminin-positive, blue) of CK-19-positive (red) oval cell ductules
(asterisks). H: Thy-1-positive (green) cells are outside the laminin-containing basement membrane (laminin, blue) surrounding the proliferating ductules (CK-19,
red) in human liver. Scale bars: 20 m (A–E, H); 200 m (F); and 10 m (G).
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Figure 4. Confocal microscopy of Thy-1 expression combined with stellate cell/myofibroblast markers SMA and desmin. Sections are from a rat liver treated
according to the AAF/PHx protocol, 9 days after PHx. A and B: Double labeling for SMA (red) and Thy-1 (green). SMA-positive myofibroblast (A) and
Thy-1-positive cells (B) are present among the oval cell ductules (asterisks). C: The white areas on the merged image show co-localization of SMA and Thy-1.
D: Double immunofluorescence for Thy-1 (green) and desmin (red). The overwhelming majority of the green and red staining marks separate structures (arrows).
There are only a few spots showing yellow signal (arrowheads), suggesting occasional co-localization of the two antibodies. E: Double-immunofluorescent
staining for SMA (green) and desmin (red) labels different structures (arrows). F: Double labeling for Thy-1 (green) and Lyve-1 (red) in the area of proliferating
ductules. Lyve-1-positive endothelium does not express Thy-1; it is localized outside the vessels. G: The CD45 (red) staining does not overlap with Thy-1 (green).
Scale bar  50 m.
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Thy-1 Expression in Rat Liver Fibrosis Model
Thy-1 also decorated the myofibroblasts in two liver fibro-
sis models (bile duct ligation-induced cholangiofibrosis
and CCl4/phenobarbital-induced cirrhosis), which were
not characterized by oval cell proliferation (Figure 6).
Discussion
We have investigated Thy-1 expression in rat livers re-
generating by the recruitment of oval/progenitor cells.
The oval cells were not labeled by the Thy-1 antibody, but
we observed a strong periductal reaction outside the
basement membrane. There was a partial overlap be-
tween the Thy-1 and SMA staining, but no co-staining of
Thy-1 and desmin could be observed. Furthermore,
Thy-1 also marked myofibroblasts in two liver fibrosis
models without oval cell reactions.
Thy-1 is a highly conserved protein anchored by a
phosphatidylinositol to the cell membrane. Its exact func-
tion is unknown, but it has been proposed to be involved
in cell recognition, adhesion, and lymphocyte activation.1
It is expressed in a wide variety of different tissues.1,19–23
Its expression has been extensively studied in the liver.
Petersen and colleagues1 reported that hepatic oval cells
expressed the hematopoietic stem cell marker Thy-1 in
the rat. This observation led to further experiments sug-
gesting that bone marrow cells can be the precursors of
oval cells/hepatocytes. Hepatic progenitor cells in human
fetal liver also have been reported to be Thy-1-positive.7
However, Hoppo and colleagues9 found in mouse that
Thy-1-positive mesenchymal cells promoted the maturation
of Thy-1-negative hepatic progenitor cells. A subpopulation
of the Thy-1-positive cells also expressed SMA.
Our results in the rat are similar to this latter group’s
observation. In our case the CK-19-positive, laminin-sur-
rounded oval/progenitor cells were not decorated by the
Thy-1 antibody. CK-19 is an established marker of oval
cells. It is also generally accepted that the oval cells are
surrounded by continuous basement membrane, which
can be visualized by laminin immunohistochemistry. The
co-staining of these three antigens on the same section
combined by confocal microscopic analysis is a very reli-
able morphological examination. Thy-1-positive cells were
also outside the proliferating ductules in human liver, con-
firming the observation of Crosby and colleagues.24 Fur-
thermore, immunoelectronmicroscopy confirmed that the
Thy-1-positive cells are outside the basement membrane.
On traditional histological sections, it is very difficult to
distinguish conclusively between the oval and the closely
associated stellate cells/myofibroblasts. Serial sections
stained by an oval cell marker, which was used by Pe-
tersen and colleagues,1 do not provide much help. Indi-
vidual cells cannot be analyzed on serial sections, and
the histological arrangement of the two cell populations is
similar (spreading outward from the periportal region).
Our Northern hybridization and qRT-PCR analysis also
strongly support the morphological observations.
The Thy-1 molecule is bound weakly to the cell mem-
brane.25,26 Triton X-100 pretreatment in our study also
deleted the Thy-1 signal from the sections. Soluble Thy-l
Figure 5. Ultrastructural localization of Thy-1 in a rat liver treated according
to the AAF/PHx protocol, 9 days after PHx. A: Black reaction product labels
the surface of a periductal cell (asterisk). Numerous long cytoplasmic
processes showing positive reaction for Thy-1 (arrowheads) can be ob-
served close to the basal surface of the oval cell ductule (D). H, Hepatocyte;
V, vessel lumen. B: Detail of A. Thy-1-positive cytoplasmic process (arrow-
head) is localized outside the basement membrane (arrows) of the ductule
(D). Scale bars: 2 m (A); 1 m (B).
Figure 6. Thy-1 expression in other rat hepatic fibrosis models. A: Bile duct ligation-induced cholangiofibrosis. B: CCl4/phenobarbital cirrhosis model. A:
Thy-1-positive (green) cells surrounding the large proliferating bile ducts. The nuclei are stained with toto-3 (blue); the basement membrane is marked by laminin (red).
B: Thy-1-positive (green) cells are situated on the edge of the laminin-positive (red) cirrhotic septum. The nuclei are stained with toto-3 (blue). Scale bar  20 m.
Thy-1 Is a Marker of Myofibroblasts 1535
AJP November 2007, Vol. 171, No. 5
               dc_301_11
has been also described in the serum.27 Enzymatic di-
gestion during the cell isolation procedures may cause
detachment of the Thy-1 molecule, which might associate
later to other cells causing misleading results in cell
suspension.
To identify the Thy-1-expressing cells, we co-stained
Thy-1 with several other marker antibodies. The negative
results with OX-62, rMPh, and Lyve-1 excluded hepatic
dendritic, Kupffer, and sinusoidal endothelial cells as the
sources of Thy-1 expression. The position and shape of
the Thy-1-positive cells refers strongly to the so-called
stellate cells/myofibroblasts, which are well known to
have close spatial relationship with the oval cells in all
oval cell proliferation models. The partial co-staining with
SMA supports this option, as well as the Thy-1 positivity of
myofibroblasts in two hepatic fibrosis models. Thy-1-pos-
itive myofibroblasts were described in other tissues, and
the ratio of the Thy-1/ populations was a function of
their activation stage.28–31
Surprisingly, co-staining of Thy-1 with desmin, another
marker of stellate cells, could not be demonstrated.
Desmin and SMA are alternatively used markers for stel-
late cells.32 These antibodies stain comparably located
and shaped cell populations, but according to our result,
the two reactions do not overlap. The origin and pheno-
type of hepatic stellate cells/myofibroblasts is one of the
most controversial issues of liver pathobiology. It is not
known if there are different differentiation/activation stages
of the same cell population, or as Ramadori and Saile32
propose, there are two (or more) cell types with partially
overlapping phenotype. Our observations on the normal
liver and during the progression of oval cell proliferation in
the rat are in support of the view of Ramadori and Saile.32
Scattered desmin/GFAP-positive cells were observed in the
parenchyma of the normal liver, which might correspond to
the (classical, perisinusoidal, vitamin A-storing) stellate
cells. SMA-decorated cells were confined to the vessel
walls in the normal liver, but they appeared in the periportal
region very early after treatment with AAF alone (data not
shown) and later spread along the oval cell ductules. This
would imply that the SMA-positive cells would be myofibro-
blasts, derived from the periportal fibroblasts, as proposed
by Ramadori and Saile32 and Beaussier and colleagues.33
As far as we know, co-staining for SMA and desmin has not
been published in oval cell proliferation experiments. Con-
sidering the above data, the Thy-1-positive cells in the zone
of the oval cells show the closest association with the myo-
fibroblasts. The increased expression of Thy-1 in two liver
fibrosis models also supports the myofibroblastic origin of
this marker molecule.
The appearance of Thy-1-positive cells in the liver
parenchyma can be explained if some of the myofibro-
blasts acquire the Thy-1 expression during the invasion
of the liver lobule. Alternatively, it has been found that the
mesenchymal stem cells in the bone marrow are Thy-1-
positive and that this cell compartment can contribute to
wound-healing processes34 including the fibrogenesis of
the liver.35 It cannot be excluded that the Thy-1 antibody
recognizes bone marrow-derived mesenchymal cells,
which may participate in oval cell-mediated liver regen-
eration. At present, we cannot distinguish between these
two possibilities, but transplantation experiments are un-
der way to study the presence of bone marrow-originated
cells among the stellate cells/myofibroblasts. Recently,
Kisseleva and colleagues36 have described a unique
CD45 fibrocyte population in the liver. However, in ac-
cordance with our results, Kamo and colleagues37 could
not demonstrate co-expression of Thy-1 and CD45.
In conclusion, we did not find Thy-1 expression in the
hepatic oval/progenitor cell population in stem cell-medi-
ated rat liver regeneration or in human ductular reactions.
Instead, Thy-1 was localized to a subpopulation of stel-
late cells/myofibroblasts. Therefore, the use of Thy-1 as a
cell surface marker for isolation of oval/progenitor cells
from the liver is not recommended. The exact origin and
function of Thy-1-expressing cells remains to be studied.
Our results are in complete agreement with the recently
published study of Dudas and colleagues.38
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2-Acetylaminoﬂuorene Dose-Dependent Differentiation
of Rat Oval Cells into Hepatocytes: Confocal and
Electron Microscopic Studies
Sa´ndor Paku,1 Peter Nagy,2 La´szlo´ Kopper,2 and Snorri S. Thorgeirsson3
The2-acetylaminoﬂuorene (AAF)/partial hepatectomy (PH)model is oneof themost extensively
studied experimental systems for oval cell proliferation and differentiation. We have previously
described the oval cells as forming ductular structures surrounded by basement membrane,
representing extensions of the canals ofHering.Hereinwe analyze the differentiationof oval cells
into hepatocytes after varying degrees of liver damage induced by AAF. At a low dose of AAF,
most oval cells synchronously differentiate into small hepatocytes by 6 days after the PH, result-
ing in complete restoration of the liver structure in 10 days. Higher doses of AAF delay the
differentiation process and the new hepatocytes form foci, in contrast to what is observed at the
lowdose.Qualitatively, the differentiationprocess seems to be identical at the cellular level under
both conditions. The transition from the expanding oval cell population into hepatocytes was
correlated with the upregulation of hepatocyte nuclear factor 4 and the disappearance of the
basement membrane. Also, the differentiation of oval cells into hepatocytes coincided with the
loss of alpha-fetoprotein and OV-6 staining, and the replacement of the biliary cell-speciﬁc 6
integrin and connexin 43with the hepatocyte-speciﬁc1 integrin and connexin 32. In addition,
bile canaliculi form between the new hepatocytes. In conclusion, these results indicate the rate of
oval cell differentiation into hepatocytes is context dependent and suggest that, under favorable
conditions, oval cells can complete this process much faster than previously appreciated.
(HEPATOLOGY 2004;39:1353–1361.)
The liver has an enormous regenerative capacity bestillustrated by the fact that in rodents a two-thirdsloss of livermass can be replaced in a few days by the
compensatory hyperplasia of the surviving hepatocytes.1,2 In
addition, two stem cell–fed back-up regenerative systems
also exist in the liver.3–6 The activation of these dormant
stem cell systems for liver regeneration takes place when re-
sidual hepatocytes are functionally compromised, are unable
to divide, or both.We and other investigators have provided
evidence that epithelial cells of the canals of Hering are the
most probable candidates for the resident adult liver stem
cells.1,7 In case of stem cell–fed liver regeneration in rat liver,
progeny of the stem cells multiply in an ampliﬁcation com-
partment composed of the so-called oval cells.8 Oval cells
form ductular structures surrounded by a continuous base-
mentmembrane,1 forming elongations of the canals of Her-
ing, and attached their distal end to a hepatocyte of the liver
plate.
Recent studies suggest bone marrow cells may be able
to transdifferentiate into hepatocytes.5,6 It is not yet clear
if the bone marrow stem cells form hepatocytes via the
oval cells. Petersen et al.9 described bonemarrow–derived
oval cells, but other investigators have detected only the
end product, the hepatocyte.10,11 Regardless of their ori-
gin, oval cells express a phenotype that is transitional be-
tween the biliary cells and hepatocytes. Although oval
cells display several phenotypic characteristics of the ma-
ture hepatocytes (e.g., liver-enriched transcriptional fac-
tors,12 albumin production13), they differ structurally and
functionally from mature hepatocytes.
The ﬁnal step of the stem cell–fed regenerative process,
that is, the differentiation of the oval cells into hepato-
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cytes, is the focus of the present study, in which we use the
well-characterized acetylaminoﬂuorene (AAF)/partial
hepatectomy (PH) experimental model to induce oval
cells in the rat liver. Earlier, we observed that differentia-
tion of oval cells into hepatocytes depends on the dose of
AAF.14 For example, a high dose of AAF caused a delay in
the differentiation of oval cells into hepatocytes.15 Similar
results also were obtained by Alison et al.16,17 We revisited
the issue of AAF dose dependency on oval cell differenti-
ation. In particular, we asked how the dose of AAF mod-
iﬁes oval cell differentiation. Herein, we demonstrate two
patterns of oval cell differentiation. At a low dose of AAF
(i.e., when the hepatocyte damage is mild), the oval cells
rapidly and synchronously differentiate into small hepa-
tocytes. In contrast, at a higher dose of AAF (i.e., more
extensive damage to hepatocytes), differentiation of oval
cells into hepatocytes is delayed and proceeds via an in-
termediate stage in which small basophilic hepatocytes
accumulate in focal nodules. However, hepatocyte differ-
entiation is eventually identical at the cellular level at both
low and high AAF doses, that is, it is correlated with
sudden upregulation of hepatocyte nuclear factor 4
(HNF-4) and the disappearance of laminin (basement-
membrane) staining. Subsequently, oval cells lost their
phenotypic characteristics (alpha-fetoprotein (AFP),
OV-6 staining, 6 integrin, connexin 43) and gained
hepatocytic features (1 integrin, connexin 32, bile can-
alicular formation) as the differentiation process ad-
vanced.
Materials and Methods
Animal Experiments. Male F-344 rats (160–180 g)
were used for all experiments and were kept under stan-
dard conditions. The animal study protocols were con-
ducted according to National Institutes of Health
guidelines for animal care.
AAF/PH Experiment. AAF 2 mg/mL suspended in
1% dimethylcellulose (low dose, 2.5 mg/kg daily; high
dose, 5mg/kg daily) was given to the rats on 6 consecutive
days by gavage. Traditional two-thirds PH was per-
formed18 on the seventh day, which was followed by six
additional AAF treatments. Animals were killed at several
time points in pilot experiments to determine the times at
which hepatocytes differentiated in the two AAF doses.
All of the histological analyses described in the present
paper were carried out on livers 6 days after PH in the
low-dose model and 12 days after the PH in the high-dose
model.
Morphological Analysis. Cryostat sections (15–20
m) were ﬁxed in methanol and were incubated over-
night with a mixture of the primary antibodies (Table 1);
appropriate secondary antibodies were used (Jackson Im-
munoresearch, West Grove, PA). All samples were ana-
lyzed by confocal laser-scanning microscopy using Bio-
Rad MRC-1024 system (Bio-Rad, Richmond, CA).
Alpha-fetoprotein reaction was visualized by ABC perox-
idase method using DAB as chromogen (Elite kit; Vector
Laboratories, Burlingame CA). Electron microscopy was
performed as described previously.1
Retrograde Cholangiography and Analysis of the
Bile Duct Structure. The rats were anesthetized with
Nembutal.A30-gaugeneedlewas inserted into the common
bile duct, and 1 mL of the 1:10 dilution of ﬂuorescein iso-
thiocyanate-labeled lycopersicon esculentum lectin (Vector
Laboratories) was injected slowly. After 15minutes, the liver
was removed and frozen. One hundred-micrometer frozen
sections were cut and ﬁxed in 4% paraformaldehyde. Stacks
of optical sections (up to 40) were taken at 0.5 to 1-m
intervals. Horizontal views of the images were made and
analyzed using the Bio-Rad Laser Sharp software.
Results
Differentiation of Oval Cells After a High Dose of
AAF. Small foci composed of small hepatocytelike cells
(Fig. 1A) appear in the liver 10 to 12 days after the partial
hepatectomy when 5 mg/kg AAF was administered daily
Table 1. Antibodies Used for the Immunohistochemical Studies
Antibody Species Manufacturer Catalog Number Dilution
AFP Nordic Immunological Labs ShARa/AFP 1:500
Desmin Mouse monoclonal Dako M0724 1:100
Pan Cytokeratin FITC labeled Dako F0859 1:20
OV6 Mouse monoclonal Gift from Dr. Hixson 1:100
Laminin Rabbit polyclonal Dako Z0097 1:300
Connexin 43 Rabbit polyclonal Zymed 71-0700 1:100
Connexin 32 Mouse monoclonal Santa Cruz SC-7258 1:100
HNF-4 Goat polyclonal Santa Cruz Sc-6556 1:100
Integrin 1 Mouse monoclonal Serotec MCA 1791 1:100
Integrin 6 Mouse monoclonal Serotec MCA 2034 1:100
CD26 Mouse monoclonal Serotec MCA 924 1:20
Abbreviations: AFP, alpha-fetoprotein; FITC, ﬂuorescein isothicyanate; HNF-4, hepatocyte nuclear factor-4.
1354 PAKU ET AL. HEPATOLOGY, May 2004
               dc_301_11
to the rats. The cells have all the ultrastructural character-
istics of hepatocytes: abundant round nuclei, cytoplasm
rich in rough endoplasmic reticulum, mitochondria, oc-
casionally peroxisomes, and glycogen particles are ob-
served. These features are not present in the oval cells. The
foci are not composed of randomly arranged individual
hepatocytes, but tightly packed cells that form tubular
structures (Figs. 1E and 2A). The foci are relatively well
circumscribed and the small basophilic hepatocytelike
cells can be distinguished easily from the larger surround-
ing “old” hepatocytes (Fig. 1A). Oval cells are still numer-
ous in the liver at this stage and are found commonly in
contact with the randomly distributed foci.
Differentiation of Oval Cells After a Low Dose of
AAF. When 2.5 mg/kg AAF was administered daily,
fewer oval cells developed, and the oval cells did not inﬁl-
trate the hepatic lobule to the same extent as seen after the
high dose was administered. The basic difference between
the two doses becomes obvious 5 to 6 days after the PH
when oval cells rapidly differentiate into small hepato-
cytes. The structural conﬁguration of the new hepatocytes
was completely different from the foci seen after the high
dose of AAF: they were arranged in more-or-less straight
ducts (Fig. 1B). However on the cellular level, these dif-
ferentiated ductular cells were similar to the cells of the
Fig. 2. Ultrastructure of the focus in the high-dose model. (A) Electron
micrograph of the periphery of a focus. Small hepatocytes containing
numerous low-density mitochondria and rough endoplasmic reticulum
form a tubular structure. From the central lumen (L) bile canaliculi
originate (arrows). The basal side of the cells face sinusoids (S). An old
hepatocyte with dense mitochondria is visible on the bottom. A large
arrow points at the area visible at higher magniﬁcation on Fig. 2D. (B) A
fragmented basement membrane (arrowheads) is visible at the basal
surface of a small hepatocyte lacking microvilli. S, sinusoid. (C) The
basement membrane is completely absent at the basal surface of the
small hepatocytes (E, endothelial cell). (D) Detail of Fig. 2A. Bile
canaliculi sealed by desmosomes can be observed between the small
hepatocytes. Numerous microvilli project into the lumen of the canaliculi.
Scale bars: (A), 10 m; (B–D), 2 m.
Fig. 1. (A) High-dose model. Basophilic focus composed of small
hepatocytes 12 days after partial hepatectomy (PH). Numerous oval cell
cords emanate radially form the portal area. (B) Low-dose model. Small
basophilic hepatocytes can be observed around the portal tract 6 days
after PH. No typical oval cells can be seen. Arrowheads point at small
hepatocytes arranged in ductular fashion. (C) High-dose model. HNF-4–
positive (green) small hepatocytes within a focus (arrowheads). Note the
high density of the nuclei and the almost complete absence of laminin
staining within the focus. Oval cell ductules near the focus are laminin
positive. (D) Low-dose model. The differentiating small hepatocytes are
HNF-4 positive (small green nuclei). OV6-positive (red) and laminin-
positive (blue) oval cell ductules close to the portal area are not stained
for HNF-4. The nuclei of interlobular bile ducts (lower left corner) are also
negative for HNF-4. (E) High-dose model. There is no OV6 (green)
staining in the focus except several entrapped oval cell ductules (arrow-
heads). The numerous oval cells surrounding the focus are strongly
stained for OV6 and laminin (red). Scraps of laminin are present in the
focus outlining the tubular architecture of the small hepatocytes (arrows).
(F) Low-dose model. Differentiating oval cell ductule close to a portal
tract. The proximal part of the ductule has continuous laminin (red)
staining, whereas distally the basement membrane is fragmented or
absent (small arrows). The old hepatocytes show ﬁne reticular cytoplas-
mic staining for pan cytokeratin (green; arrowheads). Although a strong
membranouslike reaction is present in the proximal oval cells, the
cytoplasm of the differentiating cells over the fragmented basement
membrane already has reticular cytokeratin staining (large arrowheads).
Scale bars: (A, C, E), 100 m; (B, D), 50 m; (F), 10 m.
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foci: small polygonal cells with basophilic cytoplasm and
ultrastructural features of hepatocytes (Fig. 3A). Hepato-
cytic differentiation seemed to occur synchronously in the
overwhelming majority of the oval cells. The few un-
changed oval cells were located at the proximal end of the
ducts, whereas the distal part of the same duct was com-
posed of differentiated small hepatocytes (Fig. 1F). The
liver structure was almost normal 10 to 12 days after PH
in the low-dose model, whereas it took 23 to 25 days after
the high-dose treatment.
Differentiation of Oval Cells Into Hepatocytes
HNF-4 is Upregulated in the Differentiating Cells.
HNF-4 is a liver-enriched transcriptional factor that is
expressed in the hepatocytes but not in the biliary cells of
the normal liver.12 Oval cells were not decorated by the
HNF-4 antibody. However, nuclear staining with the
HNF-4 antibody was seen in hepatocytes that formed foci
in the high-dose model and in hepatocytes in ductlike
structures in the low-dose model (Fig. 1C, D). Newly
differentiated hepatocytes were recognized after both low
and high doses of AAF by the smaller nuclei and higher
cell densities compared with the old hepatocytes. Cells
faintly HNF-4 positive also were observed occasionally at
the distal ends of the oval cell ductules in the low-dose
model (Fig. 4C).
The Basement Membrane Disappears During the
Process of Differentiation. Laminin-containing base-
ment membrane surrounds the undifferentiated oval
cells, which also have relatively strong cytoplasmic and
membranous cytokeratin staining, unlike the weak retic-
ular staining of the hepatocytes (Fig. 1F).
Differentiating oval cells enlarge and acquire a hepato-
cytelike reticular pattern of cytoplasmic cytokeratin stain-
ing. Simultaneously, the basement membrane
disintegrates, starting at the distal end of the oval cell
ducts in the low-dose model (Fig. 1F). This observation
was conﬁrmed by electron microscopy (Figs. 2B, C and
3B). The paucity or complete lack of laminin staining was
characteristic of foci (Fig. 1C,E), but occasional en-
trapped oval cell ducts were surrounded by basement
membrane (Fig. 1E). Also, numerous undifferentiated
oval cells located outside foci were still outlined brightly
by laminin staining (Fig. 1C, E) in the high-dose model.
Changes in Integrin Expression Correlate With
Loss of Basement Membrane. We analyzed the expres-
sion of the biliary integrin 6 as well as of integrin 1,
which is present on hepatocytes and sinusoidal endothe-
lial cells in the normal liver.19 The 1 integrin was absent
from the oval cell ducts, but it is clearly present on the
small hepatocytes located in the foci (Fig. 4A). The den-
sity of 1 integrin on small hepatocytes is lower than in
the surrounding parenchyma, but the sinusoidal-type ar-
rangement already could be recognized. 1 integrin also
was expressed on the small hepatocytes (Fig. 4C) in the
low-dose model.
Opposite results were obtained with the 6 integrin.
Surfaces of the oval cells facing the basement membrane
stained positively, whereas the small hepatocytes in the
foci (Fig. 4B) and in the ducts of the low-dose model (Fig.
4D) were negative.
Characteristic Changes in Differentiation Markers
OV-6, AFP Staining, and Desmin-Positive Stellate
Cells Disappear During Differentiation. OV-620 and
AFP13 are among the most frequently used antibodies to
identify oval cell rat liver. OV-6, which is a monoclonal
antibody recognizing cytokeratin (CK) 14 and 19,21 did
not react with the differentiated hepatocytes either in the
high-dose (Fig. 1E) or low-dose AAF models (Fig. 1D).
AFP staining was lost (data not shown) from the differen-
tiated hepatocytes located in the foci or in differentiated
ducts, and desmin-positive stellate cells disappeared si-
multaneously (Fig. 4E, F).
Changes in Connexin Expression. Hepatocytes ex-
press connexin 32 in normal liver, whereas cells of the
biliary system express connexin 43.22 Oval cells were pos-
itive for connexin 43, but this protein was not present in
the newly differentiated small hepatocytes (Fig. 5B). Con-
nexin 32 was entirely lacking in oval cells (Fig. 5A), but it
highlighted very clearly the new hepatocytes in bothmod-
els (Fig. 5A). (The low-dose data are not shown.)
Fig. 3. Ultrastructure of a differentiating ductule in the low-dose
model. (A) A short, differentiating ductule near a portal tract in the
low-dose model. Two of the ductular cells (D1, D2) are attached to an
old hepatocyte, which contains numerous dense mitochondria. One
ductular cell (D3) closely resembles to hepatocytes. It has a round
nucleus with prominent nucleolus, numerous mitochondria, and organiz-
ing rough endoplasmic reticulum. (B) Detail of Fig. 3A. The basement
membrane cannot be observed at the basal side of the small hepatocyte
(D3), while it is still present (arrowheads) around the nondifferentiated
ductular cell (D4). Scale bars: (A), 10 m; (B), 2 m.
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Bile Canaliculus Formation by the Differentiating
Cells. Oval cells, which extend from the canals ofHering,
form ducts that are continuous with bile canaliculi in
hepatic plates. We studied the structure of the bile drain-
age system by CD26 staining and by retrograde infusion
of a ﬂuorescein isothiocyanate–labeled lectin into the bil-
iary system via the common bile duct.
CD26 or dipeptidylpeptidase IV23 was expressed at the
apical surface or biliary pole on the hepatocytes and on the
apical domain of the biliary and oval cells (Fig. 5C). In the
low-dose model, the pattern of CD26 staining changed
sharply where laminin staining disappeared and the oval
cells differentiated. Luminal branching to form starlike
Fig. 4. (A) High-dose model. Focus (arrowheads), 12 days after
partial hepatectomy. Sinusoids of the liver parenchyma and the focus
staining positively for 1 integrin (green). Note the lower density of
sinusoids within the focus. The oval cell ductules bordering the focus are
stained red (laminin), demonstrating the lack of colocalization of the two
signals. (B) High-dose model. The same focus (arrowheads) as on Fig. 4A
in a different sectioning plane stained for 6 integrin. The focus and the
liver parenchyma are not reacting with this antibody. Yellowish color of
the oval cell ductules bordering the focus shows that 6 integrin (green)
overlaps with the positive (red) basement membrane. (C) Low-dose
model. HNF-4 positive (small red nuclei) small hepatocytes express 1
integrin (green) mainly at their basal side (arrowheads). Weak 1
integrin positivity also can be observed at the lateral side of these cells
in some locations (small arrows). Laminin positivity (blue) cannot be
observed around the small hepatocytes. Laminin-positive oval cell
ductules are negative for this integrin and HNF-4. However, note a weak
HNF-4 nuclear staining in a differentiating cell (large arrowhead). (D)
Low-dose model. The periportal area, stained for HNF-4 (red), 6 integrin
(green), and laminin (blue). Bile and oval cell ductules are positive for
this type of integrin and laminin, whereas the small hepatocytes (small
red nuclei) are not stained. (E) High-dose model. There are numerous
laminin-positive (red) oval cell ductules, also stained positively for
desmin (green). The focus (lower left corner) is negative for desmin
except some oval cell ductules enclosed into the focus (arrows). (F)
Low-dose model. Only a few desmin-positive (red) stellate cells are
visible (arrows) around the HNF-4–positive (green) and laminin-negative
(blue) small hepatocytes still forming a ductule (arrowheads). Scale bars:
(A, C, E), 100 m; (C, D, F), 50 m.
Fig. 5. (A) High-dose model. Connexin 32 (green) is expressed by the
small hepatocytes of the focus (arrowheads). The surrounding liver
parenchyma express connexin 32 at a very low level, whereas the
laminin-positive (red) oval cell ductules are negative. (B) Low-dose
model. Oval cell ductules are stained positively for connexin 43 (red) and
OV6 (blue). The small hepatocytes marked by HNF-4 (small green nuclei)
do not express this connexin and OV-6. (C) High-dose model. Numerous
CD26-positive (green) starlike structures are discernible within the focus.
CD26 staining reveals the polygonal organization of the bile canaliculi in
the normal liver. This antigen shows a linear arrangement (arrowheads)
in the oval cell ductules surrounded by basement membrane (laminin,
red). (D) High-dose model. Higher magniﬁcation of a focus. Development
of bile canaliculi (CD26 staining, green) between the small hepatocytes
takes place only where regular basement membrane (laminin, red) is not
present. (E) Low-dose model. A differentiating oval cell tube near a portal
tract. Basement membrane (laminin, red) cannot be observed around the
starlike structure (CD26, green) representing bile canaliculi development.
(F) High-dose model. Advanced stage of the bile canaliculi development
within a focus. Beside the starlike arrangement of the CD26 staining
(green), two polygonal structures (arrows) can be seen, showing close
similarity to the bile canaliculi network of the normal liver. Some rem-
nants of the basement membrane can also be observed (laminin, red).
(G) High-dose model. Peripheral zone of a focus ﬁlled partially with
ﬂuorescein isothiocyanate labeled lycopersicon esculentum lectin. The
border of the focus is marked by arrowheads. The wide lumen of an oval
cell ductule is continuous with the narrow bile canaliculi of the focus.
Starlike (large arrowhead) and polygonal (small arrows) structures can be
recognized within the focus. Scale bars: (A, C), 100 m; (B), 50 m;
(D–G), 10 m.
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structures was observed in this area, representing the
formation of bile canaliculi and the polarization of the
new hepatocytes (Fig. 5E). The situation was very sim-
ilar in the high-dose model, where numerous starlike
lumens were detected among differentiating hepato-
cytes within foci (Fig. 5C, D). Electron microscopy of
the foci clearly showed the formation of bile canaliculi
from a central lumen between the differentiated small
hepatocytes (Fig. 2A, D). Occasionally, polygonal can-
alicular structures were outlined inside the foci by
CD26 staining (Fig. 5F), similar to the pattern of bile
canaliculi in the normal liver.
Cholangiography supported the results of CD26
staining. Broad lectin-ﬁlled ducts led to foci, where the
ducts divided into smaller branches that formed polyg-
onal canalicular structures (Fig. 5G). The newly
formed bile canaliculi also could be ﬁlled between the
small hepatocytes in the low-dose model (data not
shown).
Discussion
We report two distinct patterns for the differentiation
of oval cells into hepatocytes in the AAF/PH model (Fig.
6). When a low dose of AAF was used, most of the oval
cells differentiated synchronously and rapidly into small
hepatocytes, even while AAF was being administered.
Newly formed hepatocytes maintained a ductular ar-
rangement during the early phase of the differentiation
process. In contrast, when a high dose of AAF was used,
hepatocyte differentiation was delayed by 7 to 10 days,
and even at this later time point, most of the oval cells did
not differentiate into hepatocytes. Newly formed hepato-
cytes formed foci scattered throughout the liver with the
high dose of AAF. However, the differentiation process
seemed to be identical in the two models at the cellular
level. The small basophilic cells were very similar to the
adult hepatocytes by light microscopic and electron mi-
croscopic examination. New hepatocytes lost several phe-
notypic characteristics of oval cells, for example, AFP and
Fig. 6. Schematic representation of the two differentiation models. Low-dose model: oval cell ductules penetrate into the liver lobule and
differentiate simultaneously into small hepatocytes. High-dose model: oval cells penetrate deep into the liver lobule and most of them do not change
during the observation period. The differentiating cells arranged in tortuous and branching ductules, which form the foci. The lumen of these ductules
is continuous with the larger oval cell ductules. The developing bile canaliculi between the small hepatocytes invaginate from the central lumen of
these ductules in both models. (The days mean the time after the partial hepatectomy).
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OV-6 expression. Upregulation of albumin13 and
CYP3A116 in the newly formed cells indicated their func-
tional maturation.
The disappearance of the basement membrane that
surrounds the oval cell ductules is closely associated with
initiation of the differentiation process. Oval cells always
sit on a well-structured basement membrane1 that is al-
most completely missing from the foci. Gradual disinte-
gration of the basement membrane was observed even
better in the low-dose model. It is well known that the
connection with the basement membrane inﬂuences the
differentiation state of the cell. The close contact with the
basement membrane is absolutely required for the main-
tenance of differentiated tubules in the kidney.24 In the
skin, however, the loss of contact is a stimulus for differ-
entiation for the keratinocytes.25 The hepatocytes have no
contact with laminin containing structured basement
membrane. Yin et al.26 reported that isolated hepatic stem
cells expressed biliary or hepatocytic phenotypes in cul-
ture, depending on the presence or absence of basement
membrane matrix (Matrigel). Matrigel also was found to
play an important role in maintaining the biliary pheno-
type in tissue culture in other experimental systems.27,28
These observations are in good agreement with our in vivo
results.
Integrins are heterodimeric glycoproteins, consisting
of  and  subunits, that enable cells to recognize adhe-
sive substrates in the extracellular matrix. The 6 integrin
subunit binds laminins exclusively. The expression of the
6 integrin and laminin seem to inﬂuence each other.
The induction of6-containing integrins at the surface of
developing epithelial cells is strongly correlated with the
deposition of laminin.29,30 The downregulation of the
laminin receptor was described in differentiating HBC-3
hepatic stem cells in culture.31 The disappearance of the
6 integrin from differentiating oval cells is in good agree-
ment with the disintegration of the basement membrane.
In the normal liver, 6 and 1 integrins are expressed on
biliary cells and hepatocytes, respectively.19 Therefore,
the 6-1 switch is another indicator of the hepatocytic
differentiation. The opposite change was described when
the hepatoblasts differentiated into biliary cells.32 The 1
integrin is present on the basal surface of endothelial cells
and on the basolateral surface of small hepatocytes. This
polarized expression may promote the establishment of
connections with collagenous components of the perisi-
nusoidal space, an important step in the reconstruction of
the normal trabecular liver structure.
The upregulation of HNF-4 expression may play a
central role in the induction of hepatocytic differentiation
of the oval cells. HNF-4 is not present in oval cells, but it
clearly decorates the nuclei of small hepatocytes in both
models, and a faint staining was sometimes observed in
the transitional cells in the low-dose model. In an earlier
work, we failed to detect HNF-4 mRNA in oval cells,
although other liver enriched transcriptional factors were
present.12 However, HNF-4 mRNA was upregulated in
foci of small basophilic hepatocytes, suggesting a critical
role for this transcription factor in the oval cell differen-
tiation.12 The lack of expression of a functional HNF-4
gene results in embryonic lethality in mice before devel-
opment of the liver as a result of defects in visceral
endoderm function.33 However, HNF-4 null mouse em-
bryos can be rescued until E12.0 by extraembryonic
endoderm complementation.34,35 Livers from these
endoderm-complimented embryos were morphologically
and histologically indistinguishable from wild-type em-
bryos.When themRNA level of hepatocyte-speciﬁc genes
was compared between wild-type and HNF-4 null livers,
it was found that the expression of these genes were either
downregulated or undetectable in the genetically manip-
ulated mice. Similar results were found in adult hepato-
cytes that lack HNF-4.36 These data suggest that HNF-4
is not required during ontogenesis for the competency of
hepatic precursor cells or for their speciﬁcation, but it
must be present during the ﬁnal step of hepatocyte differ-
entiation to establish the hepatocytic gene expression pat-
tern. This observation is consistent with our current
results that indicate the critical role of HNF-4 in the
transition of oval cells into hepatocytes.
HNF-4 also is expressed in the intestinal glands,37 and
intestinal metaplasia is another option for the oval cells.38
One of themajor differences between the intestinal glands
and hepatocytes is that the enterocytes reside on a lami-
nin-containing basement membrane. It is possible that
the upregulation of HNF-4 without the disintegration of
the basement membrane may be responsible for the “ab-
normal” differentiation of oval cells into intestinal epithe-
lium.
Connexins form special membrane structures, the gap
junctions (connexons), which play crucial role in the in-
tercellular communication. Connexin 32 is expressed on
hepatocytes, and connexin 43 is expressed on the biliary
epithelial cells in the normal rat liver.39 Zhang and Thor-
geirsson40 reported that the mRNA for connexin 43 is
expressed in the oval cells and connexin 32 in the small
hepatocytes of the foci. Here we conﬁrm this observation
at the protein level. The switch from connexin 43 to con-
nexin 32 can be observed in both the low-dose and high-
dose models of oval cell differentiation. Because connexin
32 and connexin 43 hemichannels do not form hetero-
topic patent channels,41 the described switch is required
for the newly formed hepatocytes to be integrated into the
preexisting liver plates and to communicate with the pre-
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existing hepatocytes. It alsomay be of importance that the
stellate cells also express connexin 43.42 The expression of
identical connexins on the oval cells and stellate cells may
be important in the establishment of the close communi-
cation between these two cell types. The loss of connexin
43 from the oval cells coincides with the disappearance of
stellate cells. It is well documented that the stellate cells
provide a battery of growth factors that support the pro-
liferation of oval cells.43 The inductive role of mesenchy-
mal cells during the speciﬁcation of hepatic lineage also is
well known.44 Stellate cells may provide support for the
growth of oval cells, as does the portal mesenchyme dur-
ing embryogenesis. This notion is supported by the sug-
gestion that the stellate cells may be derived from the
embryonic septum transversum.44
We observed the development of biliary canaliculi
among the newly formed hepatocytes in both models by
infusing the biliary system with ﬂuorescein isothiocya-
nate–labeled lectin via the common bile duct. The pen-
tagonal and hexagonal bile canalicular patterns in the foci
are similar to the arrangement present in the normal liver.
This structural similarity indicates the architectural re-
modeling in the foci toward the normal hepatic structure.
The CD26 epitope is present on the canalicular surface of
the normal hepatocytes.23 The similar CD26 staining pat-
tern on the newly formed small hepatocytes marks the
functional polarization of these cells.
The morphological and immunophenotypical charac-
teristics clearly show that oval cells differentiate into hepa-
tocytes at both low and high doses of AAF. Although both
the rate of differentiation and timing of the process differ
with AAF dose, the differentiation process at the cellular
level seems to be identical. Furthermore in both models,
the differentiating small hepatocytes can regenerate the
liver after two-thirds PH, because the old hepatocytes do
not show mitotic activity. At this point, we can only spec-
ulate about the cause of focus formation, when a high
dose of AAF was applied. A plausible explanation may be
that the high dose of AAF inhibits the low dose–type
differentiation of the oval cells, as suggested by Alison et
al.16 However, the inhibitory effect of the high dose of
AAF primarily may affect the later stages of oval cell dif-
ferentiation into hepatocytes, and this in turn can atten-
uate the necessary remodeling needed to rebuild the liver
structure. It is possible that this or a similar scenario can
contribute to the focus formation seen after administra-
tion of the high dose of AAF. Whether this process in-
volves genetic or adaptive epigenetic mechanisms, or
both, is not clear. However, we have not observed liver
tumors in the rats subjected to the high AAF doses used
here, suggesting that if a mutation(s) is involved in the
process, it may not be carcinogenic. Nevertheless, the fo-
cus formation pattern of oval cell differentiation after
high doses of AAF identiﬁes, independent of the precise
mechanism(s), an efﬁcient differentiation process that is
functional under adverse conditions. Therefore, further
characterization of the high-dose model may be very use-
ful to delineate the factors that can be used to enhance the
differentiation efﬁciency of the hepatic stem cells. This
issue may have important implications for the clinical
application of adult liver stem cells. Also, the fact that oval
cells can, under favorable conditions (e.g., in the low-dose
AAFmodel), rapidly differentiate in new hepatocytes that
effectively integrate into liver plates raises the intriguing
possibility that adult liver stem cells may contribute to
liver regeneration and repair more often than previously
anticipated. Finally, this study provides no evidence that
hematopoietic bone marrow stem cells are involved in the
generation of new hepatocytes through oval cells, which
seem to be totally derived from epithelial cells of the ca-
nals of Hering.
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Abstract The 2-acetaminoXuorene/partial hepatectomy
(AAF/Phx) model is widely used to induce oval/progenitor
cell proliferation in the rat liver. We have used this model
to study the impact of a primary hepatocyte mitogen, tri-
iodothyronine (T3) on the liver regenerating by the
recruitment of oval/progenitor cells. Administration of T3
transiently accelerates the proliferation of the oval cells,
which is followed by rapid diVerentiation into small hepa-
tocytes. The oval cell origin of the small hepatocytes has
been proven by tracing retrovirally transduced and BrdU
marked oval cells. The diVerentiating oval cells become
positive for hepatocyte nuclear factor-4 and start to express
hepatocyte speciWc connexin 32, 1 integrin, Prox1, cyto-
chrom P450s, and form CD 26 positive bile canaliculi. At
the same time oval cell speciWc OV-6 and alpha-fetoprotein
expression is lost. The upregulation of hepatocyte speciWc
mRNAs: albumin, tyrosine aminotransferase and trypto-
phan 2,3-dioxygenase detected by real-time PCR also
proves hepatocytic maturation. The hepatocytic conversion
of oval cells occurs on the seventh day after the Phx in this
model while the Wrst small hepatocytes appear 5 days later
without T3 treatment. The administration of the primary
hepatocyte mitogen T3 accelerates the diVerentiation of
hepatic progenitor cells into hepatocytes in vivo, and that
may have therapeutic potential.
Keywords Oval cell · Maturation · Regeneration · 
Retroviral transduction · Primary mitogen
Abbreviations
AAF 2-AcetaminoXuorene
BrdU Bromodeoxyuridine
HNF-4 Hepatocyte nuclear factor 4
Phx Partial hepatectomy
T3 Triiodothyronine
AFP Alpha-fetoprotein
TAT Tyrosine aminotransferase
TO2 Tryptophan 2,3-dioxygenase
Cx Connexin
Introduction
The “oval cell” proliferation in the rat liver represents a stem
cell derived regenerative process (Alison 2003; Grisham and
Thorgeirsson 1997; Batusic et al. 2005). The stem cell com-
partment is activated when hepatocytes are compromised
(e.g., viral infection, chemical toxicity) and not able to
respond to proliferative stimuli needed for liver regenera-
tion. The oval cells constitute the transit amplifying or pro-
genitor cell compartment in the liver, and form a branching
ductular network which is the extension of the canals of
Hering (Paku et al. 2001). It has been reported that bone
marrow derived oval cells may contribute to the regenerative
process (Petersen et al. 1999) but this transdiVerentiation
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               dc_301_11process is very ineYcient if it occurs at all (Wagers et al.
2002; Thorgeirsson and Grisham 2006). However, it is
generally agreed that the oval cells are able to diVerentiate
into cholangiocytes and hepatocytes replacing the lost liver
parenchyme (Alison 2003; Grisham and Thorgeirsson 1997;
Fausto 2004; Paku et al. 2004). The growth regulation of
these cells has been characterized. There are several growth
factor/receptor systems, which are active during this process
and are responsible for the expansion of the oval cell popu-
lation (Grisham and Thorgeirsson 1997; Fausto 2004). The
diVerentiation of the oval cells can be induced by diVerent
compounds in vitro (Kaplanski et al. 2000; Kamiya et al.
2002; Heng et al. 2005), but there are hardly any data about
the in vivo modulation of the diVerentiation.
The primary hepatocyte mitogens are able to induce hepa-
tocyte proliferation even without preceding liver damage
(Columbano and Shinozuka 1996). Their biological eVect has
been studied in several experimental models, but the inXu-
ence of primary hepatocyte mitogens on oval cells has not
been investigated. One of the primary mitogens, triiodothyro-
nine (T3), has been reported (Malik et al. 2003) to enhance
the regenerative capacity of the liver following Phx. Another
one, WY 14,643 induced the diVerentiation of oval cells
(Kaplanski et al. 2000) in vitro. Here we investigated, if T3
can inXuence the stem cell driven liver regeneration. Oval/
progenitor cell proliferation was generated by the widely used
AAF/Phx model (Tetamatsu et al. 1984). We found that a sin-
gle dose of the primary hepatocyte mitogen T3 (Francavilla
et al. 1994) accelerated the proliferation and diVerentiation of
oval cells into hepatocytes. The hepatocytic diVerentiation of
the oval cells was conWrmed by morphological, immuno-
phenotypical and mRNA expression characterization.
Materials and methods
Animal experiments
Male F-344 rats (160–180 g) were used for all experiments
and were kept under standard conditions. At least four ani-
mals were used for each experimental time points (unless
otherwise marked). The animal study protocols were con-
ducted according to National Institutes of Health guidelines
for animal care.
AAF/Phx experiment
2-AcetaminoXuorene (AAF) (2 mg/ml suspended in 1%
dimethylcellulose) in a dose of 5 mg/kg was administered
to rats daily for four consecutive days by gavage. Tradi-
tional two-thirds partial hepatectomy (Phx) was performed
(Higgins and Anderson 1931) on the Wfth day, which was
followed by four additional AAF treatments (Fig. 1a).
Treatment by triiodothyronine
AAF/Phx experiment was performed as described above. T3
(400 g/kg i.p.) was injected into the rats on the Wfth day fol-
lowing the Phx (Fig. 1b).The rats were sacriWced 48 h after
the mitogen treatment. Tissue samples were taken for histo-
logy, blood was drawn from the right ventricle of the heart
for laboratory examinations. The control animals were
treated by the AAF/Phx protocol but at the time of the mito-
gen treatment were administered only by the solvent.
Additional control groups
Additional preliminary control experiments were per-
formed: AAF/sham operation + T3; Phx + T3; normal
rat + T3. Neither of these protocols resulted in oval cells,
therefore these data were not shown.
For pulse, labeling 100 mg/kg BrdU (Paku et al. 2001)
was given to the rats at 18, 24, 48 and 96 h after the mito-
gen treatment and they were sacriWced 1 h later.
For pulse chase experiment 200 mg/kg BrdU was
injected into the rats 2 h before the T3 treatment. The pulse
animals were sacriWced 1 h later (without mitogen treat-
ment). The chase animals were sacriWced 48 h after the
mitogen treatment.
Apoptotic cell death has been scored histologically
based on the detection of condensed and fragmented nuclei
and cells (Wyllie et al. 1980).
Morphological analysis
Frozen sections (10–20 m) were Wxed in methanol
(4% paraformaldehyde for beta galactosidase) and were
incubated at room temperature (1 h) with a mixture of
diVerent primary antibodies (Table 1) and with appropriate
secondary antibodies afterwards (Jackson Immunoresearch).
Fig. 1 Schematic representation of the experimental protocols. The Wrst
hepatocytes appeared on the eleventh day in the control group (a),
whereas they showed up on the seventh day in the T3 treated animals (b)123
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microscopy using Bio-Rad MRC-1024 system (Bio-
Rad, Richmond CA). For the BrdU staining the sections
were pretreated with HCl as described before (Paku et al.
2004).
Determination of labeling index of oval cells and small 
hepatocytes
Labeling indexes were determined by using 3–4 animals at
each time point. About 500–1,000 nuclei were counted per
animal.
Oval cells
Oval cells basement membrane was highlighted by incubating
frozen sections with anti-laminin primary antibody followed
by biotinylated secondary antibody and TRITC conjugated
streptavidin (red Xuorescence). The same sections were
treated with 2 N HCl, followed by BrdU staining (green
Xuorescence) (Paku et al. 2001). Nuclei were stained by
DAPI. Areas around portal tracts were randomly selected
using a 100£ objective. The number of labeled and the
total number nuclei surrounded by continuous basement
membrane were determined.
Small hepatocytes
Small hepatocytes frozen sections were stained by HNF-4
antibody (green Xuorescence) followed by HCl treatment
and BrdU staining (red Xuorescence). Nuclei of small hepa-
tocytes were identiWed according to their size and density
(small hepatocytes have a considerable smaller nucleus
than the old hepatocytes and are arranged frequently as
small groups with high density). BrdU labeled and total
number of HNF-4 positive nuclei of small hepatocytes was
determined.
Real-time PCR
Frozen sections (10 m) were Wxed in acetone, dried at
room temperature and stained with RNase-free hematoxy-
lin. Laser microdissection of tissue sections was performed
by using PALM MicroBeam system. About 500–1,000
cells were collected in lysis buVer and total RNA was iso-
lated by RNeasy Mini Kit (Qiagen, Hilden, Germany).
MMLV Reverse Transcriptase (Invitrogen, Carlsbad, CA)
was used for cDNA synthesis as recommended by the sup-
plier. PCR was performed by ABI Prism 7000 Sequence
Detection System Applied Biosystems, Foster City, CA),
using ABI TaqMan assays for albumin (Assay ID:
Rn00592480_m1), AFP (Assay ID: Rn0056061_m1), tryp-
tophan 2,3-dioxygenase (Assay ID: Rn00574499_m1),
tyrosine aminotransferase (Assay ID: Rn00562011_m1),
according to the manufacturer’s instructions. Beta-actin
was used as endogenous control. Relative gene expressions
were calculated by the 2[-Delta Delta C(T)] method (Livak
and Schmittgen 2001).
Retroviral transduction
We used the amphotropic retroviral vector (kindly provided
by Nicholas Ferry, France) containing the E. coli -galacto-
sidase gene coupled to the nuclear localization signal
from a SV 40 large T antigen, produced by the TEL-
CeB6 producing cell line (Avril et al. 2004). To increase
Table 1 Primary antibodies 
used for the immunohistochemi-
cal studies
Antibody Species Manufacturer Catalog 
number
Dilution
Laminin Rabbit polyclonal Dako Z0097 1:200
HNF-4 Goat polyclonal Santa Cruz Biotechnology SC-6556 1:100
BrdU Mouse monoclonal Becton-Dickinson 347580 1:100
Connexin 32 Goat polyclonal Santa Cruz Biotechnology SC-7258 1:100
CD 26 Mouse monoclonal Serotec MCA924 1:20
OV-6 Mouse monoclonal R&D Systems MAB 2020 1:100
Cytochrome P450 Rabbit polyclonal MBL BV-3084-3 1:100
AFP Mouse monoclonal Nordic Immunological 
Laboratories
ShARa/AFP 1:50
1 integrin Mouse monoclonal Serotec MCA 1791 1:100
Thyroid hormone 
receptor beta-1
Mouse monoclonal AYnity Bioreagents MA1-216 1:10
E. coli beta 
galactosidase
Goat polyclonal Serotec 4600-1409 1:1000
Prox 1 Rabbit polyclonal Reliatech 102-PA30 1:20
Dlk-1 Goat polyclonal R&D AF1144 1:100123
1008 Histochem Cell Biol (2008) 130:1005–1014
               dc_301_11the concentration of retroviral particles the supernatant was
centrifuged at 20,000g for 4 h, as described by Yang et al.
(2002). Retroviral titer was determined by infecting NIH
3T3 cells in 24-well dishes with 500 l of serial dilutions of
the retrovirus containing supernatant. The cells were
stained 48 h later with X-gal and the titer was deWned. After
concentration, the titer routinely reached 5 £ 106 per milli-
liter. The viruses were injected into the liver of the AAF/
Phx treated animals 2 days after the Phx through the com-
mon bile duct. The Wrst sets of rats were sacriWced 3 days
later without T3 treatment (pulse). The second sets of rats
were injected by T3 on the Wfth day following the Phx and
sacriWced 2 days later (chase).
Results
T3 enhances the oval cell proliferation and accelerates 
liver regeneration
A single dose of the thyroid hormone was given on the Wfth
day after the partial hepatectomy for the rats treated accord-
ing to the AAF/Phx experimental protocol. Following the
treatment the relative liver weight (liver/body weight) of
the T3 treated rats increased in 48 h compared to the con-
trol (solvent treated) rats (Table 2).
The histological structure of the livers changed dramati-
cally in the T3 treated animals. The majority of the oval
cells disappeared. Small, sometimes trabecularly arranged
polygonal cells emerged in the periportal zone. They had
round nuclei and looked like small hepatocytes (Fig. 2a, b).
The rate of DNA synthesis was measured by BrdU pulse
labeling (Table 3.). Practically there was no labeling in the
hepatocytes in any of the studied timepoints. BrdU incorpo-
ration was signiWcantly higher in the oval cells of the rats at
18 h after administration of T3 compared to the solvent
treated rats. The BrdU was also taken-up late by the newly
formed polygonal cells, although the labeling index was
lower than in the oval cells of the control rat livers. Later at
96 h, the proliferation rate of the remaining oval cells
returned to the control level. The oval cells carry the thy-
roid hormone receptor that is they may be inXuenced by
this hormone (Fig. 2c).
The T3 treatment induced hepatocyte hyperplasia is fol-
lowed by a wave of apoptosis (Francavilla et al. 1994) in
the normal liver. Practically no such apoptosis response
was observed in the AAF/Phx treated animals after the
mitogenic treatment (2.25 § 1.26 apoptosis per 5,000 cells
vs. 19.66 § 3.21 apoptosis per 5,000 cells in the controls,
normal untreated rats 4 days after T3 administration,
P < 0.01).
The small polygonal cells derive from the oval cells
Although the dynamics of histomorphological changes
indicated the oval cell origin of the newly formed small
polygonal cells, this relationship was veriWed by two inde-
pendent pulse chase experiments.
1. BrdU was given to the rats 2 h before the T3 treatment.
The Wrst set of animals was killed 1 h later that is
before the T3 administration. BrdU was incorporated,
in addition to the non-parenchymal cells, into the
nuclei of the oval cells, no staining was present in the
“old” hepatocytes (Fig. 2d). The oval cells could be
identiWed by laminin staining, the basement membrane
surrounded tubular arrangement (Paku et al. 2004) is
highly characteristic for these cells in the AAF/Phx
model. Dlk-1, another oval cell marker (Jensen et al.
2004; Tanimizu et al. 2004) also decorates a subset of
oval cells, a portion of the BrdU positive cells are also
Dlk-1 positive (Fig. 2e). The second set of rats was
sacriWced at 48 h following the T3 treatment. BrdU
decorated the nuclei of the small, hepatocyte like cells
which were also positive for HNF-4 and CYP 450. The
BrdU staining was present in small dots indicating the
dilution of the pyrimidine analogue since the adminis-
tration (Fig. 2f, g). The “old” hepatocytes remained
negative at the 48 h time-point as well.
2. The proliferating OV-6 positive oval cells were also
exclusively marked in another experiment by beta-
galactosidase expressing retroviruses 2 days after the
Phx that is 3 days before the T3 administration
(Fig. 3a). When the labeled oval cells were traced
2 days after the T3 treatment, groups of the small
polygonal cells, expressing CYP 450 were found with
beta-galactosidase positive nuclei (Fig. 3b) without any
labeling in “old” hepatocytes.
The oval cells diVerentiate rapidly into small basophilic 
hepatocytes following triiodothyronine treatment
We have performed several studies to demonstrate that the
oval cell derived small polygonal cells are functional hepa-
tocytes indeed. The upregulation of HNF-4 (Fig. 2f, 4a, b)
in the small cells already supports this notion (Hakoda et al.
Table 2 EVect of T3 treatment on liver weight and functional activity
of the liver
* P < 0.05
Relative 
liver weight 
(%)
Serum billirubin 
concentration 
(mol/l)
Plasma 
prothrombin 
level (%)
Control 2 § 0.25 17.6 § 16.9 21.3 § 18.5
T3 2.6 § 0.41* 5.4 § 4.9* 49.2 § 25.5*123
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speciWc OV-6 (Dunsford and Sell 1989), AFP (Petropoulos
et al. 1985) and laminin reaction (Fig. 4c) indicates severe
phenotypic changes. CD 26 staining demonstrated the
formation of the bile canaliculi among the small polygonal
cells (Fig. 4d). At the same time immunohistochemistry
indicated the rapid gain of hepatocyte speciWc Cx32, 1
integrin (Fig. 4e, f) and cytochrome P450 IIE1 expression
(Fig. 2g, 3b and 4a), all these antigens are completely
missing from the oval cells. A recently described marker of
hepatocytic diVerentiation, Prox1 (Dudas et al. 2006) was
also present in the diVerentiating oval cells and small hepa-
tocytes following the T3 treatment (Fig. 4b). Interestingly a
few OV¡6+ cells was already Prox1+ but HNF4¡. This is
Fig. 2 a, b AAF/Phx experiment, H&E staining, seventh day follow-
ing Phx. Control rat (a), T3 treated animal (b), T3 was given on the
Wfth day after Phx. Note the appearance of small basophilic hepato-
cytes, oval cells can be hardly seen. c The reaction with thyroid hor-
mone receptor antibody (green) resulted in nuclear staining in the
hepatocytes as well as in the laminin (blue) surrounded oval cells.
(AAF/Phx experiment, 5 days after Phx) d–g Pulse-chase experiment,
with BrdU of AAF/Phx treated rats. d Fifth day after Phx, 1 h after
BrdU administration (“before” T3 treatment). BrdU (red) is incorpo-
rated into the nuclei of laminin (blue) surrounded oval cells (arrows)
and scattered non parenchymal cells. Note the HNF-4 positive (green)
nuclei of the hepatocytes do not contain BrdU. e The same animal as
on “D”. Dlk-1 (red) stains a subpopulation of oval cells. Note the par-
tial costaining of BrdU (green) and Dlk-1 (arrows). f Two days after
T3 treatment. Colocalization of small BrdU (red) dots and HNF-4
(green) in nuclei. Note that the HNF4 and BrdU positive nuclei of the
“new” hepatocytes (arrows) are smaller, than those of the “old” hepa-
tocytes (arrowheads). g The same liver as on “E”. Note the presence of
BrdU in CYP 450 expressing cells. Two days after T3 treatment a
group of small hepatocytes (arrows) shows weaker reaction intensity
for cytochrome P 450 (green) than the surrounding old hepatocytes.
Scale bar for a, b: 25 m; c, d, e, f, g: 50 m123
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this observation may indicate the heterogeneity of the
diVerentiation reaction or that Prox1 is an earlier marker of
the hepatocytic comittment of oval cells, than HNF4.
The changes of gene expression were studied by real-
time RT-PCR. Oval cells were microdissected from the
liver of T3 treated animals 48 h after the T3 treatment as
well as from control (solvent treated AAF/Phx) rats. Newly
formed small hepatocytes 48 h after the T3 treatment and
hepatocytes from normal, healthy untreated rats were also
dissected. The gene expression was compared in normal
hepatocytes and small polygonal cells appearing at 48 h
after the T3 treatment (Fig. 5). The expression of albumin,
TAT and TO2 was signiWcantly upregulated in the newly
formed hepatocytes compared to the oval cells, while the
AFP expression sharply dropped. There were some changes
between the T3 treated and untreated oval cells but the
change were more dramatic in the small hepatocytes indi-
cating qualitative alterations.
The functional capacity of the newly formed hepatocytes
was revealed by blood chemistry tests. The decrease of the
serum bilirubin level and increase of prothrombin level
2 days after the T3 treatment indicated better liver functions
(Table 2).
Discussion
T3 is a well known mitogen for hepatocytes. A single dose
of this hormone induces a massive hyperplastic reaction of
the hepatocytes and hepatomegaly in normal rat (Franca-
villa et al. 1994). T3 has been reported to enhance the
regenerative capacity of the liver following Phx (Malik
et al. 2003). Here we tested if T3 treatment can inXuence
oval cell dependent liver regeneration. A single dose of the
thyroid hormone was given on the Wfth day after the partial
hepatectomy for the rats treated according to the AAF/
Phx experimental protocol. This treatment resulted in
augmented relative liver weight in 48 h. The enhanced
liver growth was most probably the consequence of the
accelerated oval cell proliferation and diVerentiation. The
diVerentiation process was veriWed by the establishment of
hepatocytic morphological, immunophenotypical markers
and transcription of hepatocyte speciWc genes (TAT, TO2,
CYP 450) in the progenies of the oval cells. The blood
chemistry data indicated improving liver function.
Although it must be mentioned, that the mitogen was
administered 24 h after the last AAF treatment and the
small hepatocytes showed up after subsequent 48 h. There-
fore, the decreasing mitoinhibitory eVect of AAF on the
Table 3 Labeling index of oval cells and small hepatocytes following T3 treatment
* P < 0.05 between 18 h control and T3
** P < 0.05 between 18 and 48 h T3
18 h 24 h 48 h 96 h
Control Oval cells 17 § 1.7 18.9 § 2.1 14.9 § 0.3 11.5 § 2.9
T3 Oval cells 30.2 § 0.7* 17.6 § 3.8 11.5 § 1.8** 8.2 § 0.6
Small hepatocytes – – 8.7 § 2.5 11.3 § 2.7
Fig. 3 Pulse-chase experiment, with beta-galactosidase expressing
retroviruses of AAF/Phx treated rats. The virus was injected into the
liver 2 days after the Phx, 3 days later the rat was treated by T3 (pulse
animals were sacriWced “before” T3 treatment) and sacriWced after 2
more days (chase). a Immunohistochemical detection of beta-galacto-
sidase (green) in a “pulse” animal. The viruses transduced OV-6 posi-
tive (red) oval cells (arrows) and a few non-parenchymal cells
(arrowheads). b Immunohistochemical detection of beta-galactosidase
(green) in a “chase” animal. There is nuclear staining in groups of
small, CYP 450 (red) expressing hepatocytes indicating that they are
the progenies of the oval cells. Unlabeled small hepatocytes with less
intense CYP 450 staining are also present (arrowheads). Scale bar:
50 m123
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response of these cells can not be excluded unanimously.
Lead nitrate was also able to accelerate the diVerentia-
tion of the oval cells (data not shown). WY 14,643 another
primary hepatocyte mitogen induced the diVerentiation of
oval cells (Kaplanski et al. 2000) in vitro. That is other pri-
mary hepatocyte mitogens might also be able to promote
this form of liver regeneration. The molecular mechanism
of the rapid diVerentiation induced by the mitogens is not
known yet, but it appears to be coupled to cell proliferation.
The DNA replication increases transiently in the oval cells
after T3 treatment. It is well documented in the Wnal phase
of liver ontogeny that the terminal diVerentiation is accom-
panied with the rapid growth of the liver (Duncan 2003).
Fig. 4 Immunohistochemical characterization of the diVerentiated
“small” hepatocytes 2 days after T3 treatment. a A small island
(arrows) of new hepatocytes is characterized by pale Cyp 450 (green) and
positive nuclear HNF4 (red) staining. b The nuclei in another group of
small hepatocytes (arrows) are also positive for HNF4 (red) and Prox-
1 (green), the double staining results in mostly yellow nuclei. Note the
lack of Prox-1 reaction in the OV6 (blue) positive oval cells (right low-
er corner). A few Prox1 and OV6 positive but HNF4 negative (arrow-
head) diVerentiating cells are also present near the focus as described
by Dudas et al. (2007). c AFP (green) positive oval cell are present
within the ductules surrounded by laminin positive basement mem-
brane material (red). AFP positivity can not be observed over the
diVerentiating hepatocytes (arrows). Nuclei are stained by TOTO-3
(blue). d Star like CD26 positive structures (green, arrows) represent
the developing bile canalicules between the diVerentiating hepato-
cytes. All hepatocytes express HNF4 in their nuclei (red). e Connexin
32 (green) positive gap junctions are represented by small dot like sig-
nals between the young hepatocytes (arrows), which can be recognized
from their small nuclei (red, propidium iodide). No signal is present in
the left over laminin (blue) surrounded oval cell ductules. Hexagonally
arranged Cx 32 staining can be seen on the “old” hepatocytes. f 1 inte-
grin positivity (green) is present at the basal side of the small hepato-
cytes (right side of the picture). Note the ductular arrangement of the
nuclei of the small hepatocytes (arrows). Normal liver structure can be
observed on the left side of the picture. All hepatocytes express
HNF4 in their nuclei (red). Scale bar for a: 100 m; b, d, e, f: 50 m;
c: 25 m123
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tion models is also an indication of the intense cell prolifer-
ation at the onset of diVerentiation (Paku et al. 2004; Sell
et al. 1987; Factor et al. 1994). Finally, HGF, a well-known
mitogen for the liver, has been also reported to accelerate
oval cell proliferation and to promote their diVerentiation
(Hasuike et al. 2005). The thyroid hormone has been
recently described to increase the NF-B and STAT3
activity in the liver (Fernández et al. 2007). These tran-
scriptional factors play role in the growth regulation of
the oval cells (Sánchez et al. 2004), therefore, alterations of
these nuclear factors also might participate in the rapid
diVerentiation.
T3 was able to reduce the formation of hepatocellular
carcinomas in a rat chemical hepatocarcinogenesis model
(Ledda-Columbano et al. 1999, 2000). The exact mecha-
nism of this inhibition was not clear. Considering our
observation one can not exclude the possibility that the thy-
roid hormone induced the diVerentiation of the tumor pre-
cursor cells.
Gordon et al. (2000) described the existence of the small
hepatocyte-like progenitor cells (SHPC) in the liver as a
novel liver progenitor cell population. However, the two
pulse chase experiments in our case clearly excluded the
participation of this cell population in the presently studied
experiment. BrdU and the retroviruses marked the dividing
cell population in the pulse phase of the lineage tracing
experiments. This included, in addition to the oval cells,
endothelial and stellate/myoWbroblast cells (but no hepato-
cytes). Therefore, theoretically the mesenchymal origin of
the small hepatocytes can not be excluded, but this option is
highly unlikely. Our previous (Paku et al. 2001, 2004) and
recent tracing observations indicate the small hepatocytes
are most likely the progenies of the oval cells. The presence
of the thyroid hormone receptor in the oval cells supports,
that they can be inXuenced by this hormone.
The sequence of diVerentiation events following the T3
treatment, is almost identical with the steps we described
(Paku et al. 2004) during the spontaneous diVerentiation of
oval cells in the AAF/Phx experiment. However, the Wrst
new hepatocytes appear 11–12 days following the Phx in
the traditional (noT3) experiment (Fig. 1a), they are already
present on the seventh day when T3 was administered to
the rats (Fig. 1b). That is, the thyroid hormone accelerated
the diVerentiation process. In our recent study, the
increased expression of several hepatocyte speciWc
enzymes (TAT, TO2, CYP450) indicates the real functional
diVerentiation of the hepatocytes. The biological signiW-
cance of the maturation process is conWrmed by the blood
chemistry data. The decrease of the serum bilirubin level
and increase of prothrombin level 2 days after the T3 treat-
ment indicated better synthetic functions (Table 2). The
prolonged prothrombin time is an excellent marker of liver
failure and strong independent prognostic sign in patients
(Bosch et al. 2003). The serum bilirubin and prothrombin
time are two of the three laboratory parameters which are
used to calculate the widely accepted MELD score (Model
for End-stage Liver Disease), the best predictor of survival
among diVerent populations of patients with advanced liver
disease (Kamath and Kim 2007). No changes were
observed in the serum level of the transaminases and albu-
min (data not shown); this can be explained by the lack of
hepatocyte injury and the long half-life of albumin
(»20 days).
The T3 induced liver hyperplasia in normal rat is fol-
lowed by a rapid wave of apoptosis. This compensatory
reaction has not occurred in our model, therefore this
accelerated regeneration process secures permanently liver
function.
Hepatic progenitor cells are commonly observed in a
wide variety of human liver diseases (Roskams et al. 2003,
2004). The eYciency of this alternative regenerative pro-
cess is unclear. There are reported cases in which these
endogenous progenitor cells are able to reconstitute the
liver tissue and function (Fujita et al. 2000). However,
ductularly arranged progenitor cells are frequently seen in
failed livers at autopsy and in livers removed at transplanta-
tion indicating that the stem cell compartment is activated
but has failed re-establish liver functions in these cases.
Therefore, improving the eYciency of the regenerative
response of liver progenitor cells might have a substantial
clinical impact.
Fig. 5 Real-time RT-PCR analysis of gene expression in microdis-
sected cell populations. The gene expression of control oval cells
(AAF/Phx experiment seventh day after Phx), oval cells after T3 treat-
ment (AAF/Phx experiment, T3 was given on the Wfth day after Phx,
the rats were sacriWced on the seventh day) and small hepatocytes
(AAF/Phx experiment, T3 was given on the Wfth day after Phx, the rat
was sacriWced on the seventh day) were compared with the expression
level of hepatocytes from normal liver. The expression level of albu-
min, TAT and TO2 was compared to normal, untreated hepatocytes
(100%). Since AFP mRNA could not be detected in the normal hepa-
tocytes, the expression level of control oval cells was taken as 100%
with this probe123
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liver progenitor cells in vivo after the administration of the
primary hepatocyte mitogen, T3. In addition to the morpho-
logical alterations, functional signs of maturation were also
demonstrated. The “drug” induced accelerated diVerentia-
tion of hepatic progenitor cells might serve as a possible
treatment modality for several liver diseases.
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Although cancer cells are not generally controlled by
normal regulatory mechanisms, tumor growth is
highly dependent on the supply of oxygen, nutrients,
and host-derived regulators. It is now established that
tumor vasculature is not necessarily derived from en-
dothelial cell sprouting; instead, cancer tissue can
acquire its vasculature by co-option of pre-existing
vessels, intussusceptive microvascular growth, post-
natal vasculogenesis, glomeruloid angiogenesis, or
vasculogenic mimicry. The best-known molecular
pathway driving tumor vascularization is the hypox-
ia-adaptation mechanism. However, a broad and di-
verse spectrum of genetic aberrations is associated
with the development of the “angiogenic phenotype.”
Based on this knowledge, novel forms of antivascular
modalities have been developed in the past decade.
When applying these targeted therapies , the stage
of tumor progression, the type of vascularization of
the given cancer tissue, and the molecular machin-
ery behind the vascularization process all need to
be considered. A further challenge is finding the
most appropriate combinations of antivascular
therapies and standard radio- and chemotherapies.
This review intends to integrate our recent knowl-
edge in this field into a rational strategy that could
be the basis for developing effective clinical modal-
ities using antivascular therapy for cancer. (Am J
Pathol 2007, 170:1–15; DOI: 10.2353/ajpath.2007.060302)
Until recently, vascularization of malignant tumors was
considered the exclusive result of directed capillary
ingrowth (endothelial sprouting). However, recent ad-
vances have been made in identifying the processes
involved in angiogenesis and vascular remodeling.
Consequently, the simplistic model of an invading cap-
illary sprout has been deemed insufficient to describe
the entire spectrum of morphogenic and molecular
events required to form a neovascular network. Before
discussing the different ways a tumor is vascularized,
we should emphasize that these mechanisms are not
mutually exclusive; in fact, in most cases they are
interlinked, participating concurrently in physiological
as well as in pathological angiogenesis. Although the
various types of cancer vascularization share some
molecular features and may be controlled in part by
similar sets of regulatory factors, a considerable vari-
ety of differences also exists. Although the molecular
regulation of endothelial sprouting has been exten-
sively studied and reviewed in the literature, the mor-
phogenic and molecular events associated with alter-
native cancer vascularization mechanisms are less
understood. Therefore, this review focuses on the
pathogenesis of the different forms of “nonsprouting
angiogenesis” and, more specifically, on the possibil-
ities and the potential use of novel antiangiogenic and
vascular targeting strategies against alternative tumor
vascularization mechanisms.
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Vascularization Mechanisms in Cancer
Endothelial Sprouting
The best-known mechanism by which tumors promote
their own vascularization is inducing new capillary buds
from pre-existing host tissue capillaries. The first descrip-
tion of this process dates back to the 1970s, when Aus-
prunk and Folkman1 suggested the following sequence
for tumor-induced capillary sprouting (Figure 1, Alt. 1). 1)
The basement membrane is locally degraded on the side
of the dilated peritumoral postcapillary venule situated
closest to the angiogenic stimulus, interendothelial con-
tacts are weakened, and endothelial cells (ECs) emigrate
into the connective tissue, toward the angiogenic stimuli.
2) There is formation of a solid cord by ECs succeeding
one another in a bipolar fashion. 3) Lumen formation
occurs by cell-body curving of a single EC or by partic-
ipation of more ECs in parallel with the synthesis of the
new basement membrane and the recruitment of peri-
cytes/mural cells. The main disadvantages of this model
are its inability to identify the nature and origin of the
stimulus necessary for lumen formation and the assump-
tion that dedifferentiation and redifferentiation take place
during the same process, manifest in the loss and regain-
ing of luminal-basal EC polarity. Furthermore, although it
has been well established that the stimulus necessary for
lumen formation comes from the developing basement
membrane, according to this model, basement mem-
brane deposition occurs after lumen formation. In the
early 1990s, a different sprouting model was described2
(Figure 1, Alt. 2). This model suggests a three-stage
sequence to explain ultrastructural changes during tu-
mor-induced endothelial sprouting. 1) There is structural
alteration of the basement membrane characterized by
the loss of electron density (gel-sol transition) over the
entire circumference of the dilated “mother vessel” (al-
though basement membrane components such as lami-
nin and collagen IV can still be detected by immunohis-
tochemistry). Partial and regulated degradation of the
altered basement membrane occur only at places where
EC processes (connected by intercellular junctions) are
projecting into the connecting tissue. 2) Further migration
of ECs, which are arranged in parallel, maintaining their
basal-luminal polarity and forming a slit-like lumen, takes
place continuously with the lumen of the mother vessel
and sealed by intact interendothelial junctions. Basement
membrane of low electron density is deposited continu-
ously by the polarized ECs while only the very tip of the
growing capillary bud is free of basement membrane
material. 3) Proliferating pericytes of the mother vessel
migrate along the basement membrane of the capillary
bud, resulting in complete pericyte coverage of the new
vessel. In parallel, the appearance of electron-dense
basement membrane around the maturing capillary buds
(sol-gel transition) can be observed. According to the
above model, no stimulus is necessary for the induction
of lumen formation, because ECs do not lose their polarity
during the process.
The molecular background of capillary sprouting has
been extensively studied and reviewed in the literature.3
During the process, vessels initially dilate and become
leaky in response to vascular permeability factor/vascular
endothelial growth factor (VPF/VEGF).4 This is mediated
by the up-regulation of nitric oxide, the development of
fenestrations and vesiculo-vacuolar organelles, and by
the redistribution of CD31/PECAM-1 and vascular endo-
thelial (VE)-cadherin. The so-called gel-sol transition of
the basement membrane, probably mediated by matrix
metalloproteases (MMPs), gelatinases, and the urokinase
plasminogen activator system, could be partly responsi-
ble for the initiation of EC proliferation and migration.
Ang-2 (Angiopoetin-2, a mediator of Tie-2 signaling) is
involved in the detachment of pericytes and loosening of
the matrix. A vast number of molecules stimulate endo-
thelial proliferation and migration, including transforming
growth factor (TGF)-1, tumor necrosis factor (TNF)-,
members of the chemokine system and the VEGF, fibro-
blast growth factor, and platelet-derived growth factor
(PDGF) families.3 It could be argued that integrins repre-
sent the most important adhesion receptors in migrating
ECs.5 A wide variety of integrins have been shown to be
expressed during sprouting, including 11, 21, 31,
51, v5, and v3. Perhaps the most important among
them is v3, which mediates the migration of ECs in the
fibrin-containing cancer stroma and maintains the sol
state of the basement membrane because of its ability to
bind to MMP-2. During maturation of nascent vessels,
PDGF-BB recruits pericytes and smooth muscle cells,
Figure 1. Endothelial sprouting. Schematic representation of the EC sprout-
ing models suggested by Ausprunk and Folkman (Alt. 11) and by Paku and
Paweletz (Alt. 22). Red cells represent endothelial cells; brown cells are
pericytes. Yellow cells are mural cells of other origin (fibroblasts or bone
marrow-derived cells). See Vascularization Mechanisms in Cancer for details.
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whereas TGF-1 and Ang-1/Tie-2 stabilize the interaction
between endothelial and mural cells.3 All in all, sprouting
is controlled by a tightly regulated balance of proangio-
genic factors and inhibitors: an angiogenic cytokine pro-
motes EC proliferation, migration, or lumen formation,
whereas an inhibitor interferes with these steps and mod-
ulates the proliferation or migration activity of ECs. How-
ever, individual tumor types use various combinations of
proangiogenic and inhibitory cytokines.3
Vessel Co-Option
When tumors arise in or metastasize to a pre-existing,
usually well-vascularized, tissue, their growth not only
depends on expansion, like a balloon, more typical of
slow-growing benign tumors, but also on the invasion of
host tissue, allowing the cancer cells close contact with
the surface of blood vessels. Therefore, malignant cells
may initially associate with and grow preferentially along
pre-existing microvessels. Until recently, however, no
studies have focused on the role played by the host
vasculature in the process of tumor vascularization. Al-
though in 1987 Thompson6 had already proposed that
tumors acquire their vasculature by incorporation of host
tissue capillaries, the first study suggesting the existence
of vessel co-option was not published until 1999 by Ho-
lash et al.7 In their model, Holash and colleagues found
that co-option is limited to the initial phases of tumorigen-
esis.7 However, additional morphological evidence in hu-
man malignancies suggests that co-option of pre-existing
blood vessels might persist during the entire period of
primary or metastatic tumor growth. In cutaneous mela-
noma, we found that during tumor growth, there are no
signs of directed vessel ingrowth; instead, these tumors
appear to grow by co-opting the massive vascular plexus
present in the peritumoral connective tissue.8 In non-
small cell lung cancer, a putatively nonangiogenic growth
pattern was observed.9 In this “alveolar type” of growth,
cancer cells filled the alveoli, entrapping but not destroy-
ing the co-opted alveolar capillaries. In liver metastases
of human colorectal carcinomas, different growth pat-
terns (replacement, pushing, and desmoplastic) were
observed, depending on the degree of differentiation. In
replacement growth type, the architecture of the liver was
preserved, and the ECs of sinusoids showed low mitotic
activity. However, pushing and desmoplastic tumor types
destroyed the liver architecture.10 According to our pre-
vious results in experimental hepatic metastases, during
growth of sinusoidal-type metastases, invading cancer
cells advance between the basement membrane and the
endothelial lining of the sinusoids and evoke proliferation
of ECs. This process resulted in the development of large
tortuous vessels without basement membrane inside the
tumor nodules. Conversely, sprouting-type angiogenesis
was observed in portal-type metastases. The replace-
ment growth pattern corresponded to sinusoidal-type
metastases of undifferentiated tumors, whereas desmo-
plastic tumors showed similarities to portal-type metasta-
ses.11 In the pushing-type growth pattern, we recently
described a mechanism for the development of blood
supply and supportive connective tissue12 (Figure 2).
This process includes the proliferation of smooth muscle
actin-positive stellate, but not endothelial, cells on the
surface of the tumor spheroid accompanied by capillar-
ization of the sinusoids in this region. Because of the
pressure of the tumor and the proliferating stellate cells,
the hepatocytes disappear from the closest vicinity of the
tumor, leading to the fusion of the sinusoids and the
appearance of vascular lakes at the surface of the tumor.
Together with the collagen-producing cells, these vascu-
lar lakes are incorporated into the tumor, resulting in the
development of vessel-containing connective tissue col-
umns that traverse the tumor. These columns represent
the main structural and functional unit, providing blood
supply for the inner part of the growing metastasis. Thus,
the presence of the above mechanisms further supports
earlier observations that vascularization of metastases in
the liver is a heterogeneous process, depending on the
degree of tumor differentiation or localization of the me-
tastases within the liver.13
Although sprouting capillaries are more vulnerable to
apoptosis than their quiescent counterparts,14 mainte-
nance of incorporated mature microvessels depends on
the survival of ECs as well. The continued survival of
co-opted ECs is intimately tied to their local microenvi-
ronment and, in particular, to the presence of pericytes,
survival-promoting cytokines, and extracellular matrix
proteins. Thus, the molecular repertoire that ECs may use
to survive during vessel co-option is diverse and may
vary for a given tumor type or host environment. The
major players that control this process are angiopoetins
and VEGF.7 Based on the model of vessel co-option
described by Holash et al7 and in other recent studies,15
Ang-1 activates Tie-2 and induces subsequent signal
transduction pathways favoring EC survival, endothelial
quiescence, and tumor-vessel maintenance. Conversely,
Ang-2 is thought to act as a nonsignaling Tie-2 ligand that
binds to endothelial Tie-2 and thereby negatively inter-
feres with agonistic Ang-1/Tie-2 signals. In co-opted
blood vessels, the up-regulation of Ang-2 disrupts the
interaction between Tie-2 and Ang-1, which in turn
causes the destabilization of capillary walls (ie, the de-
tachment of pericytes from the endothelial tube).16 Once
ECs are separated from pericytes, they become particu-
larly vulnerable. In the presence of VEGF, EC survival and
new vessel growth are promoted; however, the lack of
stimulatory factors results in the regression of destabi-
lized vessels.17
VEGF was first described as a survival factor for retinal
ECs and has now been shown to promote survival in
different EC models. This antiapoptotic and survival func-
tion of VEGF seems to depend on an interaction between
vascular endothelial growth factor receptor (VEGFR)-2,
-catenin, and VE-cadherin.18 However, targeting of
VEGF has been shown to result in apoptosis only in newly
formed tumor vessels and in the developing vasculature
of the neonatal mouse but not that of adult mice or of
quiescent tumor vascular networks.17 In summary, al-
though cytokines responsible for EC survival could be the
key molecules, their precise role in initiation and mainte-
nance of vessel co-option still requires investigation.
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Intussusceptive Microvascular Growth (IMG)
IMG refers to vessel network formation by insertion of
connective tissue columns, called tissue pillars, into the
vessel lumen and to subsequent growth of these pillars,
resulting in partitioning of the vessel lumen (Figure 3).
This type of angiogenesis, which has been observed in a
wide variety of normal and malignant tissues, is faster
and more economical than sprouting, occurs within hours
or even minutes and does not primarily depend on EC
proliferation, basement membrane degradation, and in-
vasion of the connective tissue.19 However, in contrast to
sprouting, IMG can work only on existing vessel net-
works. The most important feature of IMG, therefore,
seems to be its ability to increase the complexity and
density of the tumor microvessel network already built by
sprouting, independent of EC proliferation. In addition,
IMG can provide more surface area for further sprouting.
Its molecular regulation, however, is poorly understood
since IMG was first described only a few years ago.
Nevertheless, the role of some players is gradually be-
coming clearer. We know that local stimuli, such as intra-
vascular shear stress, might induce a cascade of phys-
iological or pathological reactions in ECs, and new
capillary development by tissue pillar formation could be
one of them.20 Furthermore, intussusception is certainly
synchronized by several cytokines. Major candidates are
those capable of mediating information between ECs or
from ECs to mural cells, such as PDGF-BB, angiopoi-
Figure 2. Examples for vessel co-option. A–D: Pushing-type angiogenesis in liver metastases of colorectal cancer. A: Cross-section of a compressed invagination.
SMA-expressing cells (blue fluorescence) facing the tumor tissue, hepatocytes are crowded in the middle of the invagination (pan-cytokeratin, green
fluorescence). Continuous CD31 staining (red fluorescence), representing fused sinusoids (arrows), is visible in contact with the SMA-positive cells. Note the
paucity of sinusoids between the hepatocytes. B: Laminin (blue fluorescence) co-localizes with 6 integrin within the columns. The column tightly packed with
SMA-positive cells (red fluorescence). C: 6 integrin (green fluorescence) is present at the periphery of the column and around the central vessel. D: Schematic
representation of the development of vasculature in pushing-type liver metastases. For better visibility of the vessels, hepatocytes are depicted only in the upper
part of the drawings. At the early stage of the tumor development, the tumor faces normal liver architecture. As the compression of the tumor grows, the
hepatocytes “step back,” and fusion of the sinusoids takes place. The fused vessel, together with the newly synthesized connective tissue, is incorporated into the
tumor. The pressure of the tumor results in the separation of the vessel from the liver parenchyma. The vessel in the direction of the axis of the column remains
connected to the sinusoidal system of the liver. Column formation is finished by the back-to-back fusion of the basement membranes of the tumor bulges. Green,
tumor; brown, hepatocytes; red, sinusoids and central vessel.
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etins, and their Tie receptors, TGF-, monocyte chemo-
tactic protein-1, and ephrins and Eph-B receptors.19
After the initial stage of immature capillary network
formation by sprouting, additional vascular growth and
development of complex vascular beds, including their
continuous remodeling and adaptation, may occur by
intussusception in cancers. The absence of intense EC
proliferation in IMG implies that neovascularization by this
mechanism would be resistant to angiosuppressive treat-
ment in itself.
Glomeruloid Angiogenesis
Glomeruloid bodies (GBs) are best known in high-grade
glial malignancies, where they are one of the diagnostic
histopathological features of glioblastoma multiforme.
However, these complex vascular aggregates have also
been described in a wide variety of other malignancies.21
They are composed of several closely associated mi-
crovessels surrounded by a variably thickened basement
membrane within which a limited number of pericytes are
embedded. In recent studies, the presence of GBs was
associated with markers of aggressive tumor behavior
and significantly reduced survival in cancer patients.22 In
the first animal model,23 GBs developed in mother ves-
sels from recruitment and proliferation of ECs and peri-
cytes (in the absence of tumor cells), and VEGF was
essential for their induction and maintenance. In contrast
to this model and based on our previous results in the first
experimental tumor model of glomeruloid angiogene-
sis,24 we believe that GB formation starts immediately
after tumor cell extravasation, much earlier than necrosis
appears within the metastases. We found that the prolif-
erating and migrating tumor cells are able to pull the
capillaries and the adjacent capillary branching points
into the tumor cell nests. This process leads to the ap-
pearance of simple coiled vascular structures that later
develop into GBs with multiple narrowed afferent and
efferent capillaries (Figure 4). Despite the absence of
sprouting angiogenesis, necrosis was scarce in these
lesions, suggesting that the blood supply from the pre-
existent vascular bed is sufficient to provide the tumor
cells with oxygen and nutrients. This type of GB formation
cannot be termed as true angiogenesis; it rather repre-
sents a remodeling of the existing vasculature of the host
tissue. Whether GBs represent an accelerated form of
angiogenesis or a dysfunctional, possibly abortive, form
remains an open question. However, it cannot be ex-
cluded that “active” and “passive” types of glomeruloid
angiogenesis can operate concurrently in various cancer
types.
Postnatal Vasculogenesis: The Role of
Endothelial Progenitor Cells
Vasculogenesis (defined as the in situ differentiation of
vascular ECs from primitive precursor cells) has long
been thought to occur only in the early phases of vascular
development. Recent studies, however, have demon-
strated that circulating bone marrow-derived endothelial
progenitor cells (EPCs) home to sites of physiological
and pathological neovascularization and differentiate into
ECs (Figure 5). EPCs may be mobilized by tumor tissue-
derived cytokines from the bone marrow by a mechanism
recently described by Asahara et al.25 Best character-
ized among these cytokines is VEGF. During tumor pro-
gression, the level of circulating VEGF has been shown to
rise, and this level was found to correlate with the number
of EPCs in the circulation. Furthermore, PDGF-CC pro-
moted vascularization in part by stimulating outgrowth of
EPCs. In contrast, Ang-1 was shown to reduce EPC mo-
bilization from bone marrow (reviewed in Ref. 26).
After homing, ie, after adhesion and insertion of EPCs
into the monolayer of surrounding mature vascular ECs,
additional local stimuli may promote the activation of local
endothelium to express adhesion molecules to recruit
EPCs. This process may be completed by mechanisms
not yet elucidated. In addition to the physical contribution
of EPCs to newly formed microvessels, the angiogenic
cytokine release of EPCs may be a supportive mecha-
nism to improve neovascularization as well.27 It is also
important to note that Lyden et al recently identified
VEGFR-1 hematopoietic progenitor cells that multiply
in the bone marrow, mobilize to the peripheral blood
along with VEGFR-2 EPCs, and incorporate into peri-
capillary connective tissue, thus stabilizing tumor vas-
culature.28 More interestingly, these cells seem to
home in before the tumor cells arrive, promoting met-
astatic growth by forming niches where cancer cells
can locate and proliferate.29
Although EPCs obviously participate in the vascular-
ization process of malignant tumors, it is still unclear
whether they are essential for these processes or what
the relative contribution of EPCs is compared with that of
in situ proliferating ECs. Moreover, it has yet to be deter-
mined whether EPCs can be targeted to treat certain
types of malignancies, or alternatively—as they are en-
dowed with the capacity to home to the tumor vascula-
ture—can be used to deliver toxins or vascular-targeting
agents.
Vasculogenic Mimicry
“Vasculogenic mimicry” is defined by the unique ability of
aggressive melanoma cells to express an EC phenotype
Figure 3. Intussusceptive microvascular growth. Schematic representation of
intussusceptive microvessel growth. The first step of the process is the
development of the transluminal endothelial bridge. This is followed by the
reorganization of the endothelial lining, a process that is largely unknown.
The division of the vessel is completed by the development of a connective
tissue pillar through the vessel lumen. Red cells are endothelial cells; brown
cells are pericytes. Gray, basement membrane.
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and to form vessel-like networks in three-dimensional
culture, “mimicking” the pattern of embryonic vascular
networks and recapitulating the patterned networks seen
in patients’ aggressive tumors correlating with a poor
prognosis.30 Comparative global gene analyses of ag-
gressive and poorly aggressive human cutaneous and
uveal melanoma cell lines unexpectedly revealed the
ability of aggressive tumor cells to express genes (and
proteins) associated with multiple cellular phenotypes
and their respective precursor stem cells, including en-
dothelial, epithelial, pericyte, fibroblast, and several other
cell types.31–33 These new and intriguing findings sup-
port the premise that aggressive melanoma cells acquire
a multipotent, plastic phenotypea concept that chal-
lenges our current thinking on how to target tumor cells
that can possibly masquerade as other cell types, par-
ticularly with embryonic stem cell-like properties. The
etiology of the melanoma vasculogenic phenotype re-
mains unclear; however, it seems to involve dysregulation
of the lineage-specific phenotype and the concomitant
transdifferentiation of aggressive cancer cells into other
cell types—such as endothelial-like cells. Vasculogenic
Figure 4. Glomeruloid angiogenesis. A: Experimental brain metastases stained for laminin (green fluorescence) and CD31 (blue fluorescence), 28 days following
intracarotid inoculation of the A2058 human melanoma cell line. Glomeruloid bodies are connected to each other by a capillary that is very small in diameter
(arrows). The outlines of the metastases are clearly visible because of the strong laminin positivity of the tumor cells (arrowheads). B: Schematic representation
of glomeruloid body formation. Following extravasation, the tumor cells (green) adhere firmly to the abluminal surface of the capillary basement membrane
(gray). In the first step, because of the contractile force of the tumor cell a loop develops on the capillary. Proliferating tumor cells pull the capillary inward,
resulting in the development of further loops and reduction of the diameter of the capillary segment lying outside the glomeruloid body. The last drawing shows
the cross-section of a fully developed glomeruloid body built by ECs (red), pericytes (brown), and tumor cells (green). Extreme large cytoplasmic projections of
the tumor cells adhere to different segments of the capillary.
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mimicry has been confirmed in breast, prostate, ovarian,
chorio-, and lung carcinomas; synovial-, rhabdomyo-,
and Ewing sarcomas; and phaeochromocytoma.34 Ex-
pression profiling studies revealed that the most signifi-
cantly up-regulated genes by aggressive melanoma cells
include those that are involved in angiogenesis and vas-
culogenesis, such as the genes encoding VE-cadherin,
erythropoietin-producing hepatocellular carcinoma-A2
(EphA2), MMPs, and laminin 52 chain (LAMC2). These
molecules, with their binding partners, are a few of the
factors required for the formation and maintenance of
blood vessels and also for vasculogenic mimicry in mel-
anomas. Perhaps equally significant is the down-regula-
tion of the gene MART-1 (melanoma antigen recognized
by T cell 1, also called Melan-A), a classic marker for
melanocytes and melanoma, by aggressive melanoma
cells. The concept of vasculogenic mimicry was devel-
oped further to include the existence of a fluid-conduct-
ing, laminin-containing extracellular matrix meshwork,
providing a site for nutritional exchange for aggressive
tumors, and therefore possibly preventing necrosis (Fig-
ure 6).34,35 Functional studies revealed the close associ-
ation of tumor-cell-lined networks with angiogenic mouse
vessels at the human-mouse interface and the coopera-
tion between the two systems.36,37 The molecular dissec-
tion of the physiological mechanisms critical to the func-
tion of the fluid-conducting meshwork revealed the
biological relevance of the up-regulated expression of
tissue factor pathway-associated genes—essential for
the anticoagulation properties of the intratumoral, extra-
cellular matrix-rich extravascular fluid-conducting path-
way. Gene profiling, protein detection, and immunohisto-
chemistry validation demonstrated up-regulation of tissue
factor (TF), TF pathway inhibitor 1 (TFPI-1), and TFPI-2—
critical genes that initiate and regulate the coagulation
pathways—in aggressive, as opposed to poorly aggres-
sive, melanoma. It was found that TFPI-2 contributes to
vasculogenic mimicry and endothelial transdifferentiation
by melanoma cells, whereas TFPI-1 has anticoagulant
functions for perfusion of fluid-conduction meshworks
formed by TF-expressing melanoma cells. Additional
studies have focused on the signal transduction path-
ways that regulate blood vessel formation and stabiliza-
tion during vasculogenesis and angiogenesis, address-
ing critical signaling events that regulate melanoma
vasculogenic mimicry and their endothelia-like pheno-
type.38–40 It was demonstrated that VE-cadherin and
EphA2 were co-localized in cell-cell junctions and VE-
cadherin can regulate the expression of EphA2 at the cell
membrane by mediating its ability to become phosphor-
ylated through interactions with its membrane-bound li-
gand, ephrin-A1. These studies illuminate a novel signal-
ing pathway that could be potentially exploited for
therapeutic intervention. Additional investigation uncov-
ered the role of phosphoinositide 3-kinase (PI3K) as a
critical regulator of vasculogenic mimicry, specifically af-
fecting membrane type-1 MMP (MT1-MMP) and MMP-2
activity. Both MMPs are essential for the process of vas-
culogenic network formation by aggressive melanoma
tumor cells, and the downstream effect on the cleavage
of laminin 52 chain into the 2 and 2x promigratory
fragments.38,39 Furthermore, these results showed that
blocking PI3K resulted in abrogation of vasculogenic
mimicry. Most recent studies have identified focal adhe-
sion kinase (FAK)-mediated signal transduction path-
ways to promote not only the aggressive phenotype but
also vasculogenic mimicry of melanoma cells as well.40
In addition, expression of a negative regulator of FAK
signaling, the FAK-related non-kinase in aggressive mel-
anoma cells, resulted in an inhibition of melanoma vas-
Figure 5. Endothelial progenitor cells. Schematic representation of postnatal
vasculogenesis. The term “EPC” encompasses a group of cells existing in a
variety of stages ranging from common hemangioblasts to fully differentiated
ECs. Although their putative precursors and the exact differentiation lineage
of EPCs remain to be determined, to date it is widely accepted that early EPCs
(localized in the bone marrow or immediately after migration into the
circulation) are AC133/CD34/VEGFR-2 cells, whereas circulating EPCs
are positive for CD34 and VEGFR-2, lose AC133, and begin to express cell
surface markers typical of mature ECs such as CD31, VE-cadherin, and von
Willebrand Factor (vWF).
Figure 6. Vasculogenic mimicry. This diagram represents the current inter-
pretation of data generated from several studies involving the use of tracers
and perfusion analyses of mice containing aggressive melanoma cells
(green) during tumor development. The endothelial-lined vasculature is
closely apposed to the tumor cell-formed fluid conducting meshwork, and
hypothetically, it is presumed that as the tumor remodels, the vasculature
becomes leaky, resulting in the extravascular conduction of plasma. There is
also evidence of a physiological connection between the endothelial-lined
vasculature and the extravascular melanoma meshwork.
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culogenic mimicry concomitant with a decrease in mela-
noma cell invasion and migration. This biological effect
was mediated in part through an extracellular signal-
regulated kinase 1/2 signaling pathway that resulted in a
down-regulation of urokinase and MMP-2/MT1-MMP ac-
tivity.40 These results suggest that FAK may serve as a
new target for therapeutic intervention in treating aggres-
sive melanomas with capabilities for vasculogenic
mimicry.
Antivascular Therapy of Cancer
It has been over 30 years since Judah Folkman hypoth-
esized that tumor growth is angiogenesis dependent.41
Subsequent research has led to the identification of
several regulators of angiogenesis, some of which rep-
resent therapeutic targets. However, although antivas-
cular agents are often highly active in preclinical stud-
ies, recent clinical trials including these agents have
been both encouraging and disappointing. Because of
the predominant role of capillary sprouting and its main
molecular mediator VEGF in tumor vascularization, in-
hibition of VEGF seems to be necessary but is probably
insufficient to halt tumor progression permanently in
many cancer types. Due to the existence of multiple
vascularization mechanisms and angiogenic signaling
pathways, inhibition of just a single pathway will pre-
sumably trigger alternative vascularization mecha-
nisms and additional growth factor pathways. Conse-
quently, application of antivascular therapy in cancer
patients requires the identification of the individual vas-
cularization profile and the molecular machinery be-
hind the vascularization process and, furthermore, the
individualization of antivascular therapy to realize any
potential benefits.42,43 In the second part of this re-
view, we will briefly summarize the antivascular thera-
pies that are currently being tested in the clinic. Sub-
sequently, we will give an overview of how these
classes of agents can be incorporated in the current
multimodality of anticancer strategies. Finally, we will
discuss potential novel approaches that enforce tumor
regression by exploiting the emerging basic knowl-
edge of tumor vascularization.
Antivascular Strategies in Cancer Therapy:
Current Status of the Clinical Development
Any classification of antivascular strategies is difficult,
with overlap in several features. However, the main
categories of these approaches that have been devel-
oped are angiosuppressive (anti-angiogenic agents)
and vascular-targeting therapies (vascular-disrupting
agents).44 Although metronomic chemotherapy (MCT)
uses conventional cytotoxic drugs, the main targets of
this strategy are the tumor ECs. This is the reason that
Browder et al45 coined the term “anti-angiogenic che-
motherapy” to describe this treatment and why MCT is
discussed here.
It is beyond the scope of this review to discuss all
drugs that affect tumor capillaries. Therefore, we concen-
trate here on the agents that are at a more advanced
stage of clinical development.
Angiosuppressive Therapy (Antiangiogenic
Agents)
This approach is motivated by the fact that neoangiogen-
esis in cancer requires the induction of EC proliferation
by specific or nonspecific mitogens. These agents target
the production of endothelial mitogens, the mitogens
themselves, their endothelial receptors, the associated
signaling pathways, the endothelial integrins and the
MMPs46 (Table 1). Consequently, it is most probable that
angiosuppressive therapy can only be applied when can-
cer vascularization involves EC sprouting and/or postna-
tal vasculogenesis (Table 2).
Despite the promising preclinical results with these
agents, in the early clinical trials positive responses in
patients were rarely seen. The clinical breakthrough for
angiosuppressive therapy came from a phase III trial
demonstrating a significantly prolonged survival when
bevacizumab, an anti-VEGF antibody, was used with
chemotherapy in metastatic colorectal cancer patients.47
Based on these results, bevacizumab became the first
antiangiogenic agent to be approved by the United
States Food and Drug Administration (FDA) for cancer
treatment. In subsequent phase III trials, bevacizumab in
combination with standard chemotherapy improved over-
all survival in lung cancer patients and progression-free
survival in breast cancer patients.42 In addition, it has
been reported to be active in patients with metastatic
renal-cell cancer as monotherapy (benefit in progression-
free survival but not in overall survival).48
Further clinical success was obtained recently with
broad-spectrum multitargeted agents that target VEGF
receptors and other tyrosine kinases present in endothe-
lial and cancer cells (Table 1). Phase III trials have dem-
onstrated the efficacy of SU11248/sunitinib [targeting
VEGFR-1, -2; platelet-derived growth factor receptor
(PDGFR), FLT3, and c-Kit] and BAY-43-9006/sorafenib
(targeting VEGFR-2, -3; PDGFR, RET, c-Kit, and Raf) in
the treatment of patients with renal cancer.42 Based on
these results, sunitinib and sorafenib are now approved
by the FDA as monotherapies for kidney cancer. Prom-
ising results have also been found with the combination
of ZD6474 [targeting VEGFR2, epidermal growth factor
receptor (EGFR), and RET] and chemotherapy in non-
small cell lung cancer patients. Interestingly, replacing
bevacizumab with similar tyrosine kinase (TK) inhibitors,
such as PTK787/ZK 222584/vatalanib (targeting
VEGFR-1, -2, -3; PDGFR-, and c-Kit), in the combined
regimen did not result in similar efficacy in chemothera-
py-naive or previously treated colorectal cancer pa-
tients.49 However, the clinical success of bevacizumab,
sunitinib, and sorafenib as novel medicines for the treat-
ment of cancer patients has confirmed the relevance of
angiogenesis research and has stimulated the search for
novel and more effective antiangiogenic approaches. Ac-
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cordingly, various angiosuppressive strategies are being
actively investigated, most of which are registered with
the clinical trials database of the National Cancer Institute
(http://www.nci.nih.gov/clinicaltrials).
Vascular Targeting Therapy (Vascular Disrupting
Agents; VDAs)
Vascular targeting therapy (including anti-EC antibod-
ies and ligand based and small molecule VDAs; Table
1) recognizes the fact that clinical diagnosis of cancer
frequently occurs when the tumor tissue has already
established its vasculature.44,46 This strategy relies on
ability of VDAs to distinguish the ECs of tumor capil-
laries from normal ones based on their different phe-
notype, increased proliferative potential and perme-
ability, and inherent dependence on the tubulin
cytoskeleton. VDAs cause selective and rapid shut-
down of the established tumor capillaries, resulting in
extensive cancer cell death in the central areas of
tumors, although they leave the perfusion in peripheral
tumor regions relatively intact.44,50 It is evident from
Table 1. Examples of Antivascular Agents in Clinical Development
Agent Target/mechanism of action Phase
Angiosuppressive and anti-HIF-1 agents
Anti-VEGF agents
Bevacizumab mAb against VEGF-A III; FDA-approved in
colorectal cancer
VEGF-trap VEGF-A, PlGF, VEGF-B binding I
VEGF-AS VEGF-A, VEGF-C, VEGF-D I
VEGFR and other TK receptor targeting agents
IMC-1C11 mAb against VEGFR2 I
ZD6474 VEGFR-2, EGFR, RET I/II
PTK787/ZK222584 (vatalanib) VEGFR-1, -2, -3; PDGFR-, c-Kit II/III
BAY 43–9006 (sorafenib) VEGFR-2, -3; PDGFR, RET, c-Kit, Raf III; FDA-approved in
renal cancer
SU11248 (sunitinib) VEGFR-1, -2; PDGFR, FLT3, c-Kit III; FDA-approved in
renal cancer
AG-013736 VEGFR-1, -2, -3; PDGFR-, c-Kit I/II
Angiozyme VEGFR-1 mRNA-destroying ribozyme I/II
Integrin signaling
EMD 121974 (Cilengitide) Mimicking the RGD ligand recognition peptidic
domain common to v integrin ligands
I/II
MEDI-522 (Vitaxin) mAb against v3 I/II
Miscellaneous
Thalidomide Multiple inhibitory effect on bFGF, VEGF, and
TNF--induced EC sprouting
I/II
AE-941 Inhibitor of MMP-2, -9, -12, and VEGFR-2 II/III
Marimastat MMP2/9 III
Bay-12-9566 MMP2/9 III
AG3340 MMP2/9 III
Endostatin Integrin 51 II/III
ABT-627 Endothelin receptor II/III
Nonselective inhibitors of HIF-1
Topotecan and other camptothecin analogues,
DX-2-1, GL331
Topoisomerase I/II Preclinical; phase I
2-Methoxyestradiol Microtubules I
YC-1 Soluble guanyl cyclase Preclinical
PX-478 Translation/deubiquitination Preclinical
17-AAG, geldanamycin, radicicol, KF58333 HSP-90 Preclinical
VDAs
Ligand-directed VDAs
L19 single chain Fv ED-B domain of fibronectin Preclinical
mAb against endoglin linked to ricin-A Endoglin Preclinical
Anti-VCAM-1 AB linked to coagulation inducing
protein TF
VCAM-1 Preclinical
Anti-TES-23 linked to neocarzinostatin CD44-related EC marker Preclinical
Naked AB against phosphatidylserine Phosphatidylserine Preclinical
v3 targeting ligand delivering EC apoptosis
inducing ATP-Raf
Targeted ATP-Raf gene Preclinical
Small molecule VDAs
CA4-prodrug; AVE8062 and Oxi4503 (synthetic
analogues of combretastatin)
Actin polymerization, filament stabilization via
Rho signaling pathway
I/II
ZD6126 Inhibition of EC microtubule polymerization I
ABT-751 -Tubulin I
DMXAA (analogue of flavone acetic acid) TNF- release, induction of nuclear factor- I/II
mAb, monoclonal antibody; PlGF, placenta growth factor; bFGF, basic fibroblast growth factor; 17-AAG, 17-N-allylamino-17-demethoxygeldan-
amycin; VCAM-1, vascular cell adhesion molecule-1; CA4, combrestatin-A4.
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the mechanism of VDAs that the effects of these drugs
do not depend on the type of vascularization occurring
in a given cancer. Based on promising preclinical de-
velopments, several VDAs have entered clinical
development.51
MCT and Its Antivascular Effects
Among the different antivascular strategies, MCT merits
particular mention. MCT refers to the close, even daily,
administration of chemotherapeutic drugs in doses below
the maximum tolerated dose, over prolonged periods,
and with no extended drug-free breaks. Phase II trials of
MCT, sometimes applied in combination with antiangio-
genic drugs, have yielded promising results in adult pa-
tients with advanced cancer.52,53 Furthermore, pediatric
oncologists successfully use a metronomic-like modality
of chemotherapies called “maintenance chemotherapy”
to treat various pediatric malignancies such as acute
lymphoblastic leukemia, neuroblastoma, or Wilms’ tumor;
however, the anti-angiogenic background of mainte-
nance chemotherapy is poorly described.54
Although cytotoxic effects of MCT in the tumor paren-
chyma could still contribute to the observed efficacy of
metronomic regimens, preclinical studies suggest that
the primary targets of MCT are the tumoral ECs. Low-
dose chemotherapy affects tumor capillaries directly
(growth arrest and apoptosis of activated ECs) but also
induces the production of an angiogenesis inhibitor
thrombospondin-1 and suppresses the mobilization of
EPCs.52
As mentioned above, several phase I and II studies
were performed involving low, continuous doses of cyto-
toxic drugs, with encouraging results.53 However, the
clinical benefits of MCT remain to be validated in ran-
domized prospective phase III trials. There is also a need
for surrogate markers to help define the optimal dose of
this approach. Circulating ECs55 and EPCs56 have been
used successfully as markers in preclinical and early
clinical studies but have not yet been validated clinically.
Further challenges are the definition of valid clinical end-
points, the confirmation of long-term safety of MCT, and
the identification of suitable antiangiogenic agents and
VDAs to be combined with MCT. Finally, it will be impor-
tant to determine the types of vascularization that might
be the most responsive to this therapy. MCT is probably
more effective in EC sprouting, postnatal vasculogenesis,
IMG, and vasculogenic mimicry (Table 2). However, de-
tailed clinicopathologic analysis is needed to confirm this
hypothesis.
Considerations for Combination Treatment
Strategies
Because antivascular agents and traditional anticancer
strategies have distinctive target cells and mechanisms
of action, it should be possible to achieve an increase in
therapeutic efficacy with little or no increase in toxicity.
In fact, although some antivascular agents have dem-
onstrated activity as monotherapies, most human trials
to date indicate that they are most effective when
combined with conventional antitumor strategies, es-
pecially chemotherapy.42,43
Combination of Angiosuppressive and Chemo-
and/or Radiation Therapy
Angiosuppressive therapy reduces cancer growth by
suspending the blood supply, resulting in hypoxia. Be-
cause hypoxia itself is a major cause of ineffective
chemo-irradiation therapy,57 one would expect that a
further decrease in intratumoral oxygen levels would de-
teriorate the efficacy of a cytotoxic regime, but experi-
mental and clinical data do not support this scenario. In
Table 2. Theoretical Strategy of Antivascular Therapy of Cancer According to the Stage of Tumor Progression and to the
Mechanisms of Vascularization
Type of vascularization
Individual cancer cells
in host tissue
Microscopic tumor
pre-angiogenic phase
Microscopic tumor
angiogenic phase Macroscopic tumor
Sprouting Antiangiogenic agents;
metronomic
chemotherapy
Antiangiogenic agents;
metronomic
chemotherapy
Antiangiogenic agents;
metronomic
chemotherapy
Antiangiogenic agents;
“vascular targeting”
therapy; metronomic
chemotherapy
Intussusceptive
microvascular growth
N.A. N.A. Vascular targeting
therapy; metronomic
chemotherapy
Vascular targeting
therapy; metronomic
chemotherapy
Vessel co-option N.A. N.A. Vascular targeting
therapy
Vascular targeting
therapy
Glomeruloid angiogenesis N.A. N.A. Vascular targeting
therapy
Vascular targeting
therapy
Vasculogenic mimicry N.A. N.A. Vascular targeting
therapy; metronomic
chemotherapy
Vascular targeting
therapy; metronomic
chemotherapy
Postnatal vasculogenesis
(endothelial progenitors)
N.A. N.A. Antiangiogenic agents;
vascular targeting
therapy; metronomic
chemotherapy
Antiangiogenic agents;
vascular targeting
therapy; metronomic
chemotherapy
N.A., not applicable.
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several preclinical models, a combination of cytotoxic
drugs (taxanes, cisplatin, or 5-fluorouracil) with angio-
genesis inhibitors (TNP470, endostatin, SU11248) pro-
duced at least additive but in certain cases synergistic
antitumoral effects.46 Thalidomide, a still ill-defined an-
giogenesis inhibitor, has also been shown successful
preclinically in combination with standard anticancer re-
gimes in solid tumors.58 In addition to experimental data,
there are now clinical examples of the improved efficacy
of chemotherapy in combination with an angiosuppres-
sive agent. As mentioned above, bevacizumab in com-
bination with chemotherapy improved overall survival in
colorectal and lung cancer patients and progression-free
survival in breast cancer patients (see review42). In ad-
dition, the combination of bevacizumab and chemother-
apy was found to be active in pancreatic59 and ovarian60
cancer patients.
There are several explanations for the improved effi-
cacy. An obvious effect of angiogenesis inhibitors is the
decrease in interstitial pressure in cancer tissue improv-
ing the delivery of cytotoxic agents. Furthermore, a hy-
pothesis called “normalization of tumor vasculature” was
put forth by Jain and colleagues recently to explain the
clinical effects of antiangiogenic agents.42 According to
this theory, tumor vasculature is structurally insufficient to
provide maximal blood supply for cancer cells as a result
of capillary leakiness and tortuosity. Because the key
regulator cytokine family of tumoral vessels is the VEGF/
VEGFR system, targeting it could potentially help in the
“normalization” of tumor vasculature and in the improve-
ment of the delivery of chemotherapeutic agents.42 Ac-
cordingly, recent experimental data indicate that anti-
VEGF therapy induces rapid alterations in tumor
vasculature. Within a few hours, EC proliferation is halted,
luminal stability vanishes, and circulation ceases in tumor
capillaries. Some ECs undergo apoptosis and disappear.
Remaining capillaries lack endothelial fenestrations and
have reduced VEGFR-2 and VEGFR-3 expression.61
Thus, inhibition of VEGF signaling devastates some tumor
capillaries and transforms others into a more normal
phenotype.42
Further mechanisms for the additional benefits experi-
enced for combined chemo- and angiosuppressive ther-
apy might be the direct killing of proliferating ECs and/or
the inhibition of the mobilization/viability of EPCs by cy-
totoxic drugs. Results of preclinical studies support this
hypothesis. On the other hand, VEGF inhibition might
have direct cytotoxic effects on tumor cells that aber-
rantly express VEGF receptors and depend to some ex-
tent on VEGF for their survival. Finally, it has also been
suggested recently that antiangiogenic agents prevent
rapid cancer cell repopulation during the break periods
between courses of chemotherapy (see review43).
Experimental studies indicate that antiangiogenic ther-
apy in combination with irradiation is an encouraging
concept for the improvement of the radiation response of
tumors.62 In addition, recent discoveries show that the
EC layer of the tumor vessels is one key target of radio-
therapy.63 In fact, the antivascular effect of radiotherapy
predicts its anti-cancer effect.64 Thus far, although early
phase human trials have also yielded promising results,
there are no large phase III trials known in which such
combinations were successfully applied. Nevertheless,
the discovery of the “normalization window” of angiosup-
pressive agents when combined with radiotherapy in
preclinical models65 suggests that it would be as difficult
to design a successful combination strategy with radia-
tion as with chemotherapy.
In this normalization window (the time period during
which the vasculature normalizes and hypoxia de-
creases), the antiangiogenic drugs improve the efficacy
of chemoradiotherapy.42 Although these studies were
performed in experimental tumor systems, one may ex-
pect a similar effect on the human tumor vasculature and
oxygenation. However, intratumoral hypoxia, responsible
for chemo- and radiotherapy resistance and triggering
molecular pathways that promote cancer progression, is
due not only to the inefficient blood supply by the abnor-
mal tumor vessels but to the systemic anemia of the host
as well.66 Unfortunately, although the oxygen tension of
experimental tumors tends to rise with increasing Hb
levels67 and treatment with recombinant human erythro-
poietin (rHuEpo) significantly reduces the risk for red
blood cell transfusions in cancer patients, correction of
anemia with rHuEpo does not necessarily improve sur-
vival of cancer patients.66 The issue of Epo/EpoR co-
expression in tumor cells and EpoR expression in ECs is
critical in this perspective. The expression of EpoR in
tumor cells has raised the possibility that exogenous
rHuEPO may directly influence cancer cell proliferation,
apoptosis, or sensitivity to chemoradiation therapy. In
addition, the EpoR expression in ECs has suggested
potential effects of Epo on the tumor capillaries, such as
the stimulation of angiogenesis.68 However, as it has
been suggested by experimental studies, the overall di-
rect effect of Epo-EpoR signaling on tumor progression and
therapy is not a straightforward one. For instance, rHuEpo
administration has recently been shown to be associated
with decreased intratumoral VEGF expression, remodeling
of tumor capillaries, and increased chemosensitivity to 5-flu-
orouracil treatment of human tumor xenografts.69 In a pre-
clinical myeloma model, rHuEpo induced tumor regression
and antitumor immune responses.70 In addition, human
kidney carcinoma and myelomonocytic leukemia cell lines
treated with rHuEpo exhibited an increase in apoptosis in
response to chemotherapy.71 Overall, these findings war-
rant additional experimental and clinical research of rHuEpo
to clarify further the risks of its use as well as optimize its
known or potential benefits.
Combination of VDAs and Chemo- and/or
Radiation Therapy
VDAs work best in the poorly perfused hypoxic central
tumor areas, leaving a viable rim of well-perfused cancer
tissue at the periphery, which rapidly regrows.50 Conse-
quently, responses of tumors to VDAs given as single
agents have been poor; however, combination therapy
with chemoradiotherapy, which targets cancer cells at
the tumor periphery, has produced promising responses
in preclinical models. Nevertheless, the timing and se-
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quencing of VDAs and chemo-irradiation therapies are
important in such treatments. By far the greatest en-
hancement was observed when the VDA was adminis-
tered within a few hours after chemo- and/or irradiation
therapy. Based on these experimental results, the
VDA compounds 5,6-dimethylxantlenone-4-acetic acid
(DMXAA) and combretastatin A4 phosphate (CA4P) are
being evaluated in human phase II trials in combination
with conventional anticancer therapies.51
Combination of Angiosuppressive and Vascular
Disrupting Agents
Because both angiogenesis and the integrity of the ex-
isting vasculature are critical to tumor progression and
survival, dual targeting of the tumor vasculature would
seem to have considerable promise. Preclinical results
demonstrated that this strategy could significantly enhance
therapeutic response beyond that achieved with either an-
tivascular agent alone.51 One example of this strategy is the
combination of the inhibitor of VEGFR2-associated TK
ZD6474 with the microtubulin-disrupting VDA ZD6126.72
Further combinations that are under preclinical testing in-
clude the combination of OXi-4503, CA4P, and DMXAA with
bevacizumab. Clinical testing of combined antivascular
therapy has started with the recent initiation of a phase I
human trial combining CA4P with bevacizumab.51
Theoretical Considerations for Designing
Antivascular Therapy of Cancer
From the discussion above it is clear that the combination
of either angiosuppressive or the vascular disrupting
therapies with conventional chemoradiotherapy of can-
cer is highly problematic and must be carefully designed
in cases where the sequence of the multiple types of
agents might be critical. The molecular machinery behind
the vascularization process and type of tumor vascular-
ization are further issues that have to be taken into ac-
count. Thus, an efficient antivascular cancer therapy
could be designed based on the identification of the
molecular targets of the angiogenic geno-/phenotype
(molecular pathway-based approach) or on the vascular-
ization mechanism (vascular mechanism-based ap-
proach). However, it is most probable that the two ap-
proaches would have to be combined. We propose
below a rationale for the design of antivascular strategies
with the aim that such consideration may help to improve
the clinical efficacy of these novel therapies.
Molecular Pathway-Based Antivascular Therapy
of Cancer
Because of its pivotal role in neovascularization, the
VEGF/VEGFR axis has been a major target of basic and
clinical research. It is, therefore, not surprising that most
of the antivascular strategies currently in clinical devel-
opment focus on inhibition of VEGF signaling.46,73 How-
ever, the development of the angiogenic phenotype of
cancer is characterized by several interconnected path-
ways. One of the major triggers of this phenotype is tissue
hypoxia, which is responsible for the activation of gene
expression of angiogenic cytokines through up-regula-
tion of the transcription factor hypoxia inducible factor-1
(HIF1-). Nevertheless, HIF-1 may already be active in
particular cancers due to hyperactive growth factor sig-
naling or genetic alteration of the HIF1 gene itself or its
regulators [ie, von Hippel-Lindau (VHL) and p53].74 Be-
cause HIF-1 plays such a central role in triggering nu-
merous pathways responsible for cancer progression,
disruption of the HIF-1-mediated pathways is expected to
cause cancer cell death due to a combination of meta-
bolic dysregulation and reduced microvessel growth.
The aim of anti-HIF-1 therapy (used as an antivascular
modality) therefore might be to cause the angiogenic
phenotype of cancer to revert to a less angiogenic one,
thereby preventing the production of the major angio-
genic cytokines.75 HIF1 can be inhibited by guanyl cy-
clase or HSP90 inhibitors and even by the targeting of
topoisomerase-1, and several of such agents are in clin-
ical trials (Table 1). However, none of the currently avail-
able inhibitors seems to disrupt the HIF-1 pathway as
their exclusive target.75 If the additional targets of non-
selective HIF-1 inhibitors are also involved in cancer pro-
gression, these agents could be therapeutically benefi-
cial, but inhibition of the pathways involved in normal
cellular homeostasis could result in an unacceptable tox-
icity profile. Therefore, the design of more specific HIF-1
targeting agents is the focus of current research efforts.
However, it is also important to note that HIF-1 targeting
alone may not be enough to halt angiogenesis and tumor
progression, as HIF-independent pathways may bypass
or overcome HIF inhibition. Consequently, a combination
of anti-HIF agents with conventional anticancer modali-
ties or other molecular-targeted drugs may be required.
VEGF expression is not only associated with hypoxia or
VHL mutations but also is influenced by a broad spec-
trum of onco- and tumor suppressor genes. A growing
body of evidence suggests that inactivation of tumor
suppressor genes such as p53 and PTEN and activation
of oncogenes such as Ras, c-Src, EGFR, human epider-
mal growth factor receptor 2 (HER-2), FBJ murine osteo-
sarcoma viral oncogene homolog (FOS), neurotrophic
receptor tyrosine kinase B (trkB), V-p3K, and Bcl-2 are
connected to the up-regulation of VEGF. Consequently,
molecular targeting of these regulators is also a potential
strategy for indirectly modulating the VEGF/VEGFR axis.73
For example, based on the results of recent clinical trials,
cetuximab (a monoclonal antibody that binds to EGFR with
high specificity) induces a significant decrease in circulat-
ing VEGF levels in colon cancer patients,76 or likewise,
imatinib mesylate (a specific inhibitor of Bcr/Abl protein TK
activity) reduces VEGF plasma concentration77 and bone
marrow microvessel densities78 in patients with chronic my-
eloid leukemia. However, preclinical and early phase clini-
cal data demonstrate that the addition of anti-VEGF therapy
to anti-EGFR therapies generates further beneficial effects
on angiogenesis inhibition and tumor reduction.42 This sug-
gests that inhibiting upstream signaling of VEGF does not
necessarily provide the same benefit as the direct targeting
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of it and, more importantly, that the dual targeting of cancer
and endothelial cells might become a successful practice in
clinical oncology.
Mechanism-Based Antivascular Therapy of
Cancer
A proposal for the application of antivascular therapies
according to the alternative vascularization mechanisms
in cancer is summarized in Table 2. Probably the most
important aspect of mechanism-based antivascular ther-
apy is its strict dependence on the stage of tumor pro-
gression. Interestingly, antivascular therapy may have an
effect at the very early stages of tumor growth. This idea
was put forward by Li et al,79 who analyzed the earliest
events that take place during the onset of tumor neovas-
cularization and found that individual tumor cells exhib-
ited a chemotaxis-like growth pattern toward the host
vasculature. When the tumor cell population reached
approximately 60 to 80 cells, clear evidence of perivas-
cular tumor cell migration (ie, vessel co-option), and host
vessel dilation was observed. Moreover, in a mouse
model of glomeruloid angiogenesis, our group found that
even single tumor cells can induce radical changes in the
host tissue vasculature24 (Figure 4). These observations
are important in two ways. First, they suggest that anti-
invasive agents (which are not yet available clinically)
may have a therapeutic effect on the interaction between
cancer and endothelial cells and, consequently, on the
processes of vessel co-option and glomeruloid angio-
genesis. Second, the finding that single tumor cells can
induce increased capillary permeability/tortuosity high-
lights the need for application of angiosuppressive/anti-
angiogenic therapy at the very early stages of cancer
progression. These considerations may be true for the
next step of tumorigenesis (pre-angiogenic phase) as
well.
After the onset of “angiogenic switch,” elevated serum
levels of angiogenic growth factors in cancer patients
may activate and mobilize EPCs to support local mi-
crovessel growth.26 If we accept this assumption, then, in
addition to angiogenesis inhibitors and metronomic che-
motherapy,52 ligand-based, EPC-specific VDAs may also
be useful in eliminating circulating EPCs throughout the
further stages of tumor progression (Table 2). Further-
more, because IMG can be effective only in tumor cap-
illary networks already built by other vascularization
mechanisms (mainly sprouting and vessel co-option),
steps should be taken to impede the additional increase
in the density of the tumor tissue capillary bed following
the angiogenic switch. This could be achieved by the use
of VDAs and/or “metronomic chemotherapy,” which both
target the cytoskeleton of ECs responsible for the remod-
eling of capillary walls.
Because ischemic milieu is what forces aggressive
tumor cells to express endothelial genes and form vas-
cular channels,33,80 the initiation of this mechanism is
most likely simultaneous with the angiogenic switch.
Therefore, when vasculogenic mimicry plays a role in the
nutrient supply in cancer, besides the use of ligand-
based VDAs against cancer cells with endothelial phe-
notype, targeting those pathways responsible for the de-
velopment of this mechanism such as Eph2A, PI3K, or
FAK seems to be an appropriate strategy. On the other
hand, metronomic scheduling of chemotherapy52 may
also effectively target cancer cells with vasculogenic
geno/phenotype when both physiological angiogenesis
inhibitors and angiosuppressive drugs are unable to
modify this vascularization mechanism.80
The next stage of malignant progression is when
tumor tissue reaches macroscopic size detectable by
simple or sophisticated imaging techniques. As we
know, for cancer survival “the edge is the future and
the center is history,”81 because active tumor vascu-
larization processes, resulting in vascular networks
built by defective new capillaries, occur mainly, though
not exclusively, at the tumor periphery. Consequently,
at this stage the main target of antivascular therapies is
the invading front of the cancer tissue. However, since
in addition to causing chemo- and radiotherapy resis-
tance, reduction of vascularity in the center of tumors
can lead to the appearance of more aggressive/highly
metastatic hypoxia-resistant cancer cells and to the
induction of vasculogenic mimicry, when designing
antivascular strategies central tumor areas cannot be
neglected. We should emphasize, therefore, that in the
case of clinically detectable tumors the whole range of
antivascular weapons should be used theoretically.
Although antiangiogenic agents targeting proliferating
ECs could possibly be the key drugs at the tumor
boundary, established tumor vasculature might well be
attacked by VDAs and/or metronomic chemotherapy in
the central tumor areas. Altogether, it seems feasible
that antivascular therapy in tumors can only be suc-
cessful if the entire vascular network and all of the
possible vascularization mechanisms are targeted
and, furthermore, if the phenotypic analysis of tumor
capillaries/vascular channels is adequately performed.
Conclusion
Although tumors, as other tissues, require a vessel net-
work supplying them with blood, tumor vasculature is not
necessarily derived by EC proliferation and sprouting of
new capillaries. In addition to alternative vascularization
mechanisms, the novel antivascular strategies must be
harmonized with the stage of tumor progression and with
the molecular mechanism responsible for the angiogenic
phenotype. A further challenge is to combine antivascu-
lar strategies with the existing therapeutic regimes in at
least an additive manner. We have provided here pro-
posals for a rational application of antivascular agents
with the notion that these therapies have to be individually
tailored in a given cancer type. Better understanding of
the different vascularization mechanisms of the various
cancer types will certainly help to fine-tune these novel
anti-cancer strategies.
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Current Concepts of Tumor-Induced Angiogenesis 
Stindor PAKU 
Research Unit of Molecular Pathology, Joint Research Organization of the Hungarian Academy of Sciences and 
Semmelweis University of Medicine, Budapest, Hungary 
Tumor induced angiogenesis responsible for the 
nutr i t ion of the growing tumor  and can also 
increase the probabi l i ty of hematogenous tumor 
dissemination. Data obtained from morphological 
analysis of tumor angiogenesis can contribute to 
the development of new anti-angiogenic therapies. 
Based on in vitro and in vivo observations several 
models of angiogenesis were introduced, explain- 
ing the mechanism of lumen formation and the 
t iming of basement  membrane  depositon.  (1) 
Lumen is formed either by cell body curving or by 
fusion of intracellular vacuoles of nonpolarized 
endothel ial  cells. New basement  membrane  is 
deposi ted after lumen formation.  (2) Slit-l ike 
lumen is immediately formed by migrating polar- 
ized endothelial cells. Basement membrane is con- 
t inuously deposited uring endothelial cell migra- 
tion, only cellular processes of the endothelial cell 
migrating on the tip of the growing capillary are 
free of deposited basement membrane material. (3) 
Development  of transluminal bridges in larger ves- 
sels - a process called intussusceptive growth - 
Key words: tumor, metastasis, angiogenesis, morphology 
leads to the division of the vessels. These models, 
however, describe angiogenesis in tissues rich in 
connective tissue. Different processes of angiogen- 
esis take place in organs - such as liver, lungs, 
adrenals, which are the most frequent sites of 
metastasis - having high vessel density without 
sufficient space for capil lary sprouting. In the case 
of liver metastases of Lewis lung carcinoma the 
proliferation of endothelial cells was elicited only 
by direct contact between tumor and endothelial 
cells, leading to the development of large convolut- 
ed vessels inside the metastases. These vessels 
were continuous with the sinusoidal system, sug- 
gesting that these metastases have dual blood sup- 
ply. This observation, among others, is in contrast 
to the general ly accepted view that l iver tumors 
have arterial blood supply. The increasing number  
of data demonstrat ing the dual or venous blood 
supply of liver metastases hould be taken into 
consideration in the therapy of liver metastasis. 
(Pathology Oncology Research Vol 4, No 1, 62-75, 
1998) 
Introduction 
Two, morphologically different processes take part in 
the development of new vessels, During angiogenesis new 
vessels arise from preexisting ones, contrary to vasculoge- 
nesis, which occurs at early embryonic development, when 
vessels are organized from primordial endothelial cells. 13 
Tumor induced angiogenesis has two effects on malig- 
nancy. On the one hand the developing vasculature f eds 
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the tumor, on the other hand it increases the probability of 
tumor dissenfination via the vascular system. Although 
tumors generally lack lymphatic vessels and lymphangio- 
genesis has not been observed uring tumor progression, 4 
recent results have shown that VEGF-C transgenic mice 
develop a hyperplastic lymphatic apillary system in the 
skin, raising the possibility of lymphangiogenesis al o in 
the case of tumors. 5 
It is generally accepted that tumors cannot grow beyond 
the size of 2 mm in diameter without eliciting angiogenic 
response, in case of tumor cells lodged in distant organs, 
the temporary lack of the angiogenesis nducing ability, 
can lead to the development of dormant metastases.~'2 
There are ample data showing inverse correlation 
between tumor vascularity and patient survival. 6Opposite 
9 1998 W. B. Saunders & Company Ltd on behalf of the ArS_nyi Lajos Foundation 1219-4956/98/010062+14 $ 12.00/0 
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results suggest, however, that simple vessel counting 
(determination f vessel number in places of highest ves- 
sel density, so called hot spots) does not represent the 
more complex relationship between tumor vascularity and 
metastasis. 7 Instead, the detection of disseminated tumor 
cells at the invasion front, or determination of blood or 
lymph vessel invasion appear to be parameters that - 
although more difficult to determine - are more closely 
related to the metastatic process. 8'9 
Tumor vasculature has two important further effects on 
the therapy of tumors. It can itself be a target for therapy 
(anti-angiogcnic therapy), and it is responsible for deliver- 
ing therapeutic agents to tumor cells, m'H Morphological 
analysis of in vivo angiogenesis as well as determination 
of the spatial distribution of cell-cell, cell-matrix adhesion 
molecules, extracellular matrix components, matrix 
remodelling enzymes and angiogenesis factors during the 
process can lead to development of new anti-angiogenic 
strategies. 
Tumor angiogenesis initiated by disturbing the bal- 
ance between angiogenesis activators and inhibitors, 
already in the stage of dysplasia or in situ carcinoma 
before the progression to invasive tumor stage. '2 Positive 
mediators of this process are the angiogenic factors pro- 
duced directly by tumor cells, or by host cells recruited to 
the peritumoral space. Numerous polypeptide and small 
molecular weight angiogenic factors has been identified, 
recently reviewed by Bouck et al. ~ Similarly, extracellular 
matrix molecules and their degradation products has been 
shown to induce angiogenesis alone, or in combination 
with the above factors.~3 
Angiogenesis n vitro 
The effect of angiogenesis factors and extracellular 
matrix components On endothelial cell behaviour has been 
extensively studied using in vitro cultured endothelial cells 
of different origin. Endothelial cells can undergo a process 
called in vitro angiogenesis cultured on different matrices. 
Tubular structures consisting of several endothelial cells 
were found to develop on surfaces coated with gelatin or 
fibronectin in overconfluent cultures. ~4-'6 Similar struc- 
tures were seen to arise rapidly, alter seeding endothelial 
cells on a gel consisting of basement membrane compo- 
nents (Matrigel)] 7'1* Although the cords on the surface of 
the extracellular matrix were lbrmed by numerous elon- 
gated endothelial cells, and in cross section the cells 
enclosed a primitive lumen sealed by intercellular junc- 
tions, H-~8 the lumen often contained extracellular matrix 
material or cellular debris and the basal-apical polarization 
of the endothelial cells was not demonstrated. ~4'17 Tube 
formation proved not to be an exclusive characteristic of
endothelial cells, because many other cell types were able 
to form cords and networks on basement membrane matrix 
gelJ 9 With decreasing melleability of tile gel the cord for- 
mation diminished, suggesting that cord fomation is more 
dependent on the mechanical properties of the matrix than 
on the cell typeJ 9 This manner of endothelial cell organi- 
zation is more resemblant to the process of vasculogene- 
sis, since angiogenesis characterized by migration of 
endothelial cells into the matrix (a process called sprout- 
ing) from a polarized layer of endothelial cells. To exam- 
ine angiogenesis in vitro, it is more relevant o study the 
in vitro model systems using endothelial cells cultured to 
confluency on the top of collagen I gel or human amniot- 
ic membrane or aortic rings explanted into fibrin gel. 2~ 
In the former case the treatment of such cultures with FGF 
or PMA resulted in invasion of the gel, or the basement 
membrane by the endothelial cells which process depend- 
ed on the production of collagcnase IV and plasminogen 
activator. 2~ Tube-like structures appeared in the collagen 
matrix, which showed a lumen delineated by endothelial 
cells, connected by intercellular junct ions] ~ More 
importantly, polarized deposition of the basement mem- 
brane was observed in these structures. 2~ Similar polarized 
deposition of fibronectin, laminin, and collagen IV was 
observed around the developing capillaries in the case of 
aortic rings explanted into fibrin gel. 24 
Angiogenesis n vivo 
Angiogenesis n primate' tumors 
Fibrin and collagen I are the components of the provi- 
sorial extracellular matrix during tumor development and 
wound healing in vivo. z5 Fibrin gel was shown to induce 
angiogenesis when implanted subcutaneously. 26 The 
development of the fibrin containing stroma in and around 
the tumor is controversial. Numerous ultrastructural stud- 
ies on the angiogenic vasculature of tumors and healing 
wounds have suggested that leakiness of the vessels is 
caused by open interendothelial junctions. 27--~~ It is well 
known that tumor vessels usually show abnormal struc- 
ture, such as fragmented or ultrastructurally not detectable 
basement membrane and the absence of pericytes) ~'32 The 
lumen of the tmnor vessels is often covered by extremely 
thin fragile endothelial cells showing fenestrations, or 
vascular spaces are present delineated by tumor cells. It is 
not clear, however, whether these alterations are charac- 
teristic to the angiogenic process or are caused by the 
invasive activities of the tumor cells. The possibility that 
tumor invasive activities play role in the enhanced leaki- 
ness of tumor vessels is supporte.d by the observation - 
made on corrosion casting specimens of colon tumors -
that resin leakage was observed only in carcinomas and 
not in adenomas. 33Examination of the angiogenic vascu- 
lature under normal condition demonstrated that angio- 
genic vessels are not permeable for molecules larger than 
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20 kD. 34 Other ultrastructural reports have also shown the 
absence of open interendothelial junctions during tumor 
angiogenesis, although tumor vasculature showed leaki- 
ness for larger 70-150 kD molecules. 3sThe leakiness of 
tumor vessels, as suggested by Dvorak's group, is mediat- 
ed by vesiculo vacuolar organelles (VVO) present in 
endothelial cells of the neovasculature induced by 
VEGF. 36 However, recent results revealed that the 
endothelial cells in the vasculature of VEGF transfected 
tumor are fenestrated and contain open interendothelial 
junctions] v 
The developing tumor matrix also contains other extra- 
cellular matrix proteins, such as fibronectin, vitronectin 
and thrombospondin. The former two proteins have a pos- 
itive effect on tumor angiogenesis by inducing chemo- 
taxis of endothelial cells. The role of thrombospondin s 
more complicated, since its ability to induce angiogenesis 
indirectly in vitro as well as elevated mRNA level and 
deposition around breast carcinomas 4'42 seems to contra- 
dict its pronounced ability to inhibit angiogenesis n vitro 
and in vivo.lJ 
The morphology of in vivo angiogenesis has been stud- 
ied most frequently in subcutaneous tissue, rabbit cornea 
and chick chorioallantoic membrane, in normal and patho- 
logical conditions uch as inflammation, wound healing 
and tmnor development.3"28-31.43,15 
The main pitfall in studying angiogenesis is the 
misidentification f vesscl structures as lips or distal parts 
of growing capillaries. To avoid this, serial scctioning 
nmst be performed. The situation is less complicated in 
case of avascular tissues where the growing new vessels 
are not mingled with preexisting or older vessels, but ser- 
ial sectioning cannot be avoided when examining, for 
example, tumor angiogenesis n subcutaneous tissue. As 
shown in Figure 1A-F, sections of a small capillary loop 
can easily be misidentified as a tip. In contrast, a real tip 
as shown on Figure 2A-F is only discernible in serial 
sections9 
According to ultrastructural studies, the most common- 
ly used description of the angiogenic process (which is 
considered to be valid also in case of tumor induced anglo- 
genesis) can be summarized as follows (Figure 14A,B): a. 
dilatation of postcapillary venulcs situated around the 
tumor; h. local degradation of the basement membrane on 
the side of the vessel located more closely to the angio- 
genic stirnulus; c. weakened intercellular contacts between 
Figure 1. A-F. Serial sections of a short loop of a capillary 
(arrowheads). This loop does not show an opened lumen and 
returns to the original vessel. X 280, 
Figure 2. A-F. Serial sections of a short newlF fornted capillary 
(arrowheads). Arrows in Fig~ure 2A and 2F points to regions, 
which show that the capillary does not continue into tile con- 
nective tissue. X 280. 
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Figure 3. Part of a dilated venule near the tumor. Beneath the 
endothelial cell there is no basement membrane. X 9000. 
,. i~ ~ 
Figure 4. Similar vessels as shown on Figure 3. Basement 
membrane material reacting positively fiw laminin can be 
detected beneath the endothelial cell. X 9000 
endothelial cells and the start of emigration into the con- 
nective tissue, toward the angiogenic stimulus; d. the for- 
marion of a solid cord by endothelial cells following each 
other arranged in bipolar fashion, with mitotic endothelial 
cells observed in the middle of the sprout; e. formation of 
the lumen, occuring either by fusion of intracellular vac- 
uoles, or by cell body curving of a single endothelial cell; 
.f. loop h~rmation by fl~sion of different sprouts; g. appear- 
ance of pericytes along the sprout and the synthesis of a 
new basement membrane. 
The main disadvantage of this model is its inability to 
identify the nature and origin of the stirnulus necessary for 
lumen formation. It also assumes that dedifferentiation 
and redifferentiation take place during the process, manl- 
Iest in the loss and regaining of luminal-basal polarity. A 
large number of publications dealing with the effect of 
Matrigel on the behavior of endothelial cells suggest hat 
stimulus necessary for lumen formation derives from the 
developing basement membrane, tT'~s According to this 
model the importance of the basement membrane in the 
process of lumen formation is rather questionable, because 
basement membrane deposition occurs after lumen forma- 
tion, which presumes the existence of basal-luminal polar- 
ity. If basement membrane synthesis occurs before lumen 
formation it must proceed around the whole circumference 
of a nonpolarized cell, excluding that lumen formation 
occurs latcr by cell body curving. Lumen formation by 
fusion of intracellular vacuoles allows basement men> 
brane deposition around the cell, but to increase lumen 
size in such capillaries the cells must undergo transversal 
division, implicating a change in cell polarity. Seamless 
type endothelial cells have very rarely been found i  vivo, 
and it has been suggested that they are present only where 
growing capillaries meet preexisting vessels during loop 
formation) 6 
A different model was suggested based on data 
obtained from ultrastructural examination of angiogenesis, 
using a rat nonmetastatic pancreatic adenocarcinoma cell 
line growing subcutaneously (Figure 14C). 47 The first step 
in this type of angiogenesis was the alteration of the base- 
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Figure 5A.  In  tile wall of the extended venule three endothelial cells (E1,E2,E3) are seen in different stages of emigration into the 
connective tissue (arrowheads). X 1400. 
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mcnt menlbrane over the entire circumference of venules, 
characterized by loss of electron density (Figure 3), but 
basement membrane components (laminim collagen IV) 
could be detected by in}munoclcctronmicroscopy (Figure 
4). Interestingly, fibronectin was also detectable in these 
basement membranes. This so called gel-sol transition of 
the basemem membrane, probably mediated by matrix 
metalloproteinases or plasminogen activator, can be part- 
ly responsible lior the initiation of cell division and migra- 
tion (Figure 5A,Bt. ~s Conversely migrating endothelial 
cells express elevated level of uPA. 4~ It has been shown 
that gelatinase A can be activated by membrane type met- 
9 I8 ~0 alloproteinase and also by uPA/plasmm,"- and bFGE 
VEGF and TNF can increase lhc expression of uPA and its 
receptol@ Partial and regulated prolcolysis of the base- 
Figure 5B. Detail of the region shown in Figure 5A at another 
plane of sectioning. The emigrating endothelial cell (El) is 
dividing, the nucleus is reconstitued. The endothelial cell is in 
connection with another endothelial cell (E) via interendothe- 
lial junction (arrow). Around the leading process of the 
endothelial cell and beneath the othe~  endothelial celt (E) no 
basement membrane ca~t be observed. X 6900. 
" 20 & -.- . L"-,,". 
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Figure 6. The process (art~zt,) of the endolhelial cell (E) pro- 
jecting iHto the connective tissue is free of deposited basement 
membrane material. Other parts of the subemtotheliunl staitls 
positively for laminin. X 9000. 
merit membrane can lead to exposition of different 
domains of laminin, for example SIKVAV. which has bccn 
shown to induce endothelial cell proliferation and angio- 
genesis, and has also been able to enhance the production 
Figure Z Cross section of a newly formed capillary. The slit- 
like lumen (arrow heads) is sealed by intercelhdar juntions 
(arrows). Basement membnme cmmot be iderttij~ed around the 
endothelial cells. X 11000. 
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Figure 8. Longitudinal sections of a long newly formed capillary. Dilated lumen and pericites cannot be obserw*d. Basement mere- 
brain' material staining positively fi~r laminin is deposited around the capillary. X 2400 
of proteases) 2 bFGF can also be deliberated from the 
endothelial basement membrane during this process) ~ The 
regulated manner of basement membrane degradation is
further supported by the observation that small vessels 
express high levels of TIMP-1 mRNA. 54 Loosening of 
interccllular contacts was not observed, suggesting that 
loss of contact inhibition is not responsible for initiation of 
cell division and migration (Figure 5B). hmnunoelectron- 
microscopy showed complete degradation of basement 
membrane only at places where cellular processes were 
projccting into the connective tissue (Figure 6). During 
further migration, endothelial cells were arranged in par- 
allel maintaining their polarity (basaMuminal), conse- 
quently a slit-like lumen was immediately fomned between 
the endothelial cells (Figs. 7-9). This lumen was continu- 
ous with the lumen of the original vessel and was sealed 
by intact interendothelial junctions (Figure 7). This type 
of premature capillaries reached several hundred microns 
, ~ .., .... ;"..g,'; .
"~..~, " +' ., , ;' +~'.. ' L '  " 
~ '~,  i..., ".. ~ . . -  " " .~. 
Figure 9. Detail of a capillary with slitqike lumen (arrow). 
Amorphous laminin positive material can be observed around 
the capillary. Note the laminin positive material in the endo- 
plasmic reticulum cisternae of the endothelial cell (arro~ 
heads). X 11000. 
in length (Figure 8). Similar structures containing slit-like 
lumen were observed by others suggesting that this type 
of angiogenesis also uccurs in normal and other patholog- 
ical conditions. 43-45 The development of a slit-like lumen 
makes it easier to overcome the resistance of the connec- 
tive tissue during tip advancing, hnmunocytochemical 
analysis of the distribution of PECAM-1 during angiogen- 
esis showed that this cell adhesion molecule is evenly dis- 
tributed along the basal and luminal surfaces of endothe- 
lial cells in nonnal vessels, but is relocalized to intercel- 
lular junctions and to the apposed surface of the endothe- 
lial cells/5 These results are in accordance with the obser- 
vation that intact intercellular junctions are necessary for 
polarized migration f endothelial cells, at the same time, 
they also raise the possibility that during capillary growth 
the slit-like lumen is at least partially sealed (PECAM-1 
homotypic interaction), preventing the dilatation of the 
lmnen. 
Basement membrane was found deposited immediately 
by the polarized endothelial cells and only cellular process- 
es of cells migrating on the very tip of the growing capil- 
lary were seen to be free of basement membrane material. 
According to this model no stimulus is necessary for induc- 
tion of lumen lonnation and the retained polarity of 
endothelial cells allows the continuous deposition of the 
basement membrane. Interstitial collagens were shown to 
enhance proliferation of endothelial ceils, whereas other 
results suggested an increased eposition of collagen I by 
differentiating capillary tubes during in vitro angiogene- 
sis. 56'~7 In this model, endothelial cells are separated from 
interstitial collagens by basement membrane during capil- 
lary growth, which phenomenon questions the importance 
of these molecules in the growth and differentiation of 
endothelial cells. The role of gelatinases has been exten- 
sively studied during angiogenesis, however, in the fonner 
model its role was restricted to the initial degradation, con- 
trary to this model where it can contribute to the main- 
tainance of the sol state of the basement membrane. As it 
has been shown, only processes of endothelial cells locat- 
ed at the tip of growing capillary are in contact with inter- 
stitial collagens. This phenomenon suggests an important 
role for interstitial collagenases during tip advancing. 
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Fiu~re 10, Immunoelectromnicroscopy f a youn,,~ capillary 
composed of three endothelial cell9 Amorphous fibronectin-pos- 
itive material is dq~osited around the capillary. There is no 
positive material in the endoplasmic ~ticalum cisternae of the 
cells. Material staining positively .for fibronectin can be 
observed in the comwctive tissue farrows). X 8100. 
Supportive of this is the observation that VEGF can induce 
interstitial collagenase expression in endothelial cells. ~s As 
mentioned above the extracellular matrix surrounding the 
tumor frequently contains fibrin, fibronectin, vitronectin 
and thrombospondin. The wide substrate specificity of the 
plasminogen activator/plasmin system implicates an 
important role for these enzymes in angiogenesis. It has 
also been shown that uPA can enhance cellular migration 
independent of its proteolytic activity 59 and recently it has 
been demonstrated that uPAR is a receptor for vitronectin/'~ 
which is present in the peritumoral matrix and probable in 
the immature basement membrane of the growing capillar- 
ies. The importance of uPA in tumor angiogenesis has fur- 
ther been supported by the observation that anti-uPA anti- 
body was able to inhibit network development in vitro and 
more importantly, uPA antagonist or mutant uPA expres- 
sion was able to inhibit tumor growth. <'~'~- 
Vast number of data suggest that integrins play a pivotal 
role in cell migration, differentiation and apoptosis. 63~ 
Recently it was demonstrated that specific integrins are 
expressed iri the newly developed growing capillaries. The 
most important among them is the rxvl~3 intcgrin which, as 
it was suggested, mediates the migration of endothelial 
cells in the fibrin containing tumor matrix) 5This sugges- 
tion is in concert with the first model, but does not dis- 
agree with the second model either, where it was shown 
that the synthesized new basement membrane contains 
fibronectin (Fi<~,ure 10). Since fibronectin immunoreactiv- 
ity could not be observed in the endoplasmic reticulum of 
endothelial cells (Figure 10). in contrast o laminin and 
collagen IV (Figure 9), it is probable that this molecule is 
not synthesized by endothelial cells, but rather incorporat- 
ed into basement membrane from the tumor matrix 
(Fi<~ure lO), providing a ligand for c, vl~3 integrin. Beside 
mediating migration of endothelial cells on the developing 
basement membrane, c~vl]3 can also play a role in the 
maintenance of the sol state of the basement membrane as 
a consequence of its ability to bind the matrix metallopro- 
teinase MMP-2/'~ Interference with the ligand binding 
activity of this integrin by antibodies or RGD peptides was 
able to induce apoptosis of endothelial cells in growing 
capillaries, <'v and inhibit wound healing and tumor 
growth, e<~ Some discrepancy exists, however, between the 
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Figure 11. Newhd formed capillary still showing slit-like lumen 
(arrow heads) but well defined basement membrane (arrows) 
aml pericyte (P) ctm be observed around the capillary. X 11000. 
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second model and tire proposed role of c~vt33 integrin, 
since it was shown that Matrigel down regulates the 
expression of this integrin. ~'~ The selectivity of therapies 
based on the exclusive xpression of o~v[33 on newly grow- 
ing capillaries is somewhat questioned by a recent obser- 
vation detecting cw[33 integrin on parent vessels as well] ~ 
Other integrins may also be a target for anti-angiogenic 
therapies such as tire laminin binding o(6[34 integrin, 
detected on the entire length of the capillary sprout, and 
also in the parent vessels] 1 In contrast o these results 
reduced staining for ~x6 integrin was observed in growing 
capillaries in vivo, which is in agrccment with lhe well 
known notion that cell migration eeds reduced adhesivi- 
ty. 55 The positive effect of the reduction of adhesion on 
angiogenesis is supported by the observation that anti-inte- 
grin antibodies, enhanced, instead of reduction, the forma- 
tion of tubules it, vin'o. :2 Interesting results pointed out the 
important role of the tumor derived extracellular matrix in 
angiogenesis. Tumor cells deficient in fibronectin receptor 
or [31 integrin developed a defective vasculature, charac- 
terized by small irregular leaky vessels, which phenome- 
Fig~tre 12A-E. Serial sections of a venule in the first steps of 
dividin R. Endothelial cell (arrow) is attached to an endothel&I 
cell on the other side qf the venule. X 280. 
non resuhed in reduced tumor growth as well. 7~74 One pos- 
sible explanation for this could be, the defective anchorage 
of the basement membrane deposited by the endothelial 
cells to the surrounding extracellular matrix. This is fur- 
ther supported by earlier observations that inhibition of 
crossliuks between collagen molecules caused regression 
of newly growing capillaries] ~
Regular basement membrane and pericytes appeared at 
later stage of capillary maturation (Figure 1l). Increasing 
deposition of collagen IV, :~' the sol-gel transition of the 
basement membrane and the appearance of pericytes may 
all contribute to the cessation of endothelial cell prolifera- 
tion and migration. It has been shown that latent TGF-]3 is 
activated by uPA in cocultures of endothelial cells and per- 
icytes, 77 where the former down regulates the VEGF 
receptor on endothelial cell. w 
Numerous data suggest hat the growth of capillary 
sprouts is not oriented towards the tumor, instead the 
process yields a high density anastomosing network of 
capillaries at the tumor periphery, a process leading to the 
observed phenomenon that vessel density is higher 
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roles in angiogenesis: it allows the build-up of a gradient 
of the angiogenic factor and provides space for vessel 
sprouting. The question arises, what kind of angiogenesis 
takes place in highly vascularised organs such as liver, 
lungs or adrenals, which in humans are the most frequent 
sites of metastasis ? 
0 
J 
Figure 13. Numerous Ia~e caliber vessels (arrow heads) are 
stained positively for laminin outside the capillary sprouting 
area. T; Tumor. X 110. 
around the tumor than inside of it. A possible xplanation 
is that the continuously growing tumor incorporates the 
vessels at the tumor periphery, thereby thinning out the 
network, whereas a new network develops at the advanc- 
ing tumor border. 79 
A third type of angiogenesis nvolving larger vessels 
has been described recently. This process is called intus- 
susceptive growth of vessels, culminating in the division 
of vessels (Figure 14D). ~~ The process is not complete- 
ly known, but it starts with the projection of an endothelial 
cell into the lumen of the vessel and the attachment to 
endothelial cells on the other side (Figure 12A-E). Finally 
transluminal connective bridges develop, dividing the ves- 
sel into two or more parts. The process -which yields a 
high number of large caliber vessels situated outside the 
area of the active capillary growth (Fiy~ure 13) - probably 
does not contribute to the nutrition of the tumor signifi- 
cantly, but rather provides more sites for sprouting. 
Angiogenesis in metastases 
The above described models of angiogenesis are based 
on observations made in tissues that contain high 
amounts of connective tissue fibers, and can also be valid 
in case of tumors such as melanomas, skin-, breast-, 
colon cancer. The connective tissue has two important 
O 
0 
Figure 14A-D. Schematic representation off the different mod- 
els of angiogenesis. 
PATHOLOGY ONCOEOGY RESEARCH 
               dc_301_11
Current Concepts in Tumor-lnduced Angiogenesis 71 
B 
' . r  
.. ;t%~;;~ 
| 
9 ~o. 
~' .,~.~,,,., 
9 -~  .~ ,~; : : . . . -  . .:~ ~; 
.?. ~ r  
t &~ " 
D 4~ '' ~,' ~':~'~ ~ ~  
.:*~ ~ . ~ "  7 ,u l r~.  ~, ~,  - .  .~-!,k. '~ .~ ' :m~. .  l~b lmPlCd l~ , 
Figure 16. Cryosection qfi a liz~er melastasis stained fi)r 
laminin. The walls of the lmxc com~,ohtted vessels tain nQca- 
tively for laminin (arrow heads). X 75. 
A process of angiogenesis, was described in case of 
liver mctaslascs of Lewis lung carcinoma, showing 
remarkable differences to the models described above, u2 
Neither dilatation, or increase in the number of the vessels, 
nor enhanced proliferation of endothelial cells could be 
observed around the metastases, suggesting the absence of 
sprouting activity in this region. This indicates that the 
angiogenic stimulus could not reach the endothelial ceils 
around the tumor, which can be explained by the high vas- 
cularity of the liver being responsible for diluting or flush- 
ing out the factor. The sparse connective tissue cannot pro- 
vide sufficient space for diffusion of the angiogenic fac- 
tor, and also impedes the migration of endothelial cells, 
thereby the development of new capillaries. Initiation of 
endothelial cell proliferation was caused by direct contact 
Figure 15A-D. Serial sections qf a liver metastasis of the 3LL- 
HH tumor. Large convoluted (V) and smaller vessels (asterisks) 
cat1 be seen in the metastasis. 7~vo simlsoids of the liver are con- 
tinuous with these vessels (arrows). X 90. 
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between tumor cells and endothelial cells (Figure 18). 
Invading tumor cells migrated along the basement mem- 
brane of sinusoids and larger vessels, detaching the 
endothelial cells fi'om their own basement membrane 
(Figures 18, 19). Interestingly the basement membrane 
was not degraded and remained on the surface of hepato- 
cyles, even when these cells became enclosed into the 
tumor (Figure 20). The observation that proliferative 
activity is restricted to endothelial cells situated inside the 
metastases can be explained by results demonstrating that 
mRNAs of VEGF receptors (KDR, fit-l) were more 
strongly expressed in metastases of co]orectal tumors than 
in the surrounding liver tissue, s~ 
The proliferating endothelial cells formed large conw)- 
luted vessels deeply penetrating into the metastases 
(Figures 15B, 16). These vessels were even lacking an 
immunohistochemically detectable basement membrane 
(Figures 16. 17~. This observation is rather unusual 
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Figure 17. Immunoelectromnicroscopy of a part ~a  convolut- 
ed vessel inside a metastasis. Under the endothelial cells (E) 
laminin positve material can be observed only in small spots 
(arrow heads). Similar material is deposited in some areas by 
the tumor cells (arrows). X 1.0009 
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Figure 18. 3LL-HH tumor cells (T) migrating between the  
endothelial cells (E) and hepatocytes (H) in a sinusoid at the 
periphery of a metastasis. The endothelial cell lED in the vicin 
ity of the tumor cells shows chromatin condensatio~z. X 3.000. 
although lack of electron density is commonly observed 
in case of liver sinusoids, lymphatic apillaries or tumor 
vessels. Complete loss of basement membrane (loss of 
anchorage) - as was mentioned earlier - leads to apoptosis 
and vessel regression. It must be noted, however, that in 
3LL tumors - although having a very poorly developed 
st roma-  the tumor cells deposited some laminin contain- 
ing material, which could serve as substrate for attachment 
of endothelial cells in these new vessels9 This attachment 
took place only at some spots on the surface of tumor cells, 
resulting weak anchorage which can be responsible for the 
high fragility of these vessels (Figure 17). In serial sec- 
tions thesc vessels were continuous with the sinusoidal 
system of the liver consequently supplied mainly by the 
portal vein (Figure 15A-D). 
Another less frequently observed type of 3LL-HH liver 
metastases howed a different pattern of vasculature. 
These metastases contained small vessels with detectable 
basement membranes, and were located in the viccinity of 
portal tracts9 Their vasculature probably raised by sprout- 
ing from the peribiliary plexus, in the periportal connec- 
tive tissue, suggesting that blood supply was originating 
mainly from the hepatic artery. 
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Therapeutic onsiderations 
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Figure 19. Invading tumor cell (T) in a sinusoid detaches the 
endothelial cell (E) from the basement membrane (arrow heads). 
The laminin positive material remains associated with the hepa- 
tocyte (H). X 10.000. 
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Figure 20. The surface of a hepatocyte (H) enclosed into the 
metastasis still stains positively for laminin. E; Endothelium, 
V; Vessel lumen. X 1.300. 
The above results trongly suggest that the type of vas- 
culature and blood supply can be dependent on the local- 
ization of metastases in organs having both arterial and 
venous blood supply. Accordingly, these and other obser- 
vations support the possibility that the tissue architecture of
organs, in which angiogenesis is taking place, has an impor- 
tant impact on the process of angiogenesis and consequent- 
ly on the structure of the developing neovasculature. Onthe 
other hand the properties of tumor cells can also determine 
the outcome of the angiogenic response. For example the 
previously described process of angiogenesis in liver metas- 
tases can be valid in case of anaplastic tumors having high 
invasive ability and poorly developed tumor su'oma. Well 
differentiated tumors, however, showing the same tissue 
architecture in primary tumors as in metastases, probably 
elicit a different type of angiogenesis. The widely used 
methods in the therapy of primary and secondary liver 
tumors (hepatic artery infusion, hepatic artery ligation and 
ehemoembolization) are based on the notion that most 
tumors in the liver have an arterial blood supply, a4-s6 In con- 
trast to this, it is generally accepted that during angiogene- 
sis, new vessels originate mainly from postcapillary 
venules. 2'3 Several authors suggest, however, that new cap- 
illaries can originate from arterioles or large veins, contain- 
ing elastic laminae and smooth muscle cells, demonstrating 
the fact that such structures cannot prevent he emigration 
of endothelial cells.S7's8 A number of data suggest that a con- 
siderable portion of human and experimental liver metas- 
tases have portal blood supply, s9'91 and even vessels, origi- 
nating from hepatic sinusoids can contribute tothe nutrition 
of the entire metastatic nodule, not only to the supply of the 
tumor periphery. 92According to these facts, more attention 
should be paid in the future to the portal blood supply of 
liver metastases in the design of locoregional therapy. 
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Abstract
This study was undertaken to determine the role and the fate of the peritumoural vascular plexus
during the vascularization of human malignant melanoma (hMM) and in an appropriate murine
melanoma model system. The prognostic significance of the vascularity of different tumour areas
was also evaluated. Despite morphometry revealing several-fold higher microvessel densities
(MVDs) in the peritumoural tissue than at the centre of the tumour, the development of visceral
metastases of hMM was exclusively correlated with the MVD of the tumour centre. Furthermore,
the 5-year survival of the patient group with low tumour centre MVD (<30/mm2, n=29) was
100%, compared to 1/16 patients alive with high tumour centre MVD (>30/mm2, n=16).
Morphometric analysis and three-dimensional reconstruction of vessel networks of both human
and murine melanomas showed clearly that the peritumoural vascular plexus present at the
melanoma base is continuously being incorporated into the growing tumour mass. Once vessels
become incorporated, sprouting ceases and the proliferating endothelial cells (EC) take part only
in vessel dilatation. Moreover, the immunohistochemical and ultrastructural characterization of
microvessels demonstrated that the pericyte coverage of endothelial tubes was complete in all of
the investigated areas, in both human and murine melanomas. Copyright # 2002 John Wiley &
Sons, Ltd.
Keywords: vessel incorporation; melanoma; intratumoural vessels; prognosis
Introduction
In the past decade, systematic studies have provided
ample evidence that tumour progression correlates
with tumour-induced angiogenesis [1], but this issue
has remained controversial in the case of human
malignant melanoma (hMM) of the skin [2–13]. Most
of these studies used the principle of selecting the
vascular ‘hot spots’ as a basic approach [1,14], but it
should be kept in mind that the site of tumour cell
intravasation does not necessarily correspond to the
area of the highest MVD, especially when the ‘hot
spot’ is located outside the tumour mass. Neo-
angiogenesis has been considered as synonymous with
directed vessel ingrowth in almost all of these studies,
although alternative mechanisms seem to exist, both
experimentally and in human tumours [15,16]. It has
been reported recently that non-small cell lung carci-
noma grows without inducing neo-angiogenesis [17],
and the growing glioma and mouse adenocarcinoma
can co-opt (i.e. incorporate) host vessels [18,19].
However, the mechanisms of vessel ingrowth and
incorporation probably operate in different propor-
tions in various tumour types.
It has long been speculated [20–22] that tumour
vasculature is characterized by a distinct maturation
defect, namely the absence of pericytes, that is thought
to be at least partially responsible for the irregular,
tortuous and leaky blood vessels found within
tumours. If we accept the concept of vessel co-option,
the level of coverage by pericytes in different micro-
vascular beds must be relevant; the nascent, unstable
and vulnerable intratumoural vessels, which have not
had enough time to differentiate, might therefore
dictate the clinical course to a greater extent than the
more mature incorporated vessels.
Despite the high vascularity at the tumour base (hot
spots) observed several times in hMM [5,9,23,24], this
phenomenon has remained experimentally unex-
plained, probably because of the difficulty of modelling
the primary hMM. In experimental models, the rapid
growth kinetics of melanoma make the observation of
progression and angiogenesis difficult in the very early
stages, corresponding to human tumours in radial
growth phase. If the process of vascularization of these
rapidly growing mouse tumours is very different from
hMM, then these models may be less useful for
therapeutic studies, particularly when anti-angiogenic
drugs are investigated.
To clarify the role of the peritumoural vascular
plexus in the process of vascularization of hMM, we
decided to follow up the development and fate of this
Journal of Pathology
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peritumoural vessel network in a suitable mouse
tumour model system. For this purpose we performed
morphometry and 3D reconstruction of the vascula-
ture in hMM samples and studied the growth, mech-
anism of vascularization and EC proliferation in B16
mouse melanoma after intradermal inoculation. To
analyse microvessel maturation, we also investigated
the distribution of pericytes in human and mouse
melanomas.
Materials and methods
Clinical data
This study used 45 primary hMM cases with a mini-
mum follow-up period of 5 years, four non-tumourous
skin biopsy samples and three naevi. The two sexes
were represented equally. Tumours had no detectable
metastases at the time of diagnosis and were cate-
gorized according to thickness (thin <1.5 mm, n=13;
medium thick 1.5–4.0 mm, n=17; and thick >4.0 mm,
n=15; Table 1A) and to the actual type of progression
(non-metastatic, n=15; lymph node-metastatic, n=14;
and organ-metastatic, n=16; Table 1B).
Animal model
Inbred C57Bl/6 mice were anaesthetized and 104 B16
cells in 1 ml Hanks’ solution were inoculated intrader-
mally, next to the epidermal–dermal junction, under a
dissecting microscope by using a precision syringe
(0.15 mm diameter, Hamilton). To prove the proper
localization of the injection sites, tumour cells were
labelled with membrane permeant reactive fluorescent
tracer (CellTracker Green, Molecular Probes Inc.,
5 mm) and were injected intradermally into six mice,
which were sacrificed by anaesthesia immediately or
24 h after injection.
Morphometry of human and mouse tumours
Three different tumoural and peritumoural regions
were assessed separately for each section. These were:
(I) the tumour centre; (II) the tumour periphery—
a 100 mm wide band of tumour immediately adjacent
to the invasive edge; and (III) the peritumoural host
tissue—a 200 mm wide band of host connective tissue
immediately adjacent to the tumour periphery. MVD
and microvessel perimeter were determined by double
labelling of blood vessels for CD31 (anti-human CD31;
Dako, 1 : 40 or anti-mouse CD31, 1 : 100, Pharmingen;
DAB) and laminin (anti-laminin, Dako, 1 : 50; Fast-
Blue). Two sections per hMM and three sections from
each mouse (5–10 fields of 20r, 40r objective/section/
region) were analysed using CUE-2 software as
described previously [25]. In parallel, MVD was also
determined by applying the vascular hot spot tech-
nique, as recommended [14]. The diameter of the
tumours was determined with a 2r objective.
Table 1. Comparison of vascular parameters of the human malignant melanoma of the skin according to the thickness
(A) and to the to the clinical course (B)
A
Tumour
thickness
Tumour centre Tumour periphery Peritumoural host tissue
MVD (n/mm2) Perimeter (mm) MVD (n/mm2) Perimeter (mm) MVD (n/mm2) Perimeter (mm)
<1.5 mm
n=13 22.4t6.3 73t25.1 78.3t28.2 71t19.9 141t66.7 72.4t10.1
1.5–4 mm
n=17 32.5t10 80.8t27.3 98.9t27.7 75.7t16.4 137t55.3 75.3t17
>4 mm
n=15 31.3t7.9 104t31.7a,b 96.8t22.8 94.8t21.2 149t41.8 84.3t8.7
B
Tumour centre Tumour periphery Peritumoural host tissue
Metastasis MVD (n/mm2) Perimeter (mm) MVD (n/mm2) Perimeter (mm) MVD (n/mm2) Perimeter (mm)
None
n=15 21t5.1 77.3t24.2 77.2t27.1 70.6t21.1 140t65.2 70.8t13.8
Lymph node
n=14 25.9t5.4 82.4t30.3 98.7t28.3 76.9t17.2 120.2t54.3 77.2t12.7
Organ
n=16 39.8t6.7c 98.1t29.7 98.1t23.3 94t19.2 132.8t44.3 84.0t12.3
Data are expressed as meantSD. Statistical analysis was performed by ANOVA single factor method.
a,p<0.05 (vs. peritumoural host tissue);
bp<0.05 (vs. thin tumour group);
cp<0.05 (vs. non-metastatic group).
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Assessment of EC labelling index with
bromodeoxyuridine (BrdU)
Two hours before the mice were sacrificed, 200 mg/kg
BrdU in saline was injected intraperitoneally. Sections
were fixed in methanol and reacted sequentially with
anti-mouse CD31, rhodamine-conjugated anti-rat
IgG (1 : 50, Jackson Immunoresearch Inc.), 2N HCl
(10 min, 20uC), anti-BrdU antibody (1 : 100, Becton-
Dickinson), biotinylated anti-mouse IgG (1 : 100,
Vector), streptavidin–FITC (1 : 100, Amersham), and
with TOTO-3 (MolecularProbes Inc., 5 mm). Slices
were viewed by confocal microscopy (Bio-Rad
MRC1024). The labelling index of ECs was determined
by counting the labelled as well as all the EC nuclei
(100/studied area) along the vessel walls.
Transmission electron microscopy
Animals were perfused via the left ventricle with
phosphate-buffered saline for 10 min and with 2.5%
glutaraldehyde in 0.05 M Na-cacodylate (pH 7.2) for
15 min at room temperature. Tumour pieces were
processed as described previously [25] and analysed
on a Philips CM10 electron microscope.
3D visualization of tumour vasculature
Sections (100 mm) were cut and transferred to 24-
microwell plates containing methanol. Blood vessels
were identified by immunostaining with anti-CD31
antibodies as described above. To avoid compression,
small pieces of cover slip of 150 mm thickness were
inserted on both sides of the mounted slice. For 3D
reconstruction, up to 80 serial optical sections at
0.5–2 mm intervals were used. Digitized image stacks
were further processed using Bio-Rad-LaserSharp
software.
Characterization of vessel phenotype by
immunohistochemical double and triple labelling
On 5 mm cryosections, different combinations of pri-
mary antibodies (anti-CD31 antibodies; anti-laminin;
anti-SMA, 1 : 100, Dako) were used simultaneously.
After washing, slices were incubated simultaneously
with the appropriate secondary antibodies (Cy5-
conjugated anti-mouse IgG; FITC-conjugated anti-rat
IgG; rhodamine-conjugated anti-rabbit IgG; all from
Jackson Immunoresearch Inc., 1 : 50) with or without
nuclear staining with TOTO-3.
Statistical analysis
Experimental data were evaluated using either
ANOVA single factor analysis, Mantel–Cox general-
ized salvage analysis or two-tailed t-test. A p-value less
than 0.05 was required for significance.
Results
Microvessel density of hMM
In all the applied categories (Table 1), MVD was
highest in the peritumoural host tissue and the
tumour periphery was significantly more vascular
than the tumour centre. Comparison of the MVD of
tumour periphery and peritumoural host tissue of
hMM, characterized by various categories of thickness
and clinical progression, did not reveal any significant
differences. The MVDs of the tumour centre showed
only a slight but non-significant elevation with increas-
ing tumour thickness (Table 1A) and there was no
correlation between tumour centre MVD and growth
phase (data not shown).
The comparison of tumour centre MVDs according
the type of clinical progression of the disease indicated
a significant 90% increase in the organ-metastatic
compared to the non-metastatic tumours (Table 1B,
p<0.05). Tumour centre MVD was not statistically
significantly different in tumours characterized by
lymphatic progression, nor did peritumoural MVDs
differ in these clinical categories.
Out of the 45 patients, 15 were lost within 60 months
and the tumour centre MVD of these patients was
significantly higher than in who survived (40.12t5.07
vs. 23.78t5.04, p<0.025). Next, tumour centre MVD
ranges were established (<10, <20, <30, <40 and
<50/mm2) and compared to disease outcome (5-year
survival). We found that 100% of patients whose
tumours were categorized by a central MVD less than
30/mm2 were alive at 60 months, compared to one out
of 16 patients alive with tumours having a central
MVD higher than 30/mm2 (p<0.025, Figure 1).
Collectively, we have concluded that both the visceral
progression as well as the 5-year survival of human
skin melanoma patients were associated exclusively
with the MVD of the tumour centre.
MVDs in the peritumoural areas by the ‘hot spot
months
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Figure 1. Survival analysis of primary malignant melanoma
patients. 100% of the patients whose tumours were categorized
by tumour centre MVD less than 30/mm2 were alive after a
5-year follow-up period, compared to one survivor out of 16
patients whose tumours had a central MVD higher than 30/mm2.
Statistical analysis was performed using the Mantel–Cox general-
ized salvage analysis. *p<0.025
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technique’ were 164t48, 144t50 and 171t92 in
non-metastatic, lymph node-metastatic and organ-
metastatic cases, respectively. MVD in non-tumourous
skin was similar to the MVD of benign melanocytic
tumours (68t37.1 and 55t7.5, respectively).
Vessel perimeters of hMM
Vessel perimeters were highest in the tumour centre
and there was no difference in this respect between the
various categories (Table 1). The vessel perimeter in
the tumour centre was highest in the group of thick
(>4 mm) tumours (p<0.05 vs. peritumoural host
tissue), and was moderate in the group of medium
thick (1.5–4 mm), organ-metastatic, lymph node-
metastatic and non-metastatic tumours. There was no
increase in the group of thin (<1.5 mm) tumours.
Peritumoural host tissue and tumour periphery micro-
vessel perimeters were more similar to each other than
to tumour centre microvessel perimeters in all the
applied thickness and progression categories. The
tendency to an increased microvessel perimeter at the
tumour centre was correlated with clinical progression
and growing thickness, but only the latter proved to be
statistically significant (p<0.05).
Murine skin melanoma model
To analyse angiogenesis from an early stage, we
followed vessel network development during tumour
growth, from the intradermal inoculation of 104 B16
cells until the tumours reached 4–5 mm in diameter
(Figure 2A), which corresponds to a thick hMM. Cells
were deposited into the papillary dermis, next to the
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Figure 2. Tumour diameters (A) and alterations of vascular parameters (B, C, D) of B16 murine melanoma. Groups of three mice
were sacrificed by anaesthesia at 1, 3, 5, 7, 11, 14 and 21 days. Data are meanstSEM. The decrease of MVD and vessel perimeter
between days 1 and 3 can be explained by the regression of the existing host vessels of the dermis, following the injection of the
tumour cell suspension. The mean MVD, vessel perimeter and EC labelling index in normal mouse skin were 80.7t7, 51.5t2.5 and
0.33t0.15, respectively (meantSD, n=3).
(B) Microvessel density (n/mm2)
p<0.05 peritumoural tissue vs. tumour periphery on days 3, 5, 7, 14, 21
peritumoural tissue vs. tumour centre on days 3–21
tumour periphery vs. tumour centre on days 7–21
(C) Microvessel perimeter (mm)
p<0.05 peritumoural tissue vs. tumour periphery on days 3, 11, 14, 21
peritumoural tissue vs. tumour centre on days 3, 5, 11, 14, 21
tumour periphery vs. tumour centre on days 5, 14, 21
(D) EC labelling index
p<0.05 peritumoural tissue vs. tumour periphery on days 3, 5, 7, 21
peritumoural tissue vs. tumour centre on days 3–21
tumour periphery vs. tumour centre on days 5–21
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epidermal–dermal junction. The tumour tissue showed
a solid, nodular growth pattern, without forming a
meshwork of septa, and it was not circumscribed with
a fibrous capsule, which is a common feature of sub-
cutaneously inoculated or xenotransplanted tumours.
Three weeks after intradermal tumour implantation,
regional lymph node and lung metastases were found.
MVD of B16 melanoma (Figure 2B)
In all the investigated areas, the increasing MVDs
reached a plateau at different time points after tumour
inoculation. In the centre of the tumour, a plateau was
reached around 20/mm2 on day 7, followed by the
tumour periphery, with a plateau value around 100/mm2
on day 14. Peritumoural host tissue MVD increased up
to a level around 150/mm2, which was reached in the
middle of the third week. It is also important to note
that peritumoural host tissue MVD was highest,
tumour centre MVD was lowest and tumour periphery
MVD was intermediate, at all time points.
Microvessel perimeters of B16 melanoma
(Figure 2C)
Vessel perimeters increased with time to a different
extent in the different areas of the tumour: vessel
dilatation was slight in the peritumoural areas (from
59 mm to 105 mm), considerable in the tumour peri-
phery (from 55 mm to 126 mm), and the highest in the
tumour centre (from 53 mm to 177 mm). Similarly to
MVD, vessel dilatation also showed a tendency to
reach a plateau at different time points (day 11 in the
case of peritumoural host tissue and tumour periphery,
and day 14 in the case of tumour centre). Additionally,
the increase of perimeter followed the direction from
peritumoural host tissue towards tumour centre,
independently of tumour age and size.
EC proliferation of B16 melanoma (Figure 2D)
The EC labelling index showed the highest increase in
the peritumoural host tissue (from 2% to 21%), the
lowest increase in the tumour centre (from 0 to 12%)
and a moderate increase at the tumour periphery (from
0 to 17%). Furthermore, the EC labelling index was
always the highest peritumourally and was always
lower in the tumour centre than in the periphery. EC
proliferation reached a plateau at day 14 in the three
studied areas.
Phenotype of human and murine melanoma
microvessels
CD31 antibodies marked the vasculature intensively.
Pericytes, which are a smooth muscle actin-positive,
completely covered the microvessel walls in the differ-
ent intra- and peritumoural areas (Figure 3) and were
embedded within the basement membrane (BM) sur-
rounding the endothelial tube (Figure 6). At the tumour
boundary, the BM of microvessels was single layered,
while in the tumour centre it was multilaminated. The
space between these concentric layers was filled with
melanoma cells (Figure 4). The number of layers
increased towards the centre of the tumour, and also
with time. The presence of multilaminated BM around
the microvessels is the result of the invasive activity of
tumour cells (Figure 6), but this phenomenon did not
have an influence on the presence and distribution of
pericytes around the endothelial tube.
3D visualization of human and murine melanoma
vasculature (Figure 5)
3D reconstruction of confocal data made clear the
presence of the peritumoural vascular envelopes with
high MVDs. At the tumour boundary, the vessels were
arranged parallel to the surface of the tumour, with
Figure 3. Pericyte recruitment of melanoma vessels. Capillary
of an 11-day-old B16 tumour stained for CD31 (red fluores-
cence) and SMA (green fluorescence) shows the complete
pericyte coverage of the endothelial tube. Nuclear staining was
applied with TOTO-3 (blue fluorescence). Scale bar 25 mm
Figure 4. Concentric BM layers (laminin, red fluorescence)
around the endothelial tube (CD31, green fluorescence) of a
capillary in the centre of a 4 mm thick human melanoma nodule.
The invading tumour cells are apparently detaching the ECs from
their basal lamina (arrowheads). Nuclear staining was applied
with TOTO-3 (blue fluorescence). Scale bar 50 mm
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numerous lateral connections and blind ends. Direct
offshoots occurred with dichotomous and multiple
branching. There appeared to be no vessels present
which intruded centripetally into the tumour nodule.
The intratumoural capillaries were less densely
arranged than the peritumoural ones; they took an
arched course and exhibited dilatation towards the
centre of the tumour.
Discussion
In this study we present the novel finding that during
angiogenesis in the human and murine melanoma,
there is no morphological evidence of directed vessel
ingrowth; instead, these tumours appear to grow by
incorporating the massive, tumour-induced vascular
plexus present in the peritumoural connective tissue.
In studies comparing melanoma vascularity with
prognosis, increased vascularity at the tumour base is a
common observation [5,9,23,24]. Similarly, in our
hMM cases MVDs were several-fold higher in the
peritumoural tissue and in the tumour periphery than
in the centre of the tumour, and this difference
increased with tumour thickness. Until now, however,
no studies have focused on the role played by this
prominent peritumoural vascular plexus in the process
of melanoma vascularization. The observation of a
similar microvessel distribution in mouse mammary
adenocarcinoma has led Thompson to make the
following statement: ‘the growing tumour infiltrates
out and expands between the surrounding newly
formed vessels and thus the density of vessels is
progressively diluted’ [19]. In order to test the hypoth-
esis that hMM incorporates its peritumoural vascular
plexus, we used intradermally inoculated B16 tumours
as a relevant mouse melanoma model system. The
following observations, taken together, imply to us
that the growing melanoma engulfs its peritumoural
vasculature.
Firstly, morphometry of murine melanoma vascula-
ture indicated that tumour periphery MVD increased
dramatically, approaching peritumoural host tissue
MVD, while tumour centre MVD increased to a rela-
tively lower level. Since the increase of tumour
periphery MVD was almost twice as high as the
increase of peritumoural host tissue MVD in the
period of the first 11 days, it can be concluded that
the majority of the vessels in the tumour periphery
were derived from the pre-existing dermal and the
newly developed peritumoural capillaries. Secondly,
3D reconstruction of vessel networks using serial
optical sections revealed that the peritumoural vascular
plexus is composed of vessels running parallel to the
tumour surface, without signs of radial orientated
growth. This fact alone is sufficient to support the idea
that the vessel network at the melanoma base is
continuously becoming incorporated into and thinned
out by the growing tumour. Furthermore, it becomes
clear that the vascular architecture of human mela-
noma is comparable to that of the intradermally
inoculated murine melanoma.
The parallel increase of the tumour diameter and the
MVD of the peritumoural tissue and the tumour
periphery (between day 7 and day 11) clearly shows
the decisive role in tumour growth of the newly formed
and pre-existing vessels.
Various studies in different systems have been done
by others on the cytokinetics of ECs [26–28]. It is
important to note that in contrast to the observation of
Denekamp, who found endothelial mitoses only at the
tumour edge [28], our measurement did not give such
an extreme result: we found an increased proliferation
rate of ECs in the vessels of the peritumoural dermis,
compared to the lower proliferative activity of the ECs
in the tumour centre. This observation corresponds to
the mathematical framework described by Ramanujan
[29]. According to this model, central regions of the
tumours experience anti-angiogenic effects. Towards
the periphery of the tumour, the behaviour reverses
Figure 5. The horizontal view of a stack of confocal images
shows the 3D architecture of the prominent vascular plexus
(stained by CD31-Mab) present at the tumour boundary in a
3.75 mm thick human melanoma (80 optical sections at 1 mm
intervals). Vessels are running parallel to the surface of the
tumour spheroid. Note the delicate staining of interendothelial
junctions. The tumour is present at the upper left. Scale bar
100 mm
Figure 6. Electron micrograph of a tumour cell (T) migrating
into the space between the well-defined concentric BM layer
(arrowheads) and the BM of the microvessel (arrows). Another
tumour cell (T1) is lying on the surface of the BM. e, endothelial
cell; p, pericyte; Tp, tumour cell process. Scale bar 1 mm r4600
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and angiogenic factors predominate, with a peak of
angiogenesis at the tumour boundary.
The observation that vessel perimeters increased and
MVD decreased towards the tumour centre lets us
conclude that within the tumour the newly formed ECs
participate in vessel dilatation, instead of providing a
source of new vessel production.
At the tumour periphery and in the peritumoural
dermis, the BM adjacent to the ECs was single layered,
while in the tumour centre it becomes multilaminated.
The space between these concentric BM layers was
filled with melanoma cells. This phenomenon suggests
that the BM of the intratumoural vessels are constantly
invaded by tumour cells, during which process the ECs
and pericytes become detached from their own BM
and are forced to produce a new layer. Since the ECs
are proliferating, the disruption of the BM allows
vessel expansion, followed by new BM deposition. The
old subendothelial BM layers are pushed outwards
(away from the vessel) by the invading tumour cells.
The absence of sprouting activity of the intratumoural
vessels can be explained in two ways. The increasing
number of BM layers may impede the branching of
endothelial tubes (the increase of MVD); alternatively,
the lack of support by an appropriate extracellular
matrix within the tumour may prevent the sprouting of
new capillaries [30].
Although in all thickness and clinical progression
categories the peritumoural dermis was more vascular-
ized than the investigated tumour areas, morphometry
demonstrated significant increase in tumour centre
MVD in the case of visceral metastatic tumours,
suggesting that intratumoural vessels might be the site
of intravasation. This is consistent with a previous
study in which vascular invasion was observed within
the melanoma nodules, but not peritumourally [31].
This idea was further corroborated by the fact that all
29 patients whose tumour was characterized by central
MVD of less than 30/mm2 were alive after 5 years,
while all but one died in whom the central tumour
MVD was higher than 30/mm2. The fact that the
MVDs of the tumour centre did not relate to thickness
or growth phase, taken along with the above observa-
tions, suggests that the tumour centre MVD may be an
independent prognostic factor in hMM.
Previous studies suggest that the recruitment of
pericytes can be used as a hallmark of blood vessel
maturation in malignancies [20–22]. We assumed that
in addition to the increase of tumour centre vessel peri-
meter, the vulnerable and immature intratumoural
vessels being in intimate contact with tumour cells
might also influence the prognosis of hMM in an
unfavourable way. We therefore examined the distribu-
tion of pericytes in vessel walls of different intra- and
peritumoural areas. On the basis of both immunohis-
tochemical and electron microscopic analysis, we
found that the pericyte coverage of vessel walls was
complete in the three different areas, both in human
and murine melanomas. This suggests that the pericyte
coat most probably does not act as a passive shield
against the intravasation of tumour cells. Accordingly,
an active role for pericytes in the process of intravasa-
tion cannot be excluded.
The fact that the BM of the intratumoural vessels
was constantly invaded by tumour cells, implying a
higher intravasation rate of tumour cells in this area,
suggests that the intratumoural vessels of hMM are
more important in the metastatic process than the
peritumoural vascular plexus, which corresponds to the
‘hot spots’. This assumption, however, would need
further experimental and clinical support.
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One of the hallmarks of intussusceptive angiogenesis
is the development of intraluminal connective tissue
pillars. The exact mechanism of pillar formation has
not yet been elucidated. By using electron and confo-
cal microscopy, we observed intraluminal nascent
pillars that contain a collagen bundle covered by en-
dothelial cells (ECs) in the vasculature of experimen-
tal tumors. We proposed a new mechanism for the
development of these pillars. First, intraluminal en-
dothelial bridges are formed. Second, localized disso-
lution of the basement membrane occurs and a bridg-
ing EC attaches to a collagen bundle in the underlying
connective tissue. A pulling force is then exerted by
the actin cytoskeleton of the ECs via specific attach-
ment points, which contain vinculin, to the collagen
bundle, resulting in suction and subsequent transport
of the collagen bundle into and through the vessel
lumen. Third, the pillar matures through the immi-
gration of connective tissue cells and the deposition
of new collagenous connective tissue. The proposed
simple mechanism generates a connection between the
processes of endothelial bridging and intussusceptive
angiogenesis and identifies the source of the force be-
hind pillar formation. Moreover, it ensures the rapid
formation of pillars from pre-existing building blocks
and the maintenance of EC polarity. To describe it, wecoined the term inverse sprouting. (Am J Pathol 2011,
179:1573–1585; DOI: 10.1016/j.ajpath.2011.05.033)
Angiogenesis is the formation of new blood vessels from
pre-existing ones. Several different forms exist,1 but so
far endothelial sprouting2,3 and intussusceptive angio-
genesis4–8 have been investigated the most intensively.
Endothelial sprouting is characterized by the parallel
migration of capillary bud endothelial cells (ECs). During
this process, proliferating ECs maintain their basal-lumi-
nal polarity and form a slit-like lumen that is continuous
with the lumen of the so-called mother vessel. Basement
membrane material is deposited continuously by the
sprout ECs, whereas only the tip of the growing bud is in
contact with the collagenous connective tissue matrix. As
the final step, proliferating pericytes of the mother vessel
migrate along the basement membrane of the sprout,
resulting in the maturation of the new vessel.2
In contrast to endothelial sprouting, the other major
angiogenic mechanism, intussusceptive microvascular
growth, or intussusceptive angiogenesis, which has been
described in a wide variety of normal and pathological
conditions, is faster and does not depend primarily on EC
proliferation. The most characteristic feature of intussus-
ceptive angiogenesis is the insertion of connective tissue
columns, called tissue pillars, into the lumen and the
subsequent growth of these pillars, resulting in partition-
ing of the vessel lumen and the consequent increase in
the density of the given capillary network. According to
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ceded by the formation of vessel wall folds or the protru-
sions of the opposite points of the vessel wall into the
lumen.4–8 However, the origin of the force generating
these invaginations has not yet been clarified. Although it
is believed that perivascular cells or pericytes may play a
role in this initial step by exerting a pushing force on the
vessel wall, this concept is questionable because the
structure of the cellular cytoskeleton allows only pulling
forces at high strength, whereas pushing forces are sev-
eral hundredfold lower in magnitude.9,10
Another phenomenon thought to be different from intus-
susceptive angiogenesis, but also leading to vascular divi-
sion, was described as well. This process is characterized
by the development of intraluminal bridges formed by ECs,
followed by the development of connective tissue by an
unknown mechanism within these bridges.11–13
Based on our observation of the vascularization of s.c.
growing tumors in mice, we present herein the detailed
mechanism of intraluminal pillar formation, which offers a
rationale for the puzzles previously discussed and incor-
porates the previous two concepts.
Materials and Methods
Animals and Tumor Lines
The C38 mouse colorectal carcinoma line was main-
tained by serial s.c. transplantations in C57Bl/6 mice, as
previously described.14,15 Tumor tissue was cut into
cubes measuring 5  5  5 mm. Animals were anesthe-
tized with ketamine, 80 mg/kg, and xylazine, 12 mg/kg
(Sigma Chemical Co, St Louis, MO); one piece of tumor
tissue was transplanted into the back of each mouse.
Animals were sacrificed 3 weeks after tumor inoculation.
For analysis of immunofluorescence labeling with mono-
clonal antibodies, the tumors were transplanted into mice
with severe combined immunodeficiency to reduce non-
specific staining.
HT25 human colon carcinoma cells were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine
serum (Sigma Chemical Co). The s.c. tumors were pro-
duced by injecting 2  106 tumor cells into the back of
anesthetized male mice with severe combined immuno-
deficiency, as previously described.16 Animals were sac-
rificed 4 weeks after tumor inoculation.
Electron Microscopy and 3D Reconstruction of
Semithin Sections
Preparation of tumor samples for electron microscopy
was performed as previously described.14 In brief, the
anesthetized animals (three mice for each tumor line)
were perfused via the left ventricle with PBS for 10 min-
utes and with 4% paraformaldehyde and 1% glutaralde-
hyde in PBS (pH 7.2) for 15 minutes at room temperature.
The s.c. tumors were removed, cut into 1  2-mm pieces,
and immersed in the same fixative for an additional 2 hours.
The pieces were post-fixed in 1% OsO4, 0.5% K-ferrocya-nide in PBS for 2 hours, dehydrated in a graded series of
acetone, and embedded in Spurr’s mixture.
A total of 8 to 10 serial semithin sections were cut,
stained by 0.5% toluidine blue (pH 8.5), and analyzed for
the presence of pillars. The structures identified on the
last semithin section were followed backward to ensure
that they represented pillars and were not simply vessel
bifurcations or other structures. Areas of interest were
trimmed out by comparing the structures on the cut sur-
face of the tissue blocks with the semithin sections and
then serially sectioned by an RMC MT-7 ultramicrotome
(Research and Manufacturing Co, Tucson, AZ). The sec-
tions were placed on thin bar grids, stained with 2%
uranyl acetate and lead citrate, and analyzed using a
Philips CM10 electron microscope (Eindhoven, The
Netherlands). Pillars cut lengthwise were also examined
during analysis of serial ultrathin sections. In this case,
the entire thickness of the pillar was available for analysis
at the ultrastructural level.
Serial semithin sections were captured by an Olympus
DP50 camera (Olympus, Tokyo, Japan). Digitized images
were transferred to the Biovis3D software program
(BioVis3D, Montevideo, Uruguay). Three-dimensional
(3D) reconstructions were performed using color con-
touring to highlight the recreated structures.
Immunofluorescence Analysis
Frozen sections (15-m thick) were fixed in methanol and
were incubated at room temperature (for 1 hour) with a
mixture of the following primary antibodies: monoclonal
anti-mouse CD31 (dilution, 1:100; catalogue no. 01951D;
Pharmingen, San Diego, CA), polyclonal anti-collagen I
(dilution, 1:100; catalogue no. AB765P; Chemicon, Bil-
lerica, MA), monoclonal anti-vinculin (dilution, 1:100; cat-
alogue no. V4505; Sigma Chemical Co), monoclonal anti-
integrin -1 (dilution, 1:20; catalogue no. 555001; BD
Pharmingen, San Jose, CA), polyclonal anti-integrin -1
(dilution, 1:50; catalogue no. sc-10728; Santa-Cruz Bio-
technology, Santa-Cruz, CA), monoclonal anti-integrin
-2 (dilution, 1:100; catalogue no. 108901; Biolegend,
San Diego), polyclonal anti-integrin -2 (dilution, 1:200;
catalogue no. AB1936; Millipore, Billerica, MA), poly-
clonal anti-integrin -11 (dilution, 1:100; catalogue no.
sc-98740; Santa-Cruz Biotechnology), and monoclonal
anti-mouse CD29 (dilution, 1:100; catalogue no. 550531;
Pharmingen). After washing, appropriate secondary an-
tibodies conjugated with fluorescein isothiocyanate, tetra
rhodamine isothiocyanate, or Cy5 were used (all from
Jackson Immunoresearch Inc., Suffolk, UK). The vinculin
and integrin -2 signals were amplified by using an ap-
propriate biotinylated secondary antibody (dilution,
1:200; Vector Laboratories, Burlingame, CA), followed by
streptavidin fluorescein isothiocyanate (Jackson Immu-
noresearch Inc.). To analyze the localization of actin fila-
ments within the pillars, the sections were reacted with
phalloidin–tetra rhodamine isothiocyanate (dilution,
1:500; catalogue no. P1951; Sigma Chemical Co).
Sections were scanned by eye for the presence of
pillars using a 100 objective. Only pillars running par-
allel and lying completely within the sectioning plane
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scope (Bio-Rad, Richmond, CA). For 3D reconstructions,
30 to 40 optical sections were generated.
Determination of the Size of Collagen Bundles
The size of the collagen bundles was determined at the
ultrastructural level in the peritumoral connective tissue and
within the pillars. Measurements were made on digitalized
electron micrographs (original magnification, 1500 to
7000) taken from s.c. tumors of both cancer cell lines
using Olympus Quick Photo Micro software (Olympus). In
the peritumoral connective tissue, collagen bundles tightly
packed with collagen fibers were chosen randomly (250).
In cross sections, the smallest diameter of the bundle was
measured. After their identification in semithin sections,50
pillars were analyzed at the ultrastructural level. Only pillars
exclusively containing collagen fibers, but no pillars with
connective tissue cells, were chosen. The total thickness of
the pillars (including ECs) was also measured.
In Vivo Treatments
To study the effects of angiogenesis-modulating agents
on tumor vascularization and pillar formation, groups of
six mice bearing C38 tumors received recombinant hu-
man erythropoietin  (rHuEPO, epoetinum ; Jannsen-
Cilag, Shaffhausen, Switzerland),16 PTK787/ZK22854
(vatalanib; Novartis/Schering AG, Berlin, Germany)17
(obtained from Selleck Chemicals LLC, Houston, TX), or
the vehicle as a control. In mice treated with vatalanib,
tumors were allowed to grow for 12 days before treat-
ment. Then, mice were treated orally with 100 mg/kg vata-
lanib (PTK787/ZK222584, dissolved in water containing 5%
dimethyl sulfoxide and 1% Tween-80) for 4 days, as in a
previous study.18 Mice treated with rHuEPO were given 150
IU/kg in physiological salt solution three times per week i.p.
from day 1 after tumor inoculation, as previously de-
scribed.16 The mice in all groups were sacrificed on day 17,
and tumors were removed, weighed, and frozen.
CD31-labeled frozen sections were scanned by eye
using a100 objective to determine the number of pillars
within the entire section. The total area of the sections
was determined using Olympus Quick Photo Micro soft-
ware. To determine the area fraction of CD31-positive
blood vessels in tumor sections, two to three confocal
images were taken from each tumor section using a 4
objective (area, 11.3 mm2). The micrographs were ana-
lyzed using ImageJ software (NIH, Bethesda, MD). Re-
sults are expressed as the number of pillars per squared
millimeter of tumor tissue or microvessel area.
Analysis of Skin Wounds
Animals were anesthetized and shaved. A 1-cm-long full-
thickness incision was made in the dorsal skin of C57
black mice. The wounds were partially closed by a single
nylon suture. The mice were euthanized on days 3, 5, 7,
and 10 after wounding. Two mice were sacrificed at each
time point. The wounds and the surrounding intact skin,
measuring 2  2 mm, were removed and cut further into1  2-mm pieces, with the long axis running perpendic-
ular to the wound. These pieces were fixed and embed-
ded for electron microscopy, as previously described.
Eighty-six tissue blocks were semithin sectioned and an-
alyzed (total area, approximately 250 mm2) for the pres-
ence of pillars using a 63 objective.
Statistical Analysis
Statistical analysis was performed using the Student’s
t-test.
Results
Development of Intraluminal Connective Tissue
Pillars
Intussusceptive angiogenesis was observed in s.c. tu-
mors of both cancer cell lines. This type of angiogenesis
was the main means of new vessel formation. Endothelial
sprouting with characteristic slit-like lumen-containing
capillaries2 was scarcely detected. Intussusception was
mainly detected in angiogenic hot spots peritumorally,
but it also occurred within the tumor mass. The first step
of intussusception is thought to be the development of
protrusions or infoldings of the vessel wall within the
lumen.6 We analyzed 89 infolds sharply intruding into the
vessel lumens in 172 serially sectioned areas (semithin
sections) altogether. None of these structures projected
into the lumen by themselves. By tracing them over sev-
eral serial sections, we found that each capillary infold
was connected to a different part of the vessel lumen (on
the opposite or the same side). These infolds proved to
be pillars, part of blind-ending lumens or simple vessel
ramifications (Figure 1; see also Supplemental Figure S1
at http://ajp.amjpathol.org). In areas of intensive intussus-
ception, proliferating ECs (Figure 1, H and L; see also
Supplemental Figure S1H at http://ajp.amjpathol.org) and
intraluminal endothelial bridges were frequently ob-
served (Figure 1, H–M and K–O; and Figure 2, A–E).
These bridges either were simple EC processes project-
ing into the vessel lumen and attaching to the endothelial
tube in a different position (Figure 2F) or were formed by
the participation of cellular processes of different ECs
(Figure 2G). However, the most characteristic phenome-
non of this type of tumor-induced intussusceptive angio-
genesis was the development of transluminal pillars con-
taining tightly packed collagen fibers covered by ECs
(Figure 2H). The pillars either spanned the vessel lumen
or originated and terminated on the same side of the
vessel (Figures 1 and 3). The diameters of these collagen
bundles did not differ significantly from those within the
peritumoral connective tissue (Table 1). The overall di-
ameter (including the EC layer) of the pillars corre-
sponded well with those observed earlier in other studies
(2.5 m).4 The fibers were oriented parallel to the axis of
the pillars (Figure 3, B–D) and were covered by several
ECs. However, the basement membrane under these
cells was generally absent (Figures 2H and 3G). More-
over, neither pericytes nor other cells were present in
d in yell
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allel to their axis, high electron density areas could be
observed in the membrane of the ECs, suggesting
specific adhesion between the ECs and the collagen
Figure 1. Light microscopic appearance and 3D reconstruction of endothe
distance of 10 m in an area of intensive intussusceptive angiogenesis. Seria
runs through the lumen, and joins the vessel wall in H (section 13). There is
(small arrow) starts in C (section 6), reaches the other side of the lumen in
Two endothelial bridges are also visible. One (large arrowhead) is positione
arrowhead) starts and ends on the same side of the vessel (H–M). There is a
of 25 semithin sections represented in A–O. The vessel wall and the surroun
collagen bundles are indicated in green, and endothelial bridges are indicate
endothelial bridges.bundle. In accordance with this observation, immuno-fluorescence analysis revealed vinculin-containing ad-
hesion spots along the pillars (Figure 4, A–D). However,
although immunolabeling with antibodies against integrin
-1, -2, or -11 demonstrated high -2 and -11 ex-
ges and pillars. A–O: 0.5-m thick serial semithin sections were cut over a
s 10 m. Two pillars are visible. One starts in A (section 2, large arrow),
protrusion of the vessel wall in I (large arrow, section 15). The other pillar
n 19), makes a turn, and joins the same side of the vessel in N (section 21).
en the opposite sides of the vessel lumen (J–O); the other smaller one (small
ting EC (asterisk) inH and L. Scale bar 20 m. P andQ: 3D reconstruction
ue are indicated in red, pillars separated from the vessel wall and containing
ow. P and Q are different views from above to show the localization of bothlial brid
l section
a sharp
L (sectio
d betwe
prolifera
ding tisspression levels in the pericapillary connective tissue,
a collage
elow th
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casionally present as small dots at a low density at the
abluminal surface of pillar-forming ECs (as in the case of
-2 labeling; see Supplemental Figure S2, A and B, at
http://ajp.amjpathol.org) or totally absent (as in the case of
-1 or -11 labeling; see Supplemental Figure S2, E and
F, at http://ajp.amjpathol.org). Nevertheless, in more de-
veloped pillars, we could detect large integrin -2–con-
taining adhesion spots (see Supplemental Figure S2, C
and D, at http://ajp.amjpathol.org). Staining for integrin
-1 showed no specific localization of this subunit that
was distributed evenly under the ECs of the vessel and
pillars (data not shown).
The part of the cell body of the ECs that formed the
pillars frequently contained a high density of microfila-
ments, excluding all other cellular organelles (Figure 3, G
and H). These microfilaments were generally not in a
parallel arrangement; rather, they formed a mesh. The
presence of polymerized actin within the ECs of the pil-
lars was also confirmed by phalloidin staining (Figure 4, E
and F). The microfilaments were attached to the mem-
brane through specific structures that appeared as dots
(approximately 50 nm, Figure 5A) when the plane of the
section ran parallel to the membrane and as tiny rods
(200 nm, Figure 5B) when the plane of the section was
perpendicular to it. The adhesion spots were arranged in
a regular manner along individual collagen fibers (Fig-
Figure 2. 3D and ultrastructure of endothelial bridges and transcapillary pi
present only in two consecutive sections. The light blue staining (collagen cor
sections. The endothelial bridge and the nuclear area of the ECs are highlig
An endothelial bridge formed by a single cellular process (arrow). The proce
formed by cellular processes of several ECs. Arrows point at intercellular
bar  5 m. H: Cross section of a transluminal pillar. The pillar is formed by
at interendothelial junctions. Some basement membrane material is visible bures 3G and 5A) and were connected to each other bymicrofilaments (Figure 5B). In these attachment regions,
the collagen fibers were in close contact with the plasma
membrane of the EC (Figure 5C). Confocal and electron
microscopic analysis of serial sections of the pillars and
extensive light revealed that, in a small portion of the
pillars, the collagen bundles did not span the whole
length of the pillar. In these cases, as in the intraluminal
endothelial bridges previously described, the rest of the
pillar was composed only of ECs (Figures 6 and 7, A and
B; see also Supplemental Figure S3 at http://ajp.amj-
pathol.org). Collagen bundles situated in the nascent pil-
lars extended into the connective tissue (Figure 7, C and
D). Maturing pillars, into which cellular processes ex-
tended, or larger pillars containing pericytes and other
connective tissue cells were also present in the vessel
lumens (Figure 7, E and F).
Effects of Angiogenesis-Modulating Agents
on Tumor Capillary Parameters and Pillar
Formation
In the next set of experiments, we also studied whether
rHuEPO (which recently induced intussusceptive an-
giogenesis in the chick embryo chorioallantoic mem-
brane assay)19 or the anti-angiogenic drug vatalanib
(an oral small-molecule multitargeted tyrosine kinase
D: Serial semithin sections of an endothelial bridge. The bridge (arrows) is
n the bridge is absent. Scale bar 20 m. E: 3D reconstruction of 13 semithin
yellow, and the vessel wall and the surrounding tissue are shown in red. F:
ched to the EC itself (arrowhead). Scale bar 1 m. G: Endothelial bridges
s. The collagen bundle is located close to the vessel (arrowhead). Scale
n bundle tightly packed with fibers and by two covering ECs. Arrows point
e ECs at the upper part of the pillar (arrowhead). Scale bar  1 m.llars. A–
e) withi
hted in
ss is atta
junctioninhibitor that blocks all known vascular endothelial
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platelet-derived growth factor receptor and c-kit)17
could affect pillar formation in our C38 colon carci-
noma model system.
In C38 tumors treated with rHuEPO, pillar densities of
tumor sections were significantly increased compared
Table 1. Collagen Bundle Diameters in the Peritumoral Connect
Value
Collagen bundles within the peritumoral
connective tissue (n  260)
Mean  SD 1.61 0.9
Range 0.3–5.9*The diameters of the collagen bundles of the connective tissue and the pillawith untreated controls (Table 2). In accordance with our
previous findings,16 a tendency toward an increased tu-
mor microvessel surface in mice treated with rHuEPO
was also observed. However, when pillar density was
calculated for the area of tumor microvessels, the differ-
ence in pillar densities between tumors in the rHuEPO-
Figure 3. Ultrastructure of the pillar. A–E: Serial ultrathin sec-
tions (approximately 100 nm) of a nascent pillar (A, section 3;
B, section 14; C, section 20; D, section 22; E, section 36). The
pillar was present in 22 sections. The collagen bundle is densely
packed with fibers and oriented parallel to the axis of the pillar
(B–D). A–E: The collagen bundle does not extend into the
connective tissue (up). E: In contrast, the collagen bundle is still
visible (arrow) and runs with a sharp change in direction along
the circumference of the vessel (down). This suggests that the
putative direction of the collagen bundle transport is from right
to left. Apparently, the bundle just reached the left side of the
vessel. In A, an arrow points at a small process of the EC,
indicating the location of the pillar. The body parts of the ECs in
contact with the collagen bundle show homogeneous staining
because of the high microfilament content (arrowheads in B).
Scale bar  2 m. F–H: High-power micrographs showing
details of the pillar region (F, section 1; G, section 14; G inset,
section 10; H, section 36). F represents the first section that
suggests the presence of a pillar. The small cellular process
(arrow) is densely packed within a meshwork of microfila-
ments. Microfilaments are also present under the plasma mem-
brane in the left part of the cell. The large arrowhead points
at an area containing intermediate filaments, whereas small
arrowheads point at microtubules. Scale bar 0.5 m (F). G:
Details of B. The cell body above the collagen bundle contains
manymicrofilaments but no other organelles. The high electron
density of the plasmamembrane is cut at a low angle. Adhesion
spots are also visible (small arrowheads). A basement mem-
brane is lacking in the area where the EC faces the collagen
bundle (small arrows). However, it is present in other areas of
the vessel wall (large arrow). Inset: An adhesion area where
the plasma membrane is cut at a low angle. The adhesion spots
are situated exactly and regularly above the collagen fibers
(small arrowheads). Scale bar  0.5 m (G and inset). H:
The collagen bundle (cut perpendicularly) of the pillar extends
outside into the connective tissue and runs around the circum-
ference of the vessel. Although adhesion spots are not visible,
a basement membrane is not present at the area where the EC
faces the collage bundle. Many microfilaments are present in
this body part (arrowheads) of the EC. An intact basement
membrane is present under the other parts of the EC (arrows).
Scale bar  1 m.
ue and in Transcapillary Pillars
iameter (m)
agen bundles within the
pillars (n  55)
Pillars (including endothelium)
(n  55)
1.72 1.0* 2.5  1.1
0.4–5.0 0.8–5.8ive Tiss
D
Collrs did not differ significantly (P  0.4).
. Phalloi
d by ph
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nificant (Table 2).
In mice treated with vatalanib, significantly decreased
tumor burdens and a tendency toward reduced mi-
crovessel areas were observed. Moreover, tumor sam-
ples in the vatalanib group had significantly more pillars/
tumor microvessel areas than those in the control group
(Table 2).
Vascularization of Skin Wounds
To elucidate the process of pillar formation in conditions
other than tumor-induced angiogenesis, we also ana-
lyzed full-thickness cutaneous incision wounds (3, 5, 7,
and 10 days after wounding) for the presence of pillars.
However, endothelial sprouting was the characteristic
Figure 4. Immunofluorescent labeling of pillars. A–D: Vessel with pillar (a
pictures show horizontal views of 35 optical sections. CD31 and vinculin are
middle. D shows the merged picture. Inset: One optical section showing th
is a high density of adhesions in the connective tissue. Black areas (except
F: Vessel with pillar (arrow) stained for CD31 (green) and phalloidin (red)
at the sides of the pillar. Myofibroblasts outside of the vessel are also stainemechanism of angiogenesis in the healing wounds(mostly 5 and 7 days after wounding); we failed to detect
any signs of pillar formation (data not shown).
Discussion
Although the formation of transluminal pillars4–8 is con-
sidered the most characteristic feature of intussusceptive
microvascular growth, the exact mechanism of this pro-
cess has yet to be completely clarified. By investigating
the vascularization of experimental tumors growing in
mice, we present herein the putative sequence of steps
of transluminal pillar development during intussusceptive
angiogenesis (Figure 8). First, transluminal endothelial
bridges are formed. Second, collagen bundles adjacent
to the vessel are seized by the abluminal side of a bridge-
forming EC. The force exerted by the actin cytoskeleton
tained for CD31 (A, red), vinculin (B, green), and collagen I (C, blue). The
t mainly on the two sides of the pillar, whereas collagen is positioned in the
lin is present in small spots along the periphery of the pillar (green). There
essel lumen) correspond to tumor tissue. Scale bar  20 m (A–D). E and
din staining, representing filamentous actin, colocalizes with CD31 staining
alloidin–tetra rhodamine isothiocyanate. Scale bar  20 m (E and F).rrow) s
presen
at vincu
for the vof the EC through specific vinculin-containing attachment
n of a p
faces a c
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through the vessel lumen. Finally, maturation of these
nascent pillars occurs via the migration of pericytes and
myofibroblasts into the collagen core of the pillar and the
deposition of additional collagenous connective tissue by
these cells.
The sequence of events during intussusceptive angio-
genesis was analyzed in detail in the chicken chorioallan-
toic membrane and in developing lung tissue, and it was
concluded that the appearance of collagen bundles is
the last step of pillar formation.4,5 In these models, pro-
trusion of the vascular wall into the lumen, interendothelial
adherence, and perforation of the endothelial bilayer by
reorganization of the interendothelial junctions were the
first events. These events were promptly followed by the
appearance of perivascular cells within the pillar. Inter-
estingly, although transluminal pillars were formed under
different conditions in our study (ie, during tumor vascu-
larization because there were no signs of pillar formation
in healing cutaneous wounds), the initial size of pillars
(approximately 2.5 m) was remarkably similar to that
observed in nontumorous conditions (2.5 m).4,5
Intussusceptive angiogenesis, which results in high
local vascular density, is initiated by rapid nascent pillar
formation, followed by slow pillar enlargement (a nonin-
vasive process for which extensive connective tissue
synthesis is required). Therefore, one reason for the lack
of intussusceptive angiogenesis in skin wounds could be
that neither pillar development nor the intussusceptive
angiogenesis itself is an invasive process; thus, both are
not suitable to vascularize initially avascular spaces
(such as a fibrin clot). Also, during intussusception in
nontumorous tissues, the area covered by the vascula-
ture can be increased solely by the collagenous matrix
deposited by the connective tissue cells immigrating into
the pillars. In tumor tissues, the invading tumor mass
incorporates and occupies the newly formed vasculature
(including the developing pillars). Tumor cells are able to
both incorporate into the pillars and contribute to their
growth; therefore, they help to dilute the newly formed
Figure 5. The ultrastructure of the adhesion region. A and B: Serial sections
into rows and spaced regularly (the sectioning plane is parallel to the plasm
When the sectioning plane is perpendicular to the plasma membrane of the
rods to each other (arrows). Scale bar  0.5 m (A and B). C: Cross sectio
plasma membrane of the EC. Only one rod is visible (arrowhead), whichcapillary network. In contrast, during wound healing, thefibrin clot (an existing avascular extracellular matrix) is
invaded/occupied by sprouting vessels. This can occur
rapidly (within days) and is necessary to supply the in-
coming collagen-synthesizing cells with nutriments. An-
other reason for the difference in the presence of intus-
susceptive angiogenesis between skin wounds and
tumors could be that a sustained angiogenic stimuli elic-
ited by tumors (often referred to as never-healing
wounds)12 is necessary to induce/maintain intussuscep-
tive angiogenesis.
In the mechanism proposed herein, the formation of
transluminal endothelial bridges is immediately followed
by the appearance of a collagen bundle within the pillar.
This collagen bundle may serve as a highway for later
immigration of other cells (eg, pericytes and myofibro-
blasts) into the pillar. The deposition of an additional
extracellular matrix by these cells can result in the en-
largement of the pillar.
The driving force behind the formation of the protrusion
in the vessel lumen during intussusceptive microvascular
growth remains elusive. Although it is believed to be
exerted by perivascular cells, such as pericytes or myo-
fibroblasts,4–6 a cell’s pushing force (which can be ex-
erted only through filopodia or lamellipodia) is only in the
10 to 100 pN range.9 In contrast, contractile forces gen-
erated by cells lie in the several hundred nanonormal
range.10 According to our model, no extraluminal force is
necessary for the formation of the pillar. Slender EC pro-
cesses floating in the lumen can contact other parts of the
endothelial tube (probably to the same side initially). Ad-
ditional growth of cytoplasmic processes of ECs can
result in the repositioning of this initial contact to reach
farther parts of the lumen. This may be followed by the
formation of endothelial bridges consisting of several
ECs. The contractile force exerted by the microfilaments
present at a high density within the ECs forming the
bridge may be strong enough to pull a collagen bundle
into and through the lumen. The highly edematous and
loosely organized peritumoral connective tissue might
allow this process. However, the presence of adhesions
hesion region. A: Adhesions (appearing as dots, arrowheads) are arranged
rane of the EC). There is a high density of microfilaments in this region. B:
same adhesions appear as rods (arrowheads). Microfilaments connect the
illar at an adhesion region. The collagen fibers are in close contact with the
ollagen fiber. The plasma membrane is thickened. Scale bar  0.5 m.of an ad
a memb
EC, theat a high density on the myofibroblasts of the pericapillary
mplies t
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under tension, through either indirect (ie, fibronectin fi-
brils) or direct attachment of these cells to the collagen
bundles. These attachments may counteract the move-
ment of the collagen bundles. Although we do not have
direct evidence for the movement of the collagen bun-
dles, the observed similarity between the diameter of the
collagen bundles within the pillar and within the connec-
tive tissue, and, moreover, the discovery of collagen bun-
dles extending only halfway into the lumen (while their
other end extended into the connective tissue) have led
Figure 6. Pillar development. A–H: Developing pillar partially filled with a c
bridge is attached to the vessel wall at two positions (A and C). The collagen
The pillar increases in thickness during its further run before it joins the vess
wall on D. The large arrowhead points to a mature connective tissue pos
bar 20 m (A–I). I: 3D reconstruction of 30 semithin sections represented i
from the vessel wall and containing a collagen bundle are shown in green, a
arrow and arrowhead in yellow and green, respectively, indicates that th
sections of a pillar partially filled with a collagen bundle. The sections repres
tiny collagen bundle (arrows in J and K) contains only approximately 20 in
on J). The body part of the ECs in the vicinity of the collagen bundles (J) c
Numerous interendothelial junctions are visible in L (arrowheads), suggesti
are absent in M, suggesting that the bridge terminates in a single EC. This i
Scale bar  1 m (J–M).us to conclude that pre-existing collagen bundles aretransferred by these ECs through the lumen. The obser-
vation that collagen bundles are transferred in a hand-
over-hand cycle in the case of fibroblasts in vitro supports
this hypothesis. This process was dependent on integrin
-2/-1–mediated adhesion and on the contractile activ-
ity of the actomyosin cytoskeleton.20 However, in our
case, the adhesion receptor responsible for the binding
of collagen I in the pillar remains unknown. We could not
detect integrin -1 or -11 expression levels, and integrin
-2 was present only occasionally at a low density, which
did not correlate with the number of adhesion spots con-
bundle. Small arrows mark the part of the pillar consisting only of ECs. The
f the pillar (light blue staining) is discernible first on D (small arrowhead).
(small arrowheads). Large arrows mark a twin pillar that joins the vessel
ins the vessel wall on C and blends into it on the following sections. Scale
he vessel wall and the surrounding tissue are shown in red, pillars separated
endothelial bridges are shown in yellow. The structure marked by the small
en bundle does not fill the whole length of the pillar. J–M: Serial ultrathin
ransitional area where the pillar continues in a short endothelial bridge. The
l collagen fibers. The pillar is sealed by endothelial junctions (arrowheads
microfilaments at a high density. The collagen bundle is absent in L and M.
ore ECs of the bridge have joined each other in this region. These junctions
hat the other ECs of the bridge have not yet reached this side of the vessel.ollagen
core o
el wall
t that jo
n A–H. T
nd the
e collag
ent the t
dividua
ontains
ng that mtaining vinculin within the pillar. This calls into question
ECs (ar
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AJP September 2011, Vol. 179, No. 3               dc_301_11the role of these integrin subunits in the transport of the
collagen bundle. Nevertheless, the presence of adhesion
spots containing large -2 subunits may be the conse-
quence of the maturation process during which myofibro-
blasts migrate into the pillar. In these cells, integrin -2 was
observed at a high density in the connective tissue sur-
rounding the vessels. Despite the lack of collagen I–b-
inding  subunits within the pillar, integrin -1 was evenly
Figure 7. Pillar development and maturation. A and B: Horizontal view of 33
labeling. B: Merged red and green channels. The collagen bundle extends on
(arrowhead) is completely filled with collagen. Scale bar  20 m (B). C
collagen (blue). C: Collagen labeling. D: Merged red and blue channels. The
length of the pillar (arrow). Scale bar  20 m (D). E: Base of a maturing p
core of the pillar (arrowhead). Scale bar  1 m. F: Mature pillar containi
right side of the pillar under the endothelium (arrow). Flat cells under the
basement membrane. Scale bar  1 m.distributed along the vessel and the pillars, suggestingthat this integrin is paired with laminin-binding  subunits
at the basal surface of the ECs.
Electron-dense adhesion sites containing vinculin
were observed along the pillars, indicating that the ECs
are attached firmly to the collagen bundle. The adhesion
spots were unique in structure because they were placed
regularly along individual collagen fibers, extended100
nm from the membrane into the cytoplasm, and were
sections. Double labeling for CD31 (green) and collagen I (red). A: Collagen
ay into the vessel lumen within the developing pillar (arrow). Another pillar
Horizontal view of 32 optical sections. Double labeling for CD31 (red) and
bundle originating from the pericapillary connective tissue spans the entire
onnective tissue cell extends a process (arrow) toward the original collagen
rous cells and collagen bundles. The basement membrane is visible on the
rowheads) are presumably pericytes, although they are not covered by aoptical
ly halfw
and D:
collagen
illar. A c
ng numeconnected to microfilaments. Recently, a strikingly similar
Pillar Formation 1583
AJP September 2011, Vol. 179, No. 3               dc_301_11structure was discovered during the analysis of the ultra-
structural architecture of focal adhesions in in vitro cul-
tured cells. Patla et al21 found that the membrane-cyto-
skeleton interaction within focal adhesions is mediated
through vinculin-containing particles located at the cell
membrane and attached to actin fibers. Their observation
strongly supports our idea that the transluminal transport
of the collagen bundle is mediated by the force exerted
by the actin cytoskeleton via the adhesion spots (ie, par-
ticles).
The finding that collagen fibers touch the plasma mem-
brane of the ECs suggests that ECs adhere directly to the
collagen bundle rather than attach to other extracellular
matrix elements, such as the basement membrane or
fibronectin fibrils. This latter extracellular matrix compo-
nent is involved in the formation of fibronexus junctions,
Table 2. Effect of Angiogenesis-Modulating Agents on Tumor G
Variable
C38 colon carcinoma s.c. tumor weight (g) 2
Relative vessel area (%vessel/tumor area) 1
No. of pillars/vessel area (no./mm2)
No. of pillars/tumor area (no./mm2) 0
Results are expressed as mean  SD.
*P  0.05.which are thought to be responsible for force transmis-
sion by myofibroblasts and ECs.22,23
In a recent study,24 the tyrosine kinase inhibitor vata-
lanib (PTK787/ZK22854) delayed the intussusceptive-de-
pendent maturation of the vascular network in the devel-
oping chicken chorioallantoic membrane. In contrast,
other researchers19 reported that rHuEPO can induce
intussusceptive angiogenesis in the same angiogenesis
assay. Therefore, we also decided to study whether these
angiogenesis-modulating molecules have an effect on
pillar formation in our C38 tumor model. We found that
rHuEPO treatment resulted in a significant increase in
intratumoral pillar numbers. However, possibly because
of the concomitant increase in intratumoral capillary sur-
face (a phenomenon that corresponds with our previous
observations on rHuEPO’s effects on tumor capillaries),16
nd Pillar Densities
Treatments
ol rHuEPO Vatalanib
.72 2.77  1.12 1.46 0.82*
.32 1.75  0.28 1.21  0.14
25  5 32  6*
.04 0.43  0.06* 0.38  0.08
Figure 8. Schematic representation of the puta-
tive process of pillar formation. A: Simple endo-
thelial bridges are formed. B: Bridges can reposi-
tion themselves, and more ECs may be involved in
bridge formation. On the abluminal side of the ECs
that form the bridge, the basement membrane is
locally disrupted. An EC from the bridge adheres to
a nearby collagen bundle. C and D: The collagen
bundle, seized firmly through specific adhesion
sites, is transferred through the lumen by the
bridge-forming ECs as they exert a pulling force
on it. Arrows indicate the direction of this force.
E: The collagen bundle reaches the other side of
the lumen. The interendothelial junctions are
reorganized, ensuring that the luminal and basal
polarity of the ECs is maintained during the pro-
cess. F: The collagen bundle is transferred into
the connective tissue on the other side of the
vessel. A nascent pillar, consisting only of a col-
lagen bundle and the covering ECs, is estab-
lished. Pillar maturation and enlargement occur
through the immigration of fibroblasts/myofi-
broblasts and pericytes into the pillar and
through the subsequent extracellular matrix de-
position performed by these cells.rowth a
Contr
.73  0
.47  0
21  3
.31  0
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sities were calculated for intratumoral microvessel areas.
Thus, these results do not unequivocally indicate that
rHuEPO induces pillar formation; they may only suggest
that more capillary surface was provided for pillar forma-
tion. However, in our experiments with vatalanib, we
found a significant increase in pillar densities defined for
the microvessel areas in C38 tumors, suggesting an ac-
tivity for this drug similar to that reported in another earlier
study by the previously mentioned researchers.18 In this
study, their group observed a switch from endothelial
sprouting to intussusceptive angiogenesis after treatment
of mammary carcinoma allografts with vatalanib. Alto-
gether, both our results and theirs support the general
notion that inhibition of just a single tumor vascularization
mechanism can trigger alternative ones. This can help
tumors to develop resistance to anti-angiogenic treat-
ments.1,25
The main limitation of this study is the lack of direct in
vivo evidence for collagen bundle movement. However,
each of the available real-time imaging techniques has
serious shortcomings/confounding factors that could
hamper its use in studying in vivo pillar formation in tu-
morous conditions. Red blood cell flow makes it impos-
sible to detect an unstained transluminal collagen bundle
using common phase-contrast microscopy (S. Paku, un-
published data). The obscuring effect of the blood stream
would also exist when using confocal reflection imag-
ing.26 The only way to overcome this problem would be to
detect harmonic signals generated during multiphoton
excitation. However, although this method highlights un-
stained fibrillar collagen,27,28 the penetration depth of the
second harmonic signal is limited by the light-scattering
effect of turbid media (to approximately 200 m),29 such
as the peritumoral s.c. tissue. An additional key problem
with in vivo pillar imaging is that the equipment should be
focused on an object that does not exist at the beginning
of the observation period (ie, the probability that a colla-
gen bundle will move in front of a high-power objective is
extremely low). Nevertheless, the confocal and ultrastruc-
tural evidence we have presented strongly suggests that
the observed collagen bundles are transferred through
the lumen by the bridge-forming ECs. The evidence in-
cludes the following: i) the adhesion sites along the pil-
lars, ii) the dense actin filament network within the pillars,
iii) the similarity between pillar and connective tissue
collagen bundle diameters, and iv) collagen bundles ex-
tending only halfway into the lumen with their other end
extended into the connective tissue.
In summary, this study reports the detailed mechanism
of connective tissue pillar formation during tumor-in-
duced intussusceptive angiogenesis. This new mecha-
nism of pillar formation can also be termed inverse
sprouting. During the normal sprouting process, ECs
maintain their polarity, migrate surrounded by connective
tissue, and form a slit-like lumen.2 During pillar formation,
ECs are surrounded by the vessel lumen and the con-
nective tissue is situated inside the sprout. As in normal
sprouting, ECs involved in inverse sprouting also main-
tain their polarity. Meanwhile, the complete EC coverage
of the collagen bundle ensures that the collagen core ofthe pillar is not in contact with blood elements during the
process. These results provide a better understanding of
this type of angiogenesis and may also represent a new
piece to the puzzle of cancer therapy via angiogenesis
inhibition.
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A Novel Concept of Glomeruloid Body Formation in Experimental Cerebral Metastases
BALA´ ZS DO¨ ME, MD, JO´ ZSEF Tı´MA´ R, MD, PHD, AND SA´ NDOR PAKU, PHD
Abstract. Glomeruloid bodies (GBs), tumor-associated vascular structures with a superficial resemblance to renal glomeruli,
are important histopathological features of glioblastoma multiforme, but have also been described in other types of tumors
and in cerebral metastases. The purpose of this study was to elucidate the pathogenesis of these lesions in an appropriate
murine model of experimental brain metastases. To do so, we injected cells from 5 different tumor lines into the internal
carotid artery of mice and investigated the development, composition, and fate of GBs growing within tumor nodules.
Immunohistochemical analyses and 3-dimensional reconstruction of the cerebral vasculature showed clearly that the prolif-
erating and migrating tumor cells pull the capillaries (and the adjacent capillary branching points) into the tumor cell nest.
Initially, this process lead to the appearance of simple coiled vascular structures, which later developed into chaotic and
tortuous vascular aggregates with multiple narrowed afferent and efferent microvessels. Despite the absence of sprouting
angiogenesis, the very low level of endothelial cell proliferation index and the ruptures of the stretched and narrowed capillary
segments observed frequently between the metastatic tumor nodules, necrosis was scarce in these lesions, implying that the
blood supply from the multiple afferent microvessels and from the preexistent vascular bed sufficed to provide the tumor
cells with oxygen and nutrients.
Key Words: Experimental brain metastasis; Endothelium; Glomeruloid body; Microvessel.
INTRODUCTION
The appearance of cerebral metastases is often asso-
ciated with the terminal stage of cancer. Despite devel-
opments of both diagnostic modalities and new therapeu-
tic strategies, the median survival of patients with brain
metastases is less than 6 months, which has not substan-
tially changed during the past 2 decades (1).
In contrast to the widely accepted view that most tu-
mors and metastases begin to grow as avascular spher-
oids, there is also evidence that a subset of tumors instead
initially grows by the use of preexistent vessels, a process
referred to as co-option (2–4). Indeed, the perivascular
migration of tumor cells is a common observation, es-
pecially in the central nervous system (5–10). It has also
been hypothesized recently that in the highly vascularized
brain, metastases of tumor cells grow without the increase
of intratumoral microvessel density and the induction of
sprouting angiogenesis (11), even if these cells are en-
gineered to express recombinant VEGF-A165 (12). The
formation of complex multilumen vascular channels has
been considered to be the result of nonsprouting (i.e. in-
tussusceptive) angiogenesis in these studies, although the
presence of glomeruloid bodies (GBs) in primary and
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metastatic cerebral cancers is well known (13–16). How-
ever, there is only 1 detailed description of this type of
‘‘angiogenesis’’ in an animal model in which the authors
found that the injection of an adenoviral vector engi-
neered to express VEGF induced the development of GBs
in normal ear skin of athymic mice (17).
The purpose of the present study was to determine the
steps of GB formation in experimental brain metastases
by human and mouse cancer cells. We report the novel
finding here that the co-opted brain capillaries have a
passive role in GB pathogenesis with a relatively low
level of endothelial cell (EC) proliferation and without
morphological evidence of sprouting activity. The tumor
cells adhering and proliferating on the surface of base-
ment membranes (BM) of cerebral microvessels pull the
capillaries into the tumor nodules, looping and coiling
them up, leading to the appearance of florid microvas-
cular structures with a superficial resemblance to renal
glomeruli.
MATERIALS AND METHODS
Animals, Tumor Cell Lines, and Injections
Inbred C57Bl/6 and SCID mice were anesthetized and 2.5–5 3
105 tumor cells in 0.2 ml Hanks’ solution were injected into the
right internal carotid artery as described previously (18). The
highly metastatic 3LL-HH tumor line was maintained in C57Bl/
6 mice by serial intrasplenic transplantation of tumor cells ob-
tained from liver metastasis as described previously (18). The
B16 mouse melanoma and the A2058 and WM983 human mel-
anoma cells were cultured in RPMI-1640 supplemented with
10% fetal bovine serum and 100 Units/ml penicillin, 0.1 mg/
ml streptomycin (all from Sigma Chemical Co., St. Louis, MO).
The 293 human renal cell carcinoma cells were cultured in Ea-
gle’s MEM supplemented with 10% horse serum and 100 Units/
ml penicillin, 0.1 mg/ml streptomycin (Sigma). Before injec-
tions, cells were harvested by trypsinization and washed in
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Fig. 1. A: Lewis lung tumor cell (arrow) located in the cortex of mouse brain 3 days after tumor cell inoculation. Scale bar:
10 mm. B: Electron micrograph of the tumor cell shown in (A). Six capillary lumens (C1–C6) are visible in the vicinity of the
extravascular tumor cell. One process of the tumor cell (T1) is in contact with 5 of the 6 capillaries. Another process of the
tumor cell (T2) adheres to the outer side of capillary 5 (C5). Scale bar: 2 mm. C: Higher magnification of the area between
capillary 1 and 6. A thin cytoplasmic bridge (arrows) can be observed between the capillaries, connecting the process to the
main body of the cell. E; endothelium, Scale bar: 1 mm.
Hanks’ balanced salt solution (HBSS). Groups of 5 mice were
killed by anesthesia at various time points (3, 5, 7, 11, 14 days
after tumor cell injection in the cases of 3LL-HH and B16; 14,
21, 30 days in the cases of 293, A2058, and WM983). Exper-
iments were carried out in accordance with the animal protec-
tion laws of the Ethic Committee of Semmelweis University.
Transmission Electron Microscopy
Animals were perfused via the left ventricle with phosphate
buffered saline for 10 min and with 2.5% glutaraldehyde in 0.05
M Na-cacodylate (pH 7.2) for 15 min at room temperature.
Brains were removed, cut into 1 3 2-mm pieces and immersed
in 2.5 glutaraldehyde for 2 hours. The pieces were processed
as described previously (19) and analyzed on a Philips CM10
electron microscope.
3D Visualization of the Vasculature of Brain Metastases
Sections 100 mm in thickness were incubated at room tem-
perature for 6 to 12 hours in a mixture of anti-laminin (rabbit
polyclonal 1:50; DAKO Corp., Carpinteria, CA) antibody for
BM identification plus anti-mouse CD31 (rat monoclonal,
1:100; Pharmingen, San Diego, CA) antibody for EC identifi-
cation or anti-aSMA (mouse monoclonal, 1:100; DAKO Corp.)
or anti-desmin (mouse monoclonal 1:200; DAKO Corp.) anti-
body for pericyte identification. After several rinses with PBS,
specimens were incubated simultaneously for 6 hours at room
temperature with the appropriate secondary antibodies (Cy5-
conjugated anti-mouse IgG; FITC-conjugated anti-rat IgG; rho-
damine-conjugated anti-rat IgG; rhodamine-conjugated anti-
rabbit IgG; FITC-conjugated anti-rabbit IgG, all from Jackson
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Fig. 2. Extremely long and thin process (arrowheads) of a Lewis lung tumor cell (T) adhering and advancing along the
capillary basement membrane. One of the 3 capillaries (C1) is completely engulfed by the tumor cell. Scale bar: 2 mm. Inset
shows the region between capillary 1 and 2. The thin process of the tumor cell (arrows) adheres to both of the capillary basement
membranes (arrowheads). Scale bar: 1 mm
Immunoresearch, West Grove, PA; 1:50) with or without nu-
clear staining with TOTO-3 (Molecular Probes, Eugene, OR; 5
mM) or propidium iodide (0.5 mg/ml, 5 min). For the lectin
staining of brain vasculature, FITC-labeled Lycopersicon es-
culentum lectin (100 mg in 0,1 ml of 0.9% NaCl; Vector Lab-
oratories, Burlingame, CA) was injected into the lateral tail vein
15 min before the animals were killed with Nembutal overdose.
Sections (100 mm) were cut and transferred to 6-well plates
containing methanol (2208C). To avoid compression, small
pieces of cover slip of 150-mm thickness were inserted on both
sides of the mounted slice. For 3D reconstruction, up to 80
serial optical sections at 0.5- to 1.5-mm intervals were used.
Digitized image stacks were further processed using Bio-Rad
LaserSharp software (Bio-Rad, Hercules, CA).
Assessment of Endothelial Cell Labeling Index with
Bromodeoxyuridine (BrdU)
Two hours before the mice were killed, 200 mg/kg BrdU in
saline was injected intraperitoneally. Sections were fixed in meth-
anol (–20C8) and reacted sequentially with rat anti-mouse CD31,
rhodamine-conjugated anti-rat IgG (1:50, Jackson Immunore-
search), 2N HCl (10 min, 208C), anti-BrdU antibody (1:100, Bec-
ton-Dickinson, Franklin Lakes, NJ), biotinylated anti-mouse IgG
(1:100, Vector), streptavidin-FITC (1:100, Vector), and with
TOTO-3. Slices were viewed by confocal microscopy. The la-
beling index of ECs was determined by counting the labeled as
well as all the EC nuclei (100/studied area) along the vessel
walls.
RESULTS
To elucidate the steps of GB formation from the very
early stages, we followed serially the growth of metas-
tases from individual extravasated cells to tumors reach-
ing 1 to 1.5 mm in diameter and investigated EC prolif-
eration and the distribution of pericytes. All mice injected
with cells into the internal carotid artery developed ce-
rebral tumors, predominantly in the parenchyma and in
the choroid plexus, with smaller deposits in the meninges.
The growth rate of tumor lesions varied among the dif-
ferent cell lines. The process was most rapid in case of
murine tumors (3LL-HH and B16) and was much slower
in case of human cell lines (293, A2058, and WM983).
Injection of a higher number of cells led to a higher num-
ber of metastases; however, the morphology of the indi-
vidual lesions was not affected. Four of the 5 tumor cell
lines produced GBs subsequent to intracarotid artery im-
plantation. Although the growth pattern of the different
tumor lesions was similar (perivascular migration), we
were unable to detect GBs in B16 melanomas.
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Fig. 3. A: Single loop of a cerebral capillary (arrow) induced by a large Lewis lung tumor cell adhering to the capillary
basal membrane (laminin, green) Note the laminin positivity of the cytoplasm of the tumor cell (arrowheads). B: Immunofluo-
rescent staining of microvessels for the endothelial cell marker CD31 (red) and the basal membrane component laminin (green).
Laminin-positive Lewis lung tumor cells are attached to the capillaries (arrowheads). One of the capillaries contains a triple
helical structure (arrows). C: Irregular capillary covered by several tumor cells (small arrowheads). One pronounced loop (arrow)
is observable. The red signal, corresponding to desmin-positive pericytes follows the green signal representing the capillary
basement membrane. A ruptured blind ended capillary is also present (large arrowhead). D: Small glomeruloid body consisting
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of numerous capillary loops inside of a micrometastasis of the Lewis lung tumor cell line. The diameter of a capillary segment
(large arrow) lying outside the glomeruloid body is significantly reduced. Tumor cells (arrowheads) are attached to the other
very small diameter capillary (small arrow). E: Brain metastases stained for laminin, 28 days following inoculation of the
A2058 human tumor cell line. Glomeruloid bodies inside of the metastases are connected to each other by very small diameter
capillaries. A small discontinuity can be observed in one of these capillaries (arrow). The outline of the metastases are clearly
visible because of the strong laminin positivity of the tumor cells. F: Glomeruloid body inside of a metastasis of the WM983
human tumor cell line, 28 days following tumor cell inoculation. The capillaries of the glomeruloid body are well perfused by
FITC-labeled Lycopersicon esculentum lectin. The pictures are horizontal views of stacks of confocal images (60–80 optical
sections at 1-mm intervals). Nuclear staining was performed using propidium iodide (red) in (A) and (D). Scale bars: A–D 5
20 mm; E, F 5 50 mm.
The first changes in capillary structure were evident as
early as day 3 in the case of 3LL-HH and day 14 in the
case of human tumors. Electron microscopic analysis
showed numerous capillary lumens in the vicinity of the
extravasated tumor cells, some of them were apparently
situated within the body of the tumor cells (Fig.1). Tumor
cells produced often extremely long cellular processes,
which advanced along the basement membranes and en-
circled the capillaries (Fig. 2). Confocal microscopic
analysis has revealed that the first step in the development
of the multiluminal structures observed in sections was
the appearance of single microvascular helices induced
by the tumor cell firmly adhering to the basement mem-
brane and tugging the capillary (Fig. 3A). As the extrav-
asated tumor cells started to proliferate along the BM of
the capillaries, the number of the loops increased (Fig.
3B). The development of helical structures involved the
whole capillary tube, including pericytes (Fig. 3C).
After 3 to 7 days in the case of 3LL-HH and 14 to 21
days in the cases of 293, A2058, and WM983, the tumor
cells began to increase in number, preferentially migrat-
ing along preexisting brain vessels while also adhering to
each other, and ultimately organized into metastatic tumor
cell nests. As a result, they further looped and twisted
the capillaries, which led to the development of small
GBs in the micrometastases (Fig. 3D). Electron micro-
scopic examination has not shown damaged endothelial
cells or pericytes within these lesions.
EC labeling index within the foci elevated to a rela-
tively low level (1%–2%) and remained there. Later (7–
10 days for 3LL-HH; 21–30 days for 293, A2058, and
WM983), the continuously proliferating and migrating
tumor cells pulled the capillaries into the metastatic tu-
mor nodules, leading to a tangled and chaotic intratu-
moral vascular network with multiple microvessel loops
and spirals. This phenomenon led to the dramatic aug-
mentation of microvessel density within the metastatic
lesions, with a slightly higher EC labeling index than in
the normal brain and without morphological evidence of
branching activity. Concomitant with these events, be-
tween the tumor cell nests the diameters of the stretched
capillary segments radically decreased and, sometimes,
the increasing microvessel strain led to the rupture of the
capillary walls (Fig. 3E). There appeared to be preexist-
ing capillary branching points present, which were in-
corporated into the tumor cell nest. In the GBs supplied
by multiple afferent microvessels, perfusion was often
reduced but not shut down entirely, whereas sometimes
the devolution of GBs supplied by a single afferent mi-
crovessel could be observed. Despite the microvessel
ruptures and the absence of ‘‘neovascularization,’’ necro-
sis was scarce in the tumor cell nests, probably because
of the incorporated preexistent vascular bed and the mul-
tiple afferent microvessels supplying the tumor cells (Fig.
3F).
It is also important to note that we did not detect dif-
ferences between the vasculature within the lesions and
that in the surrounding normal brain tissue with regard
to pericyte coverage and distribution (assessed by desmin
and aSMA immunoreactivity).
DISCUSSION
In the current study we investigated the development,
composition, and fate of GBs in the central nervous sys-
tem of mice. For this purpose, we injected cells from 5
different tumor lines (3LL-HH, B16, 293, A2058, and
WM983) into the internal carotid artery of C57Bl/6 and
SCID mice and studied the growth, mechanism of vas-
cularization, and the EC proliferation of cerebral metas-
tases. Although B16 melanomas showed the uniform pat-
tern of growth (migration along preexistent vessels), they
failed to produce glomeruloid lesions. 3D reconstruction
of the vasculature by staining the capillaries with anti-
bodies against different microvessel wall components
(anti-CD31, anti-laminin, anti-desmin, and anti-aSMA)
and with Lycopersicon esculentum lectin demonstrated
that in contrast to the prevailing view, during GB for-
mation there is no morphological evidence of sprouting
or intussusceptive angiogenesis; instead, migrating and
proliferating tumor cells of the metastases pull the brain
capillaries into the tumor spheroid. The pulling force is
generated by the contractile cytoskeleton of the tumor
cells spreading on the surface of the capillary BM and
also adhering to each other. This force induces the
stretching (coupled to the reduction of the capillary di-
ameters) of the capillary segments between the tumor
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nodules and the parallel appearance of microvessel loops
(i.e. vascular coiling) within the tumor cell nests. The
growing tumor, expanding between the host vessels, in-
corporates the surrounding capillary branching points, re-
sulting in a chaotic and tortuous intratumoral vessel net-
work with multiple afferent and efferent microvessels
supplying the GB.
Various studies have analyzed the exact nature of the
cells comprising these elaborate vascular structures and
elucidated the microvascular morphology in GBs grown
in different types of human tumors and malformations.
These vascular aggregates with a superficial resemblance
to renal glomeruli are one of the diagnostic histological
features of glioblastoma multiforme (14, 20) and have
also been described in gastrointestinal carcinomas (21),
thymomas (22), cutaneous vascular tumors (23), ovarian
teratomas (24), and in brain metastases of lung cancer
(13). They are composed of several closely associated
capillaries surrounded by variably thickened BM within
which a limited number of pericytes is embedded (14).
Until now, however, the pathogenesis of GBs in experi-
mental tumor systems has remained unexplained. In a
previous study based on immunohistochemical and light
microscopic methods, the formation of multilumen vas-
cular structures and transvascular bridges in experimental
cerebral metastases is thought to be a form of nonsprout-
ing (i.e. intussusceptive) angiogenesis (11). Accordingly,
in our experimental system we observed similar struc-
tures by light and electron microscopy, which make pos-
sible only a 2D morphological assessment of the gross
vascular network, but cannot adequately describe the 3D
microvascular architecture. We applied therefore 3D re-
construction of confocal data, which revealed a different
mechanism of GB formation.
The only study dealing with this type of ‘‘angiogene-
sis’’ (in which the authors describe the steps of GB de-
velopment, stabilization, and regression induced by lo-
cally expressed VEGF) was performed in the ear skin of
nude mice in the absence of neoplastic cells (17). In this
animal model, GBs develop in mother vessels from re-
cruitment and proliferation of ECs and VEGF is essential
for their induction and maintenance. The commentary on
this article by Sundberg et al suggests a 5-stage sequence
to explain vascular changes during brain tumor progres-
sion (25): 1) vessel co-option; 2) angiopoetin-2 mediated
apoptosis of ECs; 3) tumor necrosis; 4) VEGF expression
of hypoxic tumor cells surrounding central necrosis; and
5) GB formation. In contrast to this hypothesis, we have
observed that GB formation starts immediately after tu-
mor cell extravasation, much earlier than necroses appear
within the metastases. Furthermore, our results suggest
that co-opted microvessels most probably act as a passive
string during GB development, and that this type of GB
formation is not related to neoangiogenesis. However, it
cannot be excluded that ‘‘active’’ and ‘‘passive’’ type of
GB formation can operate concurrently in various tumor
types.
The central nervous system is unique in the structure
and function of its mesenchyme. In normal adult brain
the ‘‘stroma’’ consists of a dense network of oligoden-
drocytes, astrocytes, and numerous intertwining neuronal
processes (26). The parenchyma of the adult brain is gen-
erally a counter-adhesive and nonpermissive environment
for migration of tumor cells (27). A well-defined extra-
cellular matrix, which can provide a surface for the mi-
grating tumor cells, exists only around the cerebral cap-
illaries and in the glial limitans externa. The presence of
the classical BM proteins, laminin, collagen type IV, and
fibronectin, is limited to these structures (27, 28). The
absence of a supportive connective tissue in the brain
parenchyma is important in 2 ways. The tumor cells are
forced to proliferate along the preexisting microvessels,
a process referred to as perivascular migration or vessel
co-option (3). Alternatively, the lack of anchorage of the
cerebral microvessel network allows the force exerted by
the tumor cells firmly adhering to the capillary basement
membrane to cause capillary stretching (tug of war be-
tween the adjacent tumor nests) and the appearance of
microvessel loops within the tumor nodules. Although
sprouting activity was completely absent and only a slight
increase of the EC labeling index (1%–2%) was found
within the metastatic foci, 3D reconstruction of the vas-
culature demonstrated that GBs are tufted collections of
vascular channels (including the pericytes and the BM
surrounding the endothelial tube), suggesting that the lo-
cal increase of microvessel density does not necessarily
mean active angiogenesis and EC proliferation. Despite
the fact that the microvessel segments were thinned down
or sometimes ruptured between the GBs, tumor necrosis
was scarce, although we were able to follow the fate of
GBs until the metastases reached 1.5 mm in diameter.
In summary, our results suggest that the development
of vascular aggregates in micrometastases provides sur-
face and blood supply for the proliferating tumor cells,
but this process cannot be termed as true angiogenesis;
rather, it represents a remodeling of the existing vascu-
lature of the brain.
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Lack of Angiogenesis in Experimental Brain Metastases
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Jo´zsef To´va´ri, PhD, Jo´zsef Tı´ma´r, MD, PhD, DSc, Pe´ter Nagy, MD, PhD, Walter Klepetko, MD,
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Abstract
Angiogenesis is believed to be essential for the growth of meta-
static tumors in the brain. We analyzed the vascularization of tumors
formed by 4 epithelial cell lines (C38, ZR75, HT25, and H1650) and
a ﬁbrosarcoma (HT1080) cell line injected into the brains of mice.
No peritumoral angiogenesis was observed. Tumors apparently ac-
quired their vasculature by incorporation of native vessels. Vessel
density was lower, but vessel diameter and vascular cell proliferation
were higher within all tumors versus those in the peritumoral tissue.
There was an inverse correlation between the number of incorporated
vessels and vascular cell proliferation. Epithelial tumors with push-
ing growth patterns had lower vessel density and elevated vascular
cell proliferation compared with invasive tumors. The incorporated
vessels retained their normal structure, with the exception of astro-
cyte foot processes that were replaced by tumor cells. Attachment to
the vascular basement membrane led to the differentiation of the
ZR75 breast cancer cells. In the HT1080 metastases, there was in-
tussusceptive angiogenesis, that is, the ﬁbrosarcoma cells that were
attached to the vessel caused lumen splitting and ﬁlled the develop-
ing pillars. Branching angiogenesis was not observed either in the
tumors or in control cerebral wounds. These data suggest that
sprouting angiogenesis is not needed for the incipient growth of
cerebral metastases and that tumor growth in this model is a result
of incorporation of host vessels.
Key Words: Angiogenesis, Astrocyte, Brain, Carcinoma, Endothe-
lial cell, Fibrosarcoma, Metastasis.
INTRODUCTION
It is generally accepted that angiogenesis is necessary
for sustained growth of both primary and secondary brain
tumors (1Y4). The term angiogenesis refers to an increase in
vessel density along with the increase in endothelial cell (EC)
proliferation and is frequently used as a synonym for vessel
sprouting. In addition to incorporating host vessels, tumors
can also acquire their vasculature by inducing intussuscep-
tive microvascular growth or glomeruloid angiogenesis (5).
These vascularization mechanisms can act in concert to pro-
mote tumor growth.
During sprouting, ECs degrade the underlying base-
ment membrane and migrate into the connective tissue while
they maintain their basal-luminal polarity and immediately
form a slit-like lumen, which is continuous with the lumen of
the mother vessel. The polarized ECs continuously synthesize
their own basement membrane, and only the leading process
of the tip cell keeps contact with the interstitial collagen or
with the provisional ﬁbronectin/ﬁbrin-rich extracellular ma-
trix. The connective tissue is essential for basement mem-
brane deposition because it is not deposited on the surface of
other cells under normal conditions (6).
Intussusceptive angiogenesis refers to blood vessel for-
mation by insertion of connective tissue columns, called tissue
pillars, into the vessel lumen; the subsequent growth of these
pillars results in partitioning of the lumen (5). According to
the current view, the ﬁrst steps of intussusceptive angiogen-
esis are the protrusion of the vascular wall into the lumen and
the development of inter-EC adherence. These are promptly
followed by the perforation of the EC bilayer by reorganiza-
tion of inter-EC junctions. Finally, perivascular cells appear,
and a collagenous matrix is deposited within the pillar (7).
However, our most recent ﬁndings suggest an alternative
model, that is, the suction and the subsequent transport of a
preexisting pericapillary collagen bundle through the vessel
lumen by ECs as a ﬁrst step, followed by the immigration of
connective tissue cells and the deposition of new collagenous
connective tissue (8). Nevertheless, both models require ex-
tracellular matrix material, especially collagen ﬁbers or cells
that are able to produce that material because the pillar, the
most important structure of this type of angiogenesis, contains
collagen ﬁber(s) (7). Thus, both sprouting and intussusception
require a collagenous matrix containing ﬁbronectin, ﬁbrin, and
collagen I. Because the brain parenchyma lacks these mole-
cules (with the exception of artery walls), the signiﬁcance of
these types of angiogenesis during vascularization of brain
metastasis is questionable.
In contrast, in a model of glomeruloid body formation
described earlier by our group in experimental brain metastases,
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the presence of collagenous matrix was not necessary be-
cause loops of the glomeruloid bodies were generated by the
pulling force of tumor cells ﬁrmly attached to the basement
membrane of the capillaries. This process includes a simple
reorganization of the original vascular structure of the brain
parenchyma with minimal proliferative activity of the ECs
(9). A different process of glomeruloid body formation occurs
in response to vascular endothelial growth factor (VEGF),
with proliferation of primitive ECs and pericytes in the wall
of mother vessels. Although collagen was detected around the
glomeruloid bodies in the brain (10), the question of whether
the presence of this matrix element is required in the process
is yet to be answered.
Increasing data suggest that vessel incorporation plays
an important role in the vascularization of both primary and
metastatic brain tumors, at least in the initial phase of their
progression (11, 12). Ku¨sters et al (11) showed that sprouting
angiogenesis is not necessary for vascularization of mela-
noma brain metastases in an experimental mouse model even
in the presence of high level of VEGF; instead, the tumors
they observed grew by vessel incorporation.
Previously, by injecting cancer cells into the carotid
artery of mice, we described a process of glomeruloid body
formation in brain metastases of anaplastic tumors (9). How-
ever, using that method, a very large number of microme-
tastases developed; the large overall tumor burden thereby
killed the animals before the metastases could evolve into
‘‘macrometastases’’ (1Y2 mm in diameter).
To ensure the development of ‘‘macrometastases’’ in
the present study, we injected cells of a human anaplastic
ﬁbrosarcoma cell line and murine and human epithelial tumor
cells of colonic, breast, and lung origin directly into the brain
parenchyma. These cell lines formed differentiated tumors
and did not show the frequently observed pronounced peri-
vascular spread. They therefore proved to be more suitable
to study the consequences of the presumed angiogenic switch.
Our results suggest that an angiogenic switch does not occur
during the growth of these tumors in the brain parenchyma
and that they are supplied by the incorporated host vessels.
MATERIALS AND METHODS
Animals and Tumor Cell Lines
The C38 murine colorectal carcinoma line was main-
tained by serial subcutaneous transplantations in C57BL/6
mice. To produce brain metastases, subcutaneous tumors were
removed and cut into pieces (È2 mm3) with a surgical blade
and were digested in RPMI-1640 medium (catalog no. R8758;
Sigma-Aldrich, St Louis, MO), supplemented with 0.7 mg/ml
collagenase (37-C for 45 minutes; Sigma-Aldrich). Cells were
ﬁltered through 4-fold sterile gauze and centrifuged (800 
rpm, 10 minutes, 4-C). The pellet was resuspended in 10 ml
of medium without any supplement; cells were counted, and
after centrifugation, the supernatant was removed. C57BL/6
mice received 104 cells in a volume of 2 Kl.
Zr-75-1 human breast carcinoma (ZR75), HT25 human
colorectal carcinoma, H1650 lung adenocarcinoma, and HT1080
human ﬁbrosarcoma cells were cultured in RPMI-1640 me-
dium supplemented with 10% fetal bovine serum (Sigma). Cells
in exponential growth phase were harvested by trypsinization
for 5 minutes at 37-C (trypsin-EDTA; Sigma) and resus-
pended in RPMI-1640 medium. After counting and centrifuga-
tion (800  rpm, 10 minutes, 4-C), pellets were resuspended
in serum-free RPMI-1640 medium. After centrifugation, the
supernatant was removed, and the pellet was resuspended
(40Y60  106 cells in a volume of 100Y150 Kl). Male SCID
mice received 8 to 12  105 cells in a volume of 2 Kl.
For tumor inoculation, mice were anesthetized with
intraperitoneal injection of ketamine-xylazine (80:12 mg/kg;
Sigma). A midline incision was made in the scalp and the
right parietal bone was drilled with a 21-gauge needle (Braun,
Melsungen, Germany) 2 mm posterior to the coronal suture
and 1 mm lateral to the sagittal suture. Cells were slowly in-
jected using a 10-Kl Hamilton syringe. After inoculation, the
syringe was left in place for 15 to 30 seconds to prevent the
outﬂow of cells because of pressure changes in the brain.
The overlying skin was then closed. Mice were killed 7 to
10 days after inoculation of the C38 and HT1080 tumor cell
lines and 21 to 28 days after inoculation of the ZR75, H1650,
and HT25 tumor cell lines.
To investigate the general impact of the direct injec-
tion process on brain parenchyma, we examined mouse brains
after needle wounding as a control. The wounding was per-
formed under the same conditions as those applied during
tumor inoculation with the exception of tumor cell injections.
Mice were killed after 2, 3, 4, 5, 7, 9, 14, and 21 days.
Immunoﬂuorescence
Primary antibodies and reagents used for immuno-
ﬂuorescence are listed in Table 1. Appropriate secondary
antibodies (Jackson ImmunoResearch, West Grove, PA) were
used. All samples were analyzed by confocal laser scanning
microscopy using the Bio-Rad MRC-1024 system (Bio-Rad,
Richmond, CA).
Assessment of Vascular Cell Proliferation by
Bromodeoxyuridine Incorporation
At 1 hour before mice were killed, 200 mg/kg bromo-
deoxyuridine (BrdU; Sigma) in saline was injected intraperito-
neally. Brains were removed and frozen. Ten-micrometer-thick
cryostat sections were stained with toluidine blue and exam-
ined by light microscope. The sample was selected for im-
munoﬂuorescence analysis when the tumor was localized in
the brain parenchyma without affecting the corpus callo-
sum. Methanol ﬁxed (10 minutes at j20-C) frozen sections
were incubated with 2N HCl (10 minutes at 20-C) and incu-
bated with primary antibodies against BrdU and laminin
(1 hour at 20-C; Table 1). After incubating with appropriate
secondary antibodies, sections were counterstained with
diamino-phenylindole. Sections were analyzed by a Nikon
TE300 ﬂuorescent microscope (Tokyo, Japan) using a 100
objective with a ﬁeld diameter of 200 Km. Blood vessels
within the tumor and within 200 Km distance from the
periphery of the lesion (tumor or needle wound) were identi-
ﬁed by laminin staining. All nonlabeled and labeled nuclei
lying within the basement membrane (i.e. ECs and pericytes)
were counted (100Y500 cells/animal, 3Y6 animals/tumor line).
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The labeling index (LI) was calculated by dividing the num-
ber of labeled nuclei by the total number of nuclei counted. In
C38-derived tumors, the LI was also determined for the ves-
sels touching the periphery of the tumor.
Morphometry
Tumor size was determined using micrographs captured
with the 4 objective. The brains were serially sectioned and
the largest extension (area) of the tumor was measured. A
theoretical diameter of the lesion was calculated from these
data. Vessel density (n/mm2), vessel size (diameter), and den-
sity of branching points were determined on micrographs of
CD31- and laminin-immunostained sections captured with
a 10 objective. All vessels (not only capillaries) in the in-
tratumoral and peritumoral region (up to 200 Km from the
tumor margin) were analyzed. Vessel size was determined by
measuring the smallest extension of the objects outlined by
laminin staining.
All parameters were determined using Quick Photo
Micro 2.2 software (Olympus, Tokyo, Japan). During evalu-
ation of branching points, the peritumoral area was used as
reference to avoid biased results owing to the differences in
branching intensity in the different cutting planes. Results are
expressed as fold increase compared with the surrounding
parenchyma. The above parameters, including BrdU labeling,
were determined in the cell-transferred and needle wounding
control brains. Data were evaluated using Student t-test.
Western Blot Analysis
For the C38 tumor, cells were obtained from primary
cultures and prepared as described above but without colla-
genase digestion. For all analyzed cell lines, cultured cells
were harvested by trypsinization and resuspended in RPMI-
1640 supplemented with 10% fetal bovine serum. After
counting, cells were washed in RPMI-1640 and sterile PBS.
Cells (1  107) were resuspended and homogenized in 1 ml
of lysis buffer containing 10 mmol/L Tris, pH 7.5, 1 mmol/L
EDTA, 150 mmol/L NaCl, 1% Triton X-100, 0.5 mmol/L so-
dium orthovanadate, and protease inhibitor cocktail (Sigma).
After 30 minutes of incubation (4-C), lysates were centrifuged
(15 minutes, 13,000  rpm, 4-C). Supernatants were stored at
j80-C. To determine total protein concentration, the Bio-Rad
Protein Assay based on the Bradford dye-binding procedure
(Bio-Rad) and BSA standard series were used. Protein sam-
ples were denatured in sodium dodecyl sulfate sample buffer
(95-C for 10 minutes).
About 12.5% polyacrylamide gel was prepared for
PAGE as follows: 80 Kg of protein sample was loaded per
lane, 1 ladder per gel (2 Kl; Precision Plus Dual Color Protein
Standard; Bio-Rad). After running and transfer, the mem-
brane was blocked with 5% dried milk in PBS (overnight at
4-C). The membrane was incubated with anti-VEGF antibody
(1:1000) (Abcam, Cambridge, UK), biotinylated secondary
antibody, and ﬁnally with an ABC kit (Vector Laboratories,
Burlingame, CA). The membranes were developed by ECL
(catalog no. 34077; Thermo Scientiﬁc, Hampton, NH) or
DAB (Vector).
Quantitative Real-Time Reverse
TranscriptionYPolymerase Chain Reaction
Analysis of Cell Lines and Microdissected Tissues
Vascular endothelial growth factor A, platelet-derived
growth factor A (PDGF-A), and angiopoeitin 1 (Ang-1) ex-
pressions were analyzed in cell cultures. Total RNA was
extracted from cells using TRIzol (Invitrogen). The expres-
sions of angiogenic factors and their receptors were ana-
lyzed using 12-Km-thick frozen brain sections. The sections
were ﬁxed in methanol (j20-C for 10 minutes) and were
stained with RNase-free hematoxylin. Intratumoral and peri-
tumoral (within 200 Km distance from the periphery of the
lesion) regions were microdissected (180Y250 Km2/animal,
2 animals/tumor cell line) using the PALM MicroBeam sys-
tem (Carl Zeiss MicroImaging, Jena, Germany). Total RNA
was isolated using RNAqueous-Micro Kit (Applied Biosys-
tems, Weiterstadt, Germany).
High-capacity complementary DNA (cDNA) reverse
transcription kit (Applied Biosystems) was used for cDNA
synthesis as recommended by the supplier. Pooled cDNA
TABLE 1. Primary Antibodies and Fluorescent Dyes Used for Immunoﬂuorescence
Antibody Species Manufacturer Catalog No. Dilution
BrdU Mouse monoclonal Becton Dickinson (San Jose, CA) 347580 1:50
CD31 Rat monoclonal BD Pharmingen (San Diego, CA) 550275 1:50
CD49c Mouse monoclonal Novocastra (Newcastle, UK) NCL-CD49c 1:100
Claudin 3 Rabbit polyclonal Invitrogen (Carlsbad, CA) 34-1700 1:50
Collagen I Rabbit polyclonal Chemicon (Temecula, CA) AB765P 1:100
Smooth muscle actin Mouse monoclonal DAKO (Carpinteria, CA) M0851 1:200
Desmin Rabbit polyclonal Lab Vision (Fremont, CA) RB-9014-P 1:200
Epithelial membrane antigen Mouse monoclonal Novocastra NCL-EMA 1:50
Glial fibrillary acidic protein Mouse monoclonal BD Pharmingen 556330 1:100
Laminin Rabbit polyclonal DAKO Z0097 1:200
Laminin 5 Rabbit polyclonal Abcam (Cambridge, UK) 14509 1:50
Pan-cytokeratinYFITC Mouse monoclonal Sigma (St Louis, MO) F0397 1:50
Diamino-phenylindole Sigma 32670 1:100
Propidium iodide Invitrogen P3566 1:500
TOTO-3 Invitrogen T3604 1:500
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samples of 2 animals were used for polymerase chain reac-
tion (PCR) analysis. Quantitative RT-PCR was performed by
the ABI Prism 7300 Sequence Detection System, using ABI
TaqMan gene expression assays (Table 2). A-actin (part no.
4352935E, Assay ID: Mm00607939) was used as an endog-
enous control. All samples were run in triplicate in a 20-Kl
reaction volume. Results were obtained as threshold cycle
(CT) values. Expression levels were calculated using the
$CT method. The values were calculated as a ratio to A-actin
expression. The expression levels of the human angiogenic
factors were determined using human-speciﬁc A-actin primers
in the intratumoral samples. Because the RNA of the intra-
tumoral growth factor receptors was of murine origin in the
case of the human tumors, low intratumoral murine A-actin
levels could lead to distortion of the data resulting in ex-
tremely high relative receptor RNA levels as compared with
peritumoral brain tissue. Therefore, the intratumoral values
were related to the peritumoral murine A-actin levels. The data
were also corrected by the vessel content (vessel number 
vessel size , vessel surface) of the given tissue. For a good
comparison, the same procedure was applied for the C38
murine colon carcinoma tumor line.
RESULTS
We studied the process of vascularization in 5 tumor
cell lines (C38 murine colon carcinoma, HT25 colon, H1650
lung and ZR75 mammary carcinomas and HT1080 ﬁbro-
sarcoma) injected directly into the brain parenchyma of mice.
The largest area occupied by the tumor was determined for
each case (Table 3). From these data, a theoretical diameter
of the lesion was calculated. The average of diameters in each
tumor type reached the postulated size of tumors (1Y2 mm
diameter) at which angiogenic switch should occur.
Of the 5 tumors, the 2 colon carcinomas (Figs. 1A and
2A, B) and the anaplastic ﬁbrosarcoma (Fig. 2E) showed
pushing-like growth patterns (13, 14). The H1650 lung and
ZR75 mammary carcinoma cell lines showed more invasive
characteristics; the lung adenocarcinoma cells remained cohe-
sive (Figs. 1B and 2C), but the brain parenchyma adjacent to
the mammary carcinoma contained scattered round single tu-
mor cells (Figs. 1C and 2D).
We determined the vessel density inside and within a
200-Km distance from the periphery of the tumors (Table 3).
TABLE 2. TaqMan Assays Used for Quantitative RT-PCR
Analysis
Cell Lines: C38 HT25, H1650, ZR75, HT1080
VEGF-A (Mm01281449) VEGF-A (Hs00173626)
PDGFA (Mm01298578) PDGFA (Hs00234042)
ANG-1 (Mm01129232) ANG-1 (Hs00162807)
VEGFR-2 (Mm00440099) VEGFR-2 (Mm00440099)
PDGFRA (Mm01262489) PDGFRA (Mm01262489)
TIE-2 (Mm00443242) TIE-2 (Mm00443242)
ANG-1, angiopoeitin-1; PDGF, platelet-derived growth factor; PDGFR, platelet-
derived growth factor receptor; TIE-2, receptor tyrosine kinase for ANG-1; VEGF,
vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
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All tumors had decreased vessel density compared with sur-
rounding brain parenchyma. In addition, there was no signiﬁ-
cant change in the vessel density around the tumors compared
with control animals and no sprouting vessels were observed.
Moreover, although vessel dilatation is characteristic of mother
vessel formation preceding sprouting angiogenesis (6), this
phenomenon was not observable in the peritumoral brain pa-
renchyma (Table 3 and Fig. 2). An exception was the C38
murine colon carcinoma where the vessels in touch with the
surface of the tumor were considerably dilated compared with
control vessels (Table 3 and Figs. 2A, F). The diameters of in-
tratumoral vessels were signiﬁcantly increased in all tumors
compared with the vessels in the surrounding parenchyma,
but this can be considered biologically signiﬁcant only in the
2 colon carcinomas. Supporting this theory, the LIs of the
vascular cells (ECs cells and pericytes) were considerably in-
creased only within the pushing growth type tumors. In the
2 more invasive tumors (ZR75 and H1650), the LI of the vas-
cular cells within the tumor remained at a moderate low level.
Characteristically, the proliferation rate of the peritumoral vas-
cular cells was negligibly low in the case of all tumor types
(Table 3).
In the HT 1080 tumor (which also showed a pushing-
type growth pattern), a high vascular cell proliferation rate
was not accompanied by marked dilatation of the vessels.
This can be explained by our observation that, in this tumor, a
process reminiscent of intussusceptive angiogenesis takes
place (Fig. 3A). Transluminal pillars (hallmarks of this type
of angiogenesis [7]) inserting into the vessels contained no
collagen bundles; instead, they were ﬁlled with tumor cells
(Fig. 3B). In accordance with the intussusceptive angiogenesis-
like process taking place in the HT1080 tumor, the number
of vessel ramiﬁcations (branching points) was signiﬁcantly
higher than in the other tumors (Table 3).
In connection with the proliferation activity (LI) of the
intratumoral and peritumoral vascular elements, we analyzed
VEGF, PDGF-A, and Ang-1 expressions by quantitative real-
time RT-PCR in the 5 tumor cell lines and in microdissected
intratumoral areas of their brain metastases (Fig. 4). Mes-
senger RNA (mRNA) expression levels of these angiogenic
factors in the cell lines and in the tumor samples correlated
well (Figs. 4A, B). Interestingly, the C38 murine colon car-
cinoma and the HT1080 ﬁbrosarcoma lines (i.e. those with the
two highest intratumoral vascular cell LI) showed the lowest
intratumoral angiogenic factor levels. Microdissected intra-
tumoral HT25 samples showed the highest VEGF and Ang-1
mRNA expression levels (Fig. 4B). With respect to PDGF-A,
examination of microdissected intratumoral areas revealed that
brain metastases of the ZR75 cell line exhibited the highest
mRNA expression of this angiogenic factor (Fig. 4B).
The expressions of VEGFR-2 (VEGF receptor 2),
PDGFR-A (PDGF receptor A), and Tie-2 (an angiopoietin re-
ceptor involved in blood vessel remodeling and stabilization)
were also determined in microdissected intratumoral and
peritumoral areas of brain metastases. Messenger RNA ex-
pression of these receptors was always higher in the tumor
areas than in the peritumoral brain tissue (Fig. 5). To inves-
tigate the potential role of the key angiogenic molecule VEGF
in the growth of experimental cerebral metastases further, we
carried out Western blot analysis of the 5 cell lines. Although
quantitative RT-PCR analysis showed large differences in
VEGF expression levels among the cell lines (Fig. 4A), only
small variations were observed in protein expression levels
(Fig. 4C). Neither the intratumoral angiogenic factor mRNA
FIGURE 1. Hematoxylin and eosinYstained sections of representative tumors showing invasive growth patterns. (A) The pushing-
type HT25 colon carcinoma has a smooth surface. (B) Cohesive cell islands of the H1650 lung carcinoma extend into the brain
parenchyma. (C) Scattered single cells and small tumor nests inﬁltrate at the border of the ZR75 breast carcinoma. Scale bar =
50 Km (AYC).
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levels (VEGF, PDGF-A, and Ang-1) nor the intratumoral
mRNA expression of their receptors (VEGFR-2, PDGFR-A,
and Tie-2) correlated with the proliferation rate (i.e. LI) of the
intratumoral vascular cells. Furthermore, there was no sig-
niﬁcant correlation between VEGF protein levels and the LI
of intratumoral blood vessels.
In the pushing-type tumor growth pattern, the brain pa-
renchyma was displaced and the vessels incorporated into the
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tumors (Figs. 2A, B, F). Astrocytes were detached from the
vessels in all tumor types but, with the exception of the ZR75
mammary carcinoma (Figs. 6AYD), only small numbers of
these cells were incorporated into the tumors. In contrast, desmin-
positive pericytes covered by basement membrane remained
attached to the vessels and became incorporated (Figs. 6B, D).
The intratumoral vessels showed remarkable changes. For ex-
ample, their pericytes started to express smooth muscle actin
(SMA) (Figs. 6E, F), but collagen IYcontaining extracellular
matrix material around the intratumoral vessel was not depos-
ited in any of the tumors (data not shown). In the C38 colon
carcinoma tumors, even vessels just touching the periphery of
the tumor were covered with SMA-positive pericytes. Human
tumor cells were attached to the basement membrane of the
vessels and deposited their own basement membrane on the
surface of the vascular basement membrane (Fig. 7A). This
newly synthesized basement membrane contained laminin 5;
the tumor cells attached it using the >3-integrin (Figs. 7B, C).
The consequence of this attachment process was most intri-
guing in the mammary carcinoma cell line. Scattered, round
tumor cells in the parenchyma eventually became invasive,
detached the astrocytes from the basal surface of the capil-
laries, and came into contact with the basement membrane.
This close proximity apparently induced these tumor cells to
differentiate, that is, they became polarized with claudin 3 and
EMA expression at their apical and >3-integrin at their basal
surface (Figs. 7DYH).
As a control, we also analyzed the effects on vessel
density, size, vascular cell proliferation, and extracellular ma-
trix deposition from day 1 to day 21 after needle wounding
FIGURE 2. Overview of brain metastases of tumors of different origin. Similar micrographs were used to determine the morpho-
metric parameters of the peritumoral and intratumoral vessels. Note the normal appearance and distribution of the peritumoral
vessels. (A) C38 colon carcinoma 7 days after inoculation. The section is stained for CD31 (green) and laminin (red). The tumor
(upper part of the micrograph) contains dilated vessels. (B) HT25 colon carcinoma 28 days after tumor inoculation. The section is
stained for pan-cytokeratin (green), smooth muscle actin (SMA; red), and laminin (blue). Anti-human pan-cytokeratin highlights
the smooth surface of the tumor, which is characteristic feature of the pushing type of tumor growth. The intratumoral vessels are
moderately dilated and are frequently stained positively for SMA. (C) H1650 lung carcinoma 28 days after tumor inoculation. The
section is stained for >3-integrin (green) and laminin (red). The anti-human integrin staining highlights the tumor. The border of
the tumor shows invading tumor cell groups that remain cohesive and are in contact with the main body of the tumor. The vessel
density is lower within the tumor than in the surrounding parenchyma but the vessels are not noticeably dilated. (D) ZR75
mammary carcinoma 21 days after tumor inoculation. The section is stained for pan-cytokeratin (green) and laminin (red). Anti-
human pan-cytokeratin staining highlights the tumor. Note the compact structure of the tumor in the center and the scattered
single tumor cells in the parenchyma at the periphery of the tumor. Vessels inside the tumor are not markedly dilated. (E) HT1080
ﬁbrosarcoma 8 days after tumor inoculation. The section is stained for CD31 (green) and laminin (red). Laminin synthesized by the
tumor cells highlights the tumor. As in the case of HT25 colon carcinoma, the smooth tumor-parenchyma interface indicates a
pushing-like growth pattern. Note the numerous branching of the vessels within the tumor. (F) High-power micrograph of the
periphery of the C38 colon carcinoma stained for CD31 (green) and laminin (red). Laminin is localized at the tumor (upper right
part of the picture)Yparenchyma interface. The tumor ‘‘ﬂows’’ around the vessels (arrows), thereby incorporating them into the
tumor. Arrowhead indicates an incorporated vessel. Scale bars = 200 Km (AYE); 50 Km (F).
FIGURE 3. (A) Structure of intratumoral vessels of the HT1080 ﬁbrosarcoma. The section is stained for laminin. Horizontal view of
32 optical sections. Numerous loops (intraluminal pillars) (asterisks) were formed during the intussusceptive angiogenesis-like
process. (B) Vessel loop within the HT1080 tumor. The section is stained for laminin and by propidium iodide to highlight the cell
nuclei. Numerous tumor nuclei are visible in the intraluminal pillar. The black hole labeled ‘‘X’’ is not a pillar; it represents the lumen
of a vessel originating from this area. Scale bar = 25 Km (A, B).
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FIGURE 4. (A) Analysis of vascular endothelial growth factor (VEGF), platelet-derived growth factor-A (PDGF-A), and angiopoeitin-1
(Ang-1) expression in cultured tumor cell lines by quantitative RT-PCR. (B) Analysis of VEGF, PDGF-A, and Ang-1 expressions in micro-
dissected intratumoral samples by quantitative RT-PCR. (C) Analysis of VEGF expression in cultured tumor cell lines by Western blot.
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(Figs. 8A, B). We did not detect an increase in vessel density
inside or around the wound at any time point. In contrast,
vessel numbers were signiﬁcantly lower up to day 9, and the
vessel diameters did not change. Proliferating vascular cells
were detected between days 2 and 5, with a peak at day 3, but
the LI remained negligibly low (Fig. 8B). No deposition of
collagenous extracellular matrix material within or around the
wound could be detected up to day 21 after wounding.
DISCUSSION
It is widely believed that under pathologic conditions
angiogenesis (sprouting) occurs in the brain. Increased vessel
density compared with the normal brain was observed in
brain tumors or metastases and after medial cerebral artery
occlusion or needle wounding (1, 15Y20). In contrast, others
have reported decreased vascular density within metastases
(21, 22) and that tumors in the brain can grow by vessel co-
option without inducing sprouting angiogenesis (11, 12).
These authors found that antiangiogenic therapy for exper-
imental brain metastases can trigger alternative vascularization
mechanisms (e.g. vessel co-option) and thus might promote
increased metastatic potential (11, 12). Similarly, proinvasive
effects of antiangiogenic drugs have been observed in a num-
ber of preclinical glioblastoma studies (23Y25). Thus, primary
and metastatic brain tumors targeted with angiogenesis inhib-
itors may evade their incapability to stimulate new vessel
growth by becoming more invasive and/or switching to ves-
sel co-option. Although magnetic resonance imaging (26, 27)
and autopsy tissue (28) ﬁndings in glioblastoma patients have
also suggested increased invasion as a mode of escape from
antiangiogenic therapy, there are only limited clinical data to
support the existence of such an adaptive mechanism in sec-
ondary brain tumors. However, antiangiogenic drugs have not
been systematically investigated in cerebral metastases, mainly
owing to concerns about the potential bleeding adverse ef-
fects. Nevertheless, human trials have been launched to study
the clinical effects of these drugs in metastatic brain tumors (29).
On the basis of the results of the present study, we
conclude that in the experimental system used no sprouting
and intussusceptive angiogenesis takes place in the brain pa-
renchyma during tumor growth; this was also observed af-
ter needle wounding. The tumors acquired their vasculature
merely by incorporation of preexisting host vessels. Sprouting
and intussusceptive angiogenesis are always accompanied by
an increase in vessel density compared with the normal tissue
(5, 6), but we did not observe this in the peritumoral brain
parenchyma in which there was only a very low level of vas-
cular cell proliferation that corresponded with a lack of cap-
illary sprouting. The drop in vessel density within the tumor
compared with the peritumoral tissue supports earlier obser-
vations that tumors grow into the peritumoral vessel network
and thereby dilute it (30, 31). We previously made a similar
observation in cases of human and experimental primary
melanomas in which robust sprouting angiogenesis was ob-
served in the peritumoral connective tissue but which ceased
completely as the vessels became incorporated into the tumor
tissue that lacked connective tissue (31).
The lack of sprouting and intussusceptive angiogene-
sis is most probably due to the absence of connective tissue
matrix in the brain parenchyma and within the tumors them-
selves. Collagen III was detected in a series of autopsy cases
in brain metastases of differentiated human tumors (32),
whereas in the present experimental paradigm, there was a
lack of connective tissue. This discrepancy may be due to the
FIGURE 5. Comparison of vascular endothelial growth factor
receptor-2 (VEGFR-2) (A), platelet-derived growth factor-A
(PDGF-A) (B), and Tie-2 (C) expression in microdissected peri-
tumoral brain (a 200-Km-wide band of brain tissue immediately
adjacent to the surface of the metastatic nodule; gray columns)
to those of microdissected intratumoral samples (black columns).
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FIGURE 6. (A) ZR75 tumor cells are attached to a brain capillary (C) but the capillary is not yet completely covered by tumor cells.
The tumor cells are also tightly adhered to each other. Astrocyte foot processes still cover a small area (arrow). In contrast, in
the brain parenchyma, single tumor cells (T ) are dispersed. One of these tumor cells is in mitosis (M). (B) Higher magniﬁcation
of the capillary shown in A in a different sectioning plane. The tumor cell (T ) is adhered directly to the basement membrane of
the capillary (C), similarly to the remaining astrocytes (A). The pericyte (arrow) keeps its original position between its own (small
arrowhead) and the capillary (large arrowhead) basement membrane. E indicates endothelial cell; T, tumor cell. (C) Intratumoral
area of the H1650 lung carcinoma. The section is stained for CD31 (green), glial ﬁbrillary acidic protein (GFAP, red), and laminin
(blue). The incorporated vessels are completely covered by basement membrane; GFAP-positive cells are rarely incorporated by the
tumor. (D) Section of a HT1080 brain metastasis stained for CD31 (green), GFAP (red), and desmin (blue). The incorporated vessels
are positive for the pericyte marker desmin. GFAP-positive cells are present only at the surface of the metastasis. (E, F) Section of a
HT1080 brain metastasis stained for smooth muscle actin (SMA) (green), laminin (red), and TOTO3 (blue). E corresponds to the
merged picture of the red, green, and blue channels. F shows the SMA staining. TOTO3 staining highlights tumor nuclei. In the
brain parenchyma, only arterioles are positive for SMA (arrowheads). In contrast, most of the intratumoral vessels are positive for
SMA; there is particularly strong staining at the periphery of the metastasis. Scale bars = 5 Km (A); 1 Km (B).
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FIGURE 7. (A) Sections of H1650 and HT25 (inset) tumors stained for monoclonal anti-human laminin (red) and polyclonal anti-
laminin (blue); the latter reacts with both human and mouse laminin. The tumors are highlighted by anti-human pan-cytokeratin
(green). Note that human laminin is deposited on the surface of the vascular basement membrane. Inset shows a vessel that is
incorporated partially into the tumor (arrowhead). Human laminin is deposited exactly as far as the tumor extends along the
capillary. (B) ZR75 tumor stained for laminin 5 (red). The tumor is highlighted by anti-human pan-cytokeratin (green). Laminin 5 is
deposited inside the tumor on the basal side (which corresponds to the surface of the incorporated vessels) of the polarized tumor
cell nests. Inset shows that a separate basement membrane (large arrow) of the tumor (T) is deposited in the close vicinity of the
vascular basement membrane (small arrow). E indicates endothelial cell. (C) HT25 tumor stained for >3-integrin (green) and
laminin (red). Nuclei are stained by TOTO3 (blue). Yellow color indicates colocalization of the integrin and laminin at the outer
surface of the vessels (arrows). The integrin is also present at the lateral but not at the apical surface (arrowheads) of the tumor cells.
(D, E) ZR75 mammary carcinoma stained for CD31 (green), claudin3 (red), and pan-cytokeratin (blue). D shows the triple labeled
tissue; E shows the green and the red signal. Claudin is expressed on the apical surface of the tumor cells, which show a differ-
entiated pattern organized around the vessel. (F) ZR75 tumor stained for epithelial membrane antigen (EMA, green) and laminin
(red). EMA is expressed on the apical surface of the tumor cells, which is organized in a differentiated fashion around the basement
membrane of the vessels. (G, H) ZR75 tumor stained for >3-integrin (green) and laminin (red). G shows the double labeling;
H shows the localization of the integrin. Note that the green signal outlines the outer surface of the vessels (arrows). Arrowhead
points at a vessel that is only partially populated by tumor cells. Scale bars = 50 Km (AYC, FYH); 25 Km (D, E); 1 Km (B, inset).
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longer existence of metastases in the human brain that might
allow the tumor to contact sites where collagen-producing
cells are located (e.g. the leptomeninges). Another explan-
ation could be the differentiation of pericytes into collagen-
producing cells by detachment and migration away from the
vessels (33). In the present study, there was no suggestion that
this transdifferentiation occurred; pericytes were consistently
localized near the vessels and were covered by intact base-
ment membrane to which the tumor cells attached. In contrast,
in pushing-type metastases of the C38 tumor in the liver,
collagen IYcontaining connective tissue was always situated
between the vessel and the tumor; extracellular matrixY
producing and SMA-expressing cells appeared very early at
the surface of the growing tumor nodulus and became incor-
porated into the tumor together with the vessels formed by the
fusion of sinusoids (13). Such cells were not observed in the
brain metastases or around needle wounds in the present study.
There was a correlation between the growth pattern and
the vascular structure of the tumors. The 2 epithelial tumors
with pushing growth characteristics (C38 and HT25) incor-
porated fewer vessels that were more dilated compared with
those within the 2 more invasive tumors. Together with the
ﬁnding that the proliferation of vascular cells was increased
within these tumors, this suggests that the newly formed ECs
provide a source for capillary dilatation instead of participat-
ing in new vessel formation.
Vascular cell proliferation rates did not correlate with
VEGF, PDGF-A, or Ang-1 mRNA expression of the tumor
cell lines, either in vitro or in the microdissected tumor sam-
ples. Similarly, there was no obvious association between
in vitro VEGF protein expression of the cell lines and pro-
liferation rates of vascular cells within the metastases. How-
ever, we found an increase in the mRNA levels of their
receptors as we moved from peritumoral brain tissue toward
intratumoral areas, regardless of tumor type in laser-capture
microdissection samples. This might connected either be to an
increase in intratumoral vascular cell proliferation or to the
capillary-stabilizing effects of PDGF-A or Ang-1 (34). Nev-
ertheless, the intratumoral vascular cells themselves could
produce both PDGF-A and Ang-1 (35).
The data suggest that the low level of vessel incorpo-
ration in the 2 epithelial tumors with pushing growth charac-
teristics was compensated for by an increased surface area
of the intratumoral vessels and, vice versa, the high rate of
vessel incorporation made the increase of individual vessel
surface unnecessary in the H1650 and ZR75 tumors. On the
other hand, the HT1080 tumor showed enhanced prolifera-
tion of vascular cells without an increase in vessel diameters.
This might be explained by the observed intussusceptive
angiogenesis-like process within this tumor. A similar process
was observed during in vivo microscopy in human gliomas
(36, 37). Collagen-containing pillars within the vessel lumen
are the hallmarks of intussusceptive angiogenesis and the
‘‘normal’’ mode of this angiogenesis type requires the pres-
ence of collagen bundles or cells that are able to synthesize
collagen (7). Although the mechanism of the formation of
these pillars is debated, the mechanism observed here is dif-
ferent because this process is dependent on the activities of
the tumor cells. Within the growing tumor, forces that can
press the opposite sides of the vessels inward may be gen-
erated, leading to the contact of the luminal surfaces of ECs
to each other. This can be followed by the reorganization of
the inter-EC junctions and, subsequently, the formation of a
pore in the vessel wall, as described by Burri et al (7). The
pore increases in size as it is immediately ﬁlled by invading
tumor cells. This process is another example (along with the
formation of glomeruloid bodies owing to the pulling force
exerted by tumor cells attached to the basal membrane of the
brain capillaries [9]) of how tumor cells can reorganize the
vessel structure of the brain. In this respect, this process
cannot be termed true angiogenesis because it is dependent
on the invasive capacity of the tumor cells.
In the brain parenchyma, the lack of connective tissue
(and of cells which are able to produce it) leaves the tumor
cells with only one extracellular matrix element to attach to,
that is, the vascular basement membrane. This attachment
results in a mechanical insult of the vessel (which can lead to
the development of glomeruloid bodies [9]). In response to this
impulse, pericytes of the incorporated vessels start to express
the contractile cytoskeletal element SMA. According to the
observed SMA expression patterns, this mechanical effect
seems to be the highest at the tumor periphery, including the
FIGURE 8. (A, B)Morphometric parameters of vessels (A) and
proliferation rate of vascular cells (B) after needle wounding.
There was a signiﬁcant difference (p G 0.05) between vessel
density of control brain parenchyma (ctr) and vessel density
around the wounds at days 2, 3, 4, 5, 7, and 9. LI indicates
labeling index.
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vessel incorporation zone. The basement membrane also
promotes the survival, growth of tumor, and differentiation
of tumor cells in the brain (38, 39). Indeed, we observed that
breast cancer cells ‘‘ﬂoating’’ in the brain parenchyma showed
undifferentiated morphology, but on attachment to the vascu-
lar basement membrane, they formed differentiated papillary
structures with claudin 3 and EMA expression at the apical
surface and laminin 5 and >3-integrin expression at the basal
surface.
In summary, the distinct structure and composition of
the brain parenchyma (a lack of connective tissue collagen-
producing cells) apparently prevents sprouting and intussus-
ception so that brain metastases acquire their vasculature
exclusively by vessel incorporation in the mouse brain. This
phenomenon may also be valid for small metastases in the
human brain. Although a small therapeutic window would re-
main open in the case of tumors with high intratumoral vas-
cular cell proliferation activity, conﬁrmatory human results
would prompt the need to rethink the use of antiangiogenic
agents under these conditions.
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Development of the vasculature in ‘‘pushing-type’’ liver metastases
of an experimental colorectal cancer
Sa´ndor Paku1*, La´szlo´ Kopper2 and Pe´ter Nagy2
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A mechanism for stroma formation (development of vasculature
and supportive connective tissue) is suggested in an experimental
‘‘pushing-type’’ colorectal carcinoma liver metastasis model. The
key element is the appearance of smooth muscle actin (SMA)-posi-
tive cells and the sinusoidal lakes at the border of the metastases.
These lakes are the consequence of the disappearance (‘stepping
back’ of hepatocytes from the border zone, resulting in the fusion
of partially capillarized sinusoids. The growing tumor incorpo-
rates SMA-expressing cells and sinusoidal lakes. SMA-positive
cells produce collagenous matrix, whereas the lakes become the
central vessels within the connective tissue columns. Formation of
these columns within the tumor is a consequence of the compres-
sion atrophy of the base of the incorporated liver tissue, leading to
partial separation of the innermost part of the invagination con-
taining functional vessel(s) from the surrounding liver.
' 2005 Wiley-Liss, Inc.
Key words: vasculature; pushing-type liver metastases; colorectal
cancer
Several different mechanisms of angiogenesis exist in primary
tumors and metastases, e.g., capillary sprouting,1 intussusceptive
angiogenesis,2,3 vessel incorporation4 and glomeruloid body for-
mation.5,6 Tumor-induced angiogenesis depends on both tumor
type and site of tumor growth.7 Sprouting-type angiogenesis
occurs in tissues containing large amounts of collagenous matrix
(e.g., skin).4 In contrast, in organs containing a vast number of
microvessels and a low amount of connective tissue (e.g., lungs
and liver, the main targets for metastasis), formation of new capil-
laries is less important. In this ‘‘soil’’, tumors can grow without
neoangiogenesis by simply incorporating the preexisting vascula-
ture.8 The incorporation of new and preexisting host vessels is also
a basic option for tumor vascularization in primary malignant
melanomas.4
Three different growth patterns (replacement, pushing and des-
moplastic) for liver metastasis of colorectal and breast cancers
have been described.9,10 During replacement growth, the architec-
ture of the liver is preserved and the endothelial cells of sinusoids
show low proliferative activity. However, pushing and desmoplas-
tic types of growth disturb the liver architecture. In the pushing
growth pattern, severely compressed liver parenchyma is present
at the surface metastases, whereas a ﬁbrous capsule develops at
the tumor–liver parenchyma interface in the desmoplastic growth
pattern.
Earlier, we described 2 angiogenesis patterns, depending on the
localization of the metastases of the anaplastic 3LL-HH tumor
within the liver.7 During growth of sinusoidal-type metastases,
invading tumor cells advanced between the basement membrane
and the endothelial lining of the sinusoids, evoking proliferation
of endothelial cells. This process resulted in the development of
large tortuous vessels without basement membrane inside the
tumor nodules. Conversely, sprouting-type angiogenesis was
observed in portal-type metastases. The replacement growth pat-
tern corresponds to sinusoidal-type metastases of undifferentiated
tumors, while the desmoplastic one shows similarities to portal-
type metastases.
However, no mechanism of angiogenesis is known for pushing-
type liver metastases.
In the present report, we describe a mechanism for the develop-
ment of vasculature and supportive connective tissue in pushing-
type liver metastases of an experimental colorectal cancer. The
process includes the proliferation of smooth muscle actin (SMA)-
positive hepatic stellate cells on the surface of the tumor spheroid
accompanied by fusion of the sinusoids, forming vascular lakes in
this region. Together with the proliferating and collagen-produc-
ing stellate cells, these vascular lakes are incorporated into the
tumor mass. The entrapped sinusoidal lakes are partially separated
from the liver tissue by the invading tumor mass, resulting in the
development of vessel-containing connective tissue columns,
which traverse the tumor.
Material and methods
Animals and tumor line
The C38 colorectal carcinoma line was maintained by serial s.c.
transplantations in C57Bl/6 mice. (Inbred C57Bl/6 mice from our
institute were used throughout the studies.) Tumor tissue was cut
into small pieces in serum-free RPMI-1640 medium and digested
by collagenase I (Sigma, St. Louis, MO; 7 mg collagenase/10 ml
medium) at 378C for 30 min; the suspension was ﬁltered through
4-fold gauze. After centrifugation and washing, the viability of the
tumor cells was determined by the trypan blue exclusion test.
Liver metastases were produced by injecting 2  105 tumor cells
into the spleen of mice anesthetized by sodium pentobarbital
(Nembutal, 70 mg/kg). Animals were killed 9, 13 or 20 days fol-
lowing tumor cell inoculation.
Electron microscopy
Anesthetized animals (2 at each time point) were perfused via
the left ventricle with PBS for 10 min and with 4% paraformalde-
hyde and 1% glutaraldehyde in PBS (pH 7.2) for 15 min at room
temperature. Livers were removed, cut into 1  2 mm pieces and
immersed in the same ﬁxative for an additional 2 hr. Pieces were
postﬁxed in 1% OsO4 and 0.5% K-ferrocyanide in 0.05 M
Na-cacodylate for 2 hr, dehydrated in a graded series of acetone,
contrasted en bloc with 2% uranylacetate and embedded in Spurr’s
mixture. More than 40 different metastases were analyzed on
semithin sections stained by 0.5% toluidine blue (pH 8.5), of
which 15 were processed for electron microscopic analysis. Areas
of interest were trimmed out by comparing the structures on the
cut surface of the tissue blocks with the semithin sections. Ultra-
thin sections were cut by an RMC MT-7 ultramicrotome, stained
with lead citrate and analyzed using a Philips (Hamburg,
Germany) CM10 electron microscope.
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Immunoﬂuorescence analysis
For immunoﬂuorescence studies, 3, 5 and 4 mice were used at
9, 13 and 20 days after tumor inoculation, respectively.
Livers were removed and frozen in isopentane chilled with
liquid nitrogen. Cryostat sections (15–20 mm) were ﬁxed in metha-
nol (208C) and incubated at room temperature (1 hr) with a mix-
ture of the following primary antibodies: polyclonal antibodies,
antilaminin (dilution 1:100, catalogue Z0097; Dako, Carpinteria,
CA), antiﬁbronectin receptor (dilution 1:100; GIBCO, Grand
Island, NY), antiﬁbronectin (dilution 1:100, catalogue F3648;
Sigma-Aldrich, St. Louis, MO); MAbs, antimouse CD31 (dilution
1:100, catalogue 01951D), anti-a6 integrin (dilution 1:100, cata-
logue 33771A; both from Pharmingen, San Diego, CA), anti-
aSMA (dilution 1:100, catalogue M0851), antidesmin (dilution
1:100, catalogue M0724) and FITC-conjugated anticytokeratin
(dilution 1:100, catalogue F0859; all from Dako).
After washing, appropriate secondary antibodies conjugated
with FITC, TRITC or CY5 were used (all from Jackson Immunor-
esearch, West Grove, PA).
Bromodeoxyuridine (BrdU) labeling of proliferating cells
was performed as follows. One hour before mice were killed,
200 mg/kg BrdU in saline were injected i.p. Cryostat sections
ﬁxed in methanol were reacted with 2 N HCl (15 min, 208C),
anti-BrdU antibody (dilution 1:100, catalogue 347580; Becton
Dickinson, Mountain View, CA) and ﬂuorescent secondary anti-
body. Apoptotic cells were detected using the TACS in situ ﬂuo-
rescent apoptosis detection kit (R&D Systems, Abingdon, UK).
FITC-labeled Lycopersicon esculentum lectin (100 mg in 0.1 ml
of 0.9% NaCl, catalogue FL1171; Vector, Burlingame, CA) was
injected into the lateral tail vein 15 min before killing, for supravi-
tal staining of the vasculature of the liver and metastases.
Specimens were analyzed by confocal laser-scanning micro-
scopy using the MRC-1024 system (Bio-Rad, Richmond, CA).
Morphometry
For quantitative analysis 6, 8 and 8 mice were used at 9, 13 and
20 days after tumor inoculation, respectively. To ensure that sepa-
rate metastases were studied, mice were injected with different
numbers of tumor cells (9 days, 2  105; 13 days, 5  104;
20 days, 2  104). Cross sectional areas of metastases were deter-
mined on toluidine blue–stained cryosections using Olympus-
Vanox Cue2 image analysis software (2 objective lens; Olym-
pus, Tokyo, Japan). Cross sections which contained no central
necrotic areas, representing tips of metastases, were excluded from
the study. Vascularization of the metastases was analyzed on par-
allel cryosections stained for CD31 and laminin (4 objective
lens). Metastases were considered vascularized when within them
invaginations >100 mm containing CD31 staining, lined by lami-
nin staining and surrounded by viable tumor cells were observed.
Invagination lengths or, in the case of columns, the length of the
columns’ large axis were determined using Bio-Rad LaserSharp
software. Data were analyzed using Student’s t-test.
Results
Day 9 after inoculation of tumor cells
Most of the metastases were avascular (Table I), showing cen-
tral necrosis. However, all metastases >600 mm in diameter were
vascularized. Nonvascularized metastases were circular in cross
section and composed of polarized tumor cells residing on an
incomplete basement membrane according to electron micro-
scopy. Immunohistochemistry, however, showed almost continu-
ous laminin staining around tumor spheroids (Fig. 1a). CD31 and
a6 integrin were expressed on the hepatic sinusoids in the vicinity
of the metastases (Fig. 1a,b). Laminin immunostaining was strong
around these sinusoids. SMA-expressing stellate cells accumu-
lated at the surface of metastases and around the sinusoids facing
the tumor (Fig. 1c).
Day 13 after inoculation of tumor cells
Four days later, CD31 was expressed throughout the liver on
the endothelial cells. On the contrary, a6 integrin expression
TABLE I – MORPHOMETRIC ANALYSIS OF VASCULARIZATION OF C38 COLON CARCINOMA METASTASES
Days after tumor inoculation
9 13 20
Number of metastases analyzed 181 112 81
% avascular metastases 80.1 2.7 0
Total area of metastases
analyzed (mm2)
27.1 116.1 554.1
Mean 6 SD of radius of cross
sections of metastases (mm)
206 6 71 5446 186 1,313 6 687
Range (mm) 90–478 187–1,230 444–3,395
Total length of
invaginations (mm)
13,933 142,662 595,868
Mean 6 SD of length of
invaginations/unit area
of metastases (mm/mm2)
452 6 284 1,1706 210* 1,161 6 417
We used 6, 8 and 8 mice at 9, 13 and 20 days after tumor inoculation, respectively. *p < 0.05 (vs.
9th day).
FIGURE 1 – (a) Border zone of a tumor spheroid (T) 9 days after
tumor inoculation. The tumor is covered by almost continuous laminin
staining (red). Sinusoids of the liver (L) close to the tumor express
CD31 (green). Sinusoids close to the basement membrane of the tumor
are yellow. (b,c) Border zone of a tumor spheroid (T). Triple labeling
for a6 integrin, laminin and SMA. For clarity, the localization of a6
integrin is shown in (b). (b) a6 integrin is present at the periphery of
the tumor and on sinusoids facing the tumor (arrowheads). (c) SMA-
positive cells (red) are accumulated mainly between the sinusoid and
the tumor. The sinusoid (positive for a6 integrin) shows strong laminin
staining (blue, arrowheads). (d) Localization of ﬂuorescent Lycopersi-
con esculentum lectin at the periphery of a metastasis. Note the
reduced staining of sinusoids in the vicinity of the tumor (arrowheads).
Tumor cells at the periphery of the metastasis are extensively labeled
by BrdU (red nuclei). N, Necrotic area. (e) Electron micrograph of a
sinusoid in the vicinity of the tumor 13 days following tumor inocula-
tion. Connective tissue separates the large sinusoid from the tumor
(upper left corner). On the other side of the sinusoid, hepatocytes are
visible (lower right corner). Bundles of collagen covered by endothe-
lial cells are localized within the sinusoid (arrows). (f) Detail of (e).
The endothelial cell (E) has no fenestration and structured basement
membrane. Collagen bundles are visible beneath the endothelial cell
(arrows). Pericytes are not present around the vessel. Connective tis-
sue cells with dilated endoplasmic reticulum (arrowheads) are located
far from the vessel. (g) Detail of (e). Collagen bundle covered by
endothelial cells. Arrow points at an intercellular junction between
endothelial cells. Scale bars: (a,d) ¼ 20 mm, (b,c) ¼ 50 mm, (e) ¼ 5
mm, (f) ¼ 1 mm, (g) ¼ 0.5 mm.
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remained localized to the sinusoids facing the tumor. These sinus-
oids were strongly compressed but still perfused at low level, as
shown by L. esculentum lectin staining and BrdU incorporation of
tumor cells at the periphery of the metastasis (Fig. 1d). Incomplete
capillarization of sinusoids was noticeable ultrastructurally
(Fig. 1e,f). The number of fenestrations was reduced, and struc-
FIGURE 1
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tured basement membrane could not be observed. Proliferating
SMA-positive cells (with dilated endoplasmic reticulum) accumu-
lated at the tumor side of the sinusoids, while hepatocytes disap-
peared from this region (Fig. 1e). On the contrary, neither necrotic
nor apoptotic hepatocytes could be observed. Other vessels facing
the tumor were completely surrounded by SMA-positive cells.
These cells, however, did not show the characteristic localization
of pericytes; they were neither apposed to endothelial cells nor
surrounded by basement membrane. A large amount of collagen
was deposited around them (Fig. 1f). The fusion of capillarized
sinusoids led to the appearance of large sinusoidal lakes on the
tumor surface (Figs. 1e,2). The fusion was evidenced by the pres-
ence of collagen bundles within sinusoids, which were part of the
supportive structure of the liver tissue and remained after the dis-
appearance of hepatocytes (Fig. 1e,g). Endothelial cell processes
frequently formed bridges within the sinusoids, representing the
last step of fusion (Fig. 2).
By this time, numerous deep invaginations could be observed
within the metastases (Table I, Fig. 3a), which were produced
when the new tumor masses bulged from the tumor spheroid into
the liver parenchyma. Bulges were often free of basement mem-
brane and SMA-positive cell coverage (Fig. 3a). Incorporated
liver tissue plates had a unique appearance when the sectioning
plane was perpendicular to the surface. SMA-positive cells were
found at the tip and the 2 sides; hepatocytes accumulated in the
middle of invaginations (Fig. 3a–c). Almost continuous CD31
staining (representing incorporated sinusoidal lakes) was observed
between hepatocytes and SMA-positive cells or embedded into
the latter cells (Fig. 3b,c). The sinusoidal structure was still nor-
mal at the base of invaginations (Fig. 3b).
FIGURE 2 – Serial semithin sec-
tions of C38 colorectal carcinoma
metastases 13 days following tumor
inoculation. Sections were cut at
2 mm distances. (a–l) First steps of
sinusoidal lake formation. (b–e) and
(j–l) Small cytoplasmic processes of
endothelial cells (small arrows) and
a hepatocyte (arrowheads) connect
the 2 sides of the lake. (c) Hepato-
cytes extend only halfway between
the sinusoids, where they face con-
nective tissue cells (large arrow).
(m–o) Serial tangential sections of
the tip of another metastasis are
visible. (m) Dilated sinusoids are in
contact with the metastasis. These
sinusoids are in continuity with each
other, as shown in (o), forming a
large vascular lake on the surface of
the metastasis. Scale bar¼ 25 mm.
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Day 20 after inoculation of tumor cells
By day 20, beside the deep invaginations another characteristic
structure could frequently be observed within the tumor tissue.
These structures had a circular shape in cross section composed of
an outer basement membrane and usually one central CD31-posi-
tive vessel (Fig. 4a–c). Occasionally, small columns without ves-
sels were also present (Fig. 4a,b). The central vessel consisted of a
single layer of endothelial cells (Fig. 4e), expressing a6 integrin
and surrounded by laminin-positive material (Fig. 4a,b). These
vessels showed partial capillarization similar to the peritumoral
sinusoidal lakes (low number of fenestrations, lack of regular
basement membrane and pericytes; Fig. 4e,f). The space between
the vessel and the outer basement membrane was ﬁlled by SMA-
positive cells (Fig. 4c), type I collagen (Fig. 4e,f) and ﬁbronectin
(not shown). SMA-positive cells strongly expressed ﬁbronectin
receptor, whereas this integrin was expressed only at a low level on
the central vessels (Fig. 4d). Occasionally, hepatocytes were iden-
tiﬁed between SMA-positive cells, suggesting a sinusoidal origin
of the central vessel (Fig. 5a). Proliferation of SMA-positive and
endothelial cells also continued at this stage (Fig. 5b). Capillary
sprouts with slit-like lumen were present within the large columns
(Fig. 5c,d). Serial sectioning revealed the above structures to be
branching connective tissue columns traversing the metastasis,
with the central vessels being continuous with the sinusoids of the
liver parenchyma (Fig. 6). Proliferating tumor cells were present
around these hardly perfused columns. A considerable proportion
of these columns, however, were not perfused at all, leading to
large necrotic areas in the metastases (Fig. 5e,f). The length of the
invaginations/unit area on day 20 remained unchanged compared
to day 13 (Table I).
Discussion
Here, a model is suggested for the vascularization of ‘‘pushing-
type’’ liver metastases. The key element is the appearance of
SMA-positive cells and sinusoidal lakes at the border of the meta-
stases. Stellate cells support the vessels after being incorporated
into the tumor mass by producing collagenous matrix, whereas the
sinusoidal lakes form vessels located centrally within the connec-
tive tissue columns. These columns represent the main structural
and functional unit, providing blood supply for the inner part of
the growing tumor. The putative process is depicted in Figure 7.
From a mechanical point of view, there are 2 factors that can
contribute to the development of the sinusoidal lakes: the appear-
ance of SMA-positive cells and the pressure of the tumor. These 2
factors may be responsible for the disappearance (‘‘step back’’) of
hepatocytes from the border zone of the tumor and the liver tissue.
Similar to Dingemans et al.,11 we were unable to observe apop-
totic or necrotic hepatocytes in this zone despite the severe distor-
tion of these cells. Therefore, we propose that hepatocytes move
FIGURE 3 – (a) Large invagination in a metastasis 13 days following tumor cell inoculation. In the deepest part of the invagination (arrow), hep-
atocytes stained by anticytokeratin antibody (green) are surrounded by SMA-positive cells (red) and laminin staining (blue). Note the absence of
SMA and laminin staining around the small tumor bulge (T). N, Necrotic area. (b) Basal part of an invagination. Continuous CD31 staining (red),
representing a sinusoidal lake (arrowheads), is visible in contact with SMA-positive cells (blue) at the surface of the lower tumor spheroid (T).
Note the regular sinusoidal structure of the liver in the lower right area. Areas of packed hepatocytes (green) without sinusoids are also present
(arrows). (c) Deeper part of a strongly compressed invagination. Both sides of the invagination are delineated by SMA-positive cells (blue) and
almost continuous CD31 staining (red). Sinusoids are not present between the hepatocytes (green). Scale bars: (a) ¼ 100 mm, (b,c) ¼ 50 mm.
FIGURE 4 – (a,b) Numerous columns are localized within a metasta-
sis 20 days following tumor inoculation. Triple labeling for a6 integ-
rin, laminin and SMA. For clarity, the localization of a6 integrin is
shown in (a). (a) a6 integrin is present at the periphery of the column
and around the central vessel. (b) Laminin (blue) colocalizes with a6
integrin within the columns. Note the presence of small-diameter col-
umns lacking central vessel (arrows), composed of SMA-positive cells
(red) surrounded by laminin. (c) Cross section of a column tightly
packed with SMA-positive cells (red). The column contains CD31-
positive vessels (green) and is surrounded by basement membrane of
the tumor (blue). This picture corresponds to panel 14 in Figure 6.
(d) Distribution of the ﬁbronectin receptor within a column. The basal
surface of the tumor cells (arrowheads) and the connective cells of the
column are strongly stained. In contrast, the central vessel (V) shows
weak staining. (e) Longitudinal section of a column within the tumor.
Tumor cells are visible on the upper and lower parts of the ﬁgure.
Connective tissue cells are oriented parallel to the axis of the column.
Very thin endothelial cells delineate the central vessel. Pericytes are
not present. (f) High-power micrograph of an endothelial cell of a cen-
tral vessel showing fenestrations (arrows). The endothelial cell is par-
tially covered by structured basement membrane (arrowheads). Scale
bars: (a,b) ¼ 50 mm, (c) ¼ 10 mm, (d) ¼ 25 mm, (e) ¼ 10 mm, (f) 1 mm.
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out of this zone, leaving space for the formation of sinusoidal
lakes. In an excellent study, Kuruppu et al.12 demonstrated the
presence of sinusoidal lakes at the periphery of experimental col-
orectal carcinoma liver metastases by SEM analysis of corrosion
casts; the signiﬁcance of these structures in the vascularization of
the metastases was, however, not addressed. Fusion of the sinus-
oids can be considered as a reverse intussusceptive angiogenesis.2
a6 integrin is present exclusively in large portal vessels and
capillaries around the bile ducts in normal liver. In hepatocellular
carcinomas and cirrhosis, this integrin is expressed in sinusoids as
a part of the capillarization process.13,14 In our case, however,
expression of this integrin was conﬁned to the sinusoids facing the
tumor. These sinusoids were always surrounded by stellate cells.
Yet, the capillarization process was not complete since the SMA-
positive cells were not positioned as real pericytes (they had no
basement membrane). The fragile structure of these vessels was
maintained during vascularization of the metastases. The presence
of a6 integrin in tumor vessels may negatively inﬂuence the efﬁ-
ciency of antiangiogenic treatments, based on the observation that
av and a5 integrins are upregulated during angiogenesis in endo-
thelial cells.15,16 The main cellular elements of the connective tis-
sue columns, the SMA-expressing cells, express a high level of
ﬁbronectin receptor. They could, therefore provide an alternative
target for therapy with this receptor’s antagonist.
It has been shown that the growth pattern of liver metastases is
dependent on the degree of differentiation.10 The replacement
growth pattern was characteristic for tumors showing less glandular
differentiation, whereas differentiated tumors grew by compressing
the liver parenchyma (pushing growth pattern) or eliciting a ﬁbrotic
response (desmoplastic growth pattern) at the border of the meta-
stases. The presence of a ﬁbrous capsule containing myoﬁbroblasts
and collagen I around primary and secondary liver tumors is
common. According to various studies, 20–60% of colorectal
carcinoma liver metastases are encapsulated, which is considered
to be a mechanical barrier against tumor invasion and is associated
with better prognosis.9,10,17,18 Different factors can be responsible
FIGURE 5 – (a) Longitudinal section of a well-developed column
containing a central vessel (red) and distorted hepatocytes (green) sur-
rounded by SMA-positive cells (blue). (b) Twenty-day-old tumor
stained for CD31 (red) and BrdU (green). Numerous proliferating
endothelial (arrowheads) and connective tissue cells (arrows) are
present within the column. Proliferating tumor cells are visible around
the column. (c) Large column containing SMA-positive cells (blue),
CD31-positive (red), dilated vessels and capillary sprouts (arrow-
heads). (d) Cross section of capillary sprout located in the vicinity of a
central mother vessel. The sprout has a slit-like lumen (arrowheads),
which is sealed by intercellular junctions (arrows). Note the process of
the endothelial cell (large arrow), which extends into the connective
tissue, suggesting active growth of the sprout. E, Endothelial cells of
the mother vessel. (e,f) Section of a 20-day-old liver metastasis of a
mouse injected with FITC-conjugated Lycopersicon esculentum lectin
(green) and stained for CD31 (red) and SMA (blue). For clarity, the
localization of the lectin is shown in (e). Arrows point at well-perfused
vessels within the columns; however, a considerable portion of the
columns are not or are only partially perfused (arrowheads in f and
lack of green color at these areas in e). Black areas in (f) represent via-
ble tumor tissue, whereas pink areas represent necrotic tumor tissue
(N). Scale bars: (a–c) ¼ 50 mm, (d) ¼ 1 mm, (e,f) ¼ 100 mm.
FIGURE 6 – Serial section of a
20-day-old liver metastasis stained
for laminin. Sections were cut at 20
mm distances. In panels 1–4, 24
and 25, normal liver tissue is also
present (arrowheads), whereas the
other pictures show incorporated
tissue. Note the column (arrows),
which is separated from the liver
tissue in panel 4 and shows con-
tinuity with the invagination again
in panel 17. Scale bar ¼ 300 mm.
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for the capsule formation, such as transforming growth factor-b,
hypoxia and simple mechanical pressure.19,20 There is evidence
that the main cellular components of these capsules are activated
SMA-expressing hepatic stellate cells.19 The mechanical pressure
exerted by differentiated carcinomas (pushing growth pattern) can
be a major factor for the activation and accumulation of hepatic
stellate cells around metastases.20 An important role of these con-
tractile cells can be to decrease the size of the ‘‘wound’’ in the liver
caused by the growing tumor. Hepatic stellate cells were not accu-
mulated on the surface of the metastases in sinusoidal metastases
(replacement growth pattern) of the B16 melanoma; instead, they
were scattered in the tumor nodules. They are thought to create a
proangiogenic microenvironment and to be responsible for the
recruitment and survival of endothelial cells. Similarly, Vermeulen
et al.9 reported the absence of a ﬁbrotic response in colorectal
metastases with the replacement growth pattern. These data and
our earlier observations made on the sinusoidal type of 3LL-HH
tumor metastases7 suggest that undifferentiated highly invasive
tumors do not induce a ﬁbrotic capsule.
The growth of a tumor as an avascular sphere in the liver is lim-
ited because the development of central necrosis weakens the
mechanical stability of the metastases, though the sinusoids at the
periphery would support further growth. In C38 colon carcinoma,
further expansion of the metastases takes place by the bulging of
new tumor masses from the original spheroid into the liver. This
process immediately leads to the development of invaginations,
which consequently results in early vascularization of the metasta-
ses (all metastases >600 mm in diameter are vascularized). During
the growth of the bulge(s), the pressure will increase at the base of
the incorporated liver tissue. However, the innermost part of the
invagination (base of the bulge) is a distinctive place since the
pressure of the tumor is lower here. A similar situation is when a
sheet of paper is folded and the ends are pressed together. As men-
tioned above, the sinusoids at the surface of the tumor are strongly
compressed. (The architecture of these sinusoids could be revealed
only by applying a slightly higher perfusion rate during ﬁxation.)
Following incorporation, these fused sinusoids can land at the
innermost part of the invagination, where these vessels can open
up owing to the lower pressure and start to deliver blood into the
tumor. The appearance of connective tissue columns within the
liver metastases appears to be a unique feature of the C38 tumor.
These structures are produced by the increasing pressure of the
tumor at the base of the invagination, resulting in separation of the
innermost part of the invaginated tissue from the rest of the liver.
This separation is completed by the disappearance of the back-to-
back basement membranes of the tumorous glands, which is a fre-
quent observation in colorectal cancers.21 In the axial direction,
however, the column will remain in continuity with the liver
parenchyma (Fig. 7). This ﬁnding strongly suggests that these
metastases are supplied wtith blood originating from the hepatic
sinusoids. As proliferating endothelial and SMA-positive cells are
regular observations within the columns, these structures probably
grow in length and width during tumor development. The tumor
continues to bulge not only into the liver parenchyma but also into
the columns within the tumor, pinching off further pieces from the
column. The vessels of these new columns are in all probability
produced by sprouting-type angiogenesis, observed within these
structures. However, the pinching process can also lead to the
appearance of small columns without vessels. Proliferation of
endothelial and SMA-positive cells as well as the pinching process
should result in an increase in length of the invaginations/unit area
of the metastases. Nonetheless, this parameter remained
unchanged. There are 2 mechanisms to explain this contradiction.
On the one hand, the growing tumor lowers the density of the
invaginations or columns (by dilution). On the other hand, the
pressure of the tumor, as observed frequently, obstructs the perfu-
sion of the columns, leading to necrosis not only of the tumor cells
but also of the columns.
It is conceivable that in well-differentiated tumors the back-to-
back fusion of the tumor glands does not take place, leaving the
invaginations intact, which leads to the absence of column forma-
tion. Nevertheless, also in these tumors, the vessels in the inner-
most part of the invaginations are most probably responsible for
the nutrition of the tumor.
Desmoplastic metastases, far from portal tracts, can also be con-
sidered as pushing-type metastases. The extent of connective tissue
accumulation can depend on the growth rate of the metastases. On
the surface of slow-growing metastases, more connective tissue
can accumulate due to the low incorporation rate. If the sinusoids
are embedded in connective tissue for a longer time at the surface
of the metastases, sprouting-type angiogenesis can take place.
Together with these newly developed vessels, the connective tissue
is incorporated, similarly to primary tumors. It has been shown that
metastases with the pushing growth pattern have a higher endothe-
lial cell proliferation rate than desmoplastic ones, which is in
accordance with the supposed slow growth of these metastases.9
The process for the development of vasculature in liver metasta-
ses of the C38 tumor presented here may represent a general
mechanism for the vascularization of pushing-type liver metasta-
FIGURE 7 – Schematic representation of column formation. For better visibility of vessels, hepatocytes are depicted only on the upper part of the
drawings. (a) At the early stage of tumor development, the tumor faces normal liver architecture. (b) SMA-positive cells accumulating at the
tumor–liver parenchyma interface. Owing to the compression of the tumor, hepatocytes ‘‘step back’’ and fusion of the sinusoids takes place.
(c) The fused vessel, together with SMA-positive cells, is incorporated into the tumor. (d) The pressure of the tumor bulges causes separation of the
central vessel from the liver parenchyma. The vessel in the direction of the axis of the column remains connected to the sinusoidal system of the
liver. Column formation is ﬁnished by back-to-back fusion of the basement membranes of the tumor bulges. Column is surrounded by viable tumor
cells. Light gray, tumor; dark gray, hepatocytes; black, sinusoids and central vessel; white, SMA-positive cells and cut surface of endothelial cells.
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ses of differentiated tumors of various origins (colon, breast, lung
carcinomas).
Our present study further supports earlier observations that vas-
cularization of metastases in the liver is a heterogeneous process,
depending on the degree of tumor differentiation or localization of
the metastases within the liver.7,9,10 This notion should be taken
into consideration when new antiangiogenic therapies against liver
metastases are designed.
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Development of Arterial Blood Supply in
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In this study, we present a mechanism for the devel-
opment of arterial blood supply in experimental liver
metastases. To analyze the arterialization process of
experimental liver metastases, we elucidated a few
key questions regarding the blood supply of hepatic
lobules in mice. The microvasculature of the mouse
liver is characterized by numerous arterioportal anas-
tomoses and arterial terminations at the base of the
lobules. These terminations supply one hepatic mi-
crocirculatory subunit per lobule, which we call an
arterial hepatic microcirculatory subunit (aHMS). The
process of arterialization can be divided into the fol-
lowing steps: 1) distortion of the aHMS by metastasis;
2) initial fusion of the sinusoids of the aHMS at the
tumor parenchyma interface; 3) fusion of the sinu-
soids located at the base of the aHMSs, which leads
to the disruption of the vascular sphincter (burst
pipe); 4) incorporation of the dilated artery and the
fused sinusoids into the tumor; and 5) further de-
velopment of the tumor vasculature (arterial tree)
by proliferation, remodeling, and continuous incor-
poration of fused sinusoids at the tumor–parenchyma
interface. This process leads to the inevitable arteri-
alization of liver metastases above the 2000- to
2500-m size, regardless of the origin and growth
pattern of the tumor. (Am J Pathol 2009, 175:835–843;
DOI: 10.2353/ajpath.2009.090095)
It is widely accepted that hepatic metastases and tumors
are predominantly supplied by arterial blood, a notion
that serves as the basis for hepatic arterial chemotherapy
and chemoembolization.1–7 The most cited article on this
field dates back to the 1950s.1 Since then numerous
papers have been published using human and experi-
mental materials and different methods such as corrosion
casting, confocal and electron microscopy, angiography,
radiolabeled microspheres, and in vivo microscopy, have
been used to study the blood supply of liver metasta-
ses.2–16 A large proportion of these articles have con-
firmed the original observation of Breedis and Young,1
but no mechanism for the development of the arterial
blood supply in metastases has ever been presented.2–7
On the other hand, numerous papers, including ours,
have emphasized the contribution of the portal vein, ei-
ther directly or through the sinusoids in the blood supply
of hepatic metastases.8–14 This apparent contradiction
might result from the observed continuity of the sinusoidal
with the tumor vasculature and the presumption that
blood flows in an “outside-in” direction from the sinusoids
toward the tumor vasculature. Most of the studies dealing
with the blood supply of metastases have neglected the
importance of arterioportal anastomoses and other inter-
species differences in the hepatic microcirculation, which
could lead to seriously biased results. According to the
observations of Yamamoto et al15 there are extensive
arterioportal anastomoses throughout the vascular tree in
rats, whereas a separate arterial and portal tree, without
direct arterioportal communication, can be observed in
hamster and human liver. Opinions about the presence of
arterioportal anastomoses in mice are controversial10,16;
therefore, we have addressed this question first.
The classic lobule can be divided into several conical
hepatic microcirculatory subunits (HMSs) supplied by a
single inlet portal venule. Hepatic arterioles terminate
either on the inlet venules or directly on sinusoids. The
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number of these terminations within a lobule is species-
dependent. The blood flow through the inlet venules and
terminal arterioles is regulated by sphincters.17 The most
detailed studies on microcirculation of the liver and ves-
sel architecture of liver metastases were performed by
corrosion casting. However, in these studies the livers
were completely filled with uncolored resin, which made
analyzing the three-dimensional organization of the deep
interlobular vessels difficult.10,14,15
In the present study, we used a two color corrosion
casting technique to analyze the blood supply in liver
metastases of experimental tumors in mice. A special
filling method was used to prevent the mixing of the
“portal and arterial resin” upstream of the hepatic sinu-
soids. This technique enabled us to analyze separately
the contribution of the two vascular systems to the blood
supply of liver metastases and to establish the steps of
the arterialization process.
Materials and Methods
Animals and Tumor Lines
The C38 colorectal carcinoma line was maintained by
serial subcutaneous transplantations in C57Bl/6 mice, as
described earlier.13 Liver metastases were produced by
injecting 2  104 tumor cells into the spleen of C57Bl/6
mice. Vascular casting was performed 15 to 18 days
following tumor cell injection.
The highly metastatic Lewis lung carcinoma (3LL-HH)
tumor line was maintained by serial intrasplenic trans-
plantations of tumor cells obtained from liver metastases.
Single cell suspensions were prepared from 14-day-old
3LL-HH liver metastases, as described earlier.12 103 tu-
mor cells were injected into the spleen of C57Bl/6 mice.
Vascular casting was performed 12 days following tumor
cell injection.
A2058 human melanoma cells were cultured in RPMI-
1640 supplemented with 10% fetal bovine serum (Sigma
Chemical Co., St. Louis, MO). To produce liver metasta-
ses, 2  104 cells were injected into the spleen of anes-
thetized male SCID mice. Vascular casting was per-
formed 28 to 33 days following tumor cell injection.
Vascular Corrosion Casting
A two-color corrosion casting procedure was used to
analyze the arterialization of liver metastases. Mice were
anesthetized and a ligature was placed onto the vena
cava just above the renal veins to prevent retrograde
filling of the liver. The portal vein was cannulated (22G,
Braun Melsungen AG, Melsungen, Germany) and se-
cured with a tie; the chest was opened and the vascular
system was flushed through the left ventricle with PBS
containing heparin. When the effluent was clear, the tho-
racic aorta was cannulated (22G, Braun Melsungen AG,
Melsungen, Germany). To remove air from this cannula a
ligature was placed onto the aorta above the bifurcation
into the iliac arteries. The aortic cannula was filled retro-
grade with PBS through a 30G needle connected to a
syringe inserted into the abdominal aorta below the liga-
ture. After filling, the ligature was tightened. The ligature
on the vena cave was also tightened. Blue casting me-
dium (Mercox 2-CL, Ladd Research, Williston, VT) was
injected through the portal vein. The injection was moni-
tored under a dissecting microscope and stopped when
the resin reached the sinusoids (0.2 ml resin) (Figure
1A and B). The blue resin was allowed to become thick
and 1 ml of red casting medium was injected through the
thoracic aorta. The filling of the portal system with resin
was necessary to prevent the flow of the red resin through
arterioportal anastomoses (described in Results) into the
portal system and subsequently into the sinusoids and
metastases resulting in false observations. However, all
routes were left open where the arterial system was in
direct connection with the sinusoids and metastases.
Altogether 53 animals were used for corrosion casting:
10 control, and 16, 15, and 12 mice bearing C38, 3LL-
HH, and A2058 metastases, respectively.
Determination of the Percentage of Arterial
Metastases and the Size of the Metastases
After the injection of the blue and red resins into the portal
and arterial system, the livers were removed and cut in
lobes; then every lobe was photographed from each side
(Olympus SZ61 dissecting microscope, Olympus 7070 or
DP 50 camera, Olympus Japan). Once the resin was
Figure 1. A: Liver lobes after the casting proce-
dure containing arterial (red) and mixed blood
(white) metastases of the C38 tumor line. The
blue resin fills only the terminal portal venules.
B: The same lobes after corrosion. Arrows point
to the hollow spaces of metastases not having
arterial blood supply. Arrowhead points to a
metastasis of which only the base was filled by
the red resin; therefore its arterial connection
was undetectable on the uncorroded specimen
(arrowhead on A). Scale bar  3 mm.
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cured completely the lobes were placed overnight in 35%
KOH at 60°C. The casts were washed in running tap
water and placed in distilled water. Again, every lobe was
photographed under water from each side. Metastases
on the surface of uncorroded specimens were counted
and their diameters were measured (Quick Photo Micro,
Olympus, Japan). Most of the arterial metastases were
completely filled with red resin, but some were only par-
tially filled. In this case, the resin was not always visible
on the surface of the uncorroded specimens. Therefore,
the determination of the origin of the blood supply was
performed by comparing the uncorroded and corroded
specimens (Figure 1, A and B). On the corroded speci-
mens, metastases filled with any amount of the red resin
through an artery directly connected to the metastasis
were designated as “arterial.” Metastases not having an
arterial blood supply appeared on the corroded specimens
as holes. In some cases the red color turned white either
because the color particles were filtered out or the color was
lost during the corrosion procedure. To determine the size
of the metastases and the origin of the blood supply, 484,
907, and 485 metastases were analyzed from the C38,
3LL-HH, and A2058 tumor lines respectively.
Determination of the Diameter of the Arteries
and the Accompanying Portal Veins
Livers from four control animals were used to determine
normal porto-arterial diameter ratio in 167 randomly cho-
sen branch pairs originating from seven different orders
of the vascular tree of the mouse liver. Altogether 729
arterial metastases were isolated (252, 305, 172; C38,
3LL-HH, A2058), under the dissecting microscope using
fine forceps. Each metastasis was photographed under
water, and if metastases were supplied by one arterial
branch, the diameter of the portal vein and the supplying
artery was determined at the entry into the metastases. The
diameter of the portal and arterial branches were measured
1000 m upstream from the metastasis wherever possi-
ble. The size of the completely filled metastases was easily
determined by measuring the extension of the structure
filled with the red resin. With incompletely filled metastases,
the extension of the hollow space left by the metastases in
the portal tree was measured.
Determination of the Rate of Cell Proliferation in
the Arteries Supplying the Metastases
This procedure was performed only with the C38 tu-
mor, because this tumor line produced a large propor-
tion of metastases with centrally localized (described
below), easily discernible arteries. 5-Bromo-2-de-
oxyuridine (BrdU) labeling and tissue processing, with
the exception of vascular casting were performed as
described above. Large metastases (2 mm, eight
pieces) located at the periphery of the liver were chosen
and cut perpendicular to the flat surface of the lobe. The
upper half of the metastasis was cut away. Subsequently,
serial sections were cut until the artery was discernible on
toluidine blue stained cryosections. Further 6 to 10 serial
sections were cut and double labeling was performed for
BrdU (Becton Dickinson, San Jose, CA) and NG2 proteo-
glycan (Chemicon, Billerica, MA). Nuclei were counter-
stained by 4,6-diamidino-2-phenylindole (Sigma Chemi-
cal Co., St. Louis, MO). BrdU labeled and the total
number of arterial wall cells (endothelial and smooth mus-
cle cells, 2000) was determined, using a 40 or 60
objective (Nikon TE 300 fluorescent microscope).
Determination of the Proliferation Rate of
Tumor Cells in the Arterial and Mixed
Blood Metastases
BrdU labeling of proliferating tumor cells was performed as
follows. One hour before the above described vascular
casting was performed, 200 mg/kg BrdU (Sigma Chemical
Co., St. Louis, MO) was injected intraperitoneally. Following
the casting procedure livers were removed and frozen.
Cryostat sections (10 m) were fixed in methanol (20°C)
treated with 2 N HCl (15 minutes, 20°C), anti-BrdU antibody
(dilution 1:50, Cat. No: 347580, Becton-Dickinson, San
Jose, CA), and fluorescent secondary antibody (Jackson
Immunoresearch Inc., West Grove, PA). Nuclei were coun-
terstained by TOTO3 (Molecular Probes, Carlsbad, CA) or
4,6-diamidino-2-phenylindole. The number of BrdU-labeled
and total number of tumor cells were determined using
micrographs captured by the Bio-Rad MRC-1024 (Bio-Rad,
Richmond, CA) confocal microscope (four animals for each
tumor, three to five metastases from each animal). Counting
was performed using the morphometry system described
above. Blood supply of the metastases was identified ac-
cording to the autofluorescence of the dye in the resin.
Arterial metastases had a strong red florescence (Ex568/
Em580 32). In contrast, themixed bloodmetastases were
dark, or when filled with blue resin, had weak green fluo-
rescence (Ex488/Em522  32).
Scanning Electron Microscopy
Isolated vascular trees and metastases (over 240 spec-
imens) were glued wet on metal stubs. After drying, the
samples were coated with gold by a HBA 1 high-vacuum
metal evaporator (Carl Zeiss, Jena, Germany). Observa-
tions were made using a Hitachi S-2360 N scanning
electron microscope (Hitachi, Tokio, Japan) at 15–25 KV
accelerating voltage.
Results
Microvascular Architecture of the Normal
Mouse Liver
Arterioportal anastomoses were observed throughout the
hepatic vasculature. The arterial blood entered the portal
veins either directly or through the peribiliary plexus (Fig-
ure 2, A and B). Arteries run in the vicinity of the peribiliary
plexus. From the peribiliary plexus blood was also shed
directly into sinusoids whose inlets were regularly spaced
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between terminal portal venules at the base of the lobules
(Figure 2, C–E). Short arterio-sinusoidal twigs were also
observed in this region. Since the blood was shed from
the peribiliary plexus into the closest lobules, asymmetry
could be observed in the distribution of the arterial blood
around larger portal tracts (Figure 2, C and D). Other
lobules, especially those situated on the opposite side
(according to the artery) of the portal tract, were supplied
by arterioles (marginal branches) running around the
large portal tract ending either at the base of the terminal
portal venules forming arterioportal anastomoses or run-
ning up on the portal venules. These latter arterioles
terminated on sinusoids at the base of lobules (Figure 2,
F and G). Similar terminations were observed at the pe-
ripheral areas of the vascular tree. Usually one or two
terminations were detectable per lobule. Since the sinu-
soids were intentionally not filled through the portal sys-
tem, only that part of the lobule was visible, which was
also fed directly by the arterial system. The resin entering
the lobules through the arterioles formed conical struc-
tures that corresponded to the HMSs.17 To distinguish
these HMSs from the others supplied exclusively by por-
tal inlet venules, we called this subunit arterial microcir-
culatory subunit (aHMS). However it should be kept in
mind that this subunit also drained mixed blood. No
aHMSs were observed at the surface of the liver.
The Arterialization Process of Metastases
The Rate of Arterialization
Three different tumor lines that frequently metastasize
into the liver, and exhibit different growth patterns, were
used for the experiments. The highly invasive 3LL-HH tumor
line is characterized by replacement type growth, whereas
the C38 colon carcinoma shows pushing type of growth
and the A2058 human melanoma line has an intermediate
growth pattern.12,13,18 The earliest arterialization of the me-
tastases was observed in the case of the highly invasive
Lewis lung tumor line (Figure 3). Forty percent of the
metastases had well developed arterial blood supply
below the diameter of 800 m. The other two lines, es-
pecially the differentiated colon carcinoma, acquired
their arterial blood supply at a considerably slower rate.
Only half of the metastases of the colon carcinoma were
arterialized at the size of 1500 m. However, the arte-
rialization process accelerated later and almost all C38
metastases had arterial blood supply at the diameter of
Figure 2. Normal mouse liver. A: Direct arterio-
portal anastomosis (arrow) on a large trunk of
the portal tree. A small amount of the red resin is
spread on the previously hardened blue resin.
Scale bar 1 mm. B: Detail of A (arrowhead in
A) viewed under the scanning electron micro-
scope. Anastomosis between the peribiliary
plexus and the portal vessel. Numerous capillar-
ies of the peribiliary plexus (arrowhead) joined
into one vessel that enters the large trunk of the
portal vein (arrow). Scale bar  300 m. C and
D: Detail of a vascular tree of the liver viewed
from opposite directions. The portal vein is filled
with blue resin. Scale bar for C,D  500 m. C:
Shows the side where the artery (arrowhead) is
running. Note the numerous aHMSs (arrows)
spaced regularly between terminal portal
venules (marked by arrows on D) along the
portal vein. Each space between the terminal
portal venules corresponds to one lobulus. D:
No aHMSs are visible on the other side of the
portal vein. E: Light micrograph of a single aHMS
located above the peribiliary plexus and be-
tween terminal portal venules (arrows) at the
base of the lobule. The space between the ter-
minal portal venules determines the extension of
the lobule. The red resin, which fills the sinu-
soids of the aHMS is in connection (arrow-
heads) with blue resin of the terminal portal
venules, showing that the aHMS is part of the
lobule. Scale bar 200 m. F,G: An arterial HMS
at the periphery of the vascular tree of the liver,
SEM images. F: The arteriole (large arrow-
head) runs up on the portal venule and termi-
nates in an aHMS at the base of the lobule
(small arrow). The lobule is defined by the tree
terminal portal venules (small arrowheads).
Note that the red resin (inset) is present in the
central venule (large arrow). The inset shows
light micrograph of the same area. Scale bar 
200 m. G: High power micrograph of the aHMS
shown on Figure 2F. The main branch of the
arteriole terminates in the aHMS (arrow).
Smaller branches form direct anastomoses (ar-
rowheads) with the portal venule. Scale bar 
90 m.
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2000 m, similar to the fast growing Lewis lung carci-
noma. For the slow growing human melanoma, this value
was about 2500 m.
Sequential Events of the Arterialization
Small avascular metastases and metastases supplied
with mixed blood through the sinusoids generally ap-
peared on the corrosion specimens as holes, since the
liver vasculature through the portal system was filled only
to the sinusoids (Figure 1, A and B). However, microme-
tastases which early invaded the area of terminal portal
venules were readily filled through the portal system and
stained blue (Figure 4A and B). The majority of these
metastases were not in contact with aHMSs. The process
of arterialization was deduced mostly by the examination
of the well-organized C38 metastases allowing a clear
view of the intra- and peritumoral vessels. The first step of
the arterialization process was the distortion of the
aHMSs by the metastases (Figure 4C), ie, the spherical
metastasis impressed into the aHMS while the sinusoidal
structure of the aHMS remained intact. This was followed
by initial fusion of the sinusoids of the aHMS owing to the
compression of the tumor (Figure 4, D and E). The pro-
cess of sinusoidal fusion was described earlier in detail
by our group for the C38 tumor line.13 The present cor-
rosion casting studies confirmed these data, and dem-
onstrated sinusoidal fusion at the periphery of the two
other studied tumor types, as well. However, the extent of
the fusion differed among the tumor lines. It was most
pronounced around the differentiated colon tumor fol-
Figure 3. Percentage of arterial metastases in relation to metastasis size.
Figure 4. A: A C38 micrometastasis on the surface
of the liver grows close to a terminal portal venule
(small arrowheads). The vascular lake (arrows)
at the surface of the metastasis is filled with blue
resin (inset) injected through the portal vein. An
arteriole (large arrowhead) is visible close to the
ramification of the portal venule, which later rep-
resents the base of the lobule. The metastasis has
not yet reached this region. Scale bar  500 m;
500 m (inset). B: Detail of A. The arteriole
branched off (arrows) is close the fork of the
terminal portal venule. The resin hardly entered
the aHMS (arrowheads). Scale bar  90 m. C:
Impression of a C 38 metastasis in an aHMS (small
arrowheads). The sinusoids of the aHMS are
nearly normal in structure. Inset shows the same
aHMSs filled with red resin (arrow) at the base of
the metastasis and the supplying arteriole (large
arrowhead). Broken line marks the border of the
metastasis. Small arrowheads point at the termi-
nal portal venules entrapped within the metastasis.
Scale bars: 100 m; 200 m (inset). D: Com-
pressed aHMS at the base (inset) of a C38 metas-
tasis. Initial fusion of the sinusoids of the HMS is
discernible (arrows). Other sinusoids of the aHMS
are normal in structure (small arrows). On the
inset the arrow points to an arteriole supplying
the HMS. Drops of the resin (red dot on the light
micrographmarked by arrowhead) are present in
the central venule (arrowheads). Scale bars: 90
m; 300 m (inset). E: The “nest” of a metastasis
viewed from the top (from the surface of the liver).
The sinusoids of the aHMS at the base of the metas-
tasis are partially fused (arrowheads).Arrowpoints
at a portal vessel within the metastasis projecting
toward the surface of the liver. Scale bar 100 m.
F: Fusion of sinusoids in themetastasis of the 3LL-HH
tumor. Large vascular lakes are not formed at the
surface; instead tortuous vessels appear within the
metastasis (large arrowheads). Note the impres-
sions left by small tissue pillars (arrows) within the
tumor vessels representing the last step of the fusion
(reverse intussusceptive angiogenesis). The low den-
sity tortuous tumor vessels are continuous with the
high density sinusoids of the surrounding liver tissue.
Scale bar  60 m. G: Small A2058 metastasis. The
centrally located non-dilated artery (arrow) ramifies
into delicate intratumoral vessels. Scale bars: 200m;
500 m (inset).
Arterialization of Liver Metastases 839
AJP August 2009, Vol. 175, No. 2
               dc_301_11
lowed by the highly invasive 3LL-HH tumor line (Figure
4F). The sinusoidal fusion was least advanced in the
neighborhood of the metastases of the human melanoma
cell line, which corresponded to the delicate vessel struc-
ture of its metastases (Figure 4G, and supplemental Fig-
ure S1, A and B, at http://ajp.amjpathol.org). Vasculariza-
tion of the metastases was initiated by the incorporation
of these fused sinusoids. Extensive sinusoidal fusion in
the case of the C38 colon carcinoma led to the develop-
ment of vascular lakes on the surface of the metastases
that were directly connected to the arterial system (Figure
5, A and B). When the fusion reached the base of the
aHMS, the arterialization of the metastasis was just com-
plete (Figure 5, C and D). The fused sinusoids, together
with the supplying artery, were incorporated into the tu-
mor (Figure 5E). As the aHMSs were located at the base
of the lobules, the artery entered the majority of the me-
tastases from the hilar region.
Architecture of the Supplying Arteries
A large proportion of the metastases were supplied by
one arterial branch (Table 1). However, there was a ten-
dency, especially in the case of the A2058 tumor line, for
larger tumors to acquire more supplying arterial branches
(supplementary Table S1, supplementary Figure S1C at
http://ajp.amjpathol.org). The arteries supplying the metas-
tases became strongly dilated while the neighboring ar-
terial branches originating from this supplying artery were
generally collapsed (Figure 5F). A high proportion of the
Figure 5. A,B: Formation of a vascular lake from
an aHMS at surface of the metastasis of the C38
tumor line. A: The arrow points to the non-
dilated arteriole feeding the severely distorted
and fused aHMS (arrowheads). A broken line is
drawn along two terminal portal venules that are
pushed aside by the growing tumor mass and
thereby outlines the border of the metastasis.
Scale bar  500 m. B: The area marked by
arrowheads on A is viewed from above by the
scanning electron microscope. Extensive fusion
of the sinusoids leads to vascular lake formation
(arrowheads). The arrow points to the supply-
ing arteriole. Scale bar  200 m. C: Part of an
arterialized C38 micrometastasis. The supplying
arteriole is severely dilated (arrow) and ramify-
ing into vessels, which delineate the surface (ar-
rowheads) of the metastasis. The arteriole has
not yet been incorporated into the metastasis.
Scale bar  100 m. D: Scanning electron mi-
crograph of the same structure shown on (C)
viewed from above. Fused sinusoids (arrows)
and vessels (arrowheads) are organized into
basket-like form. Scale bar  200 m. E: Arteri-
alized C38 micrometastasis. Dilated arteriole (ar-
row) feeds the metastasis. The area where most
of the branches arise (arrowheads) is just in-
corporated into the tumor but the vessels run on
or close to the surface of the metastasis. The
center of the metastasis is avascular. Scale bar 
200 m. F: 3LL-HH metastasis supplied by a
strongly dilated artery (arrow). There is an ex-
treme size difference between the artery running
toward the tumor and the artery accompanying
the neighboring portal vein (arrowhead). Note
that the two portal veins are about the same size.
Scale bar  1 mm.
Table 1. Percent of Metastases Supplied by the Different Number of Arterial Branches
Percent of metastases
supplied directly by
one arterial branch
Percent of metastases
supplied directly by
two arterial branches
Percent of metastases
supplied directly by
three or more arterial
branches
Percent of metastases
supplied through the
peribiliary plexus
Total number of
metastases
analyzed
3LL-HH 68 (n.d.) 16,5 1 14,5 294
C38 82 (50) 9  9 252
A2058 63 (9) 22 6 9 172
( ), percent of metastases with centrally positioned arterial branch. n.d., not determined.
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arterial “trees” was centrally positioned within the metas-
tases of the C38 colon carcinoma, but this phenomenon
was also observed in the metastases of the other tumor
lines (Table 1, Figure 6, A–C, and supplemental Figure
S1D at http://ajp.amjpathol.org).
The structure of the supplying artery inside the tumor,
especially in the case of the C38 colon carcinoma, was
unique. The diameter increased toward the center of the
metastasis. No ramification could be observed along the
trunk; all branches originated from a small area of this
artery, which was approximately located in the center of
the metastasis (Figure 6, A–D). The ratio of the diameters
of the portal vein running parallel to the metastasis sup-
plying artery dropped significantly compared with that in
the control liver (supplemental Table S2, at http://ajp.
amjpathol.org). This ratio decreased with increasing tu-
mor size (Figure 7A). The diameter of the supplying artery
increased linearly with increasing tumor size (Figure 7B).
The extent of dilatation dropped rapidly upstream, but
persisted to some extent up to 1 mm from the metastasis
(supplemental Table S2 at http://ajp.amjpathol.org). The
BrdU labeling index of the arterial wall cells at the base of
the metastasis was 6.9  2.3%, suggesting that cell
proliferation contributed significantly to the dilatation of
the arteries. Ten to fifteen percent of the metastases
were supplied with arterial blood through the peribiliary
plexus (Table 1). The artery accompanying the peribili-
ary plexus was not directly involved in the supply of
these metastases. The portal vessels in the majority of
the metastases were displaced, although a portion
remained central but severely compressed (Figure
6D). Rarely (5%), the metastases were supplied by
arterial blood through arterioportal anastomoses inside
the tumor.
Consequences of the Arterial Blood Supply
We questioned whether the metastases acquired an
arterial blood supply because they had grown bigger or
whether the arterial blood supply provided a growth ad-
vantage to the metastases. There was no difference in the
rate of tumor cell proliferation between metastases sup-
plied arterially or portally (mixed blood) in two of the
mouse cell lines (C38 and 3LL-HH). However, the prolif-
eration rate was slightly but significantly increased in the
arterially supplied metastases of the A2058 human mel-
anoma cell line (Table 2, supplemental Figure S1, E and
F, at http://ajp.amjpathol.org).
Discussion
Using three different tumor lines, we have shown that
metastases more than 2000 to 2500 m in diameter in the
mouse liver inevitably become arterialized. Although the
importance of arteries in nourishing metastases has long
been recognized, mechanisms for the evolution of arterial
blood supply have never been presented.1–7 Here we
describe a mechanism for the arterialization of metastases
in the mouse liver. This process can be divided into the
following steps (Figure 8): 1) distortion of the aHMS by the
metastasis; 2) initial fusion of the sinusoids of the aHMS at
the tumor parenchyma interface; 3) fusion of the sinusoids
located at the base of the HMS, leading to the disruption of
the sphincter (burst pipe); 4) incorporation of the dilated
artery and the fused sinusoids; and 5) further develop-
ment of the tumor vasculature (arterial tree) by prolifera-
tion, remodeling, and continuous incorporation of fused
sinusoids at the surface of the tumor.
Figure 6. A: C38 metastasis with a well devel-
oped central arterial tree (black arrowheads
on the inset). The portal vein was pushed aside
(arrows). No ramifications can be observed on
the SEM micorgraph along the trunk of the arte-
rial tree (white arrowheads). Scale bars: 600
m; 1 mm (inset). B: Detail of A. Vascular
branches originate from one small area of the
arterial tree (arrow) located in the center of the
metastasis. Scale bar  300 m. C: 3LL-HH me-
tastasis. The centrally located artery dilates grad-
ually toward the center of the metastasis where it
ends in tortuous vascular lakes. The metastasis is
not completely filled by the resin its borders are
defined by the portal branches (arrowheads).
Scale bars: 600 m; 500 m (inset). D: C38
metastasis with a strongly dilated funnel-like ar-
tery (arrow). Both the artery and the portal vein
(arrowhead) are located centrally. The portal
vein is extremely compressed obstructing the
resin flow. Note that there are no ramifications
along the trunk of the artery. The branching
point of the artery is located in the center of the
metastasis. Scale bars: 200 m; 500 m (inset).
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The key element in the arterialization of the metastases
is the so-called aHMS observed in the mouse liver. The
situation is more complicated in the human liver, where
no direct arterioportal anastomoses are present, but ar-
teries run in the interlobular vascular septa terminating on
sinusoids along the whole circumference of the lob-
ules.15,17 Thereby, all HMSs are connected to arterioles,
(in that sense all HMSs in the human liver are aHMSs)
increasing the probability that an arteriole will be hit by a
metastasis. This strongly suggests that metastases in the
human liver become arterialized even earlier than in the
mouse liver. Thus, arterialization takes place at the level
of liver lobules. The size of a surface lobule in the mouse
liver is approximately 500  500  600 m (unpublished
observation). However, the actual size of the arterialized
metastases is considerably larger, which can be ex-
plained by the expansive growth of the tumors resulting in
certain displacement of bases of the surrounding aHMSs.
This displacement is probably the lowest in the highly
invasive rapidly growing tumor (3LL-HH), which becomes
arterialized at a size closest to that of a lobulus.
Arteries enter the metastases from the hilar direction,
which can explain the failure to detect direct connection
between arteries and metastases in an in vivo micro-
scopic study.16 The authors of the above study sug-
gested that arterial blood entered the metastases through
portal branches. Our observation contradicts this hypoth-
esis, as in the vast majority of metastases, a separate
arterial “tree” is responsible for nourishment of the me-
tastases. The unique structure (no ramification along the
trunk) of the central arterial tree suggests that no sprout-
ing type angiogenesis takes place from this vessel and
the moderate proliferation rate of cells constructing the
arterial wall contributes only to the dilatation of the artery.
The area of extensive ramification probably represents
the original inlet of the artery into the sinusoids, modified
by fusion, cell division, and incorporation.
The preferred growth of the tumors around the arteries
may be related to the pressure difference between the
arterial and portal systems. The low pressure portal and
central veins are pushed aside by the metastasis, while the
tumor grows around the firm standing, dilated, high-pres-
sure artery. The high percentage of metastases supplied by
only one artery can be explained if we view a metastasis as
a burst pipe (reduced resistance owing to the dilated artery
and the fused sinusoids) in the arterial system, which results
Figure 7. A: Portal vein-artery ratio in relation to metastasis size. B: Diameter of
the supplying artery at the entry to the metastasis in relation to metastasis size.
Table 2. Labeling indexes of metastases supplied
preferentially by arterial or portal blood
Arterial metastases
Portal (mixed blood)
metastases
3LL-HH 50,1  3,7 50,7  5,4 n.s.
C38 55,2  1,1 55,0  4,2 n.s.
A2058 38,3  2,5 34,1  1,9*
Mean  SD; n.s., not significant; *, P  0.05.
Figure 8. Schematic representation of the arterialization process in liver
metastases. Step 0: Micrometastasis growing within the liver lobule. The
arterial HMS has normal architecture. Step 1: Distortion of the aHMS by the
metastasis. Step 2: Initial fusion of the sinusoids of the aHMSs at the tumor
parenchyma interface. Step 3: Fusion of the sinusoids located at the base of
the HMSs, leading to the disruption of the sphincter (burst pipe). Step 4:
Incorporation of the dilated artery and the fused sinusoids. Step 5: Further
development of the tumor vasculature (arterial tree) by proliferation, remod-
eling, and continuous incorporation of fused sinusoids at the surface of the
tumor. Blue - mixed portal and arterial blood, Purple - mixed blood in the
arterial HMSs, Red - arterial blood, Green - hepatocytes, Gray - tumor tissue,
Black boxes - arterial sphincters.
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in subsequent drop in the pressure and collapse of the
neighboring arteries. These arteries are then pushed away
by the growing tumor preventing the development of further
supplying artery branches. The observation that the A2058
human melanoma has a larger percentage of metastases
supplied by more arteries may be related to the small cali-
ber intratumoral vessels, which may cause higher resis-
tance to blood flow through the tumor, leaving the neigh-
boring arteries uncollapsed. From these arteries new
supplying branches can develop. Larger metastases could
acquire further arterial blood supply frommore distant, large
arterial branches where the effect of the pressure drop
caused by the metastasis is not so pronounced.
The finding that metastases with an arterial blood sup-
ply had no or only slight growth advantage over metas-
tases supplied by mixed blood suggests that metastases
become arterialized as a result of their increased size.
This supports the notion, that the process of arterializa-
tion is purely mechanical in nature, governed by the
pressure relationships in the liver vasculature.
The significant differences in the microvascular architec-
ture between the mouse and human livers can have other
consequences besides the possible earlier arterialization of
the metastases in the human liver. Since arterioles in the
human liver terminate on the whole surface of the lobules, a
growing metastasis can hit more arterioles simultaneously,
resulting in a higher portion of metastases supplied bymore
arteries. This phenomenon can also reduce the number of
human liver metastases having their arterial entry from the
hilar direction. It is also important to note, however, that
arterial connections on the surface of the metastasis might
not all be functional (they will not feed the metastasis from
an outside-in direction) if a dilated artery within the metas-
tasis forces these arteries into collapse.
The observation that metastases, during their growth,
develop an arterial blood supply contradicts the sug-
gested role of sinusoids in nourishing liver metastases.
The sinusoidal system is continuous with the vasculature
of the tumor, but according to the frequently observed
central localization of the arteries, and considering that
central veins are always located outside the metastases,
blood should flow in an inside-out direction. In fact, in vivo
microscopic studies have demonstrated that fluorescent
dye or microspheres could not enter the metastases
when injected into the portal system, whereas following
arterial delivery the fluorescence appeared first within the
metastasis, and the blood drained into the surrounding
sinusoids.6,16 Sinusoids surrounding the metastasis play
no role in supplying the inner part of the metastases. They
serve only as building blocks during the development of
the tumor vasculature by sinusoid fusion and incorpora-
tion. However, portal vessels and sinusoids could have a
role in the nourishment of the periphery of the metasta-
ses, especially when the arterial flow is blocked.
The rationale for using hepatic arterial infusion is that it
can maximize the exposure of metastatic colorectal cancer
cells in the liver to high target concentrations of chemother-
apeutic agents by their localized infusion.19 Although our
experimental results provide further theoretical background
for this therapeutic approach and hepatic arterial infusion
has demonstrated superior response rates compared with
systemic chemotherapeutic treatments,19 its impact on the
overall survival of colorectal cancer patients with hepatic
metastasis is still unclear.20–22 Nevertheless, our results
may also serve as a theoretical basis for further research
into the effects of other anticancer drugs (such as novel
targeted agents) administered intra-arterially.
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Abstract
During motility of fibroblast type cells on planar surfaces, adhesions are formed at the anterior of the protruding lamella, which remain
stationary relative to the substrate and undergo a maturation process as the cell passes over them. Through these adhesions force is exerted,
the orientation of which is parallel to the direction of the movement. Here we show that, during gliding-type motility of human tumor cells,
characterized by a semicircular shape, adhesions were found at the outer rim of the cells, along the semicircle. Time-lapse microscopy of
GFP-vinculin-expressing cells showed that these adhesions were constantly renewed at the cell edge and followed a curved trajectory
according to the graded radial extension model. Eventually, the adhesions reached the long axis of the cell where they were retracted into
the cell body. Actin cables formed arcs, with the concave face at the anterior of the lamella found to be oriented in the direction of
movement. Since adhesions moved backward with respect to the cell, actin cables connected to these adhesions must continuously grow,
reaching maximal size at the long axis of the cell. Contraction of the arcs is responsible for the forward movement of the cell body.
© 2003 Elsevier Inc. All rights reserved.
Keywords: Human fibrosarcoma; Cell migration; Adhesion dynamics; GFP-vinculin; GRE model
Introduction
There are considerable differences in the motility behav-
ior of different cell types. Fish epidermal keratocytes move
rapidly (10–30 m/min), practically gliding over the sub-
strate, showing a semicircular shape, which is maintained
during cell body translocation [1–4]. A kinematic descrip-
tion of locomotion of keratocytes was presented earlier and
termed the graded radial extension model (GRE model) [1].
This model predicts that every point along the edge of the
semicircular lamella moves perpendicularly to the cell edge
with a decreasing displacement toward the long axis of the
cell. As a result the points of the cell edge move along a
curved path with respect to the substrate.
In contrast to keratocytes, the movement of other cell
types such as fibroblasts and murine tumor cells is slow
(0.5–1 m/min) and more erratic, but, as a general rule, the
extension of the leading lamella is followed by cell body
translocation and tail retraction [5–7].
The most striking difference between the two cell types
is the direction of the exerted force during motility corre-
sponding to the organization of the cables of the actin
cytoskeleton. Actin cables show perpendicular orientation
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in keratocytes, while they are parallel to the direction of
movement in fibroblasts [2,3,6]. It is not clearly understood
how the generated forces in both cases are able to produce
cell body forward movement, despite the differences in the
organization of the actin cytoskeleton. In the case of ker-
atocytes it was suggested that strong propulsive forces,
present only in the wings of the cell, are canceled by
adhesive traction forces and only pinching forces are de-
tectable [8]. Others have shown that weak centripetal forces
in the lamellipodium cause the cell body to be pulled for-
ward and pinching forces are responsible only for detach-
ment of the adhesions [9,10].
It is generally accepted that adhesions formed at the
anterior of the cell remain stationary relative to the substrate
and undergo a maturation process as the cell passes over
them [11–13]. However, the fate of the numerous adhesions
produced at the anterior of the wide leading lamella is not
clear, considering the triangular form of migrating fibro-
blast-type cells. It has been suggested that focal adhesions
under the cell body play a role only in maintaining the
spread shape of the migrating cell [14]. Recently it was
reported that the majority of these adhesions rapidly dis-
perse in the lamella and only adhesions localized at the
lateral edge will reach the rear of the cell [5]. As polarized
bundles of actin filaments are connected to the adhesions,
the polarization of the actin filaments and adhesions must
change as the cell passes over the adhesions, which would
involve the complete remodeling of the adhesions and the
actin cytoskeleton. To exert force for forward movement of
the cell body and the tail, in the case of fan-shaped migrat-
ing cells, the bipolar actin cables originating from the tail of
the cell must be coupled to the adhesions at the front of the
leading lamella [14]. Considering that the existence of ad-
hesions depends on tension [15], after the release of the
adhesion(s) in the tail, adhesions at the front must also be
disassembled, which would negatively influence the stabil-
ity of the leading lamella.
Here we present a hypothetical model of cell migration,
which is based on the observation that, during movement of
human fibrosarcoma cells, adhesions follow a curved path with
respect to the substrate, according to the GRE model [1]. As
adhesions move clockwise and counterclockwise on the two
sides of the apex of the cell, the connecting actin arcs (oriented
perpendicularly to the direction of the movement), which pro-
duce the force for forward movement, grow in length as they
move backward with respect to the cell. Reaching the long axis
of the cell the adhesions at both end of the cable are released,
resulting in the disassembly of the entire actin cable.
Materials and methods
Time-lapse microscopy
HT1080 human fibrosarcoma cells (105 per well, six-
well tissue culture plate, Greiner, Germany) were seeded in
the presence of serum (10% FCS in RPMI 1640, Sigma, St.
Louis, MO) on coverslips coated with 50–100 g/ml Ma-
trigel (Collaborative Research, Bedford, MA). The tumor
cells were allowed to spread for 30–60 min, thereafter the
cells showed rapid movement for 1–2 h. After spreading, a
part of the surface of the coverslips was cleaned by a rubber
policeman and an identification mark was placed on the
clean area close to the cell front by means of a diamond
pencil. The cells were videotaped for 1 h on an inverted
microscope (Axiovert 35, Zeiss, Germany) equipped with a
heated plate. At the end of the recording the cells were
immediately fixed in 4% paraformaldehyde, and, for the
later identification of moving cells, a videoprint was made
over the recorded area. The coverslip was processed for
immunofluorescence and the cells actually moving at the
end of the recording were analyzed. The percentage of
moving cells in a given time point was up to 5%. In this set
of experiments, moving cells were analyzed for the distri-
bution of phosphotyrosine and vinculin.
The distribution of talin, focal adhesion kinase, 6-inte-
grin, myosin, and actin was determined in moving type cells
showing the characteristic semicircular shape.
To determine the average speed of HT1080 cells, cov-
erslips were placed under a confocal microscope (MRC
1024, Bio-Rad, Hercules, CA) equipped with a heated plate
(MP10DM, Kitazato, Japan); phase-contrast pictures then
were taken every 30–60 s using a 20 objective. The net
displacement of a nucleolus of each cell was determined (n
 31).
The same confocal microscopy system was used to de-
termine the dynamics of adhesions in GFP-vinculin trans-
fected cells. Pictures were taken every 30 s using a 100
objective. Overlay of adhesions (merged picture of all pic-
tures taken during the observation period) was made using
the Bio-Rad Lasersharp Processing software.
Transfection
HT1080 cells (106) were transfected with GFP-vinculin
fusion gene containing plasmid, kindly provided by Dr.
Benjamin Geiger (The Weizmann Institute of Science, Re-
hovot, Israel), using FuGENE 6 transfection reagent (Roche
Diagnostic, Mannheim, Germany) according to the manu-
facturer’s guidelines. The proportion of transfected cells
was 20% maximum and the cultures were used for migra-
tion tests for 3 days. The transfection influenced negatively
the locomoting activity; both the proportion (1%) and the
speed of the moving cells were found to be decreased.
Immunofluorescence
Cells were fixed in 4% paraformaldehyde for 10 min and
permeabilized with 0.5% Triton X-100 for 5 min. The
following antibodies were used: polyclonal and monoclonal
(PY20) antibody to phosphotyrosine, monoclonal anti-FAK
(Transduction Labs), anti-myosin (light chain, clone MY21,
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Sigma), anti--actinin (clone BM75.2, Sigma), anti-vincu-
lin (clone VIN-11-5, Sigma), anti-talin (cloneTA 205, No-
vocastra), and anti-6-integrin (clone GoH3, Pharmingen).
Rhodamine-phalloidin was obtained from Molecular
Probes.
Cells were incubated with the above antibodies for 60
min, with biotinylated secondary antibody for 30 min, and
then with streptavidin–DTAF (Jackson Immunoresearch)
for 30 min.
Results
During the rapid (gliding) movement on Matrigel, the
semicircular shape of HT1080 fibrosarcoma cells was main-
tained and the direction of movement was perpendicular to
the long axis of the cell (Fig. 1a, Videos 1 and 2). The
average speed of the movement was found to be 1.6  0.3
m/min (n  31).
Immunofluorescence analysis of the distribution of phos-
photyrosine-containing proteins (Fig. 1a) and adhesion
plaque components vinculin (Fig. 1b), talin, FAK, and 6
integrin (not shown) indicated that these components were
localized at the outer rim of the cells along the semicircle.
Adhesions were not observed under the cell body and a few
were found occasionally under the lamella. There were no
differences found in the size of the adhesions and distribu-
tion of the adhesion components among the different re-
gions of the semicircle, all of the above mentioned compo-
nents were present in all adhesion sites. Furthermore, no
significant differences were found among the adhesions at
the level of tyrosine phosphorylation (Fig. 1a). The adhe-
sions were spot-like (0.5 m), or several microns long,
oriented toward the rim of the cell.
Time-lapse microscopy of GFP-vinculin-expressing
HT1080 cells showed that adhesions at the cell edge were
not formed continuously; new adhesions appeared as dis-
crete spots, with increasing intensity, ahead of the existing
adhesions. Displacement of the adhesions was the largest
close to the apex (2–5 m), decreasing toward the long axis
of the cell. Adhesions were found to be stationary with
respect to the substrate. The time of the adhesion renewal at
the cell edge was in the range of minutes (Fig. 2a–c, Video
3). In contrast, retraction of the adhesions into the cell body
in the flanks of the cell took place continuously; the adhe-
sions were apparently sliding on the substrate (Fig. 2d–g,
Video 4). The retraction of the adhesions was sequential
(Fig. 2d–g), but occasionally fusion of the adhesions could
also be observed (Fig. 2a–c, Video 3), which produced
larger and brighter adhesions at the rear of the cell. These
adhesions were eventually also retracted and dispersed in
the cell. Because of the discontinuous formation of the
adhesions, the path of individual adhesions could not be
followed, but overlay of the recorded images revealed that
adhesions followed a curved path (Fig. 2h and i). The
adhesions were placed forward and sideways with respect to
the substrate, but moved backward with respect to the cell
along the cell edge. The path of the adhesions became more
and more curved, as they got closer to the long axis of the
cell, where they were retracted into the cell body. There
were slight differences in the distribution of adhesions be-
tween motile nontransfected and transfected cells. In video-
taped nontransfected cells the adhesions were mostly spot-
like, localized in one row to the cell edge, whereas in
transfected cells adhesions were frequently found in two
rows (Fig. 2h). This could be due to the high concentration
of vinculin in transfected cells that may slow down the
turnover of the adhesions.
Analysis of cytoskeletal elements in moving-type cells
showed that actin cables were present in the form of arcs at
the anterior of the lamella (Fig. 3a). The concave face of the
arcs was oriented toward the direction of the movement;
however, orientation on the dorsal side of the cell reversed
in front of the nucleus. -Actinin was present in the lamel-
lipodia and showed periodical arrangement in the lamella
cell body transition zone (Fig. 3b). Myosin aggregates were
observed close to the lamellipodium and their density grew
toward the nucleus (Fig. 3c). At higher magnification it was
Fig. 1. Distribution of adhesion plaque components. (a) Merged picture of phase-contrast image and phosphotyrosine immunofluorescence signals. The cell
shows semicircular shapes and immunofluorescence signals are localized predominantly to the outer rim of the cell. (b) Moving-type cell stained for vinculin.
The signals are distributed in a semicircular manner along the cell edge. Similar distribution of talin, focal adhesion kinase, and 6-integrin was observed
(not shown). Bar represents 10 m (a and b).
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Fig. 2. Dynamics of GFP-vinculin-containing adhesions. (a–c) Time-course of adhesion renewal during gliding motility in GFP-vinculin-transfected cells.
The series shows the right wing of the cell, turning slightly to the left. Arrowheads in b point to the developing new adhesion row. Arrow in c points toward
the position of the adhesions already removed. The adhesions marked by three and two small arrows in a are fused into the adhesions marked by the upper
and the lower large arrowheads in b. (d–f) Time-course of the sequential retraction of two adhesions in the right wing of a moving cell. Arrowheads point
to the adhesions retracted. (g) Overlay of the images recorded over 3 min, including the images shown in d–f. Arrowheads point to the retracted adhesions.
Arrow points at an adhesion that the cell was not able to retract during the observation period. All three adhesions are sliding on the surface of the substrate.
(h and i) Adhesion dynamics during gliding motility of HT1080 cells. (h) Distribution of adhesions at the start of time-lapse microscopy. (i) Overlay of images
recorded over 20-min movement of the cell. The adhesions follow a more and more curved path clockwise and counterclockwise on the two sides of the apex
of the cell. Reaching the long axis of the cell, the adhesions are retracted into the cell body. Bar represents 10 m a–i.
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discernible that myosin molecules were organized into dou-
blets, which were further assembled into ribbons (Fig. 3d).
The orientation of these ribbons was perpendicular to the
actin filaments and showed periodicity. The side view of
moving-type cells stained for myosin indicated that the
concentration of myosin was highest in the lamella and in
the lamella–cell body transition zone where the membrane
starts to rise, decreasing on both the ventral and dorsal side
of the cell toward the nuclear region (Fig. 3e).
Discussion
Based on the observed distribution and dynamics of the
adhesions and on the structure of the actin cytoskeleton, we
propose a hypothetical mechanism of cell migration. This
model differs substantially from the widely accepted loco-
motion model of fibroblast type cells [7].
The observation that adhesions in HT1080 cells were
localized and constantly renewed at the leading edge of the
Fig. 3. Distribution of cytoskeletal elements. (a) Distribution of actin cables in locomoting-type cell. Note the concave face of the arcs present in the lamella
oriented toward the semicircle. (b) Confocal image of -actinin signals in a moving-type cell. The signals are distributed periodically from the middle part
of the lamella toward the nucleus. (c) Myosin aggregates can be observed close to the cell edge (dashed line), and their density is seen to increase toward
the nucleus. The focal plane was adjusted to the ventral surface of the cell. Note the decreased staining in the nuclear region. Periodical arrangement of myosin
aggregates is discernible in the left wing of the cell. Bar represents 10 m (a–c). (d) Myosin molecules organized into doublets, forming ribbons close to
the cell edge (dashed line). Bar represents 0.5 m. (e) Side view of a 20-m-wide part of the middle of the cell shown on c. The staining for myosin decreases
on both the ventral and the dorsal surfaces from the base of the lamella toward the nuclear region. Bar represents 5 m.
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cell means that aging, as well as maturation of the adhe-
sions, does not take place along the leading edge of the cell.
This is further supported by the observation that all of the
adhesions contained components such as vinculin and FAK,
the presence of which in adhesions is considered as a sign of
maturation [13,14]. The rapid turnover of the adhesions
during migration at the cell edge results in the absence of
adhesions under the lamella and the cell body. This obser-
vation is in contrast to earlier ones, made on chick embryo
fibroblasts and keratocytes, in which talin- and vinculin-
containing adhesion sites were found in these regions
[6,11]. However, similar to our observations, recent results
have shown that, during lamella extension, stationary adhe-
sions were present only in the anterior part of the lamella
[5,12]. However, the turnover of these adhesions was some-
what slower than in the case of human fibrosarcoma cells.
As has been shown earlier in the case of keratocytes, to
maintain the semicircular shape during gliding motility, the
points of the semicircle move perpendicularly to the cell
edge, but the displacement decreases from the apex to the
long axis of the cell. This means that each point of the cell
edge will follow a curved path with respect to the substrate
(GRE model) [1]. The observed trajectory of the GFP-
vinculin-containing adhesions in HT1080 cells corresponds
well with this model. This observation and the fact that
neutrophil fragments also locomote according to the above
model [17] suggest that graded radial extension of the lead-
ing lamella may represent a universal mechanism in cellular
movement.
Since actin filaments are attached to the adhesions along
the semicircle and the adhesions follow the curved path in
the opposite direction on the two sides of the apex of the
cell, the length of the actin cables have to increase, reaching
maximal size at the long axis of the cell (Fig. 4). It is well
established that assembly of the branched network of actin
filaments beneath the plasma membrane is responsible for
the extension of the lamellipodia. The branching takes place
from the side of the preexisting filaments [18]. However,
branched actin filaments cannot assemble into a sliding
actomyosin system, which is necessary to exert force to
propel the cell body forward. Therefore, as it has been
suggested, the majority of the newly synthesized actin fil-
aments have to separate from the sides of their mother
filaments as the cell advances [18]. We hypothesize that
these separated filaments are not depolymerized; instead
they will be incorporated into the sliding actomyosin system
organized by the myosin molecules. This notion is sup-
ported by our observations that myosin aggregates appeared
close to the lamellipodium and organized into doublets,
which were further assembled into ribbons. The orientation
of these ribbons was perpendicular to the actin filaments and
showed periodicity, as observed by others, in the case of
mammalian fibroblasts [19]. This kind of organization of
myosin molecules suggests that a sliding actomyosin system
is working immediately behind the lamellipodium. This is
in contrast to keratocytes, in which the lamellipodia, which
is devoid of myosin molecules, is wide, thereby the con-
tractile zone is localized in front of the nucleus [2,4]. The
periodical arrangement of myosin and -actinin observed
by us suggests that actin cables containing filaments with
alternating polarity are responsible for force generation in
moving HT1080 cells.
In a portion of moving HT1080 cells, adhesions were
elongated and oriented more or less perpendicularly to the
cell edge. The orientation of the adhesions is determined by
the direction of the force exerted by actomyosin cables
coupled to the adhesions [15]. As HT1080 cells moved
forward, a new row of adhesions was formed in front of the
old one. (To ensure continuous force generation, actin ca-
bles must always be connected to the substrate, which
means that disassembly of the old adhesions should not take
place before assembly of new ones.) Recent results have
shed light on a possible mechanism of actin cable elonga-
tion. It was shown that the Arp2/3 complex transiently
associates with vinculin in adhesions at the leading edge,
implicating that branching of actin filaments can also take
place within these structures [20]. In the case of keratocytes,
the force exerted by the actomyosin system grows toward
the long axis of the cell [8,9]. Considering the resemblance
in distribution and orientation of the main actin cables
between keratocytes and human fibrosarcoma cells, we sup-
pose a similar distribution of forces in the moving HT1080
Fig. 4. Schematic representation of the fate of adhesions and actin cables
in moving cells. Curved arrows show the path of adhesions in time (t0–t4).
The actin cables connecting the adhesions grow in length as the cell
advances. At t3 new adhesions and actin cables are added at the apex of the
cell. Straight arrows (t2) represent the forces exerted by an actin cable (a)
and the substrate (a). To generate the resultant force, the forces exerted by
the substrate (a) were shifted from the adhesion points to the middle of the
actin cable. The resultant force oriented in the direction of the migration is
responsible for cell body forward movement.
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cells. The increasing force decreases the concavity of the
actin cables and causes the new adhesions to have a differ-
ent orientation compared to the old ones. During this pro-
cess the orientation of the adhesions becomes more and
more parallel to the long axis of the cell. As the adhesions
during migration of HT1080 cells remain more or less
perpendicularly oriented to the edge, the change in the
orientation corresponds to the predictions of the GRE
model, which includes the lateral flow of the adhesions.
In keratocytes, propulsive (rearward directed) forces
were detected either in the wings of the cell [8] or centrip-
etally oriented in the lamellipodia [9,10]. In the human
fibrosarcoma cells, vinculin-containing adhesion sites were
observed along the semicircular leading edge through which
adhesions, as recent results suggested, force can be exerted
[21]. The distribution of the vinculin-containing adhesions
and the structure of the actomyosin arcs in HT1080 cells
suggest a centripetal orientation of the propulsive forces.
Adhesions and actin cables have to be produced at the
apex of the cell, making a continuous force generation
possible, resulting in the gliding motility of the human
fibrosarcoma cells. The continuous retraction or fusion of
adhesions in the flanks and their production at the apex of
the cell ensure a steady number of adhesions along the
leading edge of the cell.
As adhesions were present only occasionally under the
lamella, the actin cables span the entire width of the cell; the
interconnected actin cytoskeleton acts as a rubber sheet
nailed down at the adhesions. As this system alone deter-
mines the shape of the migrating cell, no adhesions are
needed under the lamella and the cell body.
The actin cables in the lamella formed arcs due to the
dragging force of the cell body, but at the same time the
contractile force of the arcs propel the cell body forward
(Fig. 4). Similar actomyosin arcs—present exclusively in
front of the cell body—have been observed in fish kerato-
cytes and are considered to be responsible for mediating cell
body translocation [2,4]. If the actomyosin system is inter-
connected, the dragging force of the cell body is transmitted
to the front of the cell, causing the organizing actin cables
behind the leading lamella to take up the concave shape.
(The actin arcs observed by confocal microcopy can be
rather considered as local increase in the density of the actin
filaments of the interconnected actin network.) It must be
noted that, to ensure the gliding-type motility, theoretically
all of the actin cables have to exert force of the same
magnitude in the direction of the movement. Consequently,
the component, which is directed perpendicularly to the
direction of the movement, grows, as the cables become less
concave during backward movement with respect to the cell.
For the most efficient forward movement of the cell it is a
prerequisite that no adhesions are present under the lamella and
the cell body, as these would hamper the free contraction of
the arcs, thereby slowing down the movement.
Actomyosin cables were observed on both the ventral
and the dorsal sides of the HT1080 cells. It is important to
note that the actomyosin cables on the dorsal side were also
connected to the adhesions located at the cell edge, thereby
also able to exert force on the substrate, contributing to the
forward movement of the cell. A proportion of the actomy-
osin cables on the ventral side moved under the nucleus,
while the cables on the dorsal side became stuck at the
lamella–cell body boundary, where the membrane starts to
rise. The latter forms the large actin cable, apparently ex-
erting force in the opposite direction of the movement,
probably responsible for the retraction of adhesions at the
long axis of the cell. However, the force exerted by this
cable could be rather low, as the adhesion at its ends glide
on the surface of the substrate.
The continuous growth of the actin cables in moving
human tumor cells, suggested by us, questions the existence
of treadmilling of actin filaments in the sense that, in the
lamella, there is no simultaneous polymerization and depo-
lymerization of the filaments; there is only filament growth,
until the actin cables reach maximal size.
The release of the adhesions took place simultaneously
in the flanks of the cell, probably leading to the disassembly
of the entire actin cable. The process can be repeated con-
tinuously during movement as the adhesions and actin ca-
bles reach the long axis of the cell. The disassembly of the
actin cables at the rear of the cell has no direct influence on
the tension of the force exerting cables in the front of the
lamella.
Moving fibrosarcoma cells with tails have also been
observed, showing the classical form of locomoting fibro-
blast-type cells [6]. In the leading lamella of these cells,
however, the distribution and dynamics of the adhesions
were identical to the semicircular-shaped cells, except that
at the end of the tail one adhesion site was detectable. Actin
cables originating from this adhesion spanned the entire cell
and were oriented parallel to the direction of movement.
However, other cables forming arcs in the leading lamella
have been oriented perpendicularly to the direction of
movement. These observations strongly suggest that the
lamella alone is responsible for the forward movement of
the human fibrosarcoma cells. According to the model pro-
posed here, the adhesion in the tail or any other adhe-
sions under the cell body, which the cell were not able
to disassemble at the start of the movement, only retard
migration.
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Abstract
The process of extravasation of the high metastatic Lewis lung carcinoma line was examined in different organs. Four of
the five organs (liver, lungs, brain and adrenals) represent the most frequent metastatic sites in humans. In the case of
each organ 150–350 tumor cells were analysed. The interaction of tumor cells with endothelial cells and the basement
membrane showed significant differences between the organs. In the liver and lungs, endothelial cells were found to migrate
onto the surface of the tumor cells, resulting in the removal of tumor cells from the circulation. The process was initiated
by development of cytoplasmic projections on the luminal surface of the endothelial cells. In the liver only half of the
tumor cells showed basement membrane degradation even after 24 h, although 6 h after injection 40% of the tumor cells
were sequestered from the circulation. In the adrenals and brain, tumor cells were not covered by endothelial cells instead,
limited retraction of endothelial cells was followed by penetration of the basement membrane. In the kidney both types
of tumor cell-endothelial cell interactions were observed, but the process of extravasation was not completed, stopping as
the tumor cells reached the basement membrane or the mesangial matrix. The time course of tumor cell extravasation also
showed significant differences between the organs. The process was most rapid in case of the liver and adrenals. By 6 h
40–50% of the tumor cells were in the process of extravasation or were in an extracapillary position. These organs are
preferential metastatic sites of this tumor line. The time of extravasation was much longer in the other organs (lungs 16 h,
brain 48 h), for which this tumor line shows no preference. Conclusions: (1) Type and duration of tumor cell extravasation
differ between the organs. (2) The time needed to reach extraluminal position, but not the type of extravasation correlates
with the organ preference. (3) Endothelial cells of the lungs and liver can play a much more active role in the process of
extravasation than previously suggested. (4) Tumor cells can complete the metastatic process without reaching a complete
extracapillary position; contact with the basement membrane or extracellular matrix seems to be sufficient.
Introduction
Extravasation of tumor cells is an important step in complet-
ing successful metastasis formation. The cause of metastatic
inefficiency is debated, but destruction of tumor cells in the
circulation by mechanical forces or the immune system can
lead to significant reduction of the number of extravasating
tumor cells [1]. Therefore the time spent in the hostile envi-
ronment of the microcirculation can have a decisive role on
the efficiency of the metastatic process and organ preference.
According to in vivo ultrastructural studies, extravasation
in capillaries can take place in several ways: (1) by tumor
cells penetrating the endothelium and basement membrane
similarly to leukocytes [2–6]; (2) by retraction of endothelial
cells followed by fragmentation of the basement membrane
by cellular processes, leading to the destruction of the cap-
illary [7–10]; (3) by endothelial cells covering the tumor
cells before the penetration of the basement membrane [11];
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(4) by intracapillary proliferation of tumor cells leading to
the mechanical destruction of the capillary [12].
These observations are based on studies which analyse
the ultrastructure of extravasation of tumor cells of different
origin in the lung and liver. In the lung, the time needed for
penetration of the endothelium to get into contact with the
subendothelial basement membrane and to reach an extra-
capillary position varied significantly among the tumor lines
studied [4, 6–12].
Regarding two other frequent metastatic sites, only two
studies were found dealing with the process of extravasation
in the brain [4, 6] and one report showing the interaction of
hepatoma cells with the capillary endothelium of the adrenal
gland [13].
Based on earlier in vitro studies, it is generally accepted
that the interaction of the tumor cells with the endothe-
lium results in the retraction of endothelial cells, leading
to the attachment of the tumor cells to the subendothe-
lium. Subsequently, the adhered tumor cells migrate under
the endothelium and spread on the subendothelial basement
membrane, followed by reformation of the endothel mono-
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layer integrity [15]. However, this process represents only
elements of the observed diverse interactions between tumor
cells of different origin and the capillary wall in vivo, which
suggest, that during extravasation the properties of the tumor
cells determine the response of the endothelium.
The well known variability in ultrastructure and cell
surface molecules of the endothelium of different organs
[14], is also thought to be responsible for organ preference,
however can also play an important role in the process of
extravasation.
In this paper we test the hypothesis that a given tumor
cell line reaching the capillary bed of different organs, is
able to elicit distinct responses of the endothelium. We also
investigated the correlation between the time needed to reach
extraluminal position in the different organs and organ pref-
erence, using the 3LL-HH Lewis lung carcinoma tumor line
with a well known metastatic pattern.
Materials and methods
Animals, tumor line and injections
Inbred C57Bl/6 mice from our Institute were used through-
out the studies. The high metastatic 3LL-HH tumor line was
maintained by serial intrasplenic transplantations of tumor
cells obtained from liver metastases. Single cell suspensions
were prepared from 14-day-old 3LL-HH liver metastases.
Tumor tissue was minced by crossed scalpels and filtered
through 4-fold gauze. After centrifugation and washing in
medium 199, the viability of tumor cells was determined by
a trypan-blue exclusion test (40–50%).
An analysis of extravasation was performed in five or-
gans ( liver, lungs, adrenals, brain and kidney).
For the analysis of extravasation in the liver, tumor cells
were injected into the splenic vein. Mice were anesthetized
and the spleen exposed. The splenic vein was cleaned and
tumor cells (5 × 105/0, 2 ml) were injected by inserting a
30-gauge needle into the vein. After injection, blood was
allowed to flow for a minute to ensure that all tumor cells
reached the microvasculature of the liver. After removing
the needle a small piece of gelaspon was pressed onto the
vein to prevent excessive bleeding.
In the case of the lungs 5×105 tumor cells (0.2 ml) were
injected into the lateral tail vein.
In the case of the adrenals and kidney, tumor cells
(106/0.2 ml) were injected into the left ventricle of the heart,
as previously described [16].
To analyse the extravasation in the brain, the tumor cells
were injected into the left ventricle or into the carotid artery.
Injection of tumor cells into the left ventricle yielded a lower
cell number in the brain than injection into the carotid artery.
When cells were injected into the left ventricle the number
of tumor cells in the brain 2–3 days after injection, it was not
enough to perform the ultrastructural analysis of extravasa-
tion, therefore the tumor cells were injected into the carotid
artery. For this the mice were anesthetized and carotid artery
prepared for injection under a dissecting microscope. A lig-
ature was placed proximally and the artery was elevated by
curved tweezers. A 30-gauge needle was inserted into the
artery just above the elevation and a slow injection of 5×105
cells in 0.2 ml was started ensuring free blood flow through-
out the process as well as for another 30 s. The ligature was
then tightened and the skin closed.
Electron microscopy
Animals were sacrificed at various time points after tumor
cell injection. Two mice were used at each time point: (lungs
3, 6, 11, 16, 24 h, liver 1, 3, 6, 16, 24 h; adrenals 1,
3, 6, 16, 24 h; kidney 3, 6, 16, 24 h; brain 3, 24, 48,
72 h). Anesthesized animals were perfused via the left ven-
tricle with phosphate buffered saline for 10 min and with
2.5% glutaraldehyde in 0.05 M Na-cacodylate (pH 7.2) for
15 min at room temperature. Organs were removed, cut into
1×2 mm pieces and immersed in 2.5 glutaraldehyde for 2 h.
The pieces were postfixed in 1% OsO4, 0.5% K-ferrocyanide
in 0.05 M Na-cacodylate for 2 h, dehydrated in graded series
of acetone, contrasted en bloc with 2% uranylacetate and
embedded in Spurr’s mixture. Tumor cells were detected on
semithin sections stained by 0.5% toluidine blue (pH 8.5).
Areas of interest were trimmed out and ultrathin sections
were cut, stained with lead citrate and analysed on Philips
CM10 electron microscope. From each area 30–40 ultrathin
sections were cut and lifted onto formvar coated 75 mesh
grids.
Quantitative analysis of tumor cell extravasation
The time necessary for tumor cells to reach an extraluminal
position was determined by analysing the interaction of the
tumor cells with the capillary wall of the organs at different
time points after tumor cell inoculation.
The process of extravasation was divided into the fol-
lowing steps: (1) arrested tumor cells facing intact capillary
endothelium; (2) beneath the tumor cells, retraction of the
endothelial cells is observable, tumor cells are in contact
with the basement membrane; (3a) tumor cells penetrate
the endothelium and the basement membrane with cellu-
lar processes; (3b1) tumor cells are partially covered by
endothelial cells; (3b2) tumor cells, which are completely
covered by endothelial cells, are in contact with the basal
side of the endothelium and/or basement membrane is pen-
etrated by cellular processes; (4) tumor cells are completely
extravascular in contact with connective tissue or parenchy-
mal cells. It must be noted that steps 3a and 3b are parallel
events.
A minimum of 20 cells were analysed at each time point.
To include into a category, each cell on at least 10 ultrathin
sections was analysed to ensure that the most advanced stage
is recorded. Altogether over 1,000 cells were analysed.
Confocal microscopy
Tumor cells isolated as described above, were labeled by
membrane permeant reactive fluorescent tracer, CellTracker
Green (Molecular Probes Inc.) at a concentration of 5 µM
for 20 min. (The treatment had no influence on the metastatic
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potential of the tumor cells). After washing in PBS, the num-
ber of tumor cells was adjusted to 2×106/ml, and 0.2 ml cell
suspension was injected into the splenic vein of four mice,
which were sacrified 6 and 24 h after injection. Livers were
removed, frozen in isopentane chilled with liquid nitrogen
and 5 µm cryosections were cut. The sections were fixed
in 4% freshly depolymerized paraformaldehyde for 15 min,
washed in PBS and reacted with polyclonal antibody against
laminin in 1:50 dilution (DAKO) for 60 min. The primary
antibody was detected by rhodamine conjugated goat anti-
rabbit antibody (Jackson ImmunoResearch Lab. Inc.) The
sections were analysed on BIO-RAD MRC1024 confocal
microscopy system.
The integrity of the basement membrane was analysed
around the circumference of 100 cells for each time point.
Since small discontinuities can be detected in the basement
membrane of normal sinusoids, degradation was recorded
only if one-third of the circumference of the cell was free of
any basement membrane label.
Results
Liver (Table 1A)
Tumor cells were arrested mainly in sinusoids close to the
periportal area. One hour after injection small cytoplasmic
processes were observed protruding through the pores of
sinusoidal endothelial cells. (Figure 1). These small projec-
tions persisted up to 3–6 h without any significant changes
in size. Retraction of endothelial cells was observed by this
time, but the endothelial cells were separated at the interen-
dothelial junctions (Figure 2). This event was preceded or
paralleled by the development of cytoplasmic projections
on the luminal surface of endothelial cells, which were at-
tached to the cell surface of the tumor cells (Figure 3). The
attachment points showed increased electron density (Fig-
ure 4). The size of the endothelial cell cytoplasmic processes
increased and by 6 h 33% of the tumor cells were either
partially or completely covered by thin endothelial processes
(Figure 5). During this process the shape of the tumor cells
showed no significant changes and tumor cell processes
projecting under the endothelial cell or spreading on the
subendothelial matrix were not observable. Ten percent of
the tumor cells were found in extrasinusoidal position, but
around the surface of these cells – probably because of the
inappropriate sectioning plane – no endothelial cells were
detected; these cells were surrounded by hepatocytes. By
16 h only one, and by 24 h no cells were found in intrasinu-
soidal position, the tumor cells were completely covered by
endothelial cells or surrounded by hepatocytes. The extra-
luminal tumor cells often invaginated into the hepatocytes,
which event was accompanied by the disappearance of the
cell surface microvilli of hepatocytes (Figure 6).
Since the basement membrane is not detectable in the
liver by electron microscopy, we injected fluorescently la-
beled tumor cells and detected the basement membrane of
liver sinusoids around these cells by confocal microscopy,
to determine the degree of basement membrane degradation
during the extravasation process.
Surprisingly, after 6 h of injection 90% of the tumor
cells were still surrounded by intact basement membrane
(Figure 7), although by this time 40% of the cells were
in extraluminal position. Even after 24 h only 50% of the
cells showed partial or complete degradation of the basement
membrane (Figure 8).
Lung (Table 1B)
The majority of tumor cells were trapped in capillaries and
faced intact endothelium for up to 6 h. Even by 11 h follow-
ing injection, the proportion of tumor cells, around which
retracted endothelial cells were present, did not increase sig-
nificantly, instead projections originating from the luminal
surface of the intact endothelial lining, started to cover the
tumor cells (Figures 9 and 10). In contrast to the liver, how-
ever, no specific adhesion points were observed between
the tumor cell surface and the endothelial projections. The
size of these cytoplasmic projections was limited, since no
cells were found completely covered by the endothelium,
while facing the intact endothelial layer of the capillary wall.
Having a certain projection size, the endothelial cells were
separated at their intercellular junction under or near the tu-
mor cell. Subsequently the tumor cells were found to lie on
the surface of the basement membrane and were in contact
with the basal surface of the endothelial cells (Figure 11).
Fibrin and platelets were frequently associated with the free
surface of the tumor cells, but these components were never
found between the tumor cells and the capillary wall (Fig-
ure 10). Although a considerable number of tumor cells were
already completely covered by endothelial cells (17%), the
basement membrane was penetrated by only 4% of the cells.
Extravascular tumor cells were not found by this time (11 h).
After 16 h the majority of the tumor cells were cov-
ered by endothelial cells, which cover consisted of several,
single-layered endothelial cells (Figure 12). Half of the
endothelialized tumor cells penetrated the basement mem-
brane and a considerable proportion of tumor cells were
located extravascularly. Similarly to the liver, during the
sequestration of tumor cells from the circulation by the en-
dothelial cells, no significant changes were found in the
tumor cell shape. The penetration of the basement mem-
brane, however, took place through small holes (2–4 µm)
requiring significant deformation of the tumor cell (Fig-
ure 13). No simultaneous penetration of endothelium and
the basement membrane was observed. Basement membrane
breakthrough always took place in the direction of the con-
nective tissue. Cells moving through the double layered
basement membrane separating the alveolar space from the
capillary lumen were not observable. 24 h after injection the
majority of the tumor cells were situated in the connective
tissue.
Adrenals (Table 1C)
Following intraarterial injection the tumor cells were ar-
rested in adrenal capillaries of the subcapsular region (Fig-
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Figures 1–5. (1) Detail of a tumor cell arrested in a sinusoid 6 h after tumor cell inoculation; ×12,000; bar = 1 µm. A. Small cytoplasmic processes
(arrows) of the tumor cell (T) penetrate through the fenestrations (arrowheads) of the endothelium (E). H – hepatocyte. B. The same area at a different
section. No interendothelial junctions are visible in this area. (2) Tumor cell in a sinusoid 6 h after inoculation. Retraction of the endothelial cells (E) is
observable. Through the opening (arrowheads) the tumor cell (T) is in contact with the subendothelial matrix. The arrow points at an intercellular junction
at border of the opening. H – hepatocyte; × 12,000; bar= 1 µm. (3) Cytoplasmic process originating form the luminal surface of the endothelial cell (E) is
attached to the tumor cell (T) (arrow). Gaps are visible in the endothelial lining (arrowheads), through which the tumor cell is attached to the subendothelial
matrix (open arrowheads). H – hepatocyte; ×8,300; bar = 1 µm. (4) Cytoplasmic process of a sinusoidal endothelial cell (E) is attached to the surface of
an intraluminal tumor cell (T) Note the increased electron density of the attachment point (arrow). H – hepatocyte; ×20,000; bar = 1 µm. (5) Tumor cell
(T) covered partially by an endothelial cell (E) (arrows) 6 h after inoculation. The tumor cell is in contact at a large area with the subendothelial matrix
(arrowheads); ×6,400; bar = 2 µm.
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Figures 6–10. (6) Extraluminal tumor cell 24 h following inoculation. The endothelial (E) lining is intact on surface of the tumor cell. The tumor cell
invaginated into the hepatocyte. Arrowheads point in areas where microvilli of the hepatocyte are completely absent. S – sinusoidal lumen; ×4,400; bar
= 2 µm. (7) Intrasinusoidal tumor cell (green) 6 h following inoculation. The basement membrane (red) is intact around the tumor cell. Bar = 20 µm.
(8) Extravasated tumor cell (green) in the liver 24 h following inoculation. The tumor cells is in contact with two sinusoids but large part of the tumor cell
surface is free from basement membrane label (red fluorescence) Bar = 20 µm. (9) Tumor cell (T) arrested in a lung capillary 11 h following inoculation.
Cytoplasmic projection (arrows) originating from the luminal surface of the endothelial cell covers a part of the surface of the tumor cell. The endothelial
lining is intact under the tumor cell (arrowheads). C – capillary lumen; ×10,400. Bar = 1 µm. (10) Large process (arrows) of the endothelial cell (E)
covers the half of the surface of the tumor cell (T). Retraction of the endothelial cells under the tumor cell is not observable (arrowheads). Tr – thrombus
material; ×8,200; bar = 1 µm.
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Figures 11–13. (11) Tumor cell (T) partially covered by an endothelial cell (small arrows) 11 h after inoculation. The basal surface of the endothelial
cell is in contact with the tumor cell, which lies on the basement membrane. Small piece of the endothelial cell is still present under the tumor cell (large
arrow). E – endothelium; C – capillary lumen; A – alveolar space; ×8,200; bar = 1 µm. (12) Tumor cell (T) completely covered by endothelial cells (small
arrows) 16 h following inoculation. Large arrow point at an intercellular junction. The tumor cell is in contact with the intact basement membrane (arrow
heads). Parts of the endothelium are still present under the tumor cell (open arrowheads). C – capillary lumen; A – alveolar space; ×6,200; bar = 1 µm.
(13) Tumor cell (T) process (P) completely covered by endothelial cells (E) penetrates the endothelial basement membrane (arrowheads) 16 h following
inoculation. The process is in contact with the basement membrane of the alveolar epithelium (arrow). The large arrow points at an intercellular junction
between the covering endothelial cells. BM – basement membrane; C – capillary lumen; A – alveolar space; ×8,200; bar = 1 µm.
ure 14). No tumor cells were found in the medulla. As
early as 3 h after injection tumor cells developed projec-
tions through the endothelium and the basement membrane
(Figure 15). The size of the opening in the capillary wall
was similar to that observed in the lungs (2–4 µm), through
which the tumor cells moved into the connective tissue space
(Figure 16). The endothelial cells were separated similarly
to the liver and lungs, at or near intercellular junctions.
(Figure 17). During the extravasation process extensive re-
traction of endothelial cells was not observed, the size of
the gap in the endothelial lining was always similar to the
one seen in the basement membrane. By 6 h 21% of the
cells were already in extracapillary position and another 17%
were in the process of extravasation. By 16 h a considerable
proportion of the cells were localised intravascularly, but
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Table 1. Relative distribution of tumor cells among the steps of
extravasation in different organs.
A Time after inoculation
Liver 1 h 3 h 6 h 16 h 24 h
Percentage of tumor cells in the
different steps of extravasation
(1) TC contact with EC 93 65 16
(2) EC retraction 7 35 38 3
(3a) TC process 5
penetrating EC and
BM
(3b1) TC partially 24 3
covered by EC (TC in (12)
contact with the
subendothelium)
(3b2) TC completely 8 32 57
covered by EC
(4) TC extravascular 11 62 43
No EC visible around
TC
Number of cells examined
Total number of cells 28 31 102 31 47
examined 239
Table 1. Continued.
B Time after inoculation
Lung 3 h 6 h 11 h 16 h 24 h
Percentage of tumor cells in the
different steps of extravasation
(1) TC contact with EC 97 91 69 15
(2) EC retraction 3 6 3 4
(3a) TC process
penetrating EC and
BM
(3b1) TC partially 3 12 1
covered by EC (TC (6)
in contact with BM)
(3b2) TC completely 17 65 26
covered by EC (BM (4) (31) (17)
pierced)
(4) TC extravascular 14 74
Number of cells examined
Total number of cells 29 32 203 72 23
examined 359
interestingly no cells were found penetrating the capillary
wall.
Brain (Table 1D)
Following intraarterial injection the majority of tumor cells
were surrounded by intact endothelium for up to 24 h. Ex-
travascular cells were first found 48 h following injection of
tumor cells (13%). Endothelial cells were separated at in-
tercellular junctions, but extensive retraction of endothelial
Table 1. Continued.
C Time after inoculation
Adrenals 1 h 3 h 6 h 16 h 24 h
Percentage of tumor cells in the
different steps of extravasation
(1) TC contact with EC 97 83 58 19 4
(2) EC retraction 3 4 2 4
(3a) TC process 13 17
penetrating EC and
BM
(3b1) TC partially 2
covered by EC
(3b2) TC completely
covered by EC
(4) TC extravascular 21 77 96
Number of cells examined
Total number of cells 31 24 48 26 27
examined 156
Table 1. Continued.
D Time after inoculation
Brain 3 h 24 h 48 h 72 h
Percentage of tumor cells
in the different steps of
extravasation
(1) TC contact with EC 100 95 77 24
(2) EC retraction 5 7
(3a) TC process 3
penetrating EC and
BM
(3b1) TC partially
covered by EC
(3b2) TC completely
covered by EC
(4) TC extravascular 13 76
Number of cells examined
Total number of cells 20 21 73 34
examined 148
cells was not observed. (Figure 18). Tumor cells arrested
in capillaries were never covered by endothelial cells. The
penetration of the basement membrane, which was a very
rare event, took place through a small gap as observed in
case of the lungs and adrenals. (Figure 19). 72 h after in-
jection, tumor cells were still found in the microvasculature
of the brain, although 76% of the cells were already in an
extracapillary position. No cells were found in the process
of extravasation at this time.
Kidney (Table 1E)
Tumor cells were found only in glomerular capillaries. En-
dothelial cell retraction was observed as early as 3 h after
injection. The proportion of tumor cells in contact with
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Figures 14–17. (14) Three tumor cells (T1, T2, T3) arrested in the subcapsular region of the adrenal gland, 3 h following intra-arterial inoculation. Ca –
adrenal capsule; ×1,400; bar = 10 µm. (15) Higher magnification of T1 in a different sectioning plane. The larger process of the tumor cell penetrated the
endothelium (arrowheads) and the basement membrane (small arrows). The gap in the endothelium is somewhat larger than the opening in the basement
membrane. The smaller process of the tumor cell penetrated the endothelium and punctured basement membrane (large arrow), ×6,000; bar = 1 µm.
(16) Tumor cell in an advanced stage of extravasation 6 h following inoculation. The tumor cell protrudes through a small gap in the capillary wall (arrows)
The body of the tumor cell (TB) locates in the capillary (arrowheads) whereas the large (TP) process extends into the connective tissue, ×4,400; bar =
2 µm. (17) Detail of Figure 16. The small gap through which the tumor cell protrudes is bordered by endothelial cells. Inset: The area of the gap in the
capillary wall in a different sectioning plane. An interendothelial junction (arrow) is visible at this area. E – endothelium; BM – basement membrane; TB
– tumor cell body; TP – tumor cell process; ×13,000; bar = 1 µm.
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Figures 18–21. Detail of a tumor cell (T) arrested in a capillary of the brain, two days following inoculation. A small gap is visible (arrowheads) between
the endothelial cells, through which the tumor cell is attached to the basement membrane. Arrow points at the intercellular junction; ×14,000; bar = 1 µm.
(19) Tumor cell (T) arrested in a capillary of the brain two days following inoculation. A small process of the tumor cell protrudes into the perivascular
space. The gap (arrows) is bordered by endothelium on the right side (E) whereas on the left side of the gap the endothelium is absent, the tumor cell
is attached to the basement membrane (arrowheads); ×14,000; bar = 1 µm. (20) Tumor cell arrested in a glomerular capillary 16 h after inoculation.
The tumor cell is completely covered by the endothelium (arrowheads). Arrows point at the sites where the endothelium is detached from the basement
membrane. C – capillary lumen; E – endothelial cell; ×6,300; bar = 1 µm. (21) Tumor cell (T) in the process of extravasation 16 h following inoculation.
The endothelial cells of the glomerular capillary are retracted under the tumor cell (arrowheads). The tumor cells protrudes through a small gap in the
basement membrane (arrows) into the mesangium. P – process of the tumor cell; M – mesangial cell; ×4,700; bar = 2 µm.
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Table 1. Continued.
E Time after inoculation
Kidney 3 h 6 h 16 h 24 h
Percentage of tumor cells
in the different steps of
extravasation
(1) TC contact with EC 87 46 10 8
(2) EC retraction 13 46 52 43
(3a) TC process 8 12 23
penetrating EC and
BM
(3b1) TC partially 14 14
covered by EC
(3b2) TC completely 10 13
covered by EC
(4) TC extravascular
Number of cells examined
Total number of cells 23 26 49 64
examined 162
Steps of the extravasation process: (1) tumor cells facing
intact endothelium, (2) retraction of the endothelial cells
is observable, tumor cells are in contact with the base-
ment membrane, (3a) tumor cells penetrate the endothe-
lium and the basement membrane with cellular processes,
(3b1) tumor cells are partially covered by endothelial cells
, (Number in parentheses represents the pecentage of tu-
mor cells in contact with the basement membrane or with
the subendothelium), (3b2) tumor cells which are com-
pletely covered by endothelial cells, and are in contact
with the basal side of the endothelium. (in Table 1B
number in parentheses represents the percentage of tu-
mor cells penetrating the basement membrane by cellular
processes). Steps 3a and 3b are parallel events. (4) tumor
cells completely extravascular in contact with connective
tissue or parenchymal cells.
A minimum of 20 cells were analysed at each time
point. To include into a category, each cell on at least 10
ultrathin sections was analysed to ensure, that the most
advanced stage is recorded.
the basement membrane increased significantly by 6 h, but
only a small number of tumor cells penetrated the base-
ment membrane. Extracapillary tumor cells were not found
at this time. After 16 h tumor cells appeared, which were
partially or fully covered by endothelial cells (Figure 20),
but the proportion of these cells had not changed for up
to 24 h. The number of tumor cells penetrating the base-
ment membrane by cellular processes increased for up to
24 h, but surprisingly tumor cells in extravascular posi-
tion were still not found. The cellular processes penetrating
the basement membrane were always oriented toward the
mesangium. (Figure 21). Tumor cells penetrating the double
layered basement membrane, which separates the capillary
lumen from the urinary space were not detected.
Discussion
In this study we analysed the ultrastructure of extravasation
of the high metastatic 3LL-HH tumor line in different or-
gans. Four of the five organs chosen (liver, lungs, adrenals,
brain) are the most frequent target organs in humans. Signifi-
cant differences were found in respect to the time needed for
and to the type of extravasation between the organs. Tumor
cells reached extraluminal position most rapidly in the liver
and adrenals. By 6 h about 20% of the tumor cells were in
extravascular position in case of the adrenals, or sequestered
from the circulation by endothelial cell cover in case of the
liver. Another 20% of the tumor cells were in an advanced
stage of extravasation. Earlier we demonstrated, that this
3LL-HH carcinoma line showed liver specificity and pref-
erence for adrenals, following intraarterial inoculation [16].
No or negative preference was demonstrated in the case of
the lung, kidney and brain, respectively. In accordance with
the negative brain preference of this tumor line, the time
needed for extravasation proved to be the longest in the
brain (>2 days) among the organs examined. This result is
in agreement with the observations obtained from the two
other studies dealing with the extravasation of hepatoma and
Walker carcinosarcoma cells in the brain [4, 6]. Both stud-
ies suggested that extravasation took place 3 days following
injection. The delay in the onset of extravasation in the
brain capillaries is probably caused by the resistance of the
specific intercellular junctions present between endothelial
cells.
In the lung it took approximately 11 h for the tumor
cells to reach extraluminal position, and 16 h were needed
for full extravasation. According to other studies, the time
necessary to complete the process of extravasation varied
significantly among tumor lines (9–48 h), but the majority
of lines needed at least 24 h to break through the capillary
basement membrane [7–11].
In the lung, adrenal gland and brain a proportion of tumor
cells remained in intracapillary position, while the major-
ity of tumor cells were already extravasated with no further
cells found in the process of extravasation. This observation
suggests that the intracapillary cells do not enter the process
of extravasation and will probably be cleared later from the
microcirculation.
Two main types of extravasation were observed. In the
liver and lung, tumor cells became covered by endothelial
cells before penetrating the basement membrane, whereas
in the adrenal gland and brain penetration of the basement
membrane was preceded only by minor retraction of the en-
dothelial cells. In the lung, data suggest that the tumor cells
apparently pause under the endothelial cover before base-
ment membrane invasion and emigration into the connective
tissue.
Endothelialization of tumor cells was observed in the
case of liver and lung whereas retraction of the endothelium
and penetration basement membrane took place in adrenals
and brain. Since organ preference was observed only in the
case of liver and adrenals, in which organs the tumor cells
reached most rapidly extraluminal position, it can it can be
concluded that not the type but the speed of extravasation
correlates with organ preference.
It must be emphasized that in the liver, penetration of the
basement membrane is not necessary (sequestration of the
tumor cells by endothelial cells from the circulation seems to
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be sufficient) for successful metastasis formation, because –
as shown in our study – by 6 h 10%, while by 24 h only
50% of tumor cells showed degradation of the sinusoidal
basement membrane. In organs with well defined basement
membranes (lungs, adrenals, brain) the tumor cells moved
through small gaps in this structure, similarly to leukocytes.
Such a type of movement was not observed in the liver, in-
stead the tumor cells practically sank into the hepatocytes
without major changes in shape, during which process the
microvilli of the hepatocytes disappeared. Since in the liver
the basement membrane is localised between the microvilli
of the hepatocytes, the above process can contribute to the
disappearance of the basement membrane material. This
observation is in contrast with other earlier results, show-
ing large globular cellular processes of lymphosarcoma and
mammary carcinoma cells to protrude into the hepatocytes
[5, 17].
The phenomenon, that in the liver the basement mem-
brane was present around a significant proportion of tumor
cells, is in accordance with our earlier finding, accord-
ing to which angiogenesis in liver metastases of this tumor
line is initiated by the migration of tumor cells on the sur-
face of sinusoidal basement membrane. During this process
the endothelial cells become separated from their basement
membrane, which is thought to initiate the proliferation of
the endothelial cells and of the development of tortuous in-
tratumoral vessels, lacking basement membrane [18]. These
observations question the necessity of basement degradation
following endothelialization of these tumor cells in the liver.
In the kidney, both types of extravasation could be ob-
served. Since tumor cells localised entirely in the mesangial
matrix were not found, the process of extravasation prob-
ably stopped, either when tumor cells became sequestered
by endothelial cells in glomerular capillary loops having no
contact with the mesangium, or when the tumor cells pene-
trated the endothelium and their processes became projected
into the mesangial matrix. Some of the endothelialized tu-
mor cells were found facing entirely the double layered
basement membrane, which they were obviously not able
to penetrate. A similar observation was made in the lungs,
however, in this case the tumor cells were able to pene-
trate the epithelial basement membrane provided they were
already extravasated and localised in the connective tissue.
[19]. In other organs such as lungs, adrenals and brain, the
tumor cells have to cross only a thin layer (100–200 nm)
of basement membrane to reach a compartment with differ-
ent matrix composition. The tumor cell processes projecting
into the mesangial matrix cannot sense other matrix compo-
nents than that of the basement membrane (mesangial matrix
contains basement membrane components such as laminin
and collagen IV) [19], which can be a stop signal for mi-
gration. The fate of the tumor cells arrested halfway in the
process of extravasation is not known, but they probably
continue to proliferate, since intravascular mitotic figures
were frequently found in all organs.
In the liver and adrenals, most of the tumor cells were
arrested in zone 1 and in the subcapsular region, respectively,
which observation suggests that tumor cells were trapped
mechanically by size restriction. In all of the organs, the
arrested cells suffered extreme deformations, which as it
was suggested also by others, excludes rolling of the tu-
mor cells on the surface of endothelial cells [1, 20]. These
observations are in contrast to recent results, obtained by
intact organ microscopy, showing the arrest of tumor cells
in pre-capillary arterioles exceeding the size of the tumor
cells [28].
Earlier in vitro studies have shown that penetration of
endothelial monolayer starts with retraction of endothelial
cells followed by migration of the tumor cells under the en-
dothelial cells and spreading on the subendothelial matrix
[15]. Retraction of endothelial cells proved to be reversible,
leading to the restoration of monolayer integrity above the
tumor cells. Sublethal concentrations of H2O2 , 12-S-HETE
and tumor derived retraction factor were shown to mediate
reversible retraction of endothelial cells [21–23]. Endothe-
lial cell injury, which can also be caused by H2O2 produced
by tumor cells may also lead to the exposure of subendothe-
lial extracellular matrix facilitating firm attachment of tumor
cells to the capillary wall [24]. Damaged endothelial cells in
contact with the arrested tumor cells were never observed in
our study, not even in case of the brain, where the long stay
of compressed tumor cells in the capillaries caused extreme
flattening of the endothelial cells.
In the adrenals, the tumor cells caused only a very lim-
ited retraction of endothelial cells. The tumor cells moved
through the endothelium and basement membrane simulta-
neously, similarly to leukocytes, except for neutrophils. In
the brain, the retraction of endothelial cells was not closely
coupled to the penetration of the basement membrane, but
was most probably a rapid event, because an extremely
low proportion of tumor cells were found in the process of
extravasation compared to the other organs.
Retraction of endothelial cells took place mainly beneath
the tumor cells, suggesting that a putative retraction factor
cannot be present in a soluble form, but rather it should be
expressed on the surface of the tumor cells.
In the liver and adrenals, shortly after initial arrest, small
processes were found projecting through the fenestrations of
the endothelial cells, but these projections do not seem to
play a role in the process of extravasation, since they did not
grow with time and endothelial cells were later separated at
intercellular junctions. They may, however, have a role in the
firm attachment of the tumor cells to the capillary wall. The
behaviour of endothelial cells in the liver and lung showed
a similarity to that of in vitro observations, but flattening
of the tumor cells was never observed before penetration of
the basement membrane. More importantly, a new feature
was noted in the process of tumor cell sequestration from
the circulation. In the lung, the retraction of endothelial cells
was preceded by the appearance of cytoplasmic projections
originating from the apical surface of the endothelial cells.
The size of these projections was limited, never covering the
entire tumor cell. After dissolution of interendothelial junc-
tions the endothelial cells probably roll their membrane on
the surface of the tumor cell, during which process a switch
takes place in the membrane polarity from apical to basal,
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since the completely covered tumor cells were in contact
exclusively with the basal side of the endothelial cells. This
observation suggests a more active role of the endothelial
cells in the process of extravasation in the liver and lung,
as previously suggested. Similarly, endothelium covers neu-
trophils during extravasation, but the process is different
from that observed by us, since – as it was recently shown
– the openings in the endothelium are within the body of
the endothelial cells (transcellular) [25]. In the liver the dis-
solution of the interendothelial junctions occurred probably
earlier or simultaneously with development of these apical
projections. In this case, however, specific attachment points
with increased electron density were detected between the
tumor and endothelial cell membranes. These structures can
play a role in the rapid sequestration of tumor cells from
the circulation and thereby in the observed liver preference.
The nature of these attachment points, observed only in the
liver is not known , but they may contain adhesion mole-
cules, which were shown to redistribute during tumor cell
attachment to endothelial monolayer in vitro [26].
IL-1 dependent and independent metastasis were de-
tected in organ clusters, during arterial dissemination of B16
melanoma cells [27]. The liver lung and adrenals fall into
the group of IL-1 dependent metastasis. Our ultrastructural
study showed different types of extravasation of tumor cells
in the lungs and adrenals, whereas in the brain, falling into
the IL-1 independent group, extravastion proceeded in a
similar way as in the adrenals. These observations suggest
that IL-1 inducible adhesion molecules cannot mediate the
observed difference in the interaction of tumor cells with
endothelial cells of the organs studied.
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ROLE OF SINUSOIDAL HEPARAN SULFATE PROTEOGLYCAN IN LIVER
METASTASIS FORMATION
Jo´zsef TO´VA´RI, Sa´ndor PAKU, Erzse´bet RA´SO´, Ga´bor POGA´NY, Ilona KOVALSZKY, Andrea LADA´NYI, Ka´roly LAPIS and Jo´zsef TI´MA´R*
1st Institute of Pathology and Experimental Cancer Research, Semmelweis University of Medicine, Budapest, Hungary
Previous studies have indicated that the predominant sites
of tumor cell extravasation in the liver are the sinusoidal
vessels, where tumor cells contact the sinusoidal endothe-
lium and the subendothelial extracellular matrix containing
the basic components of the basement membrane. We
studied the role of sinusoidal extracellularmatrix inmetastat-
sis formation by 3LL-HH murine tumor cells selected for
their preferential liver colonization. 3LL-HH tumor cells did
not efficiently adhere to cryosections of the liver, but they
recognized the sinusoids and vessel walls. Pre-treatment of
the mice with polyclonal anti-basement membrane antibod-
ies [anti-laminin, anti-fibronectin and anti-heparan sulfate
proteoglycan (HSPG)] significantly modulated the organ
distribution of tumor cell colonies following intracardial
injection: all 3 antibodies inhibited kidney colonization; anti-
laminin and anti-fibronectin antibodies inhibited lung coloni-
zation; and only anti-HSPG antibody inhibited liver coloniza-
tion. In several organs such as the heart, stomach, pancreas
and bladder, anti-basement membrane antibody treatment
did not alter the process of colonization. Immunofluores-
cence studies showed that anti-HSPG antibody recognized
the basement membranes of sinusoids and blood vessels. Our
data suggest a specific involvement of sinusoidal HSPG in the
liver colonization of 3LL-HH cells. Int. J. Cancer 71:825–831,
1997.
r 1997 Wiley-Liss, Inc.
The metastatic cascade consists of various aspects of tumor
cell-matrix interactions including adhesion, digestion and migra-
tions mediated by cell membrane receptors (Liotta, 1986). Al-
though the sequential steps of the metastatic cascade are well
characterized, the mechanism of the organ-specific tumor dissemi-
nation is poorly understood. Tumor dissemination consists of both
random and non-random mechanisms, and organ-specific metasta-
sis is characteristic of several tumor types such as lung, breast or
prostate cancers.
Liver metastasis is one of the most frequent complications of
tumor dissemination in humans. Therefore, an understanding of the
underlying mechanisms might have clinical significance. Studies
on liver-specific experimental metastasis models have suggested
that tumor cells specifically recognize the liver sinusoidal endothe-
lium and positively respond to a local factor (Hamada et al., 1993;
Long et al., 1994). Analysis of the liver-specific tumor phenotype
revealed that heparan sulfate proteoglycans (HSPGs) are overex-
pressed in carcinoma and melanoma cells metastatic to the liver
(Tı´ma´r et al., 1987, 1992) although the mechanism by which these
PGs influence organ-specific metastasis remains unknown.
Morphological analysis of liver dissemination indicated that the
predominant sites of tumor cell extravasation are the liver sinusoids
(Dingemans et al., 1978; Paku and Lapis, 1993), where tumor cells
interact with the sinusoidal endothelium, with the subendothelial
basement membrane (Griffiths et al., 1991) and with hepatocytes
before initiating local proliferation. Tumor cell-endothelial cell
interaction is a complex process in which early steps are mediated
by cell-adhesion molecules, subsequently followed by endothelial
cell retraction and establishment of tumor cell-subendothelial
basement membrane contacts (Honn and Tang, 1992). This implies
that to understand the liver-specific metastasis process better, we
need more data on the molecular mechanism of tumor cell-
sinusoidal basement membrane interactions. We have used here
3LL-HH lung carcinoma cells, characterized by their preferential
liver metastatic properties, as an in vivo model throughout our
studies. Our in vivo and in vitro data suggest that a component of
the sinusoidal basement membrane, the HSPG, plays a critical role
in the formation of liver metastasis.
MATERIAL AND METHODS
Purification of proteoglycans
Liver tissues were homogenized in 3.4 M NaCl, 50 mMTris HCl
(Merck, Darmstadt, Germany), 10 mM EDTA (Serva, Heidelberg,
Germany), 5 mM N-ethylmaleimid (Merck), 0.5 mM phenylmeth-
anesulphonyl fluorid (Serva), 0.001% soy bean trypsin inhibitor
(Sigma, St. Louis, MO), 5% Gordox (Reanal, Budapest), pH 7.4,
and then extracted with 4 M guanidine HCl (Merck), 1% Triton
X-100 (Serva), 50 mM sodium acetate (Merck), 10 mM EDTA and
protease inhibitors as above, pH 5.0, at 4°C for 48 hr. Cell debris
were removed by centrifugation (600g for 30 min). TCA precipita-
tion of supernatant was carried out as described by Lyon and
Gallagher (1991) to remove the nucleic acids and most liver
proteins. The supernatant containing PGs was dialyzed against 7 M
urea (Serva), 0.05 M Tris HCl, pH 7.0 (containing protease
inhibitors as above). Dialyzed extract was applied on 1 ml DEAE
52 (Whatman, Clifton, NJ) column equilibrated with 7M urea, 0.05
M Tris-HCl, pH 7.0. The column was washed with 10 ml of the
same buffer containing 0.1 and 0.2 M NaCl, and PGs were eluted
by NaCl gradient increasing from 0.2 to 0.8 M.
The protein content of each fractions was determined by a
modified Lowry method (Hartree et al., 1972).
Adhesion assays
Five micrometer cryosections were prepared from mouse organs
and placed on glass slides. Tumor cells (104/ml) in medium 199
were incubated on cryosections at 37°C in CO2 atmosphere for 1 hr.
The non-adherent cells were removed by repeated washings in
medium (23), and the adherent cells were fixed with 4% parafor-
maldehyde for 15 min and stained with methylene blue; the cell
number/unit area was then counted under light microscope using a
203 lens.
In other tests, 96-well plates were coated overnight at 37°C with
isolated PG fractions in PBS (1 µg protein/well or PBS alone) and
further incubated for another hour with anti-HSPG antibody (1
µg/well; Tı´ma´r and Kovalszky, 1995; Gallai et al., 1996) or PBS.
The control wells contained only PBS and PBS 1 antibody; 104
3LL-HH cells in medium 199 were added to each well and
incubated for 1 hr at 37°C. After removal of the non-adherent cells,
the adherent ones were fixed and counted by phase contrast
microscopy.
Motility assay
Chemotaxis was assayed by using 48-well Boyden chamber
(Neuro Probe, Pleasanton, CA) and 8 µm pore size uncoated
Nucleopore filters (NeuroProbe). The PG fractions or the organ-
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derived proteins (500g supernatant of normal homogenized mouse
organs) were added in PBS to the lower wells (1 µg protein/well),
while upper wells were filled with 3LL-HH cells (50,000/well) in
medium 199 supplemented with 10% FCS (Serva). The chamber
was incubated for 4 hr at 37°C in a 5% CO2 atmosphere. At the end
of the assay, filters were removed, fixed in methanol and stained.
Cells that had migrated through the pores to the lower side of the
filter were counted by light microscopy.
Proliferation assay
Tumor cells were plated on 24-well plates (Costar, Cambridge,
MA) at a concentration of 5 3 104 cells/well in 1 ml RPMI
supplemented with 5% FCS (Serva). GAGs (50–100 µg/ml) were
added to the wells for 48 hr, and viable cell numbers were counted
at the end of the assay after EDTA detachment the using Trypan
blue dye exclusion assay and a hemocytometer. Hyaluronic acid
(m.w. .700 kDa; Sigma), chondroitin 4/6-sulfate (m.w. 55 kDa;
Sigma), heparin (m.w. 12 kDa; Choay, Paris, France) and heparan
sulfate (m.w. 35 kDa; Bioetica, Lyon, France) were used as GAGs.
Antibodies to basement membrane components
Polyclonal rabbit anti-serum was raised against purified laminin
and fibronectin and was kindly provided by A. Vaheri (Helsinki,
Finland). These antibodies recognized their corresponding proteins
by Western blot at a dilution of 1:5,000. The rabbit polyclonal
anti-HSPG antibody was raised against HSPG fraction, isolated
from EHS sarcoma and shown to react predominantly with a high
m.w. HSPG having a core protein of 400 kDa corresponding to
perlecan (Tı´ma´r and Kovalszky, 1995).
Antibody-dependent cell-mediated cytotoxicity
3LL-HH cells were labeled in vitro with 2 µCi/ml Br[3H]dUrd
(Amersham, Aylesbury, UK) in RPMI 1640 medium containing
10% FCS for 24 hr at 37°C, washed 3 times with medium to
remove the unbound isotope and incubated with anti-HSPG
antibody for 30 min at a 1:100 dilution (control cells were
incubated with non-immune rabbit antibody). Syngenic spleen
cells were added to the wells at an effector-target ratio of 100:1 for
24 hr in a total volume of 200 µl/well in 96-well tissue culture
plates (Nunc, Roskilde, Denmark), and the released isotope in the
medium was determined by liquid scintillation counting (Beck-
mann), measuring 150 µl samples from each well. The total
releasable label was determined after treating the target cells with
1% SDS. Spontaneous release was measured in the absence of
effector cells. Three to 6 replicates were used for each determina-
tion.
Anti-HSPG antibody ELISA
Animals were treated with 0.1 ml undiluted polyclonal rabbit
antibody to HSPG; 30, 60, 90 and 120 min after administration of
the antibody, the serum was isolated from the animals. Purified
extracellular matrix from EHS sarcoma (2 µg/well; Gallai et al.,
1996) was dried onto ELISA plates (Greiner, Nu¨ztigen, Germany)
and blocked with 1% BSA (Sigma); the wells were then incubated
with the serum of antibody-treated animals at a dilution of 1:10 for
1 hr, followed by horseradish peroxidase-conjugated anti-rabbit
IgG (Vectastain, Vector, Burlingame, CA) for another hour and
then TMB substrate (Sigma) (5 washings with buffer between each
step). The immunoreaction was measured with an ELISA reader
(Labsystems, Shrewsbury, MA).
Animals and tumor lines
Inbred C57Bl/6 mice from our Institute were used throughout
our studies. The high liver metastatic 3LL-HH tumor line was
maintained by serial intrasplenic transplantations of tumor cells
obtained from the liver metastases. Single-cell suspensions were
prepared from 14-day-old 3LL-HH liver metastases. Tumor tissue
was minced with crossed scalpels and filtered through 4-fold gauze.
After centrifugation (550g) and washing in medium 199, the
viability of the tumor cells was determined by the Trypan blue
exclusion test (.50%).
In vivo treatments
Animals were injected i.v. with 0.1 ml undiluted polyclonal
rabbit antibody to laminin, fibronectin and HSPG. Two hours after
administration of the antibodies, 2 3 104 tumor cells in 0.1 ml PBS
were injected into the left heart ventricle of the mice as described
by Paku et al. (1989). Animals were sacrificed by a Nembutal
overdose 11 days after tumor cell inoculation. The numbers of
tumor colonies in internal organs were determined, and the relative
percentages of the tumor colonies in organs were calculated.
Immunofluorescence
The distribution of antibodies within the organs 2 hr after
injection was determined by immunofluorescence. From each
antibody-treated group one animal was sacrificed by Nembutal
overdose; the kidneys, adrenal glands and liver were then removed
and frozen in isopentane cooled by liquid nitrogen. Five microme-
FIGURE 1 – Interaction of Lewis lung tumor clones with mouse liver tissue. (a)Adhesion of 3LL (open bars) and 3LL-HH (black bars) tumor
cells to cryosections of mouse organs in vitro. Tumor cells were incubated with organ sections for 1 hr at 37°C, the non-adherent cells were
removed by repeated washings with fresh medium and the adherent cells were fixed with PFA, stained with methylene blue and counted under the
light microscope using a 203 lens. Data are expressed as number of cells/unit area6 SD; n5 3. (b) Chemotactic migration of 3LL (open bars) and
3LL-HH (black bars) cells toward mouse organ homogenates in vitro. Organs were homogenized, filtered as described in Material and Methods
and used at standard protein concentration (1 µg/ml) in the lower well of a Boyden chamber. Tumor cells were placed into the upper chamber for 4
hr. The filter was fixed, and cells were stained and counted by light microscopy. Data are expressed as mean number of cells migrated (6SD;
n 5 4). Sp, spleen; L, liver; K, kidney; M, muscle; P, pancreas; Sk, skin; sB, small bowel.
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FIGURE 2 – Distribution of adherent 3LL-HH cells over a cryosection of the mouse liver. (a) Light microscopy indicates that tumor cells
accumulated over the sinusoids and the portal vessels (arrowheads). Scale bar 5 100 µm. (b) Adherent 3LL-HH cells spread along the liver
sinusoids (arrows) and the portal vein (arrowheads). Scale bar 5 50 µm.
FIGURE 3 – Ultrastructure of 3LL-HH cell-liver interactions. Tumor cells were incubated with cryosections of the mouse liver as in Figure 1,
and were then fixed and processed for electron microscopy.After 1 hr of incubation, interaction of the tumor cell with the subendothelial basement
membrane of a major portal vessel could be observed (arrowheads). T, tumor cell. Scale bar 5 1 µm.
FIGURE 4 – Localization of anti-HSPG antibody by immunofluorescence in mouse organs 4 days after i.v. injection of the antibody. Rabbit
polyclonal antibody against basement membrane HSPG was injected i.v. into mice (0.1 ml/animal). The animals were sacrificed by Nembutal
overdose on day 4 post-injection, organs were removed and cryosections were made. The anti-HSPG antibody in organs was detected in organ
cryosections by a TRITC-conjugated anti-rabbit IgG and photographed using a fluorescent microscope. (a) Mouse kidney. Note the presence of
anti-HSPG antibody along the glomerulus basement membrane. Scale bar 5 50 µm. (b) Mouse liver. Note the presence of anti-HSPG antibody
along the liver sinusoids and the basement membrane of the portal vessels. Scale bar 5 50 µm.
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ter frozen sections were reacted with rhodamine-conjugated goat
anti-rabbit antibody (Jackson ImmunoResearch, West Grove, PA).
The sections were analyzed on an Olympus (Tokyo, Japan) Vanox
epifluorescent microscope.
Electron microscopy
Cryosections (10 µm) were incubated with tumor cells as
described above. After incubation, sections were fixed in 2.5%
glutaraldehyde for 10 min, rinsed in PBS and post-fixed in 1%
OsO4. Dehydrated sections were embedded by placing gelatin
capsules filled with resin (Spurr, Serva, Heidelberg, Germany) on
the mounted sections. After polymerization (70°C, 16 hr) capsules
with sections were removed by immersing the slides in liquid
nitrogen. Semi-thin sections were stained with 0.5% toluidine blue
to select the desired areas for ultrathin sectioning. Ultrathin
sections were examined by a Philips (Eindhoven, the Netherlands)
CM10 electron microscope.
RESULTS
3LL-HH tumor cells are characterized by preferential metastatic
potential to the liver (Paku et al., 1989); we attempted to determine
the key factor(s) that might regulate this phenotype. Interestingly,
adhesion of unselected and selected Lewis lung tumors (3LL and
3LL-HH) to cryosections of mouse organs did not indicate
selective recognition of the liver tissue (Fig. 1a). Similarly, proteins
isolated from the liver did not exhibit selective chemotactic activity
for 3LL-HH cells when compared with other organs such as lung or
kidney (Fig. 1b), suggesting that the recognition of this organ by
the 3LL-HH tumor cells is not mediated by a liver cell-specific
factor(s). On the other hand, the distribution of 3LL-HH tumor
cells over the liver sections was non-random; it showed significant
preference for portal vessels and the sinusoids (Fig. 2a), and even
tumor cell spreading was observed over these areas (Fig. 2b).
Ultrastructural analysis indicated that 3LL-HH tumor cells adhered
to the basement membranes of blood vessels and the sinusoids (Fig.
3).
We have used polyclonal antibodies produced against major
basement membrane proteins (laminin, fibronectin and perlecan-
HSPG) to study the role of basement membrane in the liver-specific
dissemination of 3LL-HH tumor cells in vivo. These antibodies
have been administered into animals i.v. before the inoculation of
tumor cells to mask the basement membrane protein epitopes
theoretically involved in tumor cell-extracellular matrix interac-
tions. The injected antibodies accumulated in the basement mem-
branes of various organs such as kidneys (Fig. 4a) and liver (Fig.
4b), as demonstrated by immunofluorescence. In the liver, the
anti-basement membrane antibodies could be detected by immuno-
fluorescence in the sinusoids and portal vessels (Fig. 4b). No
serious side effects were detected in animals treated with anti-
basement membrane antibodies during the 11 day period. ELISA
analysis of the serum of anti-HSPG antibody-injected animals
indicated 80% of the antibody in the circulation at 2 hr and 50% on
the 2nd day, indicating slow clearance (data not shown).
Among the various anti-basement membrane antibody pretreat-
ments, only anti-HSPG antibody was successful in inhibiting the
overall organ colonization of 3LL-HH cells (Table I), although the
anti-laminin as well as anti-fibronectin antibodies also exhibited a
slight inhibitory potential. In analyzing the number of colonies in
various organs, anti-HSPG antibody proved to be effective in the
case of the liver (Fig. 5a), all 3 anti-basement membrane antibodies
were inhibitory in the case of the kidneys (Fig. 5c) and the
anti-laminin antibody was the most effective for the lung coloniza-
tion (Fig. 5b). The antibody pretreatments did not modulate the
colonization of 3LL-HH cells to the heart, stomach, pancreas,
muscle and bladder (Table I), suggesting an organ-specific mecha-
nism. Since 3LL-HH cells express all 3 basement membrane
components at their surface (Lapis et al., 1986; Tı´ma´r et al., 1987)
and the injected polyclonal antibodies were detectable in the
circulation at the time of tumor cell injection, it is possible that the
altered organ distribution of 3LL-HH cells is due to antibody-
dependent cell-mediated cytotoxicity. 3LL-HH cells were shown to
be resistant to the cytotoxic effects of autologous splenocytes in the
presence of polyclonal anti-HSPG antibody (at the same concentra-
tion that was found in the serum of the antibody-treated mice:
1:100 dilution) (data not shown) excluding an immunological
mechanism involved in the modulatory effects of anti-basement
membrane antibodies on organ colonization of 3LL-HH cells.
The above data suggest that the liver-specific colonization
pattern of 3LL-HH cells depends on the sinusoidal HSPG mol-
ecules. We thus next analyzed the interaction of 3LL-HH tumor
cells with mouse liver-derived HSPG species. Murine liver PGs
have been isolated and step-eluted from the DEAE cellulose
column with increasing NaCl concentrations. Further analysis of
the PG fractions using HPLC revealed a high molecular mass
HSPG (.500 kDa) eluted by 0.4 M NaCl (Tı´ma´r and Kovalszky,
1995). Immunoblot analysis indicated that this PG corresponded to
perlecan and reacted with the antibody raised against EHS-derived
large HSPG (Tı´ma´r and Kovalszky, 1995).
To reveal the function of HSPG in the liver colonization of
3LL-HH cells, we analyzed 3 aspects of tumor cell-HSPG interac-
tions: adhesion, migration and proliferation. The 3LL-HH tumor
cells adhered in vitro to isolated PG fractions of mouse liver, with
significant preference for the fraction eluted by 0.4 M NaCl (Fig.
6a). The anti-HSPG antibody (1 µg/well) significantly inhibited the
adhesion of tumor cells to this fraction, suggesting the presence of
the high m.w. HSPG (perlecan) (Fig. 6a). The liver-derived
proteoglycans were not chemotactic for 3LL-HH tumor cells in
migration assay when compared with the highly chemotactic liver
homogenate itself (Fig. 6b). Finally, 3LL-HH tumor cells were
treated with basement membrane-derived heparan sulfate, heparin,
chondroitin sulfate and hyaluronic acid in vitro for 48 hr, and the
effects on cell proliferation were determined. The results indicated
a preferential, dose-dependent stimulation by exogenous heparan
sulfate and inhibition by hyaluronic acid on the in vitro prolifera-
tion of 3LL-HH cells (Fig. 7).
DISCUSSION
To understand the mechanism of liver metastasis, we have used a
tumor line, the 3LL-HH lung carcinoma, selected for its liver
metastatic potential by sequential intrasplenic injections (Pa´l et al.,
1983). This procedure resulted in a significantly increased liver
colonization potential as well as resistance to non-specific immune
effector cells (Paku et al., 1989; Lada´nyi et al., 1993).
The mechanism of organ-specific metastatic potential of malig-
nant tumor cells is not fully understood. It has been demonstrated
TABLE I – ANTI-BASEMENTMEMBRANEANTIBODY PRETREATMENT
OF THE HOST1
Control
Treatment
a-HSPG a-LM a-FN
Effect on dissemination of 3LL-HH cells in vivo
No. of
metastases/
animal 3626 103 1916 672 2586 89 2796 103
Lack of effects on the colonization of various organs by 3LL-HH
cells
Heart 22.86 6.0 26.06 5.0 18.26 8.0 17.06 6.0
Stomach 13.86 6.1 12.56 7.0 10.36 3.0 11.06 4.0
Pancreas 21.36 10.3 18.76 10 25.06 10.0 29.06 10.0
Bladder 3.56 1.8 4.96 5.0 4.16 2.0 5.06 2.0
1Mice were pretreated with 0.1 ml of rabbit polyclonal antibody/
animal (tail vein injection) 2 hr before intracardial inoculation of 2 3
104 tumor cells. Animals were sacrificed by a Nembutal overdose on
day 11 post inoculation. Organs were examined and counted for tumor
colonies using a stereo-microscope. Data are expressed as mean
number of metastases (6SD; n 5 10). HSPG, heparan sulfate proteo-
glycan; LM, laminin; FN, fibronectin.–2p , 0.05.
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that the microvessel endothelium of the individual organs ex-
presses an organ-specific membrane phenotype, providing a basis
for organ-specific recognition of vessels by the disseminated
intravascular tumor cells (Nicolson, 1988). Furthermore, it has
been shown that the basement membrane proteins, as common
ECM components of organs, are also expressed in an organ-specific
manner, providing another tool for selective recognition. A third
aspect of the organ specificity of the metastatization is the local
cytokine milieu, which provides a unique and organ-specific
paracrine mechanism for the local regulation of metastasis-
associated events, such as tumor cell-extracellular matrix interac-
tion and proliferation (Nicolson, 1993).
Our present and previous data indicate that 3LL-HH cells do not
specifically recognize the liver tissue sections or the liver cells
themselves (Lapis et al., 1986), and the liver homogenate does not
provide a specific motogenic signal. However, blocking of the
basement membrane HSPG epitopes in vivo by the pretreatment of
mice with a polyclonal antibody inhibits the liver and kidney
colonization by 3LL-HH cells. In the case of the liver, it is the only
basement membrane component that is important, according to our
in vivo data. Interestingly, in other organs such as lung or kidney,
laminin or fibronectin proved to be equally or more important than
HSPG. The role of a selective antibody-mediated effector cell-
dependent cytotoxicity against 3LL-HH cells in vivo is highly
FIGURE 5 – Effect of anti-basement membrane protein antibody
pretreatments on organ colonization by 3LL-HH tumor cells. Animals
were pretreated with rabbit polyclonal antibodies against basement
membrane HSPG (black bars), laminin (LM; gray bars) or fibronectin
(FN; light gray bars), and then tumor cells were inoculated into the left
cardiac ventricle. Animals were sacrificed by Nembutal overdose on
day 11 post-inoculation. Organs were removed and tumor colonies
were counted with a stereo-microscope. Data are expressed as mean
number of tumor colonies 6 SD; n 5 10. Control, open bars. (a) Effect
of antibody treatment on liver colonization. (b) Effect of antibody
treatment on lung colonization. (c) Effect of antibody treatment on
kidney colonization.
FIGURE 6 – Effects of mouse liver proteoglycans (PG) on the 3LL-HH tumor cells in vitro. Proteoglycans were isolated from mouse liver and
fractionated on a DEAE 52 column by NaCl gradient into 4 fractions (eluted by 0.26 M, 0.32 M, 0.4 M and 0.6 M NaCl). (a)Adhesion of tumor
cells to liver proteoglycans in vitro. Tumor cells were incubated on PG-covered microvessels for 1 hr, preincubated with the anti-HSPG antibody
(1 hr), washed with serum-free medium (23) and counted under a phase contrast microscope. Data are expressed as number of adherent cells/unit
area (using a 203 lens) 6 SD; n 5 3. Control PG, proteoglycan substrate alone (open bars); PG 1 a-HSPGAb, proteoglycan substrate covered by
anti-HSPG antibody (black bars). (b) Chemotactic effect of liver proteoglycans on 3LL-HH cells in vitro. Boyden chamber assay. Tumor cells
were placed on 8 µm pore size filters for 4 hr, the isolated proteoglycans were used as chemoattractant and liver homogenate was used as positive
control. Data are expressed as number of cells migrated/unit area 6 SD; n 5 4. Dotted bar, PG/0.26 M; light gray bar, PG/0.32 M; dark gray bar,
PG/0.40 M; striped bar, PG/0.60 M; black bar, liver-homogenate.
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unlikely, since the 3LL-HH cells are resistant to non-immune
effectors in vitro and in vivo (Lada´nyi et al., 1993) and spleen cells
were not cytotoxic for 3LL-HH cells in vitro in the presence of the
anti-HSPG antibody.
Our present results call attention to the importance of basement
membrane heparan sulfate PGs in the regulation of liver metastasis
formation. Immunofluorescence studies and biochemistry provided
evidence that perlecan, the major HSPG component of basement
membranes, localizes to sinusoids of the liver lobules besides the
elementary bile ducts and major vessels (Gallai et al., 1996).
Perlecan is produced by endothelial and Ito cells (Rescan et al.,
1993; Gallai et al., 1996) whereas hepatocytes express syndecan, a
small transmembrane HSPG (Kovalszky et al., 1994). Since
3LL-HH tumor cells extravasate to the liver parenchyma predomi-
nantly from liver sinusoids (Paku and Lapis, 1993), interaction
with the subendothelial basement membrane must be considered as
the first interaction of tumor cells with the local extracellular
matrix. 3LL-HH cells were shown to recognize the HSPG fraction
of mouse liver in an adhesion assay, and this could be abrogated by
an anti-HSPG antibody, suggesting specificity of the interaction.
What could be the significance of such an interaction? Basement
membranes are not only boundaries between various tissue compart-
ments but also provide a source for local regulatory molecules
involved in tissue differentiation or remodeling (Vlodavsky et al.,
1993). Tumor cells are able to proliferate on or migrate along
basement membrane of the target organ during metastasis forma-
tion (Paku et al., 1990). Since a great majority of cytokines are
characterized by their heparan sulfate binding potential (Ruoslahti
and Yamaguchi, 1991), it is well accepted that basement membrane
HSPG(s) is responsible for such a storage function. In the case of
the liver tissue, local growth factors are hepatocyte growth factor
(HGF), transforming growth factor-a (TGF-a) and basic fibroblast
growth factor (bFGF) (Michalopoulos, 1990). HGF is produced by
Ito cells (Ramadori et al., 1992) localized in the perisinusoidal
area, whereas TGF-a is produced by proliferating hepatic cells
(Michalopoulos, 1990). Other cytokines such as TGF-b are mostly
produced by mesenchymal cells (macrophages, fibroblasts and Ito
cells) accumulating in the portal area (Michalopoulos, 1990). It is
tempting to speculate that the peri-sinusoidal basement membrane
may store heparin-binding cytokines, which may affect tumor cell
extravasation into the liver parenchyma. Analysis of the putative
function of liver-derived HSPG in the metastatic cascade indicated
that this HSPG (perlecan) is a preferred adhesive substrate for
3LL-HH tumor cells, but it is not chemotactic for them. We also
provided evidence that only heparan sulfate, but not other GAGs, is
mitogenic for 3LL-HH cells, suggesting another possible role for
liver-derived HS(PG) in tumor metastasis.
Previous studies suggested that liver-metastatic tumor cells,
irrespective of their tissue of origin (carcinoma or melanoma),
overexpress heparan sulfate and HSPGs. However, no clear
connection of this phenotypic marker to the liver metastatic
potential has been elucidated (Tı´ma´r et al., 1987, 1992). We
suggest that local heparan sulfate-binding cytokines of the liver
(HGF, TGFb, bFGF) may localize in the peri-sinusoidal area
temporarily associated with HSPG/perlecan. These molecules
could be mitogenic and/or motogenic for tumor cells expressing
appropriate receptors and HSPG at the cell surface. Interference
with the local recognition of perlecan-bound cytokines by anti-
HSPG antibody may disrupt the sequence of key events in the
metastatic cascade of the liver by decreasing the efficiency of
extravasation, migration and local proliferation of tumor cells.
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